{"PMC2751755": [["BackgroundGoose parvovirus (GPV) is the causative agent of Gosling plague (GP), an acute, contagious, and fatal disease, which is also known as Derzsy's disease [1].", [["Goose parvovirus", "DISEASE", 10, 26], ["Gosling plague", "DISEASE", 59, 73], ["Derzsy's disease", "DISEASE", 144, 160], ["Goose parvovirus", "ORGANISM", 10, 26], ["GPV", "GENE_OR_GENE_PRODUCT", 28, 31], ["Gosling plague", "ORGANISM", 59, 73], ["Goose parvovirus", "SPECIES", 10, 26], ["Goose parvovirus", "SPECIES", 10, 26], ["GPV", "SPECIES", 28, 31], ["BackgroundGoose parvovirus", "PROBLEM", 0, 26], ["Gosling plague", "PROBLEM", 59, 73], ["an acute, contagious, and fatal disease", "PROBLEM", 80, 119], ["Derzsy's disease", "PROBLEM", 144, 160], ["Goose parvovirus", "OBSERVATION", 10, 26], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["contagious", "OBSERVATION_MODIFIER", 90, 100], ["fatal", "OBSERVATION_MODIFIER", 106, 111], ["disease", "OBSERVATION", 112, 119]]], ["GPV has been formally classified as a member of the genus Dependovirus in family Parvoviridae [2].", [["GPV", "CHEMICAL", 0, 3], ["GPV", "GENE_OR_GENE_PRODUCT", 0, 3], ["GPV", "PROTEIN", 0, 3], ["GPV", "SPECIES", 0, 3]]], ["It causes considerable economic losses, especially in countries with an industrialized goose production system, because the virus infection spreads rapidly worldwide causing high rate of morbidity and mortality [1,4-6].BackgroundRegular methods for identifying GPV include agar-gel diffusion precipitin test, virus neutralization (VN) assay, and enzyme-linked immunosorbent assay (ELISA) [5].", [["infection", "DISEASE", 130, 139], ["GPV", "SPECIES", 261, 264], ["considerable economic losses", "PROBLEM", 10, 38], ["an industrialized goose production system", "PROBLEM", 69, 110], ["the virus infection", "PROBLEM", 120, 139], ["high rate of morbidity", "PROBLEM", 174, 196], ["BackgroundRegular methods", "TREATMENT", 219, 244], ["GPV", "TEST", 261, 264], ["agar", "TEST", 273, 277], ["gel diffusion precipitin test", "TEST", 278, 307], ["virus neutralization (VN) assay", "TEST", 309, 340], ["enzyme-linked immunosorbent assay", "TEST", 346, 379], ["considerable", "OBSERVATION_MODIFIER", 10, 22], ["economic losses", "OBSERVATION", 23, 38]]], ["However, these methods have certain limitations; they are tedious and are not always reliable because of the requirement of specific-pathogen-free (SPF) gosling embryos and standard positive anti-GPV serum [7,8].BackgroundRecently, the highly conserved VP3 region of the GPV gene was cloned and sequenced and analyzed by qualitative polymerase chain reaction (PCR) assays [9-12].", [["embryos", "ANATOMY", 161, 168], ["serum", "ANATOMY", 200, 205], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 161, 168], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["VP3", "GENE_OR_GENE_PRODUCT", 253, 256], ["GPV", "GENE_OR_GENE_PRODUCT", 271, 274], ["VP3 region", "DNA", 253, 263], ["GPV gene", "DNA", 271, 279], ["standard positive anti-GPV serum", "TEST", 173, 205], ["qualitative polymerase chain reaction", "PROBLEM", 321, 358], ["PCR", "TEST", 360, 363], ["assays", "TEST", 365, 371], ["VP3", "OBSERVATION", 253, 256]]], ["Although qualitative PCR was useful for the diagnosis of GPV infection, it had some problems: it involved the electrophoresis and staining processes, which made the procedure lengthy, increased the risk of contamination, or rendered the method unsuitable for large-scale investigations [13-15].", [["GPV infection", "DISEASE", 57, 70], ["GPV", "CANCER", 57, 60], ["GPV", "SPECIES", 57, 60], ["qualitative PCR", "TEST", 9, 24], ["GPV infection", "PROBLEM", 57, 70], ["the electrophoresis", "PROBLEM", 106, 125], ["staining processes", "PROBLEM", 130, 148], ["the procedure lengthy", "TREATMENT", 161, 182], ["contamination", "PROBLEM", 206, 219], ["large-scale investigations", "TEST", 259, 285], ["infection", "OBSERVATION", 61, 70]]], ["Moreover, determination of the amount of virus in different tissues and cells was very useful for investigating the nosogenesis, virus replication, host-virus interactions, tropism, and effective for screening anti-viral drugs; all these factors could not be assessed by qualitative PCR [16,17].BackgroundIn recent years, a method based on PCR with an automatic confirmation phase has been developed.", [["tissues", "ANATOMY", 60, 67], ["cells", "ANATOMY", 72, 77], ["tissues", "TISSUE", 60, 67], ["cells", "CELL", 72, 77], ["virus in different tissues and cells", "PROBLEM", 41, 77], ["the nosogenesis", "PROBLEM", 112, 127], ["virus replication", "TREATMENT", 129, 146], ["screening anti-viral drugs", "TREATMENT", 200, 226], ["qualitative PCR", "TEST", 271, 286], ["a method", "TEST", 322, 330], ["PCR", "TEST", 340, 343], ["an automatic confirmation phase", "TEST", 349, 380], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["virus", "OBSERVATION", 41, 46]]], ["This method, which is known as the fluorescent quantitative real-time PCR (FQ-PCR), has been used widely to quantify the number of genomic copies of pathogenic microorganisms [18,19].BackgroundGPV detection by real-time PCR has only been reported by Bi [20]; in that study, the method was not optimized and a FQ-PCR standard curve was not generated.", [["This method", "TEST", 0, 11], ["pathogenic microorganisms", "PROBLEM", 149, 174], ["BackgroundGPV detection", "TEST", 183, 206], ["real-time PCR", "TEST", 210, 223], ["that study", "TEST", 262, 272], ["the method", "TEST", 274, 284], ["a FQ-PCR standard curve", "TEST", 307, 330]]], ["In this study, we reported the optimization of a FQ-PCR assay to quantify GPV DNA in vivo after experimental infection.", [["FQ", "CHEMICAL", 49, 51], ["infection", "DISEASE", 109, 118], ["GPV", "TISSUE", 74, 77], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["GPV DNA", "DNA", 74, 81], ["GPV", "SPECIES", 74, 77], ["this study", "TEST", 3, 13], ["a FQ-PCR assay", "TEST", 47, 61], ["experimental infection", "PROBLEM", 96, 118], ["infection", "OBSERVATION", 109, 118]]], ["The results of this study provide some interesting data that may be beneficial to understand the regular distribution pattern and nosogenesis of GPV in vivo in goslings.Concentration of standard pVP3 plasmid DNA ::: ResultsThe concentration of standard pVP3 plasmid DNA was 2 \u03bcg/\u03bcL, and the A260/A280 (ratio) was 1.84; the copy numbers of pVP3 plasmid DNA were 2.76 \u00d7 1011 copies/\u03bcL.Development and optimization of FQ-PCR and conventional PCR ::: ResultsAfter the optimization of FQ-PCR, we selected the final concentrations of each primer as 0.2 \u03bcmol/L and that of probe as 0.16 \u03bcmol/L. The MgCl2 concentration was adjusted to 10 mM to obtain optimal FQ-PCR assay conditions.", [["FQ", "CHEMICAL", 415, 417], ["FQ", "CHEMICAL", 480, 482], ["MgCl2", "CHEMICAL", 592, 597], ["FQ", "CHEMICAL", 652, 654], ["MgCl2", "CHEMICAL", 592, 597], ["GPV", "GENE_OR_GENE_PRODUCT", 145, 148], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["DNA", "CELLULAR_COMPONENT", 266, 269], ["pVP3", "GENE_OR_GENE_PRODUCT", 339, 343], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["MgCl2", "SIMPLE_CHEMICAL", 592, 597], ["pVP3 plasmid DNA", "DNA", 195, 211], ["pVP3 plasmid DNA", "DNA", 253, 269], ["pVP3 plasmid DNA", "DNA", 339, 355], ["GPV", "SPECIES", 145, 148], ["this study", "TEST", 15, 25], ["standard pVP3 plasmid DNA", "TEST", 244, 269], ["pVP3 plasmid DNA", "TEST", 339, 355], ["FQ-PCR", "TEST", 415, 421], ["conventional PCR", "TEST", 426, 442], ["FQ-PCR", "TEST", 480, 486], ["the final concentrations of each primer", "TREATMENT", 500, 539], ["The MgCl2 concentration", "TREATMENT", 588, 611], ["optimal FQ", "TEST", 644, 654]]], ["Therefore, the optimized 25-\u03bcL FQ-PCR reaction system for GPV detection was as follows: 1\u00d7 PCR buffer, 10 mmol/L MgCl2, 0.2 mmol/L dNTPs, 0.2 \u03bcmol/L of each primer, 0.16 \u03bcmol/L of probe, 1 U Taq, and 1 \u03bcL DNA template.Development and optimization of FQ-PCR and conventional PCR ::: ResultsThe optimized conventional PCR reaction system used in this study was as described by Huang et al. [12]: 1\u00d7 PCR buffer, 1.5 mmol/L MgCl2, 0.2 mmol/L dNTPs, 1.0 pmol/L of each primer, 2.5 U Taq, and 1 \u03bcL DNA template.", [["FQ", "CHEMICAL", 31, 33], ["MgCl2", "CHEMICAL", 113, 118], ["dNTPs", "CHEMICAL", 131, 136], ["FQ", "CHEMICAL", 250, 252], ["MgCl2", "CHEMICAL", 420, 425], ["dNTPs", "CHEMICAL", 438, 443], ["MgCl2", "CHEMICAL", 113, 118], ["dNTPs", "CHEMICAL", 131, 136], ["MgCl2", "CHEMICAL", 420, 425], ["dNTPs", "CHEMICAL", 438, 443], ["GPV", "SIMPLE_CHEMICAL", 58, 61], ["MgCl2", "SIMPLE_CHEMICAL", 113, 118], ["Taq", "GENE_OR_GENE_PRODUCT", 191, 194], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["MgCl2", "SIMPLE_CHEMICAL", 420, 425], ["DNA", "CELLULAR_COMPONENT", 492, 495], ["GPV", "SPECIES", 58, 61], ["GPV detection", "TEST", 58, 71], ["MgCl2", "TREATMENT", 113, 118], ["dNTPs", "TREATMENT", 131, 136], ["each primer", "TREATMENT", 152, 163], ["1 U Taq", "TREATMENT", 187, 194], ["1 \u03bcL DNA template", "TREATMENT", 200, 217], ["FQ-PCR", "TEST", 250, 256], ["conventional PCR", "TEST", 261, 277], ["this study", "TEST", 344, 354], ["PCR", "TEST", 397, 400], ["buffer", "TEST", 401, 407], ["MgCl2", "TEST", 420, 425], ["dNTPs", "TREATMENT", 438, 443], ["2.5 U Taq", "TREATMENT", 472, 481], ["1 \u03bcL DNA template", "TREATMENT", 487, 504]]], ["The optimized annealing temperature was 52\u00b0C.Establishment of FQ -PCR standard curve ::: ResultsThe FQ-PCR amplification curves and the corresponding FQ-PCR standard curve (Figure 1) were generated by employing the successively diluted known copy numbers of pVP3 for real-time PCR reaction under the optimized conditions.", [["FQ", "CHEMICAL", 100, 102], ["pVP3", "GENE_OR_GENE_PRODUCT", 258, 262], ["pVP3", "PROTEIN", 258, 262], ["The optimized annealing temperature", "TEST", 0, 35], ["The FQ-PCR amplification curves", "TEST", 96, 127], ["the corresponding FQ", "TEST", 132, 152], ["pVP3", "TREATMENT", 258, 262], ["real-time PCR reaction", "PROBLEM", 267, 289]]], ["On the basis of the results of correlation coefficient (0.999) and PCR efficiency (98.7%), it was confirmed that the standard curve and the established FQ-PCR protocol were extremely effective.", [["PCR efficiency", "TEST", 67, 81], ["the standard curve", "TEST", 113, 131], ["the established FQ-PCR protocol", "TREATMENT", 136, 167]]], ["By using the following formula, we were able to quantify the amount of unknown samples: Y = -3.353X + 51.142 (Y = threshold cycle, X = log starting quantity).Sensitivity, specificity, reproducibility and dynamic range analysis of the established FQ-PCR ::: ResultsTen-fold dilutions of the pVP3 plasmid DNA were tested by the established FQ-PCR assay to evaluate the sensitivity of the system, and the detection limit was found to be 2.8 \u00d7 101 copies/reaction.", [["FQ", "CHEMICAL", 338, 340], ["pVP3", "GENE_OR_GENE_PRODUCT", 290, 294], ["DNA", "CELLULAR_COMPONENT", 303, 306], ["pVP3 plasmid DNA", "DNA", 290, 306], ["Sensitivity", "TEST", 158, 169], ["dynamic range analysis", "TEST", 204, 226], ["the pVP3 plasmid DNA", "TEST", 286, 306], ["the established FQ-PCR assay", "TEST", 322, 350], ["the detection limit", "TEST", 398, 417]]], ["Comparisons were made between the conventional PCR method and our established FQ-PCR method using dilution series of pVP3 plasmid DNA to calculate the end-point sensitivity of each assay.", [["FQ", "CHEMICAL", 78, 80], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["pVP3 plasmid DNA", "DNA", 117, 133], ["the conventional PCR method", "TEST", 30, 57], ["dilution series", "TEST", 98, 113], ["pVP3 plasmid DNA", "TREATMENT", 117, 133]]], ["The results indicated that the established FQ-PCR is approximately 1000-times more sensitive than the conventional PCR method; the former method can detect pVP3 copies down to dilutions of 2.8 \u00d7 101 copies/reaction and the latter one that can detect copies up to the dilutions of 2.8 \u00d7 104 copies/reaction.Sensitivity, specificity, reproducibility and dynamic range analysis of the established FQ-PCR ::: ResultsThe test was performed using DNA from pVP3, GPV-CHv and several other bacteria and viruses as templates to examine its specificity; the result of this analysis showed that none of the bacteria or viruses (other than GPV-CHv and pVP3) yielded any amplification signal, suggesting that the established FQ-PCR assay was highly specific (Figure 2).Sensitivity, specificity, reproducibility and dynamic range analysis of the established FQ-PCR ::: ResultsThe intraassay and interassay CV of this established FQ-PCR was in the range of 0.8-3% for most of the dynamic range (from 2.8 \u00d7 1011 to 2.8 \u00d7 101 pVP3 plasmid copies/\u03bcL).", [["FQ", "CHEMICAL", 43, 45], ["FQ", "CHEMICAL", 712, 714], ["FQ", "CHEMICAL", 915, 917], ["pVP3", "GENE_OR_GENE_PRODUCT", 156, 160], ["DNA", "CELLULAR_COMPONENT", 441, 444], ["pVP3", "GENE_OR_GENE_PRODUCT", 450, 454], ["GPV-CHv", "GENE_OR_GENE_PRODUCT", 456, 463], ["GPV-CHv", "GENE_OR_GENE_PRODUCT", 628, 635], ["pVP3", "GENE_OR_GENE_PRODUCT", 640, 644], ["pVP3 copies", "DNA", 156, 167], ["GPV", "PROTEIN", 456, 459], ["GPV", "DNA", 628, 631], ["CHv", "DNA", 632, 635], ["pVP3", "DNA", 640, 644], ["the established FQ-PCR", "TEST", 27, 49], ["the conventional PCR method", "TEST", 98, 125], ["pVP3 copies", "PROBLEM", 156, 167], ["dilutions", "TEST", 176, 185], ["the dilutions", "TEST", 263, 276], ["Sensitivity", "TEST", 306, 317], ["dynamic range analysis", "TEST", 352, 374], ["The test", "TEST", 412, 420], ["pVP3", "TEST", 450, 454], ["GPV", "TEST", 456, 459], ["CHv", "TREATMENT", 460, 463], ["several other bacteria", "PROBLEM", 468, 490], ["viruses", "TREATMENT", 495, 502], ["this analysis", "TEST", 558, 571], ["the bacteria", "PROBLEM", 592, 604], ["viruses", "PROBLEM", 608, 615], ["GPV", "TEST", 628, 631], ["pVP3", "TEST", 640, 644], ["any amplification signal", "PROBLEM", 654, 678], ["the established FQ-PCR assay", "TEST", 696, 724], ["Sensitivity", "TEST", 756, 767], ["dynamic range analysis", "TEST", 802, 824], ["The intraassay", "TEST", 862, 876], ["interassay CV", "TEST", 881, 894], ["PCR", "TEST", 918, 921], ["plasmid copies", "TEST", 1014, 1028]]], ["The results demonstrated that the established FQ-PCR method was characterized by a wide dynamic range (11 logarithmic decades) of detection from 2.8 \u00d7 1011 to 2.8 \u00d7 101 pVP3 plasmid copies/\u03bcL with high precision.", [["FQ", "CHEMICAL", 46, 48], ["the established FQ-PCR method", "TEST", 30, 59], ["detection", "TEST", 130, 139], ["plasmid copies", "TEST", 174, 188], ["high precision", "OBSERVATION", 197, 211]]], ["Therefore the dynamic range of the method was between 2.8 \u00d7 1011 to 2.8 \u00d7 101 pVP3 plasmid copies/\u03bcL, which is relatively broad.Dynamic distribution of in vivo GPV test by using the established FQ-PCR assay ::: ResultsViral load quantification using the established FQ-PCR demonstrated that the GPV DNA copy number of each sample could be calculated using the cycle threshold (Ct) value determined from the standard curve.", [["sample", "ANATOMY", 323, 329], ["FQ", "CHEMICAL", 194, 196], ["FQ", "CHEMICAL", 266, 268], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["plasmid copies", "TEST", 83, 97], ["vivo GPV test", "TEST", 155, 168], ["ResultsViral load quantification", "TEST", 211, 243], ["the established FQ-PCR", "TEST", 250, 272], ["the GPV DNA copy", "TEST", 291, 307], ["the cycle threshold", "TEST", 356, 375], ["Ct) value", "TEST", 377, 386], ["the standard curve", "TEST", 403, 421], ["\u03bcL", "OBSERVATION_MODIFIER", 98, 100], ["relatively", "OBSERVATION_MODIFIER", 111, 121], ["broad", "OBSERVATION_MODIFIER", 122, 127]]], ["The dynamic distribution of GPV within the tissues after oral infection with GPV was intermittently determined by means of the FQ-PCR in separate segments of tissues over a 9-day period.", [["tissues", "ANATOMY", 43, 50], ["oral", "ANATOMY", 57, 61], ["tissues", "ANATOMY", 158, 165], ["infection", "DISEASE", 62, 71], ["FQ", "CHEMICAL", 127, 129], ["GPV", "GENE_OR_GENE_PRODUCT", 28, 31], ["tissues", "TISSUE", 43, 50], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["tissues", "TISSUE", 158, 165], ["GPV", "PROTEIN", 28, 31], ["GPV", "SPECIES", 77, 80], ["oral infection", "PROBLEM", 57, 71], ["GPV", "PROBLEM", 77, 80], ["the FQ-PCR", "TEST", 123, 133], ["dynamic", "OBSERVATION_MODIFIER", 4, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24], ["GPV", "OBSERVATION", 28, 31], ["tissues", "ANATOMY", 43, 50], ["infection", "OBSERVATION", 62, 71], ["tissues", "ANATOMY", 158, 165]]], ["Results of this analysis revealed that the blood, heart, liver, spleen, kidney, Bursa of Fabricius (BF), thymus, and Harder's glands were positive at 4-h postinoculation (PI), with about 104.93-107.57 copies/g.", [["blood", "ANATOMY", 43, 48], ["heart", "ANATOMY", 50, 55], ["liver", "ANATOMY", 57, 62], ["spleen", "ANATOMY", 64, 70], ["kidney", "ANATOMY", 72, 78], ["BF", "ANATOMY", 100, 102], ["thymus", "ANATOMY", 105, 111], ["Harder's glands", "ANATOMY", 117, 132], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["heart", "ORGAN", 50, 55], ["liver", "ORGAN", 57, 62], ["spleen", "ORGAN", 64, 70], ["kidney", "ORGAN", 72, 78], ["Fabricius", "TISSUE", 89, 98], ["BF", "TISSUE", 100, 102], ["thymus", "ORGAN", 105, 111], ["glands", "ORGAN", 126, 132], ["this analysis", "TEST", 11, 24], ["the blood", "TEST", 39, 48], ["blood", "ANATOMY", 43, 48], ["heart", "ANATOMY", 50, 55], ["liver", "ANATOMY", 57, 62], ["spleen", "ANATOMY", 64, 70], ["kidney", "ANATOMY", 72, 78], ["Bursa", "ANATOMY", 80, 85], ["Fabricius", "ANATOMY", 89, 98], ["thymus", "ANATOMY", 105, 111], ["glands", "ANATOMY", 126, 132]]], ["GPV was consistently detected in all the segments of the organs at 8-h PI.", [["organs", "ANATOMY", 57, 63], ["GPV", "GENE_OR_GENE_PRODUCT", 0, 3], ["organs", "ORGAN", 57, 63], ["GPV", "PROTEIN", 0, 3], ["GPV", "SPECIES", 0, 3], ["GPV", "PROBLEM", 0, 3], ["organs", "ANATOMY", 57, 63]]], ["The copy numbers of GPV in each tissue reached a peak at 48-72-h PI.", [["tissue", "ANATOMY", 32, 38], ["GPV", "GENE_OR_GENE_PRODUCT", 20, 23], ["tissue", "TISSUE", 32, 38], ["GPV", "PROTEIN", 20, 23]]], ["Numbers of GPV DNA decreased at 6 days, and by 9 days, the level of GPV DNA decreased remarkably.", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["GPV", "GENE_OR_GENE_PRODUCT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["GPV DNA", "DNA", 11, 18], ["GPV DNA", "DNA", 68, 75], ["GPV", "SPECIES", 11, 14], ["GPV", "SPECIES", 68, 71], ["GPV DNA", "PROBLEM", 11, 18], ["GPV DNA", "TEST", 68, 75], ["GPV", "OBSERVATION_MODIFIER", 11, 14], ["DNA", "OBSERVATION_MODIFIER", 15, 18], ["decreased", "OBSERVATION_MODIFIER", 19, 28], ["decreased", "OBSERVATION_MODIFIER", 76, 85]]], ["Importantly, the level of GPV DNA was comparable to that in the other organs at 3-days PI; the liver, spleen, thymus, Harder's glands, and BF had significantly higher numbers of GPV DNA than the rest of the tissues, with >1010 copies/g in the former tissues compared to <108 copies/g in the rest of the tissues.", [["organs", "ANATOMY", 70, 76], ["liver", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 102, 108], ["thymus", "ANATOMY", 110, 116], ["Harder's glands", "ANATOMY", 118, 133], ["BF", "ANATOMY", 139, 141], ["tissues", "ANATOMY", 207, 214], ["tissues", "ANATOMY", 250, 257], ["tissues", "ANATOMY", 303, 310], ["GPV", "GENE_OR_GENE_PRODUCT", 26, 29], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["organs", "ORGAN", 70, 76], ["liver", "ORGAN", 95, 100], ["spleen", "ORGAN", 102, 108], ["thymus", "ORGAN", 110, 116], ["glands", "ORGAN", 127, 133], ["GPV", "GENE_OR_GENE_PRODUCT", 178, 181], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["tissues", "TISSUE", 207, 214], ["tissues", "TISSUE", 250, 257], ["tissues", "TISSUE", 303, 310], ["GPV DNA", "DNA", 26, 33], ["GPV DNA", "DNA", 178, 185], ["GPV", "SPECIES", 26, 29], ["GPV", "SPECIES", 178, 181], ["GPV DNA", "PROBLEM", 26, 33], ["significantly higher numbers of GPV DNA", "PROBLEM", 146, 185], ["GPV DNA", "OBSERVATION", 26, 33], ["organs", "ANATOMY", 70, 76], ["liver", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 102, 108], ["thymus", "ANATOMY", 110, 116], ["glands", "ANATOMY", 127, 133], ["significantly", "OBSERVATION_MODIFIER", 146, 159], ["higher", "OBSERVATION_MODIFIER", 160, 166], ["numbers", "OBSERVATION_MODIFIER", 167, 174], ["GPV DNA", "OBSERVATION", 178, 185], ["tissues", "ANATOMY", 207, 214], ["tissues", "ANATOMY", 303, 310]]], ["In addition, the control group did not show any positive results at any time point or in any tissue (Table 1)DiscussionHere, we describe a real-time PCR assay for the quantification of GPV genome coupes in goslings.", [["tissue", "ANATOMY", 93, 99], ["tissue", "TISSUE", 93, 99], ["GPV genome coupes", "DNA", 185, 202], ["GPV", "SPECIES", 185, 188], ["PCR assay", "TEST", 149, 158], ["GPV genome", "OBSERVATION", 185, 195]]], ["We confirmed that this assay was highly sensitive, specific, and reproducible.DiscussionReal-time PCR has become a potentially powerful alternative in microbiological diagnostics because of its simplicity, rapidity, reproducibility, and high sensitivity compared to other diagnostic methods [21-23].", [["this assay", "TEST", 18, 28], ["DiscussionReal-time PCR", "TEST", 78, 101], ["microbiological diagnostics", "TEST", 151, 178], ["high sensitivity", "PROBLEM", 237, 253], ["diagnostic methods", "TEST", 272, 290]]], ["In this study, we clearly established the applicability of real-time PCR for the quantification of GPV because of its remarkable sensitivity and high-throughput potential, which is beyond the scope of other diagnostic methods.DiscussionThe real-time PCR assay permits the simultaneous detection and quantification of DNA.", [["DNA", "CELLULAR_COMPONENT", 317, 320], ["GPV", "SPECIES", 99, 102], ["this study", "TEST", 3, 13], ["real-time PCR", "TEST", 59, 72], ["GPV", "PROBLEM", 99, 102], ["its remarkable sensitivity", "PROBLEM", 114, 140], ["PCR assay", "TEST", 250, 259], ["the simultaneous detection", "TEST", 268, 294], ["DNA", "PROBLEM", 317, 320], ["high", "OBSERVATION_MODIFIER", 145, 149]]], ["It is useful for understanding the pathogenesis of the disease and the mechanisms of virus transmission by enabling the investigation of viral dynamics [21].", [["the disease", "PROBLEM", 51, 62], ["virus transmission", "PROBLEM", 85, 103], ["viral dynamics", "PROBLEM", 137, 151], ["disease", "OBSERVATION", 55, 62]]], ["The assay can be used to determine the amount of viral DNA in different tissues at various times after infection; this infection data could be interesting and useful for expanding the understanding on viruses.", [["tissues", "ANATOMY", 72, 79], ["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 119, 128], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["tissues", "TISSUE", 72, 79], ["viral DNA", "DNA", 49, 58], ["The assay", "TEST", 0, 9], ["viral DNA", "PROBLEM", 49, 58], ["infection", "PROBLEM", 103, 112], ["this infection data", "PROBLEM", 114, 133], ["viral DNA", "OBSERVATION", 49, 58], ["different tissues", "OBSERVATION_MODIFIER", 62, 79], ["infection", "OBSERVATION", 103, 112]]], ["Quantification of the viral load makes it possible to study the kinetics and tropism of GPV in different birds, tissues, and cells.", [["tissues", "ANATOMY", 112, 119], ["cells", "ANATOMY", 125, 130], ["GPV", "GENE_OR_GENE_PRODUCT", 88, 91], ["tissues", "TISSUE", 112, 119], ["cells", "CELL", 125, 130], ["the viral load", "PROBLEM", 18, 32], ["the kinetics", "TEST", 60, 72], ["GPV", "PROBLEM", 88, 91], ["viral load", "OBSERVATION", 22, 32], ["tissues", "ANATOMY", 112, 119]]], ["Our study is different from other studies that examined the distribution of viruses and the characteristics of the lesions induced in experimentally infected geese and Muscovy ducts by performing comparative pathological studies or other assays [24,25].DiscussionPrevious studies have examined the distribution of GPV in infected Muscovy ducks by qualitative PCR [9], including a study that used quantitative PCR [20].", [["lesions", "ANATOMY", 115, 122], ["Muscovy ducts", "ANATOMY", 168, 181], ["lesions", "PATHOLOGICAL_FORMATION", 115, 122], ["geese", "ORGANISM", 158, 163], ["Muscovy ducts", "MULTI-TISSUE_STRUCTURE", 168, 181], ["GPV", "GENE_OR_GENE_PRODUCT", 314, 317], ["Muscovy ducks", "ORGANISM", 330, 343], ["GPV", "PROTEIN", 314, 317], ["Muscovy ducks", "SPECIES", 330, 343], ["geese", "SPECIES", 158, 163], ["Muscovy ducks", "SPECIES", 330, 343], ["Our study", "TEST", 0, 9], ["other studies", "TEST", 28, 41], ["viruses", "PROBLEM", 76, 83], ["the lesions", "PROBLEM", 111, 122], ["experimentally infected geese and Muscovy ducts", "PROBLEM", 134, 181], ["comparative pathological studies", "TEST", 196, 228], ["other assays", "TEST", 232, 244], ["DiscussionPrevious studies", "TEST", 253, 279], ["GPV", "PROBLEM", 314, 317], ["qualitative PCR", "TEST", 347, 362], ["a study", "TEST", 378, 385], ["quantitative PCR", "TEST", 396, 412], ["viruses", "OBSERVATION", 76, 83], ["lesions", "OBSERVATION", 115, 122], ["infected", "OBSERVATION_MODIFIER", 149, 157], ["Muscovy ducts", "ANATOMY", 168, 181]]], ["However, Bi et al. did not optimize the FQ-PCR assay for future application.", [["FQ", "CHEMICAL", 40, 42], ["the FQ-PCR assay", "TEST", 36, 52]]], ["Limn et al. found that GPV could be first detected at 2-d PI in the liver and other organs.", [["liver", "ANATOMY", 68, 73], ["organs", "ANATOMY", 84, 90], ["GPV", "SIMPLE_CHEMICAL", 23, 26], ["liver", "ORGAN", 68, 73], ["organs", "ORGAN", 84, 90], ["GPV", "PROTEIN", 23, 26], ["GPV", "PROBLEM", 23, 26], ["GPV", "OBSERVATION", 23, 26], ["liver", "ANATOMY", 68, 73], ["organs", "ANATOMY", 84, 90]]], ["Because the real-time PCR method was more sensitive than regular qualitative PCR methods [26], we could first detect GPV at 4-h PI in the liver and other tissues, which was less than 40 h compared to the time required by regular qualitative PCR methods.", [["liver", "ANATOMY", 138, 143], ["tissues", "ANATOMY", 154, 161], ["liver", "ORGAN", 138, 143], ["tissues", "TISSUE", 154, 161], ["the real-time PCR method", "TEST", 8, 32], ["GPV", "TEST", 117, 120], ["liver", "ANATOMY", 138, 143], ["other tissues", "ANATOMY", 148, 161]]], ["This finding is important because the prevention and early detection are presently the most logical strategies for virus control [27].DiscussionIslam et al. reported that in orally infected ducks, duck plague virus (DPV) first invaded the epithelial cells of the intestinal tract, following which it was transported to other immune organs, such as BF, thymus, and spleen, from where it finally invaded to all the other host tissues via blood circulation [28].", [["epithelial cells", "ANATOMY", 239, 255], ["intestinal tract", "ANATOMY", 263, 279], ["immune organs", "ANATOMY", 325, 338], ["BF", "ANATOMY", 348, 350], ["thymus", "ANATOMY", 352, 358], ["spleen", "ANATOMY", 364, 370], ["tissues", "ANATOMY", 424, 431], ["blood", "ANATOMY", 436, 441], ["duck plague", "DISEASE", 197, 208], ["ducks", "ORGANISM", 190, 195], ["duck plague virus", "ORGANISM", 197, 214], ["DPV", "ORGANISM", 216, 219], ["epithelial cells", "CELL", 239, 255], ["intestinal tract", "ORGAN", 263, 279], ["organs", "ORGAN", 332, 338], ["BF", "TISSUE", 348, 350], ["thymus", "ORGAN", 352, 358], ["spleen", "ORGAN", 364, 370], ["tissues", "TISSUE", 424, 431], ["blood", "ORGANISM_SUBSTANCE", 436, 441], ["epithelial cells", "CELL_TYPE", 239, 255], ["ducks", "SPECIES", 190, 195], ["duck plague virus", "SPECIES", 197, 214], ["duck plague virus", "SPECIES", 197, 214], ["DPV", "SPECIES", 216, 219], ["virus control", "TREATMENT", 115, 128], ["orally infected ducks", "PROBLEM", 174, 195], ["duck plague virus", "PROBLEM", 197, 214], ["epithelial cells", "OBSERVATION", 239, 255], ["intestinal tract", "ANATOMY", 263, 279], ["thymus", "ANATOMY", 352, 358], ["spleen", "ANATOMY", 364, 370]]], ["Similarly, our study showed that GPV was distributed in the blood, heart, liver, spleen, kidney, BF, thymus, and Harder's glands at 4-h PI.", [["blood", "ANATOMY", 60, 65], ["heart", "ANATOMY", 67, 72], ["liver", "ANATOMY", 74, 79], ["spleen", "ANATOMY", 81, 87], ["kidney", "ANATOMY", 89, 95], ["BF", "ANATOMY", 97, 99], ["thymus", "ANATOMY", 101, 107], ["Harder's glands", "ANATOMY", 113, 128], ["GPV", "GENE_OR_GENE_PRODUCT", 33, 36], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["heart", "ORGAN", 67, 72], ["liver", "ORGAN", 74, 79], ["spleen", "ORGAN", 81, 87], ["kidney", "ORGAN", 89, 95], ["BF", "TISSUE", 97, 99], ["thymus", "ORGAN", 101, 107], ["glands", "ORGAN", 122, 128], ["GPV", "PROTEIN", 33, 36], ["GPV", "SPECIES", 33, 36], ["our study", "TEST", 11, 20], ["GPV", "PROBLEM", 33, 36], ["Harder's glands", "PROBLEM", 113, 128], ["GPV", "OBSERVATION", 33, 36], ["blood", "ANATOMY", 60, 65], ["heart", "ANATOMY", 67, 72], ["liver", "ANATOMY", 74, 79], ["spleen", "ANATOMY", 81, 87], ["kidney", "ANATOMY", 89, 95], ["BF", "ANATOMY_MODIFIER", 97, 99], ["thymus", "ANATOMY", 101, 107], ["glands", "ANATOMY", 122, 128]]], ["Subsequently, GPV was consistently distributed in all the segments of the organs at 8-h PI.", [["organs", "ANATOMY", 74, 80], ["GPV", "GENE_OR_GENE_PRODUCT", 14, 17], ["organs", "ORGAN", 74, 80], ["GPV", "PROTEIN", 14, 17], ["GPV", "TREATMENT", 14, 17], ["organs", "ANATOMY", 74, 80]]], ["The copy numbers of GPV in the liver, spleen, thymus, Harder's glands, and BF was significantly higher than that in the other regions.", [["liver", "ANATOMY", 31, 36], ["spleen", "ANATOMY", 38, 44], ["thymus", "ANATOMY", 46, 52], ["Harder's glands", "ANATOMY", 54, 69], ["GPV", "GENE_OR_GENE_PRODUCT", 20, 23], ["liver", "ORGAN", 31, 36], ["spleen", "ORGAN", 38, 44], ["thymus", "ORGAN", 46, 52], ["glands", "ORGAN", 63, 69], ["GPV", "PROTEIN", 20, 23], ["numbers", "OBSERVATION_MODIFIER", 9, 16], ["GPV", "OBSERVATION", 20, 23], ["liver", "ANATOMY", 31, 36], ["spleen", "ANATOMY", 38, 44], ["thymus", "ANATOMY", 46, 52], ["glands", "ANATOMY", 63, 69], ["significantly", "OBSERVATION_MODIFIER", 82, 95], ["higher", "OBSERVATION_MODIFIER", 96, 102]]], ["Therefore, these immune organs could be considered as the primary sites of invasion in normal goslings after GPV infection.DiscussionLive GPV vaccine is widely used to immunize adult geese to prevent GPV infection [12].", [["immune organs", "ANATOMY", 17, 30], ["sites", "ANATOMY", 66, 71], ["goslings", "ANATOMY", 94, 102], ["infection", "DISEASE", 113, 122], ["infection", "DISEASE", 204, 213], ["organs", "ORGAN", 24, 30], ["geese", "ORGANISM", 183, 188], ["GPV", "SPECIES", 109, 112], ["geese", "SPECIES", 183, 188], ["GPV", "SPECIES", 200, 203], ["invasion", "PROBLEM", 75, 83], ["GPV infection", "PROBLEM", 109, 122], ["DiscussionLive GPV vaccine", "TREATMENT", 123, 149], ["GPV infection", "PROBLEM", 200, 213], ["invasion", "OBSERVATION", 75, 83], ["normal goslings", "OBSERVATION", 87, 102], ["infection", "OBSERVATION", 113, 122], ["infection", "OBSERVATION", 204, 213]]], ["Real-time PCR and qualitative PCR assays [10-12] can amplify the highly conserved VP3 region of the GPV gene, which is distributed in the high-virulence strain and live-vaccine strain of GPV.", [["VP3", "GENE_OR_GENE_PRODUCT", 82, 85], ["GPV", "GENE_OR_GENE_PRODUCT", 100, 103], ["GPV", "CANCER", 187, 190], ["VP3 region", "DNA", 82, 92], ["GPV gene", "DNA", 100, 108], ["GPV", "SPECIES", 187, 190], ["Real-time PCR", "TEST", 0, 13], ["qualitative PCR assays", "TEST", 18, 40], ["the high-virulence strain", "PROBLEM", 134, 159], ["GPV", "PROBLEM", 187, 190], ["VP3", "ANATOMY_MODIFIER", 82, 85], ["region", "ANATOMY_MODIFIER", 86, 92], ["GPV gene", "ANATOMY", 100, 108]]], ["Theoretically, these methods would not be able to differentiate the GPV vaccine strain from the high-virulence strain; nonetheless, we could perform the study on the dynamic distribution of GPV in vivo using these methods, because the animals were certificated as GPV-free by qualitative PCR assay before being infected with the high-virulence strain.", [["GPV", "CHEMICAL", 264, 267], ["GPV", "GENE_OR_GENE_PRODUCT", 68, 71], ["GPV", "GENE_OR_GENE_PRODUCT", 190, 193], ["animals", "ORGANISM", 235, 242], ["GPV", "SPECIES", 190, 193], ["the GPV vaccine strain", "PROBLEM", 64, 86], ["the high-virulence strain", "PROBLEM", 92, 117], ["the study", "TEST", 149, 158], ["these methods", "TEST", 208, 221], ["GPV", "TEST", 264, 267], ["qualitative PCR assay", "TEST", 276, 297], ["the high-virulence strain", "PROBLEM", 325, 350]]], ["For standardization, the VP3 gene was cloned into a plasmid.", [["plasmid", "ANATOMY", 52, 59], ["VP3", "GENE_OR_GENE_PRODUCT", 25, 28], ["VP3 gene", "DNA", 25, 33], ["plasmid", "DNA", 52, 59], ["the VP3 gene", "TREATMENT", 21, 33], ["a plasmid", "TREATMENT", 50, 59]]], ["The available live vaccine could have been used as the standard.ConclusionIn conclusion, the established real-time PCR assay was rapid, sensitive, and specific for the detection and quantification of GPV DNA.", [["GPV", "ORGANISM", 200, 203], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["GPV DNA", "DNA", 200, 207], ["GPV", "SPECIES", 200, 203], ["The available live vaccine", "TREATMENT", 0, 26], ["the established real-time PCR assay", "TEST", 89, 124], ["the detection", "TEST", 164, 177], ["GPV DNA", "PROBLEM", 200, 207], ["GPV DNA", "OBSERVATION", 200, 207]]], ["In addition, our results provide significant data for clarifying that the immune organs were the primary sites of GPV invasion in infected goslings.Virus and PCR template DNA preparation ::: MethodsGPV CHV strain, a high-virulence strain of GPV, was obtained from Key Laboratory of Animal Diseases and Human Health of Sichuan Province.Virus and PCR template DNA preparation ::: MethodsAleutian disease virus (ADV), canine parvovirus (CPV), porcine parvovirus, (PPV), Newcastle disease virus (NDV), Pasteurella multocida (5: A), Salmonella enteritidis (No. 50338), and Escherichia coli (O78) were provided by Key Laboratory of Animal Diseases and Human Health of Sichuan Province.Virus and PCR template DNA preparation ::: MethodsTemplate DNA was extracted from the viral and bacterial stock solutions using the High Pure PCR Template Preparation kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions.PCR primer and probe design ::: MethodsThe FQ-PCR assay primers and probe (namely, GPV-F, GPV-R, and CPV-FP) were designed on the basis of the highly conserved VP3 region of GPV (GenBank Accession No.", [["immune organs", "ANATOMY", 74, 87], ["sites", "ANATOMY", 105, 110], ["GPV", "ANATOMY", 114, 117], ["goslings", "ANATOMY", 139, 147], ["Animal Diseases", "DISEASE", 282, 297], ["MethodsAleutian disease", "DISEASE", 378, 401], ["canine parvovirus", "DISEASE", 415, 432], ["porcine parvovirus", "DISEASE", 440, 458], ["Newcastle disease virus", "DISEASE", 467, 490], ["Pasteurella multocida", "DISEASE", 498, 519], ["Salmonella enteritidis", "DISEASE", 528, 550], ["FQ", "CHEMICAL", 982, 984], ["immune organs", "ORGAN", 74, 87], ["GPV", "GENE_OR_GENE_PRODUCT", 114, 117], ["goslings", "CANCER", 139, 147], ["Virus", "ORGANISM", 148, 153], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["GPV", "CANCER", 241, 244], ["Human", "ORGANISM", 302, 307], ["Virus", "ORGANISM", 335, 340], ["DNA", "CELLULAR_COMPONENT", 358, 361], ["MethodsAleutian disease virus", "ORGANISM", 378, 407], ["ADV", "ORGANISM", 409, 412], ["canine parvovirus", "ORGANISM", 415, 432], ["CPV", "ORGANISM", 434, 437], ["porcine parvovirus", "ORGANISM", 440, 458], ["(PPV)", "ORGANISM", 460, 465], ["Newcastle disease virus", "ORGANISM", 467, 490], ["NDV", "ORGANISM", 492, 495], ["Pasteurella multocida", "ORGANISM", 498, 519], ["5: A", "ORGANISM", 521, 525], ["Salmonella enteritidis", "ORGANISM", 528, 550], ["No. 50338", "ORGANISM", 552, 561], ["Escherichia coli", "ORGANISM", 568, 584], ["Human", "ORGANISM", 646, 651], ["Virus", "ORGANISM", 679, 684], ["DNA", "CELLULAR_COMPONENT", 702, 705], ["DNA", "CELLULAR_COMPONENT", 738, 741], ["GPV-F", "GENE_OR_GENE_PRODUCT", 1022, 1027], ["GPV-R", "GENE_OR_GENE_PRODUCT", 1029, 1034], ["CPV-FP", "GENE_OR_GENE_PRODUCT", 1040, 1046], ["GPV", "GENE_OR_GENE_PRODUCT", 1113, 1116], ["MethodsTemplate DNA", "DNA", 722, 741], ["PCR primer", "DNA", 939, 949], ["FQ-PCR assay primers", "DNA", 982, 1002], ["GPV", "DNA", 1022, 1025], ["F", "DNA", 1026, 1027], ["GPV", "DNA", 1029, 1032], ["R", "DNA", 1033, 1034], ["CPV", "DNA", 1040, 1043], ["FP", "DNA", 1044, 1046], ["VP3 region", "DNA", 1099, 1109], ["GPV", "DNA", 1113, 1116], ["Human", "SPECIES", 302, 307], ["MethodsAleutian disease virus", "SPECIES", 378, 407], ["canine parvovirus", "SPECIES", 415, 432], ["porcine parvovirus", "SPECIES", 440, 458], ["Newcastle disease virus", "SPECIES", 467, 490], ["NDV", "SPECIES", 492, 495], ["Pasteurella multocida", "SPECIES", 498, 519], ["Salmonella enteritidis", "SPECIES", 528, 550], ["Escherichia coli", "SPECIES", 568, 584], ["Human", "SPECIES", 646, 651], ["CHV", "SPECIES", 202, 205], ["GPV", "SPECIES", 241, 244], ["MethodsAleutian disease virus", "SPECIES", 378, 407], ["ADV", "SPECIES", 409, 412], ["canine parvovirus", "SPECIES", 415, 432], ["CPV", "SPECIES", 434, 437], ["porcine parvovirus", "SPECIES", 440, 458], ["Newcastle disease virus", "SPECIES", 467, 490], ["NDV", "SPECIES", 492, 495], ["Pasteurella multocida", "SPECIES", 498, 519], ["Salmonella enteritidis (No. 50338)", "SPECIES", 528, 562], ["Escherichia coli", "SPECIES", 568, 584], ["the immune organs", "PROBLEM", 70, 87], ["GPV invasion", "PROBLEM", 114, 126], ["Virus", "PROBLEM", 148, 153], ["MethodsGPV CHV strain", "PROBLEM", 191, 212], ["a high-virulence strain of GPV", "PROBLEM", 214, 244], ["Virus", "PROBLEM", 335, 340], ["MethodsAleutian disease virus", "PROBLEM", 378, 407], ["canine parvovirus (CPV", "PROBLEM", 415, 437], ["porcine parvovirus", "PROBLEM", 440, 458], ["Newcastle disease virus (NDV)", "PROBLEM", 467, 496], ["Pasteurella multocida", "PROBLEM", 498, 519], ["Salmonella enteritidis", "PROBLEM", 528, 550], ["Escherichia coli", "PROBLEM", 568, 584], ["Virus", "PROBLEM", 679, 684], ["MethodsTemplate DNA", "TREATMENT", 722, 741], ["the viral and bacterial stock solutions", "TREATMENT", 761, 800], ["the High Pure PCR", "TREATMENT", 807, 824], ["PCR primer", "TEST", 939, 949], ["Methods", "TREATMENT", 971, 978], ["The FQ-PCR assay primers", "TEST", 978, 1002], ["GPV", "TEST", 1022, 1025], ["GPV", "TEST", 1029, 1032], ["GPV", "OBSERVATION_MODIFIER", 114, 117], ["invasion", "OBSERVATION", 118, 126], ["infected goslings", "OBSERVATION", 130, 147], ["Escherichia coli", "OBSERVATION", 568, 584], ["bacterial stock", "OBSERVATION", 775, 790], ["VP3", "OBSERVATION", 1099, 1102]]], ["U25749).", [["U25749", "CHEMICAL", 0, 6], ["U25749", "CHEMICAL", 0, 6]]], ["The position and sequence of the primers and probe are shown in Table 2.", [["the primers", "TEST", 29, 40]]], ["The product size was 60 bp.", [["The product size", "TEST", 0, 16], ["bp", "TEST", 24, 26], ["size", "OBSERVATION_MODIFIER", 12, 16]]], ["The fluorogenic probe was labeled at the 5' position with 6-carboxyfluorescein (FAM) dye as a reporter and at the 3' position with tetra-methylcarboxyrhodamine (TAMRA) as a quencher and with Minor Groove Binder (MGB\u2122).PCR primer and probe design ::: MethodsThe sequences of the forward and reverse primers used for the conventional PCR were as described by Huang et al., and this primer pair yielded a 441-bp amplicon [12].PCR primer and probe design ::: MethodsAll the probes and primers were synthesized by TakaRa Biotech Co., Ltd.", [["6-carboxyfluorescein", "CHEMICAL", 58, 78], ["FAM", "CHEMICAL", 80, 83], ["tetra-methylcarboxyrhodamine", "CHEMICAL", 131, 159], ["TAMRA", "CHEMICAL", 161, 166], ["6-carboxyfluorescein", "CHEMICAL", 58, 78], ["FAM", "CHEMICAL", 80, 83], ["tetra-methylcarboxyrhodamine", "CHEMICAL", 131, 159], ["TAMRA", "CHEMICAL", 161, 166], ["6-carboxyfluorescein", "SIMPLE_CHEMICAL", 58, 78], ["FAM) dye", "SIMPLE_CHEMICAL", 80, 88], ["tetra-methylcarboxyrhodamine", "SIMPLE_CHEMICAL", 131, 159], ["TAMRA", "SIMPLE_CHEMICAL", 161, 166], ["Ltd", "GENE_OR_GENE_PRODUCT", 529, 532], ["PCR primer", "DNA", 218, 228], ["forward and reverse primers", "DNA", 278, 305], ["primer pair", "DNA", 380, 391], ["PCR primer", "DNA", 423, 433], ["The fluorogenic probe", "TREATMENT", 0, 21], ["6-carboxyfluorescein (FAM) dye", "TREATMENT", 58, 88], ["tetra-methylcarboxyrhodamine (TAMRA)", "TREATMENT", 131, 167], ["a quencher and with Minor Groove Binder", "TREATMENT", 171, 210], ["PCR primer", "TEST", 218, 228], ["Methods", "TREATMENT", 250, 257], ["reverse primers", "TREATMENT", 290, 305], ["the conventional PCR", "TEST", 315, 335], ["bp amplicon", "TREATMENT", 406, 417], ["PCR primer", "TEST", 423, 433], ["Methods", "TREATMENT", 455, 462]]], ["(Dalian, China) and purified by the corresponding high-performance liquid chromatography (HPLC) system.Preparation of standard plasmid DNA templates ::: MethodsThe recombinant plasmid DNA (namely, pVP3) and primer constructs (namely, VP3-1 and VP3-2) were designed to amplify an expected 1658-bp PCR product that included positions 3,008-4,665 bp of GPV (GenBank Accession No.", [["plasmid", "ANATOMY", 127, 134], ["plasmid", "ANATOMY", 176, 183], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["pVP3", "GENE_OR_GENE_PRODUCT", 197, 201], ["VP3-1", "GENE_OR_GENE_PRODUCT", 234, 239], ["VP3-2", "GENE_OR_GENE_PRODUCT", 244, 249], ["plasmid DNA templates", "DNA", 127, 148], ["recombinant plasmid DNA", "DNA", 164, 187], ["pVP3", "DNA", 197, 201], ["primer constructs", "DNA", 207, 224], ["VP3", "DNA", 234, 237], ["VP3", "DNA", 244, 247], ["GPV", "DNA", 350, 353], ["Methods", "TREATMENT", 153, 160], ["The recombinant plasmid DNA", "PROBLEM", 160, 187], ["pVP3", "TEST", 197, 201], ["primer constructs", "TEST", 207, 224], ["VP3", "TEST", 234, 237], ["VP3", "TEST", 244, 247], ["bp PCR product", "TREATMENT", 293, 307], ["positions", "TEST", 322, 331], ["bp", "TEST", 344, 346], ["plasmid DNA", "OBSERVATION", 176, 187]]], ["U25749) (Table 2).", [["U25749", "CHEMICAL", 0, 6], ["U25749", "CHEMICAL", 0, 6]]], ["The product was ligated into the pGM-T vector (Tiangen Corp., Beijing, China) and transformed into E. coli DH5\u03b1 competent cells [27].", [["cells", "ANATOMY", 122, 127], ["cells", "CELL", 122, 127], ["pGM", "PROTEIN", 33, 36], ["E. coli DH5\u03b1 competent cells", "CELL_LINE", 99, 127], ["E. coli", "SPECIES", 99, 106], ["E. coli", "SPECIES", 99, 106]]], ["The pVP3 was extracted using the TIANprep plasmid extraction kit (Tiangen Corp., Beijing, China).", [["pVP3", "GENE_OR_GENE_PRODUCT", 4, 8], ["pVP3", "DNA", 4, 8], ["the TIANprep plasmid extraction", "TREATMENT", 29, 60]]], ["The pVP3 DNA concentration was determined by measuring the absorbance at 260 nm using a Smartspec 3000 spectrophotometer (Bio-Rad Corp., Hercules, CA), and the purity was confirmed using the 260/280 nm ratio.", [["pVP3", "GENE_OR_GENE_PRODUCT", 4, 8], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["pVP3", "PROTEIN", 4, 8], ["The pVP3 DNA concentration", "TEST", 0, 26], ["a Smartspec 3000 spectrophotometer", "TREATMENT", 86, 120], ["the purity", "TEST", 156, 166]]], ["On the basis of the molecular weight, we calculated the pVP3 copy number using the equations described by Ke [29].Development and optimization of FQ-PCR ::: MethodsThe FQ-PCR was performed using the ABI AmpliTaq Gold DNA polymerase system with an icycler IQ Real-time PCR Detection System (Bio-Rad Corp., Hercules, CA) according to the manufacturer's instructions.", [["FQ", "CHEMICAL", 146, 148], ["FQ", "CHEMICAL", 168, 170], ["FQ", "SIMPLE_CHEMICAL", 146, 148], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["pVP3", "PROTEIN", 56, 60], ["FQ-PCR", "TEST", 146, 152], ["Methods", "TREATMENT", 157, 164], ["The FQ-PCR", "TEST", 164, 174], ["the ABI", "TEST", 195, 202], ["Bio", "TEST", 290, 293]]], ["The reaction, data acquisition, and analysis were performed using iCycler IQ optical system software.", [["data acquisition", "TEST", 14, 30], ["analysis", "TEST", 36, 44]]], ["The FQ-PCR was performed in a 25-\u03bcL reaction mixture containing 1\u00d7 PCR buffer, 0.3 mmol/L dNTPs, 1.25 U Taq, and 1 \u03bcL DNA template according to the manufacturer's instructions.", [["FQ", "CHEMICAL", 4, 6], ["dNTPs", "CHEMICAL", 90, 95], ["dNTPs", "CHEMICAL", 90, 95], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["The FQ-PCR", "TEST", 0, 10], ["a 25-\u03bcL reaction mixture", "TREATMENT", 28, 52], ["PCR buffer", "TEST", 67, 77], ["dNTPs", "TREATMENT", 90, 95], ["U Taq", "TEST", 102, 107], ["1 \u03bcL DNA template", "TREATMENT", 113, 130]]], ["Autoclaved nanopure water was added to make the final volume to 25 \u03bcL.", [["Autoclaved nanopure water", "TREATMENT", 0, 25]]], ["Each run comprised an initial activation step of 30 s at 95\u00b0C, followed by 40 cycles of denaturation at 94\u00b0C for 10 s and annealing at 60\u00b0C for 30 s; the fluorescence was measured at the end of the annealing/extension step.", [["denaturation", "TREATMENT", 88, 100], ["the fluorescence", "TEST", 150, 166], ["the annealing/extension step", "TREATMENT", 194, 222]]], ["The tests were performed using 0.2-mL PCR tubes (ABgene, UK).", [["The tests", "TEST", 0, 9]]], ["FQ-PCR reactions were optimized in triplicate based on the primer, probe, and MgCl2 concentration selection criteria, which was performed according to 4 \u00d7 4 \u00d7 4 matrix of primer concentrations (0.10, 0.12, 0.16, and 0.20 \u03bcmol/L), probe concentrations (0.10, 0.12, 0.16, and 0.20 \u03bcmol/L), and MgCl2 concentrations (1.0, 5.0, 10.0, and 15.0 mmol/L).", [["FQ", "CHEMICAL", 0, 2], ["MgCl2", "CHEMICAL", 78, 83], ["MgCl2", "CHEMICAL", 292, 297], ["MgCl2", "CHEMICAL", 78, 83], ["MgCl2", "CHEMICAL", 292, 297], ["MgCl2", "SIMPLE_CHEMICAL", 78, 83], ["MgCl2", "SIMPLE_CHEMICAL", 292, 297], ["FQ-PCR reactions", "TEST", 0, 16], ["probe concentrations", "TEST", 230, 250], ["MgCl2 concentrations", "TEST", 292, 312]]], ["Conditions were selected to ensure that both the fluorescence acquisition curves were robust and Ct values were the lowest possible to the known template DNA concentrations.Development and optimization of FQ-PCR ::: MethodsAn internal positive control was introduced into the FQ-PCR assay to verify that DNA was not lost during the extraction step and PCR inhibitors were absent in the DNA templates as described by Guo et al. [27].Establishment of the FQ-PCR standard curve ::: MethodsThe FQ-PCR standard curve was generated by successive dilutions of pVP3 with known copy numbers.", [["FQ", "CHEMICAL", 490, 492], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["DNA", "CELLULAR_COMPONENT", 304, 307], ["DNA", "CELLULAR_COMPONENT", 386, 389], ["pVP3", "GENE_OR_GENE_PRODUCT", 553, 557], ["DNA templates", "DNA", 386, 399], ["pVP3", "PROTEIN", 553, 557], ["the fluorescence acquisition curves", "TEST", 45, 80], ["Ct values", "TEST", 97, 106], ["the known template DNA concentrations", "PROBLEM", 135, 172], ["MethodsAn internal positive control", "TREATMENT", 216, 251], ["the FQ-PCR assay", "TEST", 272, 288], ["DNA", "PROBLEM", 304, 307], ["the extraction step", "TEST", 328, 347], ["PCR inhibitors", "TREATMENT", 352, 366], ["the DNA templates", "PROBLEM", 382, 399], ["Methods", "TREATMENT", 479, 486], ["The FQ-PCR standard curve", "TEST", 486, 511], ["successive dilutions of pVP3", "TREATMENT", 529, 557], ["DNA concentrations", "OBSERVATION", 154, 172], ["positive control", "OBSERVATION", 235, 251]]], ["The purified pVP3 plasmid DNA was serially diluted 10-fold in TE buffer, pH 8.0, from 2.8 \u00d7 108 to 2.8 \u00d7 104 plasmid copies/\u03bcL.", [["pVP3", "GENE_OR_GENE_PRODUCT", 13, 17], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["purified pVP3 plasmid DNA", "DNA", 4, 29], ["The purified pVP3 plasmid DNA", "TREATMENT", 0, 29], ["pH", "TEST", 73, 75], ["plasmid copies", "TEST", 109, 123]]], ["These dilutions were tested in triplicate and used as quantification standards to construct the standard curve by plotting the plasmid copy number logarithm against the measured Ct values.", [["These dilutions", "TEST", 0, 15], ["the measured Ct values", "TEST", 165, 187]]], ["The Bio-Rad iCycler IQ detection software was used to generate the standard curve and to calculate the correlation coefficient (R2) of the standard curve and the standard deviations of the triplicate samples.FQ-PCR sensitivity, specificity, reproducibility, and dynamic range analysis ::: MethodsThe sensitivities of the conventional PCR and FQ-PCR were each determined using triplicates of different concentrations of the recombinant plasmid pVP3.", [["plasmid", "ANATOMY", 435, 442], ["FQ", "CHEMICAL", 208, 210], ["FQ", "CHEMICAL", 342, 344], ["pVP3", "GENE_OR_GENE_PRODUCT", 443, 447], ["recombinant plasmid pVP3", "DNA", 423, 447], ["the standard curve", "TEST", 63, 81], ["the standard curve", "TEST", 135, 153], ["the triplicate samples", "TEST", 185, 207], ["FQ-PCR sensitivity", "TEST", 208, 226], ["specificity", "TEST", 228, 239], ["reproducibility", "TEST", 241, 256], ["Methods", "TREATMENT", 289, 296], ["the conventional PCR", "TEST", 317, 337], ["FQ-PCR", "TEST", 342, 348], ["the recombinant plasmid pVP3", "TREATMENT", 419, 447]]], ["Template DNA was prepared as follows: plasmids of pVP3 were serially diluted 10-fold from 2.8 \u00d7 106 copies/\u03bcL to 2.8 \u00d7 100 copies/\u03bcL using sterile ultra pure water.", [["plasmids", "ANATOMY", 38, 46], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["pVP3", "GENE_OR_GENE_PRODUCT", 50, 54], ["Template DNA", "DNA", 0, 12], ["pVP3", "DNA", 50, 54], ["plasmids of pVP3", "TREATMENT", 38, 54], ["sterile ultra pure water", "TREATMENT", 139, 163]]], ["From each dilution, 1 \u03bcL was used as a template and subjected to the conventional PCR and FQ-PCR protocol.", [["FQ", "CHEMICAL", 90, 92], ["the conventional PCR", "TEST", 65, 85], ["FQ-PCR protocol", "TEST", 90, 105]]], ["The detection limit of the conventional PCR was determined based on the highest dilution that resulted in the presence of clear and distinct amplified fragments (441 bp) on the agarose gel.", [["fragments", "ANATOMY", 151, 160], ["agarose", "SIMPLE_CHEMICAL", 177, 184], ["amplified fragments", "DNA", 141, 160], ["the conventional PCR", "TEST", 23, 43], ["the highest dilution", "TEST", 68, 88], ["clear and distinct amplified fragments", "PROBLEM", 122, 160], ["bp", "TEST", 166, 168], ["the agarose gel", "TREATMENT", 173, 188], ["clear", "OBSERVATION", 122, 127], ["distinct", "OBSERVATION_MODIFIER", 132, 140], ["amplified", "OBSERVATION_MODIFIER", 141, 150], ["fragments", "OBSERVATION_MODIFIER", 151, 160]]], ["The detection limit of the FQ-PCR was determined based on the highest dilution that resulted in the presence of Ct value in real-time PCR detection.FQ-PCR sensitivity, specificity, reproducibility, and dynamic range analysis ::: MethodsDNA from pVP3, GPV-CHv and several other pathogens, including ADV, CPV, PPV, NDV, Pasteurella multocida (5: A), Salmonella enteritidis (No. 50338), and Escherichia coli (O78) (kindly provided by Key Laboratory of Animal Diseases and Human Health of Sichuan Province) were used as templates in the triplicate analyses to confirm the specificity of the technique.FQ-PCR sensitivity, specificity, reproducibility, and dynamic range analysis ::: MethodsWithin-run and between-run reproducibilities of the FQ-PCR assay were assessed by multiple measurements of pVP3 samples of different concentrations.", [["pVP3 samples", "ANATOMY", 792, 804], ["FQ", "CHEMICAL", 27, 29], ["FQ", "CHEMICAL", 148, 150], ["Salmonella enteritidis", "DISEASE", 348, 370], ["FQ", "CHEMICAL", 597, 599], ["FQ", "CHEMICAL", 737, 739], ["pVP3", "GENE_OR_GENE_PRODUCT", 245, 249], ["GPV-CHv", "GENE_OR_GENE_PRODUCT", 251, 258], ["ADV", "ORGANISM", 298, 301], ["CPV", "ORGANISM", 303, 306], ["PPV", "GENE_OR_GENE_PRODUCT", 308, 311], ["NDV", "ORGANISM", 313, 316], ["Pasteurella multocida", "ORGANISM", 318, 339], ["5: A", "ORGANISM", 341, 345], ["Salmonella enteritidis", "ORGANISM", 348, 370], ["No. 50338", "ORGANISM", 372, 381], ["Escherichia coli", "ORGANISM", 388, 404], ["Human", "ORGANISM", 469, 474], ["GPV", "PROTEIN", 251, 254], ["NDV", "SPECIES", 313, 316], ["Pasteurella multocida", "SPECIES", 318, 339], ["Salmonella enteritidis", "SPECIES", 348, 370], ["Escherichia coli", "SPECIES", 388, 404], ["Human", "SPECIES", 469, 474], ["ADV", "SPECIES", 298, 301], ["CPV", "SPECIES", 303, 306], ["NDV", "SPECIES", 313, 316], ["Pasteurella multocida", "SPECIES", 318, 339], ["Salmonella enteritidis (No. 50338)", "SPECIES", 348, 382], ["Escherichia coli", "SPECIES", 388, 404], ["the FQ-PCR", "TEST", 23, 33], ["Ct value", "TEST", 112, 120], ["PCR detection", "TEST", 134, 147], ["FQ-PCR sensitivity", "TEST", 148, 166], ["specificity", "TEST", 168, 179], ["reproducibility", "TEST", 181, 196], ["pVP3", "TEST", 245, 249], ["GPV", "PROBLEM", 251, 254], ["CHv", "PROBLEM", 255, 258], ["several other pathogens", "PROBLEM", 263, 286], ["ADV", "TREATMENT", 298, 301], ["CPV", "PROBLEM", 303, 306], ["PPV", "PROBLEM", 308, 311], ["NDV", "PROBLEM", 313, 316], ["Pasteurella multocida", "PROBLEM", 318, 339], ["Salmonella enteritidis", "PROBLEM", 348, 370], ["Escherichia coli", "PROBLEM", 388, 404], ["Sichuan Province)", "TREATMENT", 485, 502], ["the triplicate analyses", "TEST", 529, 552], ["FQ-PCR sensitivity", "TEST", 597, 615], ["specificity", "TEST", 617, 628], ["reproducibility", "TEST", 630, 645], ["the FQ-PCR assay", "TEST", 733, 749], ["different concentrations", "PROBLEM", 808, 832], ["NDV", "ANATOMY", 313, 316], ["Escherichia coli", "OBSERVATION", 388, 404]]], ["The assay was conducted by assessing the agreement between the replicates in five replicates (within-run precision) and in five separate experiments (between-run precision) of the serially diluted pVP3 plasmid samples through transforming the raw data to their common logarithms and performing analysis of the mean coefficient of variation (CV) values of each pVP3 standard dilution [27].FQ-PCR sensitivity, specificity, reproducibility, and dynamic range analysis ::: MethodsDilutions of pVP3 plasmid were used to determine the dynamic ranges of the FQ-PCR assay.", [["samples", "ANATOMY", 210, 217], ["FQ", "CHEMICAL", 388, 390], ["FQ", "CHEMICAL", 551, 553], ["pVP3", "GENE_OR_GENE_PRODUCT", 489, 493], ["pVP3 plasmid", "DNA", 489, 501], ["The assay", "TEST", 0, 9], ["the serially diluted pVP3 plasmid samples", "TREATMENT", 176, 217], ["performing analysis", "TEST", 283, 302], ["FQ-PCR sensitivity", "TEST", 388, 406], ["specificity", "TEST", 408, 419], ["reproducibility", "TEST", 421, 436], ["pVP3 plasmid", "TREATMENT", 489, 501]]], ["The lower and upper limits of quantification were defined by the pVP3 recombinant standard plasmid sample concentrations possessing reasonable precision [27].Goslings and tissue preparation ::: MethodsGPV-free goslings (10-day-old) that were certificated with qualitative PCR as described by Huang [12] were obtained from the breeding facility of the Institute of Poultry Sciences in Sichuan Agricultural University, China.", [["sample", "ANATOMY", 99, 105], ["tissue", "ANATOMY", 171, 177], ["tissue", "TISSUE", 171, 177], ["pVP3", "PROTEIN", 65, 69], ["the pVP3 recombinant standard plasmid sample concentrations", "TREATMENT", 61, 120], ["qualitative PCR", "TEST", 260, 275], ["lower", "ANATOMY_MODIFIER", 4, 9], ["upper limits", "OBSERVATION_MODIFIER", 14, 26], ["free", "OBSERVATION_MODIFIER", 205, 209]]], ["Animals were bred and maintained in an accredited facility at the Institute of Poultry Sciences in Sichuan Agricultural University (Sichuan, China), and the experiments conducted during this study conform to the principles outlined by the Animal Welfare Act and the National Institutes of Health guidelines for the care and use of animals in biomedical research.Goslings and tissue preparation ::: MethodsFifty goslings were randomly divided into 2 groups.", [["tissue", "ANATOMY", 375, 381], ["Animals", "ORGANISM", 0, 7], ["tissue", "TISSUE", 375, 381], ["this study", "TEST", 186, 196], ["MethodsFifty goslings", "TREATMENT", 398, 419]]], ["In brief, a group of 40 goslings were orally infected with GPV CHV strain, using 0.1 mL of 103 LD50 per gosling.", [["GPV", "SPECIES", 59, 62], ["CHV", "SPECIES", 63, 66], ["GPV CHV strain", "TREATMENT", 59, 73]]], ["Another group of 10 goslings was treated with an equal volume of physiologic saline and used as a control [20].Goslings and tissue preparation ::: MethodsThree goslings from the infected group and 1 gosling from the control group were killed at each time point.", [["goslings", "ANATOMY", 20, 28], ["tissue", "ANATOMY", 124, 130], ["saline", "SIMPLE_CHEMICAL", 77, 83], ["tissue", "TISSUE", 124, 130], ["an equal volume of physiologic saline", "TREATMENT", 46, 83], ["Methods", "TREATMENT", 147, 154], ["the infected group", "TREATMENT", 174, 192], ["infected", "OBSERVATION", 178, 186]]], ["Blood, heart, liver, spleen, lung, kidney, BF, thymus, esophagus, trachea, brain, Harder's glands, duodenum, jejunum, ileum, cecum, and rectum were analyzed by the real-time PCR at different postinoculation (PI) time points, at 30 min; 1, 2, 4, 8, 12, and 24 h; and 2, 3, 6, and 9 days.", [["Blood", "ANATOMY", 0, 5], ["heart", "ANATOMY", 7, 12], ["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 21, 27], ["lung", "ANATOMY", 29, 33], ["kidney", "ANATOMY", 35, 41], ["BF", "ANATOMY", 43, 45], ["thymus", "ANATOMY", 47, 53], ["esophagus", "ANATOMY", 55, 64], ["trachea", "ANATOMY", 66, 73], ["brain", "ANATOMY", 75, 80], ["Harder's glands", "ANATOMY", 82, 97], ["duodenum", "ANATOMY", 99, 107], ["jejunum", "ANATOMY", 109, 116], ["ileum", "ANATOMY", 118, 123], ["cecum", "ANATOMY", 125, 130], ["rectum", "ANATOMY", 136, 142], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["heart", "ORGAN", 7, 12], ["liver", "ORGAN", 14, 19], ["spleen", "ORGAN", 21, 27], ["lung", "ORGAN", 29, 33], ["kidney", "ORGAN", 35, 41], ["BF", "MULTI-TISSUE_STRUCTURE", 43, 45], ["thymus", "ORGAN", 47, 53], ["esophagus", "ORGAN", 55, 64], ["trachea", "MULTI-TISSUE_STRUCTURE", 66, 73], ["brain", "ORGAN", 75, 80], ["glands", "ORGAN", 91, 97], ["duodenum", "MULTI-TISSUE_STRUCTURE", 99, 107], ["jejunum", "MULTI-TISSUE_STRUCTURE", 109, 116], ["ileum", "MULTI-TISSUE_STRUCTURE", 118, 123], ["cecum", "MULTI-TISSUE_STRUCTURE", 125, 130], ["rectum", "ORGAN", 136, 142], ["Blood", "TEST", 0, 5], [", heart, liver, spleen, lung, kidney, BF, thymus, esophagus, trachea, brain, Harder's glands, duodenum, jejunum, ileum, cecum, and rectum", "PROBLEM", 5, 142], ["heart", "ANATOMY", 7, 12], ["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 21, 27], ["lung", "ANATOMY", 29, 33], ["kidney", "ANATOMY", 35, 41], ["BF", "ANATOMY_MODIFIER", 43, 45], ["thymus", "ANATOMY", 47, 53], ["esophagus", "ANATOMY", 55, 64], ["trachea", "ANATOMY", 66, 73], ["brain", "ANATOMY", 75, 80], ["glands", "ANATOMY", 91, 97], ["duodenum", "ANATOMY", 99, 107], ["jejunum", "ANATOMY", 109, 116], ["ileum", "ANATOMY", 118, 123], ["cecum", "ANATOMY", 125, 130], ["rectum", "ANATOMY", 136, 142]]], ["Tissues were surgically removed from the goslings and frozen at -80\u00b0C, weighed, and homogenized using an Omni PCR Tissue Homogenizer (Omni).", [["Tissues", "ANATOMY", 0, 7], ["goslings", "ANATOMY", 41, 49], ["Tissues", "CANCER", 0, 7], ["an Omni PCR Tissue Homogenizer", "TREATMENT", 102, 132], ["surgically", "OBSERVATION", 13, 23]]], ["Normal tissue sample sizes were 20 mg.", [["tissue sample", "ANATOMY", 7, 20], ["tissue", "TISSUE", 7, 13], ["tissue", "OBSERVATION_MODIFIER", 7, 13], ["sample", "OBSERVATION_MODIFIER", 14, 20], ["sizes", "OBSERVATION_MODIFIER", 21, 26]]], ["For the assays, tissue samples were homogenized in 1 mL of phosphate buffered saline (PBS, pH 7.4).", [["tissue samples", "ANATOMY", 16, 30], ["phosphate buffered", "CHEMICAL", 59, 77], ["phosphate", "CHEMICAL", 59, 68], ["tissue samples", "CANCER", 16, 30], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 59, 84], ["the assays", "TEST", 4, 14], ["tissue samples", "TEST", 16, 30], ["phosphate buffered saline (PBS", "TREATMENT", 59, 89], ["pH", "TEST", 91, 93]]], ["The homogenizer was washed multiple times between each tissue homogenization.", [["tissue", "ANATOMY", 55, 61], ["tissue", "TISSUE", 55, 61], ["The homogenizer", "TREATMENT", 0, 15], ["each tissue homogenization", "TREATMENT", 50, 76]]], ["DNA was extracted from the tissue samples by using the method described by Cheng [30].", [["tissue samples", "ANATOMY", 27, 41], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["tissue samples", "TISSUE", 27, 41], ["DNA", "PROBLEM", 0, 3]]], ["Using this assay, we could quantify the viral load.", [["this assay", "TEST", 6, 16], ["the viral load", "PROBLEM", 36, 50], ["viral load", "OBSERVATION", 40, 50]]], ["All the samples were analyzed 3 times.", [["samples", "ANATOMY", 8, 15], ["All the samples", "TEST", 0, 15]]], ["The viral concentrations were expressed as the mean log10 virus genome copy numbers per g or 1 mL of the tested tissue or blood.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsJY carried out most of the experiments and wrote the manuscript.", [["tissue", "ANATOMY", 112, 118], ["blood", "ANATOMY", 122, 127], ["tissue", "TISSUE", 112, 118], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["The viral concentrations", "PROBLEM", 0, 24], ["viral concentrations", "OBSERVATION", 4, 24]]], ["KP, ML, YG, CL, DZ and XC helped with the experiment.", [["KP", "CHEMICAL", 0, 2], ["DZ", "CHEMICAL", 16, 18], ["CL", "OBSERVATION", 12, 14], ["DZ", "OBSERVATION", 16, 18]]]], "0658bc0061c055a74a99dd98d458dbd087b58fc4": [["IntroductionThe COVID-19 epidemic is a major threat to both public health and global economy.", [["The COVID", "TEST", 12, 21]]], ["To minimize death toll and economic loss, countries worldwide have assumed various strategies (not always officially declared).", [["death", "DISEASE", 12, 17], ["death", "PROBLEM", 12, 17], ["economic loss", "PROBLEM", 27, 40]]], ["Two main strategies to counteract the epidemic spread are eradication and suppression.", [["the epidemic spread", "PROBLEM", 34, 53], ["main", "OBSERVATION_MODIFIER", 4, 8], ["epidemic", "OBSERVATION_MODIFIER", 38, 46], ["spread", "OBSERVATION_MODIFIER", 47, 53]]], ["Countries such as China, South Korea, Japan, Taiwan, New Zealand, Australia, and others, decided to fully eradicate the disease on their territories and then limit and control incoming travelers.", [["the disease", "PROBLEM", 116, 127], ["disease", "OBSERVATION", 120, 127]]], ["Geographic isolation helps to implement such strategy.", [["Geographic isolation", "TREATMENT", 0, 20], ["such strategy", "TREATMENT", 40, 53]]], ["Most European countries have chosen the suppression strategy that aims to limit the exponential growth of the outbreak and then reduce daily new cases to a small number.", [["the suppression strategy", "TREATMENT", 36, 60], ["small", "OBSERVATION_MODIFIER", 156, 161]]], ["Both the eradication and the suppression strategy are founded on the expectation that a vaccine will be developed in near future, and that massive vaccination will ultimately enable governments to lift imposed restrictions.", [["the suppression strategy", "TREATMENT", 25, 49], ["a vaccine", "TREATMENT", 86, 95], ["massive vaccination", "TREATMENT", 139, 158], ["eradication", "OBSERVATION", 9, 20]]], ["A third strategy, in which it is anticipated that, on the contrary, no effective vaccine will be available soon and thus long-term containment is not realistic, is to rely on mitigation and ultimately acquisition of herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 216, 220], ["effective vaccine", "TREATMENT", 71, 88], ["long-term containment", "TREATMENT", 121, 142]]], ["This strategy had been initially declared in the UK but was promptly abandoned due to a rapid increase in the death toll and the threat of overwhelming the health system.IntroductionIn the conceptual framework of mathematical models of infectious diseases, any policy that aims at reducing transmission of the virus seeks to decrease the effective reproduction number R(t) (sometimes denoted R t ), which within S(E)IR-type epidemic models [1] is equal to the ratio of the contact rate\u02dbof the infectious and susceptible individuals and removal rate \u201a of the infectious individuals, R =\u02db/\u201a.", [["death", "DISEASE", 110, 115], ["infectious diseases", "DISEASE", 236, 255], ["a rapid increase", "PROBLEM", 86, 102], ["the death", "PROBLEM", 106, 115], ["infectious diseases", "PROBLEM", 236, 255], ["the virus", "PROBLEM", 306, 315], ["susceptible individuals", "PROBLEM", 508, 531], ["removal rate", "TEST", 536, 548], ["the infectious individuals", "PROBLEM", 554, 580], ["rapid", "OBSERVATION_MODIFIER", 88, 93], ["increase", "OBSERVATION_MODIFIER", 94, 102], ["infectious", "OBSERVATION", 236, 246], ["infectious", "OBSERVATION", 493, 503], ["infectious", "OBSERVATION", 558, 568]]], ["In terms of policy-making, the contact rate\u02dbcan be reduced by prohibition of mass gatherings that increase the risk of super-spreading events, social distancing, and hygienic precautions, which decrease the risk that a given contact is infectious, and by quarantine in which the individuals are forced to stay home or at least significantly limit their out-of-home activity.", [["mass gatherings", "PROBLEM", 77, 92], ["hygienic precautions", "TREATMENT", 166, 186], ["infectious", "PROBLEM", 236, 246], ["mass", "OBSERVATION", 77, 81]]], ["The removal rate \u201a can be increased by enhanced testing and contact tracing, which both enable prompt isolation of (potentially) infectious individuals.", [["The removal rate", "TREATMENT", 0, 16], ["enhanced testing", "TEST", 39, 55], ["contact tracing", "TEST", 60, 75], ["infectious individuals", "PROBLEM", 129, 151]]], ["While a nation-wide quarantine (lockdown) is an effective mean of reducing\u02db (and R) and saving lives, it hampers economic activity and may thus incur a significant loss of country GDP, in addition to psychological and social costs.", [["GDP", "CHEMICAL", 180, 183], ["GDP", "SIMPLE_CHEMICAL", 180, 183], ["a significant loss of country GDP", "PROBLEM", 150, 183]]], ["In individual countries the policy-making is thus intuitively understood as a balancing act between health and fiscal risks of the pandemic.Introduction2 .", [["the pandemic", "PROBLEM", 127, 139]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprintIntroductionWe show that when the strategies of multiple countries are juxtaposed, there is effectively no trade-off between the death toll and the economic toll.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 484, 489], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 339, 346], ["med", "ANATOMY", 105, 108]]], ["As the cumulative deaths per capita and cumulative lockdown are the two quantities that have to be jointly minimized, we constructed Pareto fronts that help to evaluate the European suppression and Australasian eradication policies and, as such, provide a reference for the assessment of policies applied in the United States and other countries of the Americas.", [["deaths", "DISEASE", 18, 24], ["Australasian eradication policies", "TREATMENT", 198, 231], ["the assessment", "TEST", 270, 284]]], ["We show that there is a strong correlation between cumulative deaths per capita and cumulative lockdown, and interpret this result by dissecting the impact of testing and nation-wide quarantine on the effective reproduction number.ResultsSeverity of national lockdowns can be inferred from data on the reduction of mobility gathered in Google COVID-19 Community Mobility Reports [2] .", [["deaths", "DISEASE", 62, 68], ["testing", "TEST", 159, 166]]], ["We expect that the relative reduction of mobility in locations belonging to two categories-workplaces and places related to retail and recreation-is strongly associated with economic slowdown.", [["economic slowdown", "PROBLEM", 174, 191], ["reduction", "OBSERVATION_MODIFIER", 28, 37], ["mobility", "OBSERVATION_MODIFIER", 41, 49], ["slowdown", "OBSERVATION", 183, 191]]], ["We thus assume that the cumulative average mobility reduction in these two categories serves as a good indicator of the impact the epidemic has on economy.", [["the cumulative average mobility reduction", "TREATMENT", 20, 61], ["cumulative", "OBSERVATION_MODIFIER", 24, 34], ["average", "OBSERVATION_MODIFIER", 35, 42], ["mobility", "OBSERVATION_MODIFIER", 43, 51], ["reduction", "OBSERVATION_MODIFIER", 52, 61]]], ["In Fig. 1 we plotted national trajectories of cumulative mobility reduction vs. deaths per million inhabitants (the latter on the logarithmic scale) for Western, Central, and South European countries that have populations of at least four million.", [["deaths", "DISEASE", 80, 86], ["cumulative mobility reduction", "TREATMENT", 46, 75]]], ["These countries nearly unanimously adopted the suppression strategy.", [["the suppression strategy", "TREATMENT", 43, 67]]], ["We also marked present-day data points for several Australasian countries that adopted the eradication strategy.ResultsThe current Pareto-optimal front (darkest gray dotted line) is spanned by Slovakia, Bulgaria, and three Scandinavian countries: Norway, Denmark, and Sweden.", [["the eradication strategy", "TREATMENT", 87, 111], ["marked", "OBSERVATION_MODIFIER", 8, 14]]], ["The countries that have the smallest number of reported deaths per capita are two non-Western European countries, Slovakia (5/million) and Bulgaria (26/million).", [["deaths", "DISEASE", 56, 62], ["smallest", "OBSERVATION_MODIFIER", 28, 36]]], ["The Scandinavian countries have higher death tolls (ranging from 45/million for Norway to 483/million for Sweden) but lower cumulative lockdown.", [["death", "DISEASE", 39, 44], ["higher death", "PROBLEM", 32, 44], ["lower cumulative lockdown", "PROBLEM", 118, 143]]], ["Since we consider cumulative values, over time the Pareto-optimal front moves away from the origin of the coordinate system (in Fig. 1 , adjacent dotted gray lines indicate front positions in two-week intervals) and countries forming the front may change.", [["gray lines", "CELL", 153, 163], ["1 , adjacent dotted gray lines", "CELL_LINE", 133, 163], ["cumulative values", "TEST", 18, 35], ["adjacent dotted gray lines", "TREATMENT", 137, 163], ["origin", "ANATOMY_MODIFIER", 92, 98], ["gray lines", "OBSERVATION", 153, 163], ["front", "OBSERVATION_MODIFIER", 173, 178], ["positions", "OBSERVATION_MODIFIER", 179, 188]]], ["The five Australasian countries that adopted the eradication strategy have small death tolls not exceed-3 .", [["death", "DISEASE", 81, 86], ["the eradication strategy", "TREATMENT", 45, 69], ["small death", "PROBLEM", 75, 86], ["small", "OBSERVATION_MODIFIER", 75, 80], ["death", "OBSERVATION", 81, 86]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)ResultsThe copyright holder for this preprint this version posted June 29, 2020. . which means that they have simultaneously a high death toll and a high cumulative lockdown.4.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 334, 339], ["ND", "PROBLEM", 9, 11], ["a high death toll", "PROBLEM", 327, 344], ["a high cumulative lockdown", "TREATMENT", 349, 375], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint model we used to estimate R [3] ) is calculated from the number of daily new registered cases as explained in Methods.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint model", "TREATMENT", 602, 624], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 381, 384]]], ["In the initial phase, characterized by a high R value and no mobility reduction, R decreases due to suppression of super-spreading events and social distancing.", [["a high R value", "PROBLEM", 39, 53], ["mobility reduction", "PROBLEM", 61, 79], ["super-spreading events", "PROBLEM", 115, 137], ["no", "UNCERTAINTY", 58, 60], ["mobility", "OBSERVATION_MODIFIER", 61, 69], ["reduction", "OBSERVATION_MODIFIER", 70, 79]]], ["In the next phase, R drops below 1 due to the reduction of mobility, which leads to a decrease of the contact rate\u02db.", [["the reduction of mobility", "PROBLEM", 42, 67], ["mobility", "OBSERVATION", 59, 67], ["decrease", "OBSERVATION_MODIFIER", 86, 94]]], ["When analyzing individual trajectories plotted in Fig. 2 we may notice that in the second phase the number of tests per case (indicated by line width and color intensity) remains constant or decreases (possibly due to saturation of the capacity of facilities that perform tests), suggesting that in this phase the removal rate \u201a remains constant or decreases.", [["color intensity", "TEST", 154, 169], ["tests", "TEST", 272, 277], ["the removal rate", "TREATMENT", 310, 326], ["decreases", "OBSERVATION_MODIFIER", 349, 358]]], ["This confirms that the reduction of mobility, and thus\u02db, was instrumental in bringing R below 1.", [["reduction", "OBSERVATION_MODIFIER", 23, 32], ["mobility", "OBSERVATION_MODIFIER", 36, 44]]], ["We think that this latter scaling is more adequate as it reflects the idea of contact tracing, when the individuals that had contact with an infected individual undergo testing.", [["this latter scaling", "PROBLEM", 14, 33], ["contact tracing", "TEST", 78, 93]]], ["The bigger is the tested cluster of individuals, the higher is the probability that majority of the secondary infectious will be identified and \"removed\".", [["the secondary infectious", "PROBLEM", 96, 120], ["bigger", "OBSERVATION_MODIFIER", 4, 10], ["cluster", "OBSERVATION_MODIFIER", 25, 32], ["higher", "OBSERVATION_MODIFIER", 53, 59], ["secondary", "OBSERVATION_MODIFIER", 100, 109], ["infectious", "OBSERVATION", 110, 120]]], ["Therefore we assume that \u201a grows monotonically with the number of 'tests per case'.", [["'tests", "TEST", 66, 72]]], ["Another measure related to 'tests per case' and \u201a is the ratio of the delayed daily new cases to daily new deaths.", [["deaths", "DISEASE", 107, 113], ["'tests", "TEST", 27, 33]]], ["A large number of 'cases per death' indicates that a large fraction of infected individuals have been identified (and isolated), and thus implies large \u201a.(which was not certified by peer review)6 .", [["death", "DISEASE", 29, 34], ["individuals", "ORGANISM", 80, 91], ["a large fraction of infected individuals", "PROBLEM", 51, 91], ["large", "OBSERVATION_MODIFIER", 2, 7], ["large", "OBSERVATION_MODIFIER", 53, 58], ["fraction", "OBSERVATION_MODIFIER", 59, 67], ["infected", "OBSERVATION", 71, 79], ["large", "OBSERVATION_MODIFIER", 146, 151]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint(which was not certified by peer review)In the third phase, while the mobility is increasing, R is smaller than 1 and remains nearly constant, suggesting that the inevitable growth of\u02dbis compensated by a proportionate growth of \u201a.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the inevitable growth of\u02dbis", "PROBLEM", 542, 569], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["third phase", "OBSERVATION_MODIFIER", 430, 441], ["mobility", "OBSERVATION", 453, 461], ["increasing", "OBSERVATION_MODIFIER", 465, 475], ["smaller", "OBSERVATION_MODIFIER", 482, 489], ["constant", "OBSERVATION", 516, 524], ["proportionate", "OBSERVATION_MODIFIER", 587, 600], ["growth", "OBSERVATION_MODIFIER", 601, 607]]], ["Indeed, when R is kept below 1, there is epidemic regression, during which the number of daily new cases is steadily decreasing, which leads to an increase of the average number of tests per case as can be seen for nearly all countries in Fig. 2 .", [["epidemic regression", "PROBLEM", 41, 60], ["epidemic", "OBSERVATION_MODIFIER", 41, 49], ["regression", "OBSERVATION", 50, 60], ["steadily", "OBSERVATION_MODIFIER", 108, 116], ["decreasing", "OBSERVATION_MODIFIER", 117, 127], ["increase", "OBSERVATION_MODIFIER", 147, 155]]], ["As a consequence, a given value of mobility reduction (and, thus, of\u02db) corresponds to two values of R: higher than 1 in the second phase (when \u201a is low) and lower than 1 in the third phase (when \u201a is high).(which was not certified by peer review)An essentially similar three-phase dynamics can be seen also when R is calculated from the number of daily registered deaths (not cases; see Methods).", [["deaths", "DISEASE", 364, 370], ["mobility reduction", "PROBLEM", 35, 53], ["essentially", "OBSERVATION_MODIFIER", 249, 260], ["similar", "OBSERVATION_MODIFIER", 261, 268], ["three-phase", "OBSERVATION_MODIFIER", 269, 280]]], ["In Supplementary Figure S1 we show that the number of the delayed cases per death is higher in the third than in the second phase, indicating that a larger fraction of cases is detected in the epidemic regression phase.(which was not certified by peer review)Considered countries that introduced restrictions when the number of daily cases was relatively small were able to perform a higher number of tests per case and thus achieved higher \u201a.", [["death", "DISEASE", 76, 81], ["higher", "OBSERVATION_MODIFIER", 85, 91], ["larger", "OBSERVATION_MODIFIER", 149, 155], ["fraction", "OBSERVATION_MODIFIER", 156, 164]]], ["This explains a positive correlation between the death toll and cumulative lockdown (visible in Fig. 1 ), implying that, when the epidemic eradication or suppression is the objective, there is no trade-off between public health and economic loss.(which was not certified by peer review)Up-to-date analysis shows that in most European countries the lockdown, even when introduced with some delay, allowed to bring R below 1 and proved to be an effective strategy to suppress the spread of the epidemic.", [["death", "DISEASE", 49, 54], ["the epidemic eradication", "PROBLEM", 126, 150], ["economic loss", "PROBLEM", 232, 245], ["an effective strategy", "TREATMENT", 440, 461], ["no", "UNCERTAINTY", 193, 195], ["economic loss", "OBSERVATION", 232, 245]]], ["However, when larger Latin American countries and the most populated states of USA are considered, the current picture is different.", [["different", "OBSERVATION_MODIFIER", 122, 131]]], ["As shown in This may be attributed to a considerable difference in the number of tests per case with respect to European countries.", [["considerable", "OBSERVATION_MODIFIER", 40, 52], ["difference", "OBSERVATION", 53, 63]]], ["Much less extensive (and sometimes even dwindling) testing coverage leads to smaller \u201a, which at comparable mobility reduction yields larger R. Due to economic and societal pressures, many Latin American countries are currently perilously decreasing mobility restrictions while having R > 1.(which was not certified by peer review)Among the considered American countries, Peru, Ecuador, and Bolivia achieved the highest cumulative lockdowns (see Fig. 5 ).", [["testing coverage", "TREATMENT", 51, 67], ["economic and societal pressures", "TREATMENT", 151, 182], ["Bolivia", "TREATMENT", 391, 398], ["less", "OBSERVATION_MODIFIER", 5, 9], ["extensive", "OBSERVATION_MODIFIER", 10, 19], ["pressures", "OBSERVATION_MODIFIER", 173, 182]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. the number of tests per case in this country is currently very low, it is possible that a potential increase in the number of new cases is unreported and thus the current R estimate should be considered with caution.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["potential", "OBSERVATION_MODIFIER", 365, 374], ["increase", "OBSERVATION_MODIFIER", 375, 383], ["new", "OBSERVATION_MODIFIER", 401, 404]]], ["Trajectories presented in Fig. 4 suggest that the administrative suppression strategy may fail at least in some Latin American countries.(which was not certified by peer review)In the United States, only in the New York State and in Illinois-that are among top 10 most populated states and were most severely affected by the epidemic-current R remains below 1.", [["the administrative suppression strategy", "TREATMENT", 46, 85], ["Fig", "OBSERVATION_MODIFIER", 26, 29]]], ["In the remaining eight states, R \u2265 1, while mobility restrictions are gradually lifted (Fig. 4) .(which was not certified by peer review)As the number of daily new cases is increasing, improved testing efficient and reduction of R by increasing \u201a becomes difficult.", [["increasing", "OBSERVATION_MODIFIER", 173, 183]]], ["Trajectories of American countries and states of the USA plotted in the cumulative deaths vs. cumulative lockdown plane (see Fig. 5 ) indicate that the most devastating may be the changing of the strategy.", [["deaths", "DISEASE", 83, 89]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . and states are above the European Pareto optimal-front, and, additionally having R \u2265 1, are moving fast along the cumulative deaths axis.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 402, 408], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["However, since the outbreak of the epidemic in the Americas has been delayed with respect to Europe, it is too early to evaluate strategies or scenarios in these countries.DiscussionConstruction of Pareto fronts allowed us to select countries that up to a given time point minimized the number of fatalities and economic cost more effectively than others.", [["fatalities", "DISEASE", 297, 307], ["epidemic", "OBSERVATION_MODIFIER", 35, 43]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint and Bulgaria (with coordinates of Poland and Czechia lying nearby), and three Scandinavian countries: Norway, Denmark and Sweden.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Without some additional criteria weighting the number of deaths and the severity of lockdown one may not compare countries on a Pareto front.", [["deaths", "DISEASE", 57, 63]]], ["Countries forming this front or lying close to it encountered first a lot of deaths due to the delayed lockdown decision and then had a long and strict lockdown that was introduced to stop the spread of the epidemic.(which was not certified by peer review)We showed that when the number of daily new cases exceeds some threshold, the further epidemic growth can be suppressed only by strict quarantine.", [["deaths", "DISEASE", 77, 83], ["a long and strict lockdown", "TREATMENT", 134, 160]]], ["In the growth phase, the number of tests per case decreases, implying reduction of the removal rate \u201a.", [["the removal rate", "TREATMENT", 83, 99], ["growth phase", "OBSERVATION_MODIFIER", 7, 19], ["reduction", "OBSERVATION_MODIFIER", 70, 79]]], ["This in turn implies that the reproduction number R =\u02db/\u201a is decreased only due to quarantine that reduced the contact rate\u02db.", [["decreased", "OBSERVATION", 60, 69]]], ["Only after the imposed quarantine reduced R below 1 can the epidemic be further suppressed by the increased efficiency of testing (number of test per case), increasing the removal rate \u201a.", [["testing", "TEST", 122, 129], ["increasing the removal rate", "TREATMENT", 157, 184]]], ["The increase of \u201a allows for curbing the number of daily new cases (and resulting deaths) at gradual relaxation of lockdown measures.(which was not certified by peer review)Our analysis shows that in Latin American countries that perform a relatively small number of tests and thus have small removal rate \u201a, reduction of the contact rate\u02dbthrough national quarantine turned out to be insufficient to reduce R below 1.", [["deaths", "DISEASE", 82, 88], ["gradual relaxation of lockdown measures", "TREATMENT", 93, 132], ["Our analysis", "TEST", 173, 185], ["tests", "TEST", 267, 272], ["small removal rate", "TREATMENT", 287, 305], ["the contact rate\u02dbthrough national quarantine", "TREATMENT", 322, 366], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["small", "OBSERVATION_MODIFIER", 287, 292], ["removal", "OBSERVATION", 293, 300]]], ["In the United States significant suppression of the epidemic seems to be within technological reach, as in all ten most populated states the lockdown had reduced R below 1, however subsequent increase of mobility caused that R returned above 1 in eight of these states.", [["subsequent increase of mobility", "PROBLEM", 181, 212], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["suppression", "OBSERVATION", 33, 44], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["mobility", "OBSERVATION_MODIFIER", 204, 212]]], ["As the number of daily new cases is growing, it becomes increasing difficult to boost the removal rate \u201a by enhanced testing, thus the only option to reduce R below 1 is to restore lockdown (which seems politically unrealistic in the USA).", [["the removal rate", "TREATMENT", 86, 102], ["enhanced testing", "TEST", 108, 124]]], ["In such a case the preceding transient lockdown may be not beneficial as it adds economic cost to the unavoidable death toll.(which was not certified by peer review)Over time, countries may leave and (re)appear on the Pareto front.", [["death", "DISEASE", 114, 119]]], ["The \"velocity\" of a country on the cumulative mobility reduction vs. effective reproduction number (R) plane is given 10 .", [["the cumulative mobility reduction", "TREATMENT", 31, 64], ["velocity", "OBSERVATION_MODIFIER", 5, 13]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint by the number of daily deaths and current mobility reduction.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 366, 372], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 326, 333], ["current mobility reduction", "TREATMENT", 377, 403], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In a bit longer perspective, the countries currently having R > 1 are in the worst situation as their number of daily new cases is still increasing.", [["increasing", "OBSERVATION_MODIFIER", 137, 147]]], ["In a longer time scale, both the cumulated death toll and the country-specific history of lockdown accumulation (lockdown fatigue) should be taken into consideration when predicting plausible further country trajectory as these two factors influence risk avoidance and risk acceptance, respectively.", [["death", "DISEASE", 43, 48], ["fatigue", "DISEASE", 122, 129], ["lockdown accumulation (lockdown fatigue", "PROBLEM", 90, 129]]], ["Countries that managed to prevent a high death toll by early and effective lockdown may find themselves in a psychologically more challenging situation as they will face lockdown fatigue that will not be counterbalanced be the \"cumulated fear\".Data sourcesThe COVID-19 dataset maintained by Our World in Data [4] is used as the source of data on the number of confirmed cases and deaths (original data source being European Centre for Disease Prevention and Control) and the number of tests (collected from national government reports).Data sourcesFor the states of the USA, analogous data were extracted from The COVID Tracking Project [5] .Data sourcesMobility reduction has been taken from the Google COVID-19 Community Mobility Reports [2] .Data sourcesMissing counts of daily new cases and deaths are filled with zeros and missing cumulative counts of cases and deaths are taken from the previous available counts.", [["death", "DISEASE", 41, 46], ["fatigue", "DISEASE", 179, 186], ["deaths", "DISEASE", 380, 386], ["deaths", "DISEASE", 795, 801], ["deaths", "DISEASE", 867, 873], ["COVID-19 dataset", "DNA", 260, 276], ["fatigue", "PROBLEM", 179, 186], ["The COVID", "TREATMENT", 256, 265], ["Disease Prevention", "TREATMENT", 435, 453], ["tests", "TEST", 485, 490], ["analogous data", "TEST", 575, 589]]], ["When the number of tests is not available daily, their number is linearly interpolated between available data points.Data sourcesTo avoid artifacts in analyzed trends that would result from temporally non-uniform reporting, We should notice that the official data on the deaths associated with the COVID-19 epidemic depend on the way of counting (especially, on the inclusion of out-of-hospital deaths) and may be underestimated, especially in the most affected countries.", [["deaths", "DISEASE", 271, 277], ["deaths", "DISEASE", 395, 401], ["tests", "TEST", 19, 24], ["artifacts", "PROBLEM", 138, 147], ["the COVID", "TEST", 294, 303], ["may be", "UNCERTAINTY", 407, 413]]], ["The extent of underreporting may be estimated for a given period based on the \"excess deaths\" [6] that appear 11 .", [["deaths", "DISEASE", 86, 92]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint above the expected number of deaths when the officially recorded COVID-19 fatalities are subtracted from the total number of deaths (for example, in Italy, between 24 February and 26 April, there were nearly 43,000 more deaths than would be expected for this period with only about 60% of these deaths attributed to COVID-19 [7] ).(which was not certified by peer review)Testing density is analyzed according to:(which was not certified by peer review), where x i is rolling mean of the respective daily new counts (calculated within a 14-day window with equal weights) and the time span is set to w = 14 days.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 372, 378], ["deaths", "DISEASE", 468, 474], ["deaths", "DISEASE", 563, 569], ["deaths", "DISEASE", 638, 644], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 326, 333], ["COVID", "TEST", 659, 664], ["new counts", "TEST", 847, 857], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["density", "OBSERVATION", 722, 729]]], ["Let us notice that T d is positive when the number of daily cases (or deaths) is increasing, and T d is negative when the number of daily cases is decreasing; when the number of daily cases remains constant in time, then T d = \u221e.", [["deaths", "DISEASE", 70, 76], ["T d", "GENE_OR_GENE_PRODUCT", 19, 22], ["T d", "GENE_OR_GENE_PRODUCT", 97, 100], ["positive", "PROBLEM", 26, 34], ["decreasing", "OBSERVATION_MODIFIER", 147, 157]]], ["The reproduction number R on i-th day was then computed in accordance with Wallinga and Lipsitch [8] and Wearing, Rohani, and Keeling [9] as:(which was not certified by peer review)assuming m = 6, n = 1, ff = 1/(5.28 days), \u201a = 1/(3 days).", [["ff", "TEST", 204, 206]]], ["These parameter values reflect the assumption that the incubation period is Erlang-distributed with the shape parameter 6 and mean of 5.28 days [10] , while the period of infectiousness is distributed exponentially with the mean of 3 days [11] .", [["These parameter values", "TEST", 0, 22], ["infectiousness", "PROBLEM", 171, 185], ["infectiousness", "OBSERVATION", 171, 185], ["distributed", "OBSERVATION_MODIFIER", 189, 200], ["exponentially", "OBSERVATION_MODIFIER", 201, 214]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)12The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint has been assumed in all countries, however, as discussed in the Results section, the period of infectiousness is affected by testing capacity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 329, 336], ["infectiousness", "PROBLEM", 441, 455], ["testing capacity", "TEST", 471, 487], ["med", "ANATOMY", 105, 108], ["infectiousness", "OBSERVATION", 441, 455]]], ["For given m, n, and ff the reproduction number R is a decreasing function of \u201a for T d > 0 and an increasing function of \u201a for T d < 0.", [["T d", "TEST", 83, 86]]], ["For T d = \u221e, we obtain R = 1, regardless of remaining parameters; thus the critical point in which R passes 1 in Fig. 2, Fig. 4 , and Supplementary Figure S1 is independent of the specific values of model parameters.Quantification of mobility reductionTo account for mobility reduction related to the decrease of economic activity, we averaged daily mobility reduction in categories of 'workplaces' and 'retail and recreation' (includes shopping centers and restaurants) on weekdays, excluding days of country-wide holidays in each country.", [["mobility reduction", "TREATMENT", 234, 252], ["mobility reduction", "PROBLEM", 267, 285], ["the decrease of economic activity", "PROBLEM", 297, 330], ["daily mobility reduction", "TREATMENT", 344, 368], ["mobility", "OBSERVATION", 234, 242], ["decrease", "OBSERVATION_MODIFIER", 301, 309]]], ["National epidemic trajectories shown in Fig. 2 are drawn by taking current R(i) (computed based on the daily new cases as described above) and mobility reduction in previous days weighted according to the (time-reversed) distribution of infection-to-removal times, which is the hypoexponential distribution with rates {-, -, -, -, -, -, \u201a} where -= 6ff.", [["infection", "DISEASE", 237, 246], ["{-, -, -, -, -, -, \u201a}", "CHEMICAL", 318, 339], ["National epidemic trajectories", "PROBLEM", 0, 30], ["mobility reduction", "TREATMENT", 143, 161], ["infection", "PROBLEM", 237, 246], ["removal", "TREATMENT", 250, 257], ["rates", "TEST", 312, 317], ["infection", "OBSERVATION", 237, 246]]], ["National epidemic trajectories shown in Supplementary Figure S1 are drawn by taking current R(i) computed based on the daily deaths as described above) and mobility reduction in previous days weighted according to the (time-reversed) distribution of infection-to-death times, which results from the convolution of the incubation time distribution (Erlang with k = 6 and -= 6ff, as previously) and the distribution of the onset-to-death time (log-normal with median of 13.2 days and standard deviation of 0.44, as determined by [12] ; the resulting infection-todeath distribution has the mean of 19.8 days).Quantification of mobility reduction.", [["deaths", "DISEASE", 125, 131], ["infection", "DISEASE", 250, 259], ["death", "DISEASE", 263, 268], ["death", "DISEASE", 430, 435], ["infection", "DISEASE", 548, 557], ["National epidemic trajectories", "PROBLEM", 0, 30], ["mobility reduction", "TREATMENT", 156, 174], ["infection", "PROBLEM", 250, 259], ["k", "TEST", 360, 361], ["the resulting infection-todeath distribution", "PROBLEM", 534, 578], ["mobility reduction", "TREATMENT", 624, 642], ["infection", "OBSERVATION", 250, 259], ["infection", "OBSERVATION", 548, 557], ["mobility reduction", "OBSERVATION", 624, 642]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Quantification of mobility reductionThe copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["mobility reduction", "TREATMENT", 220, 238], ["medRxiv preprint", "TREATMENT", 363, 379], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Quantification of mobility reductionThe copyright holder for this preprint this version posted June 29, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["mobility reduction", "TREATMENT", 220, 238], ["med", "ANATOMY", 105, 108]]], ["Supplementary Figure S1 : Epidemic trajectories of Western, Central, and South European and Australasian countries in the mobility reduction vs. effective reproduction number (R) plane.", [["Australasian countries", "TREATMENT", 92, 114], ["Central", "OBSERVATION_MODIFIER", 60, 67]]], ["In contrast to Fig. 2 and Fig. 4 in the main text, R has been estimated based on the daily number of deaths.", [["deaths", "DISEASE", 101, 107]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)15The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.06.27.20141747 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 105, 108]]]], "eecd6840969537d143fa32fe659fa2911b8a679f": [["to achieve the goals of the Paris Agreement, investigations regarding the impact of trade openness on the decoupling of economic growth and carbon emissions is necessary to develop more effective carbon reduction policies.", [["carbon", "CHEMICAL", 140, 146], ["carbon", "CHEMICAL", 196, 202], ["economic growth", "PROBLEM", 120, 135], ["carbon emissions", "TREATMENT", 140, 156], ["effective carbon reduction policies", "TREATMENT", 186, 221]]]], "68671219e4453cae8ff7209fb84db97c1b12bf13": [["INTRODUCTIONBovine respiratory disease (BRD) complex is the most common and extensively studied cattle disease of all ages, especially feedlot cattle and veal calves.", [["respiratory disease", "DISEASE", 19, 38], ["BRD", "DISEASE", 40, 43], ["cattle", "ORGANISM", 96, 102], ["calves", "ORGANISM_SUBDIVISION", 159, 165], ["cattle", "SPECIES", 96, 102], ["cattle", "SPECIES", 143, 149], ["calves", "SPECIES", 159, 165], ["BRD", "SPECIES", 40, 43], ["cattle", "SPECIES", 96, 102], ["cattle", "SPECIES", 143, 149], ["veal", "SPECIES", 154, 158], ["INTRODUCTIONBovine respiratory disease (BRD) complex", "PROBLEM", 0, 52], ["respiratory disease", "OBSERVATION", 19, 38], ["most common", "OBSERVATION_MODIFIER", 60, 71], ["veal calves", "ANATOMY", 154, 165]]], ["BRD represents the major indication for cattle antimicrobials worldwide, especially for prophylaxis and metaphylaxis.", [["BRD", "DISEASE", 0, 3], ["cattle", "SPECIES", 40, 46], ["BRD", "PROBLEM", 0, 3], ["cattle antimicrobials worldwide", "TREATMENT", 40, 71], ["prophylaxis", "TREATMENT", 88, 99], ["metaphylaxis", "TREATMENT", 104, 116]]], ["Coupled with mortalities, treatment costs, decreased performance and reduced carcass value, BRD leads to major economic losses for cattle feeders (Ives and Richeson 2015) .INTRODUCTIONThe complex of viral, bacterial and/or mycoplasmal infections is described with blanket terms, 'enzootic pneumonia', 'shipping fever' or 'bovine respiratory disease complex', often used without precise definitions.", [["respiratory", "ANATOMY", 329, 340], ["BRD", "DISEASE", 92, 95], ["mycoplasmal infections", "DISEASE", 223, 245], ["pneumonia'", "DISEASE", 289, 299], ["shipping fever", "DISEASE", 302, 316], ["respiratory disease", "DISEASE", 329, 348], ["bovine", "ORGANISM", 322, 328], ["bovine", "SPECIES", 322, 328], ["cattle", "SPECIES", 131, 137], ["treatment costs", "TREATMENT", 26, 41], ["decreased performance", "PROBLEM", 43, 64], ["reduced carcass value", "PROBLEM", 69, 90], ["BRD", "PROBLEM", 92, 95], ["cattle feeders", "TREATMENT", 131, 145], ["viral, bacterial", "PROBLEM", 199, 215], ["mycoplasmal infections", "PROBLEM", 223, 245], ["blanket terms", "TREATMENT", 264, 277], ["'enzootic pneumonia'", "PROBLEM", 279, 299], ["'shipping fever'", "PROBLEM", 301, 317], ["'bovine respiratory disease complex'", "PROBLEM", 321, 357], ["complex", "OBSERVATION_MODIFIER", 188, 195], ["viral", "OBSERVATION", 199, 204], ["bacterial", "OBSERVATION_MODIFIER", 206, 215], ["mycoplasmal", "OBSERVATION_MODIFIER", 223, 234], ["infections", "OBSERVATION", 235, 245], ["enzootic pneumonia'", "OBSERVATION", 280, 299], ["respiratory disease", "OBSERVATION", 329, 348]]], ["Viruses and other stressors predispose cattle to opportunistic bacterial pneumonias, including bovine respiratory syncytial virus, parainfluenzavirus-3, infectious bovine rhinotracheitis virus, bovine herpes virus-1 and possibly bovine coronavirus (O'Neill et al. 2014) .", [["opportunistic bacterial pneumonias", "DISEASE", 49, 83], ["bovine respiratory syncytial virus", "DISEASE", 95, 129], ["bovine rhinotracheitis virus", "DISEASE", 164, 192], ["bovine herpes virus", "DISEASE", 194, 213], ["bovine coronavirus", "DISEASE", 229, 247], ["cattle", "ORGANISM", 39, 45], ["bovine", "ORGANISM", 95, 101], ["respiratory syncytial virus", "ORGANISM", 102, 129], ["parainfluenzavirus-3", "ORGANISM", 131, 151], ["infectious", "ORGANISM", 153, 163], ["bovine rhinotracheitis virus", "ORGANISM", 164, 192], ["bovine", "ORGANISM", 194, 200], ["herpes virus-1", "ORGANISM", 201, 215], ["bovine", "ORGANISM", 229, 235], ["coronavirus", "ORGANISM", 236, 247], ["cattle", "SPECIES", 39, 45], ["bovine", "SPECIES", 95, 101], ["respiratory syncytial virus", "SPECIES", 102, 129], ["bovine", "SPECIES", 164, 170], ["rhinotracheitis virus", "SPECIES", 171, 192], ["bovine", "SPECIES", 194, 200], ["herpes virus-1", "SPECIES", 201, 215], ["bovine", "SPECIES", 229, 235], ["coronavirus", "SPECIES", 236, 247], ["cattle", "SPECIES", 39, 45], ["bovine respiratory syncytial virus", "SPECIES", 95, 129], ["bovine rhinotracheitis virus", "SPECIES", 164, 192], ["bovine herpes virus-1", "SPECIES", 194, 215], ["bovine coronavirus", "SPECIES", 229, 247], ["Viruses", "PROBLEM", 0, 7], ["opportunistic bacterial pneumonias", "PROBLEM", 49, 83], ["bovine respiratory syncytial virus", "PROBLEM", 95, 129], ["parainfluenzavirus", "TEST", 131, 149], ["infectious bovine rhinotracheitis virus", "PROBLEM", 153, 192], ["bovine herpes virus", "PROBLEM", 194, 213], ["bovine coronavirus", "PROBLEM", 229, 247], ["opportunistic", "OBSERVATION_MODIFIER", 49, 62], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["pneumonias", "OBSERVATION", 73, 83], ["respiratory syncytial virus", "OBSERVATION", 102, 129], ["infectious bovine", "OBSERVATION", 153, 170], ["rhinotracheitis virus", "OBSERVATION", 171, 192], ["possibly", "UNCERTAINTY", 220, 228], ["bovine coronavirus", "OBSERVATION", 229, 247]]], ["These viruses trigger BRD by damaging upper respiratory tract mucosa and/or modifying host pro-and anti-inflammatory immune responses.", [["upper respiratory tract mucosa", "ANATOMY", 38, 68], ["BRD", "DISEASE", 22, 25], ["BRD", "ORGANISM", 22, 25], ["upper respiratory", "ORGANISM_SUBDIVISION", 38, 55], ["tract mucosa", "MULTI-TISSUE_STRUCTURE", 56, 68], ["BRD", "SPECIES", 22, 25], ["These viruses trigger BRD", "PROBLEM", 0, 25], ["damaging upper respiratory tract mucosa", "PROBLEM", 29, 68], ["viruses", "OBSERVATION", 6, 13], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61]]], ["Bacterial BRD pathogens include Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Arcanobacterium pyogenes, Mycoplasma dispar and M. bovis that exist commonly as commensals, often as biofilms within the upper respiratory tract and tonsils.INTRODUCTIONClassical BRD field diagnosis are visual signs, including depression, anorexia, nasal and/or ocular discharge, coughing, laboured breathing (Buhman et al. 2000) or a semi-objective four-point clinical illness score (Perino and Apley 1998) .", [["upper respiratory tract", "ANATOMY", 219, 242], ["tonsils", "ANATOMY", 247, 254], ["nasal", "ANATOMY", 347, 352], ["ocular", "ANATOMY", 360, 366], ["Mannheimia haemolytica", "DISEASE", 32, 54], ["Pasteurella multocida", "DISEASE", 56, 77], ["Mycoplasma dispar", "DISEASE", 124, 141], ["depression", "DISEASE", 325, 335], ["anorexia", "DISEASE", 337, 345], ["coughing", "DISEASE", 378, 386], ["Mannheimia haemolytica", "ORGANISM", 32, 54], ["Pasteurella multocida", "ORGANISM", 56, 77], ["Histophilus somni", "ORGANISM", 79, 96], ["Arcanobacterium pyogenes", "ORGANISM", 98, 122], ["Mycoplasma dispar", "ORGANISM", 124, 141], ["M. bovis", "ORGANISM", 146, 154], ["upper", "ORGANISM_SUBDIVISION", 219, 224], ["respiratory tract", "ORGANISM_SUBDIVISION", 225, 242], ["tonsils", "ORGAN", 247, 254], ["nasal", "ORGANISM_SUBDIVISION", 347, 352], ["Mannheimia haemolytica", "SPECIES", 32, 54], ["Pasteurella multocida", "SPECIES", 56, 77], ["Histophilus somni", "SPECIES", 79, 96], ["Arcanobacterium pyogenes", "SPECIES", 98, 122], ["Mycoplasma dispar", "SPECIES", 124, 141], ["M. bovis", "SPECIES", 146, 154], ["Mannheimia haemolytica", "SPECIES", 32, 54], ["Pasteurella multocida", "SPECIES", 56, 77], ["Histophilus somni", "SPECIES", 79, 96], ["Arcanobacterium pyogenes", "SPECIES", 98, 122], ["Mycoplasma dispar", "SPECIES", 124, 141], ["M. bovis", "SPECIES", 146, 154], ["Bacterial BRD pathogens", "PROBLEM", 0, 23], ["Mannheimia haemolytica", "PROBLEM", 32, 54], ["Pasteurella multocida", "PROBLEM", 56, 77], ["Histophilus somni", "PROBLEM", 79, 96], ["Arcanobacterium pyogenes", "PROBLEM", 98, 122], ["Mycoplasma dispar", "PROBLEM", 124, 141], ["M. bovis", "PROBLEM", 146, 154], ["visual signs", "PROBLEM", 301, 313], ["depression", "PROBLEM", 325, 335], ["anorexia", "PROBLEM", 337, 345], ["nasal", "PROBLEM", 347, 352], ["ocular discharge", "PROBLEM", 360, 376], ["coughing", "PROBLEM", 378, 386], ["laboured breathing", "PROBLEM", 388, 406], ["BRD", "OBSERVATION", 10, 13], ["Mannheimia haemolytica", "OBSERVATION", 32, 54], ["Arcanobacterium pyogenes", "OBSERVATION", 98, 122], ["upper", "ANATOMY_MODIFIER", 219, 224], ["respiratory tract", "ANATOMY", 225, 242], ["tonsils", "ANATOMY", 247, 254], ["nasal", "ANATOMY", 347, 352], ["ocular", "ANATOMY", 360, 366]]], ["This is subjective, non-standardised but the typical basis for deciding on further antimicrobials treatments, or combined with rectal temperature, although bovine fever thresholds vary throughout the scientific literature (Ives and Richeson 2015) .", [["rectal", "ANATOMY", 127, 133], ["fever", "DISEASE", 163, 168], ["rectal", "ORGANISM_SUBDIVISION", 127, 133], ["bovine", "ORGANISM", 156, 162], ["bovine", "SPECIES", 156, 162], ["further antimicrobials treatments", "TREATMENT", 75, 108], ["rectal temperature", "PROBLEM", 127, 145], ["bovine fever thresholds", "PROBLEM", 156, 179]]], ["Comparing BRD field diagnostics to pulmonary lesions evident at slaughter reveals several cattle (e.g. >50%) with lung lesions, not previously identified and treated for BRD (Thompson, Stone and Schultheiss 2006; Tennant et al. 2014) .", [["pulmonary lesions", "ANATOMY", 35, 52], ["lung lesions", "ANATOMY", 114, 126], ["pulmonary lesions", "DISEASE", 35, 52], ["lung lesions", "DISEASE", 114, 126], ["BRD", "DISEASE", 170, 173], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 35, 52], ["lung lesions", "CANCER", 114, 126], ["cattle", "SPECIES", 90, 96], ["cattle", "SPECIES", 90, 96], ["BRD", "SPECIES", 170, 173], ["BRD field diagnostics", "TEST", 10, 31], ["pulmonary lesions", "PROBLEM", 35, 52], ["lung lesions", "PROBLEM", 114, 126], ["BRD", "PROBLEM", 170, 173], ["pulmonary", "ANATOMY", 35, 44], ["lesions", "OBSERVATION", 45, 52], ["several", "OBSERVATION_MODIFIER", 82, 89], ["cattle", "OBSERVATION_MODIFIER", 90, 96], ["lung", "ANATOMY", 114, 118], ["lesions", "OBSERVATION", 119, 126], ["Stone", "OBSERVATION", 185, 190]]], ["These limitations contribute largely to the justification for routine antimicrobial prophylaxis/metaphylaxis in place of identifying, pulling and treating sick calves/cattle.", [["calves", "ORGANISM", 160, 166], ["cattle", "ORGANISM", 167, 173], ["calves", "SPECIES", 160, 166], ["cattle", "SPECIES", 167, 173], ["cattle", "SPECIES", 167, 173], ["routine antimicrobial prophylaxis", "TREATMENT", 62, 95], ["metaphylaxis", "TREATMENT", 96, 108]]], ["The culmination of stressors (e.g. recently weaned, auctioned, transported, environmental/nutritional changes, co-mingling, castrated) results in each cohort of feedlot cattle/veal calves expressing the majority of visual BRD cases (up to 90%) within the first 27 days after arrival (Edwards 1996; Buhman et al. 2000) .INTRODUCTIONSoon after the introduction of antimicrobial agents, their growth-promoting effects were discovered in animals (Moore et al. 1946) .", [["visual BRD", "DISEASE", 215, 225], ["cattle", "ORGANISM", 169, 175], ["calves", "ORGANISM", 181, 187], ["cattle", "SPECIES", 169, 175], ["calves", "SPECIES", 181, 187], ["cattle", "SPECIES", 169, 175], ["veal", "SPECIES", 176, 180], ["feedlot cattle/veal calves", "TREATMENT", 161, 187], ["visual BRD cases", "PROBLEM", 215, 231], ["antimicrobial agents", "TREATMENT", 362, 382]]], ["Antimicrobials were approved for growth promotion in the USA since 1949 and since 1953 in the UK (Swann 1969) .", [["Antimicrobials", "TREATMENT", 0, 14]]], ["However, mounting evidence about antimicrobial resistance and transference of resistance genes from animal to human microbiota led to a full withdrawal of antimicrobial growth promoters in the European Union, since 2006 (Regulation 1831 .", [["human", "ORGANISM", 110, 115], ["resistance genes", "DNA", 78, 94], ["antimicrobial growth promoters", "DNA", 155, 185], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["antimicrobial resistance", "PROBLEM", 33, 57], ["resistance genes", "PROBLEM", 78, 94], ["antimicrobial growth promoters", "TREATMENT", 155, 185], ["antimicrobial resistance", "OBSERVATION", 33, 57]]], ["The European support to recommendations of the World Health Organization (WHO), the Food and Agriculture Organization (FAO) and the World Organization or Animal Health for a ban on antimicrobial growth promoters has encouraged other countries to follow (e.g. Canada, USA, South Korea).", [["antimicrobial growth promoters", "DNA", 181, 211], ["antimicrobial growth promoters", "TREATMENT", 181, 211]]], ["Since the ban, then antimicrobial 'mass medications' for the purposes of disease prevention has become the most common use in healthy food animals.", [["antimicrobial 'mass medications", "TREATMENT", 20, 51], ["disease prevention", "TREATMENT", 73, 91]]], ["Different terms describe 'mass medication' concepts in food animals, such as prophylaxis, prevention and metaphylaxis.", [["metaphylaxis", "DISEASE", 105, 117], ["'mass medication", "TREATMENT", 25, 41], ["prophylaxis", "TREATMENT", 77, 88], ["metaphylaxis", "PROBLEM", 105, 117]]], ["Antimicrobial prophylaxis for BRD first appeared in the scientific literature in the 1950s (King et al. 1955) , and metaphylaxis appeared later in the 1980s.", [["BRD", "DISEASE", 30, 33], ["BRD", "SPECIES", 30, 33], ["Antimicrobial prophylaxis", "TREATMENT", 0, 25], ["BRD", "PROBLEM", 30, 33], ["metaphylaxis", "TREATMENT", 116, 128]]], ["Both concepts are believed to still be heavily used, but exact consumption figures for food animal antimicrobial mass medications are largely unknown.INTRODUCTIONVarious definitions describe prophylaxis, prevention and metaphylaxis.", [["metaphylaxis", "DISEASE", 219, 231], ["food animal antimicrobial mass medications", "TREATMENT", 87, 129], ["prophylaxis", "TREATMENT", 191, 202], ["metaphylaxis", "PROBLEM", 219, 231]]], ["Prophylaxis and prevention are defined similarly as the administration of a veterinary medicinal product (VMP) to healthy animals to prevent infection/s based on risk or possible consequences (ECDC/EFSA/EMA 2015; EMA 2016).", [["VMP", "CHEMICAL", 106, 109], ["infection", "DISEASE", 141, 150], ["VMP", "SIMPLE_CHEMICAL", 106, 109], ["Prophylaxis", "TREATMENT", 0, 11], ["prevention", "TREATMENT", 16, 26], ["a veterinary medicinal product (VMP)", "TREATMENT", 74, 110], ["infection/s", "PROBLEM", 141, 152], ["infection", "OBSERVATION", 141, 150]]], ["Typically, the risk is neither clearly defined nor quantified, but common reasons include:INTRODUCTIONI. previous history of herd outbreaks II. traditional herd management practices or attitudes: a. introduction of new animals into groups (e.g. 'welcome shots') b. high stocking densities (i.e. increased 'risk' of disease) c. scheduled events in the production animal cycle (e.g. dry-off cow period, transport) d. stressful events (e.g. weaning, parturition, castration, dehorning) e. diet quality problems or diet changes f. intercurrent disease-e.g. viral or protozoal diseases Originally, 'metaphylaxis' was defined the same as prophylaxis, the difference being that prophylaxis was applied to individuals and metaphylaxis was for whole groups/flocks/herds (Urban-Chmiel and Grooms 2012).", [["intercurrent disease", "DISEASE", 527, 547], ["viral or protozoal diseases", "DISEASE", 553, 580], ["cow", "ORGANISM_SUBDIVISION", 389, 392], ["cow", "SPECIES", 389, 392], ["traditional herd management", "TREATMENT", 144, 171], ["high stocking densities", "PROBLEM", 265, 288], ["disease)", "PROBLEM", 315, 323], ["stressful events", "PROBLEM", 415, 431], ["parturition", "TREATMENT", 447, 458], ["castration", "TREATMENT", 460, 470], ["diet changes", "PROBLEM", 511, 523], ["intercurrent disease", "PROBLEM", 527, 547], ["viral or protozoal diseases", "PROBLEM", 553, 580], ["'metaphylaxis'", "TREATMENT", 593, 607], ["prophylaxis", "TREATMENT", 632, 643], ["prophylaxis", "TREATMENT", 671, 682], ["metaphylaxis", "TREATMENT", 714, 726], ["high stocking", "OBSERVATION_MODIFIER", 265, 278], ["densities", "OBSERVATION", 279, 288], ["protozoal diseases", "OBSERVATION", 562, 580]]], ["Now, others re-define 'metaphylaxis' as mass medication of healthy animals when the disease of interest is present within the group/flock/herd (EMA 2016) .", [["metaphylaxis", "DISEASE", 23, 35], ["mass medication", "TREATMENT", 40, 55]]], ["Others define as, 'Metaphylaxis is indicated for high-risk individuals, when the number of clinical cases within a group reaches a threshold, the remainder of the in-contact animals are treated simultaneously in order to restrict the spread and impact of the disease' (Lees and Shojaee Aliabadi 2002) .", [["animals", "ORGANISM", 174, 181], ["high-risk individuals", "PROBLEM", 49, 70], ["the disease'", "PROBLEM", 255, 267]]], ["According to Edwards (2010) and Smith et al. (2001) , the criterion for antimicrobial metaphylaxis occurs when morbidity (i.e. attack rate) exceeds 10% for two to three consecutive days.", [["metaphylaxis", "DISEASE", 86, 98], ["antimicrobial metaphylaxis", "TREATMENT", 72, 98], ["morbidity", "PROBLEM", 111, 120]]], ["Thus, prophylaxis/prevention and metaphylaxis involves administering antimicrobials to 'healthy' individuals to 'prevent' infections, but for prophylaxis/prevention there is a perceived 'risk', whereas metaphylaxis could be a definable 'hazard'.INTRODUCTIONRoutine antimicrobial prophylaxis/metaphylaxis are uniquely veterinary concepts since equivalent modern examples in human medicine of routine antimicrobial mass medications to healthy individuals would be difficult to specify.", [["infections", "DISEASE", 122, 132], ["metaphylaxis", "DISEASE", 202, 214], ["human", "ORGANISM", 373, 378], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 373, 378], ["prophylaxis", "TREATMENT", 6, 17], ["prevention", "TREATMENT", 18, 28], ["metaphylaxis", "TREATMENT", 33, 45], ["antimicrobials", "TREATMENT", 69, 83], ["' infections", "PROBLEM", 120, 132], ["prophylaxis", "TREATMENT", 142, 153], ["prevention", "TREATMENT", 154, 164], ["INTRODUCTIONRoutine antimicrobial prophylaxis", "TREATMENT", 245, 290], ["metaphylaxis", "TREATMENT", 291, 303], ["human medicine", "TREATMENT", 373, 387], ["routine antimicrobial mass medications", "TREATMENT", 391, 429], ["infections", "OBSERVATION", 122, 132]]], ["Routine prophylaxis/metaphylaxis leads to substantial antimicrobial consumption since 'healthy' individuals will always outnumber sick individuals, in all but exceptional situations.", [["Routine prophylaxis", "TREATMENT", 0, 19], ["metaphylaxis", "TREATMENT", 20, 32]]], ["Many food animal antimicrobial VMP formulations are designed for easy mass medication, for dissemination in either bulk animal feed or common drinking water.", [["VMP", "SIMPLE_CHEMICAL", 31, 34], ["animal antimicrobial VMP formulations", "TREATMENT", 10, 47], ["easy mass medication", "TREATMENT", 65, 85], ["dissemination in either bulk animal feed", "TREATMENT", 91, 131]]], ["Since it is considered 'inconvenient' or impractical to separate diseased from healthy animals, under intensive livestock production conditions, then routine prophylaxis/metaphylaxis is employed commonly, even if unintended.", [["intensive livestock production conditions", "TREATMENT", 102, 143], ["routine prophylaxis/metaphylaxis", "TREATMENT", 150, 182]]], ["For example, assuming antimicrobial VMPs for dissemination in either bulk animal feed or drinking water are preferred for prophylaxis/metaphylaxis (e.g. premixes, oral powders/granules/solutions for drinking water) then European data (29 countries for 2014: overall sales = 9,009.5 tonnes of active ingredient of antimicrobials) reveals just over 90% of antimicrobial sales reported, in mg/PCU (Population correction unit, in 1,000 tonnes : The estimated weight at treatment of livestock and of slaughter animals.), were these VMP formulations (ESVAC 2016).", [["oral", "ANATOMY", 163, 167], ["granules", "ANATOMY", 176, 184], ["VMPs", "CHEMICAL", 36, 40], ["VMPs", "SIMPLE_CHEMICAL", 36, 40], ["oral", "ORGANISM_SUBDIVISION", 163, 167], ["granules", "ORGANISM_SUBSTANCE", 176, 184], ["antimicrobial VMPs", "TREATMENT", 22, 40], ["dissemination", "PROBLEM", 45, 58], ["prophylaxis", "TREATMENT", 122, 133], ["metaphylaxis", "TREATMENT", 134, 146], ["premixes", "TREATMENT", 153, 161], ["oral powders/granules/solutions", "TREATMENT", 163, 194], ["active ingredient of antimicrobials", "TREATMENT", 292, 327], ["The estimated weight at treatment", "TREATMENT", 441, 474]]], ["Furthermore, injectable antimicrobials can also be used for prophylaxis/metaphylaxis in food animals.INTRODUCTIONEvidence-based recommendations for food animal antimicrobial mass medications are sparse but mostly embody the antithesis of prudent use.", [["injectable antimicrobials", "TREATMENT", 13, 38], ["prophylaxis", "TREATMENT", 60, 71], ["metaphylaxis", "TREATMENT", 72, 84], ["food animal antimicrobial mass medications", "TREATMENT", 148, 190]]], ["The need for antimicrobial mass medications is based on beliefs that a group/s of animals (especially newly received, stressed) will contract a major bacterial disease (i.e. morbidity) and/or die (i.e. mortality), resulting in economic and welfare consequences.", [["bacterial disease", "DISEASE", 150, 167], ["antimicrobial mass medications", "TREATMENT", 13, 43], ["a major bacterial disease", "PROBLEM", 142, 167]]], ["Ancillary benefits are better average daily weight gains (i.e. growth promotion) and belief that less antimicrobial treatments are required later in the production cycle (i.e. reduced labour costs).", [["less antimicrobial treatments", "TREATMENT", 97, 126], ["reduced labour costs", "PROBLEM", 176, 196]]], ["Given the growing recognition of the one health agenda that animal and human systems are connected, it is relevant to better understand/question the original scientific evidence for antimicrobial prophylaxis/metaphylaxis in food animals to reduce morbidity and mortality from bacterial diseases.", [["bacterial diseases", "DISEASE", 276, 294], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["antimicrobial prophylaxis", "TREATMENT", 182, 207], ["metaphylaxis", "TREATMENT", 208, 220], ["morbidity", "PROBLEM", 247, 256], ["bacterial diseases", "PROBLEM", 276, 294], ["bacterial diseases", "OBSERVATION", 276, 294]]], ["Beef production (feedlots or veal) is one of the world's largest food animal industries, and thus an appropriate choice for investigating antimicrobial prophylaxis/metaphylaxis.INTRODUCTIONThe objectives were to perform a systematic review and meta-analysis of randomised controlled clinical trials (RCTs) investigating antimicrobial prophylaxis and/or metaphylaxis for preventing naturally occurring BRD.", [["BRD", "DISEASE", 401, 404], ["veal", "ORGANISM_SUBDIVISION", 29, 33], ["veal", "SPECIES", 29, 33], ["BRD", "SPECIES", 401, 404], ["antimicrobial prophylaxis", "TREATMENT", 138, 163], ["metaphylaxis", "TREATMENT", 164, 176], ["a systematic review", "TEST", 220, 239], ["randomised controlled clinical trials (RCTs)", "TREATMENT", 261, 305], ["antimicrobial prophylaxis", "TREATMENT", 320, 345], ["metaphylaxis", "TREATMENT", 353, 365], ["BRD", "PROBLEM", 401, 404]]], ["The primary objective was to assess RCTs investigating BRD antimicrobial prophylaxis/metaphylaxis for their impact on preventing morbidity.", [["BRD", "SPECIES", 55, 58], ["RCTs", "TREATMENT", 36, 40], ["BRD antimicrobial prophylaxis", "TREATMENT", 55, 84], ["metaphylaxis", "TREATMENT", 85, 97], ["morbidity", "PROBLEM", 129, 138]]], ["The secondary objective was to assess RCTs investigating BRD antimicrobial prophylaxis/metaphylaxis for their impact on preventing mortality.", [["BRD", "SPECIES", 57, 60], ["RCTs", "TREATMENT", 38, 42], ["BRD antimicrobial prophylaxis", "TREATMENT", 57, 86], ["metaphylaxis", "TREATMENT", 87, 99]]], ["Other objectives were to assess the characteristics of antimicrobials (e.g. type, route of administration) on preventing BRD morbidity and mortality and compare prophylaxis to metaphylaxis.MATERIALS AND METHODSAn open literature search involved online search engines, including Pub-Med, Google Scholar, Scopus, Web-of-Science, CAB abstracts and VetMed Resource, using the following search terms:MATERIALS AND METHODSAt least one of: cattle, calf, calve, veal, bovine, cow, steer, bull, AND at least one of: antibiotic, antimicrobial, antibacterial, cillin, mycin, cycline, sulpha, floxacin, ceftiofur, tilmicosin, tildipirosin, florfenicol, trimethoprim, tylosin AND at least one of: respiratory, shipping, pneumonia, AND at least one of : prophylaxis, prophylactic, prevent, prevention, preventive, preventative, control, metaphylaxis, metaphylactic Google searches were also performed to find other sources of potential publications.", [["calve", "ANATOMY", 447, 452], ["bull", "ANATOMY", 480, 484], ["BRD", "DISEASE", 121, 124], ["metaphylaxis", "DISEASE", 176, 188], ["cillin, mycin, cycline, sulpha, floxacin", "CHEMICAL", 549, 589], ["ceftiofur", "CHEMICAL", 591, 600], ["tilmicosin", "CHEMICAL", 602, 612], ["tildipirosin", "CHEMICAL", 614, 626], ["florfenicol", "CHEMICAL", 628, 639], ["trimethoprim", "CHEMICAL", 641, 653], ["tylosin", "CHEMICAL", 655, 662], ["pneumonia", "DISEASE", 707, 716], ["cycline", "CHEMICAL", 564, 571], ["floxacin", "CHEMICAL", 581, 589], ["ceftiofur", "CHEMICAL", 591, 600], ["tilmicosin", "CHEMICAL", 602, 612], ["tildipirosin", "CHEMICAL", 614, 626], ["florfenicol", "CHEMICAL", 628, 639], ["trimethoprim", "CHEMICAL", 641, 653], ["tylosin", "CHEMICAL", 655, 662], ["cattle", "ORGANISM", 433, 439], ["calf", "ORGANISM_SUBDIVISION", 441, 445], ["veal", "ORGANISM_SUBDIVISION", 454, 458], ["bovine", "ORGANISM", 460, 466], ["cow", "ORGANISM_SUBDIVISION", 468, 471], ["bull", "ORGANISM_SUBDIVISION", 480, 484], ["cillin", "SIMPLE_CHEMICAL", 549, 555], ["mycin", "SIMPLE_CHEMICAL", 557, 562], ["cycline", "SIMPLE_CHEMICAL", 564, 571], ["sulpha", "SIMPLE_CHEMICAL", 573, 579], ["floxacin", "SIMPLE_CHEMICAL", 581, 589], ["ceftiofur", "SIMPLE_CHEMICAL", 591, 600], ["tilmicosin", "SIMPLE_CHEMICAL", 602, 612], ["tildipirosin", "SIMPLE_CHEMICAL", 614, 626], ["florfenicol", "SIMPLE_CHEMICAL", 628, 639], ["trimethoprim", "SIMPLE_CHEMICAL", 641, 653], ["tylosin", "SIMPLE_CHEMICAL", 655, 662], ["cattle", "SPECIES", 433, 439], ["calf", "SPECIES", 441, 445], ["bovine", "SPECIES", 460, 466], ["cow", "SPECIES", 468, 471], ["BRD", "SPECIES", 121, 124], ["cattle", "SPECIES", 433, 439], ["veal", "SPECIES", 454, 458], ["bovine", "SPECIES", 460, 466], ["cow", "SPECIES", 468, 471], ["antimicrobials", "TREATMENT", 55, 69], ["BRD morbidity", "PROBLEM", 121, 134], ["metaphylaxis", "TREATMENT", 176, 188], ["antibiotic", "TREATMENT", 507, 517], ["antimicrobial", "TREATMENT", 519, 532], ["antibacterial", "TREATMENT", 534, 547], ["cillin", "TREATMENT", 549, 555], ["mycin", "TREATMENT", 557, 562], ["cycline", "TREATMENT", 564, 571], ["sulpha", "TREATMENT", 573, 579], ["floxacin", "TREATMENT", 581, 589], ["ceftiofur", "TREATMENT", 591, 600], ["tilmicosin", "TREATMENT", 602, 612], ["tildipirosin", "TREATMENT", 614, 626], ["florfenicol", "TREATMENT", 628, 639], ["trimethoprim", "TREATMENT", 641, 653], ["tylosin", "TREATMENT", 655, 662], ["pneumonia", "PROBLEM", 707, 716], ["prophylaxis", "TREATMENT", 740, 751], ["prophylactic", "TREATMENT", 753, 765], ["metaphylaxis", "TREATMENT", 823, 835], ["Med", "ANATOMY", 282, 285], ["calf", "ANATOMY", 441, 445], ["calve", "ANATOMY", 447, 452], ["veal", "ANATOMY", 454, 458], ["respiratory", "ANATOMY", 684, 695], ["pneumonia", "OBSERVATION", 707, 716], ["prophylaxis", "OBSERVATION", 740, 751], ["publications", "OBSERVATION", 922, 934]]], ["Prophylaxis and prevention were defined as the same type of mass medication.MATERIALS AND METHODSInclusion criteria for the publications were as follows:MATERIALS AND METHODSI.", [["Prophylaxis", "TREATMENT", 0, 11], ["prevention", "TREATMENT", 16, 26], ["mass medication", "TREATMENT", 60, 75], ["mass", "OBSERVATION", 60, 64]]], ["Clinical trial involving visually healthy cattle comparing an antimicrobial prophylaxis/metaphylaxis group against a negative control group for naturally occurring BRD.", [["metaphylaxis", "CHEMICAL", 88, 100], ["BRD", "DISEASE", 164, 167], ["cattle", "ORGANISM", 42, 48], ["cattle", "SPECIES", 42, 48], ["cattle", "SPECIES", 42, 48], ["visually healthy cattle", "TREATMENT", 25, 48], ["an antimicrobial prophylaxis", "TREATMENT", 59, 87], ["metaphylaxis group", "TREATMENT", 88, 106], ["BRD", "PROBLEM", 164, 167]]], ["II.", [["II", "CHEMICAL", 0, 2]]], ["No antimicrobials administered to cattle immediately prior to transport or start of the trial.", [["cattle", "SPECIES", 34, 40], ["cattle", "SPECIES", 34, 40], ["antimicrobials", "TREATMENT", 3, 17]]], ["Explanation of the establishment of the negative control group (e.g. group of cattle either not treated or given a placebo).", [["cattle", "ORGANISM", 78, 84], ["cattle", "SPECIES", 78, 84], ["cattle", "SPECIES", 78, 84], ["a placebo)", "TREATMENT", 113, 123]]], ["IV.", [["IV", "TREATMENT", 0, 2]]], ["No antimicrobials given to healthy individuals in the negative control group during the course of the clinical trial.", [["antimicrobials", "TREATMENT", 3, 17], ["the clinical trial", "TREATMENT", 98, 116], ["antimicrobials", "OBSERVATION", 3, 17]]], ["V. Criteria (definition) for either prophylactic or metaphylactic medications.", [["prophylactic", "TREATMENT", 36, 48], ["metaphylactic medications", "TREATMENT", 52, 77]]], ["Prophylaxis was defined as group medication of asymptomatic cattle upon 'arrival' at the test facility.", [["cattle", "SPECIES", 60, 66], ["cattle", "SPECIES", 60, 66], ["Prophylaxis", "TREATMENT", 0, 11]]], ["Too few publications were identified as defining prophylaxis as group medication 'prior' to transport of cattle, and thus excluded from this investigation.", [["cattle", "ORGANISM", 105, 111], ["cattle", "SPECIES", 105, 111], ["cattle", "SPECIES", 105, 111], ["group medication", "TREATMENT", 64, 80], ["this investigation", "TEST", 136, 154], ["few", "OBSERVATION_MODIFIER", 4, 7], ["publications", "OBSERVATION", 8, 20]]], ["Definitions for metaphylaxis varied between publications, including:MATERIALS AND METHODSa. group medication of asymptomatic cattle upon arrival at the test facility. b. group medication of cattle with pyrexia and no other symptoms. c. group medication of cattle in contact with clinical BRD cattle. d. group medication of cattle when the BRD morbidity within the group \u226510%.MATERIALS AND METHODSPublications defining metaphylaxis as group medication of asymptomatic cattle upon arrival were re-defined as prophylaxis to be consistent with the other prophylaxis RCTs.", [["metaphylaxis", "DISEASE", 16, 28], ["pyrexia", "DISEASE", 202, 209], ["BRD", "DISEASE", 339, 342], ["metaphylaxis", "DISEASE", 418, 430], ["cattle", "ORGANISM", 125, 131], ["cattle", "ORGANISM", 190, 196], ["cattle", "ORGANISM", 256, 262], ["cattle", "ORGANISM", 323, 329], ["cattle", "ORGANISM", 467, 473], ["cattle", "SPECIES", 125, 131], ["cattle", "SPECIES", 190, 196], ["cattle", "SPECIES", 256, 262], ["cattle", "SPECIES", 292, 298], ["cattle", "SPECIES", 323, 329], ["cattle", "SPECIES", 467, 473], ["cattle", "SPECIES", 125, 131], ["cattle", "SPECIES", 190, 196], ["cattle", "SPECIES", 256, 262], ["BRD cattle", "SPECIES", 288, 298], ["cattle", "SPECIES", 323, 329], ["cattle", "SPECIES", 467, 473], ["metaphylaxis", "PROBLEM", 16, 28], ["pyrexia", "PROBLEM", 202, 209], ["other symptoms", "PROBLEM", 217, 231], ["cattle", "TREATMENT", 323, 329], ["the BRD morbidity", "PROBLEM", 335, 352], ["METHODSPublications", "TREATMENT", 389, 408], ["metaphylaxis", "TREATMENT", 418, 430], ["asymptomatic cattle", "PROBLEM", 454, 473], ["prophylaxis", "TREATMENT", 506, 517], ["the other prophylaxis RCTs", "TREATMENT", 540, 566]]], ["All other definitions were accepted as metaphylaxis.MATERIALS AND METHODSVI.", [["metaphylaxis", "DISEASE", 39, 51], ["metaphylaxis", "TREATMENT", 39, 51]]], ["Specification of randomisation in the study design.", [["the study", "TEST", 34, 43]]], ["Randomisation was accepted if individuals were randomised to groups or pens of cattle were randomly chosen (i.e. random-block design).", [["cattle", "ORGANISM", 79, 85], ["cattle", "SPECIES", 79, 85], ["cattle", "SPECIES", 79, 85]]], ["According to Perino and Apley (1998) , every-other-calf or odd-and-even number schemes as cattle arrived and processed into pens were accepted as randomisation (i.e. systematic randomisation).", [["calf", "ORGANISM", 51, 55], ["cattle", "ORGANISM", 90, 96], ["calf", "SPECIES", 51, 55], ["cattle", "SPECIES", 90, 96], ["cattle", "SPECIES", 90, 96], ["calf", "ANATOMY", 51, 55]]], ["The intent was not to bias cattle allocations but to serve as a practical method under field conditions.", [["cattle", "SPECIES", 27, 33]]], ["Random but unequal allocations were also acceptable if the allocations did not exceed a 2-to-1 ratio.", [["unequal", "OBSERVATION_MODIFIER", 11, 18]]], ["VII.", [["VII", "GENE_OR_GENE_PRODUCT", 0, 3], ["VII", "PROTEIN", 0, 3]]], ["Disclosure of all treatments given during the clinical trial (i.e. type of antimicrobial, dosing regimen, route of administration, other medications).", [["all treatments", "TREATMENT", 14, 28], ["antimicrobial, dosing regimen", "TREATMENT", 75, 104], ["administration", "TREATMENT", 115, 129], ["other medications", "TREATMENT", 131, 148]]], ["VIII.", [["VIII", "GENE_OR_GENE_PRODUCT", 0, 4], ["VIII", "PROTEIN", 0, 4]]], ["Disclosure of relevant results for the primary objective of the study (i.e. total number of cattle in each group, morbidity data, animals excluded).MATERIALS AND METHODSOther potential publications were identified by examining the reference lists of obtained articles.", [["cattle", "SPECIES", 92, 98], ["the study", "TEST", 60, 69], ["morbidity data", "TEST", 114, 128]]], ["If clinical trials were focused on the treatment of clinical BRD cattle and not prophylaxis and/or metaphylaxis of visually healthy cattle.", [["BRD", "DISEASE", 61, 64], ["cattle", "SPECIES", 65, 71], ["cattle", "SPECIES", 132, 138], ["BRD", "SPECIES", 61, 64], ["cattle", "SPECIES", 65, 71], ["cattle", "SPECIES", 132, 138], ["the treatment", "TREATMENT", 35, 48], ["clinical BRD cattle", "TREATMENT", 52, 71], ["prophylaxis", "TREATMENT", 80, 91]]], ["II.", [["II", "CHEMICAL", 0, 2]]], ["If there was no negative control group as part of the study design.", [["the study", "TEST", 50, 59]]], ["If antimicrobials were given to healthy cattle in the negative control group (e.g. premixes) during the course of the clinical trial.", [["cattle", "SPECIES", 40, 46], ["cattle", "SPECIES", 40, 46], ["antimicrobials", "TREATMENT", 3, 17], ["the clinical trial", "TREATMENT", 114, 132]]], ["IV.", [["IV", "TREATMENT", 0, 2]]], ["If the clinical trial involved artificial BRD infections instead of naturally occurring BRD.", [["BRD infections", "DISEASE", 42, 56], ["BRD", "DISEASE", 88, 91], ["BRD", "SPECIES", 42, 45], ["artificial BRD infections", "PROBLEM", 31, 56], ["BRD", "PROBLEM", 88, 91]]], ["V. If randomisation was not described as part of the study design.", [["V", "GENE_OR_GENE_PRODUCT", 0, 1], ["the study", "TEST", 49, 58]]], ["VI.", [["VI", "GENE_OR_GENE_PRODUCT", 0, 2]]], ["If data could not be extracted for the primary objective of the study.", [["the study", "TEST", 60, 69]]], ["VII.", [["VII", "GENE_OR_GENE_PRODUCT", 0, 3], ["VII", "PROTEIN", 0, 3]]], ["If other diseases occurred during the clinical trial and specific BRD morbidity could not be derived from the results.MATERIALS AND METHODSDescriptive and quantitative data were extracted from each RCT described in publications meeting the inclusion criteria.", [["BRD", "DISEASE", 66, 69], ["other diseases", "PROBLEM", 3, 17], ["specific BRD morbidity", "PROBLEM", 57, 79], ["quantitative data", "TEST", 155, 172], ["diseases", "OBSERVATION", 9, 17]]], ["Some publications described the RCTs performed at multiple geographically separate sites; if negative control and treatment groups were reported for each test facility, then separate lines of data were specified.", [["Some publications", "PROBLEM", 0, 17], ["the RCTs", "TEST", 28, 36], ["treatment groups", "TREATMENT", 114, 130]]], ["If accepted RCTs were published in both a peer-reviewed and other types of articles, then only the peer-reviewed article was used.MATERIALS AND METHODSData extracted from each publication included:MATERIALS AND METHODS-Total number of cattle in control and treatment groups.MATERIALS AND METHODS-BRD morbidity after the observation period for control and treatment groups. -BRD mortality after the observation period for control and treatment groups. -Type of production system (e.g. feedlot, veal calf facility, etc.Data analysisAnalysis of the morbidity data was performed with a random effects model (R package 'metafor' 1.9-8) (Viechtbauer 2010) using restricted maximum likelihood as the method for estimation of \u03c4 2 (the true between-study variance).", [["BRD", "DISEASE", 374, 377], ["cattle", "ORGANISM", 235, 241], ["calf", "ORGANISM_SUBDIVISION", 498, 502], ["cattle", "SPECIES", 235, 241], ["calf", "SPECIES", 498, 502], ["cattle", "SPECIES", 235, 241], ["veal", "SPECIES", 493, 497], ["cattle in control and treatment groups", "TREATMENT", 235, 273], ["BRD morbidity", "PROBLEM", 296, 309], ["control and treatment groups", "TREATMENT", 343, 371], ["BRD mortality", "PROBLEM", 374, 387], ["control and treatment groups", "TREATMENT", 421, 449], ["Type of production system", "PROBLEM", 452, 477], ["Data analysis", "TEST", 517, 530], ["the morbidity data", "TEST", 542, 560], ["a random effects model (R package 'metafor'", "TREATMENT", 580, 623], ["calf", "ANATOMY", 498, 502]]], ["Heterogeneity between studies was identified by the I 2 and \u03c4 2 statistics.", [["studies", "TEST", 22, 29]]], ["Due to the heterogeneity between studies, the summary effect measure (in casu relative risk-RR) was calculated using random effect metaanalysis with inverse-variance weights.", [["studies", "TEST", 33, 40], ["RR", "TEST", 92, 94], ["heterogeneity", "OBSERVATION", 11, 24]]], ["Potential factors affecting heterogeneity were analysed with a random effects metaregression.", [["Potential factors affecting heterogeneity", "PROBLEM", 0, 41], ["a random effects metaregression", "PROBLEM", 61, 92]]], ["Separate analysis was performed for morbidity and mortality data, respectively.Data analysisData distribution from the RCTs was assessed with funnel plots (Viechtbauer 2010) .", [["Separate analysis", "TEST", 0, 17], ["morbidity", "PROBLEM", 36, 45], ["mortality data", "TEST", 50, 64], ["the RCTs", "TEST", 115, 123], ["funnel plots", "TEST", 142, 154]]], ["Also, a trim-and-fill analysis (Duval and Tweedie 2000) was performed on the residuals using the trimfill function in metafor to test for funnel plot asymmetry and identify missing studies.", [["the residuals", "TEST", 73, 86], ["funnel plot asymmetry", "TEST", 138, 159], ["missing studies", "TEST", 173, 188]]], ["The analysis assumes funnel plot symmetry and attempts to remove (trimming) smaller studies associated with asymmetry while filling the distribution with missing studies to balance the distribution.Data analysisRCTs morbidity data were further assessed using the number needed to treat (NNT = 1/ARR) and absolute risk reduction (ARR).", [["The analysis", "TEST", 0, 12], ["funnel plot symmetry", "PROBLEM", 21, 41], ["smaller studies", "TEST", 76, 91], ["asymmetry", "PROBLEM", 108, 117], ["missing studies", "TEST", 154, 169], ["Data analysisRCTs morbidity data", "TEST", 198, 230], ["NNT", "TEST", 287, 290], ["absolute risk reduction", "TREATMENT", 304, 327], ["funnel", "OBSERVATION", 21, 27], ["plot symmetry", "OBSERVATION", 28, 41], ["asymmetry", "OBSERVATION", 108, 117]]], ["To calculate the expected relation between the NNT and attack rate (CER), the following expression was used (Fig. 4) :Data analysiswhere CER is the control group event rate, EER is the experimental group event rate and RR is the relative risk estimate.Data analysisMortality data differed from morbidity data in that most studies showed very low mortality rates with several zero-event cells for mortality in the control and/or treatment groups.", [["cells", "ANATOMY", 386, 391], ["cells", "CELL", 386, 391], ["zero-event cells", "CELL_TYPE", 375, 391], ["Data analysisMortality data", "TEST", 252, 279], ["morbidity data", "TEST", 294, 308], ["most studies", "TEST", 317, 329], ["very low mortality rates", "PROBLEM", 337, 361], ["several zero-event cells", "TREATMENT", 367, 391], ["treatment groups", "TREATMENT", 428, 444]]], ["Therefore, mortality data were analysed with the Mantel-Haenszel method to calculate the summary RR and 95% confidence inter-vals (CI) (Higgins and Green 2011) .", [["mortality data", "TEST", 11, 25], ["RR", "TEST", 97, 99], ["CI", "TEST", 131, 133]]], ["For studies with zero-events, a value of 0.5 was added to all cells for zero-cell correction.RESULTSEach online search engines identified several publications, ranging from 62 to 706 titles/abstracts.", [["cells", "ANATOMY", 62, 67], ["zero-cell", "ANATOMY", 72, 81], ["cells", "CELL", 62, 67], ["zero-cell", "CELL", 72, 81], ["studies", "TEST", 4, 11], ["zero-events", "TEST", 17, 28], ["a value", "TEST", 30, 37], ["zero-cell correction", "TREATMENT", 72, 92]]], ["A total of 58 publications (38 peer-reviewed + 5 international conferences + 15 other sources) met the criteria for the primary objective, summarizing 169 individual RCTs, and published between 1966 and 2016 (Scheel 1966; Perry et al. 1971 Perry et al. , 1986 Janzen and McManus 1980; Breeze et al. 1982; Lofgreen 1983; Peters 1985; Albak, Bradstock and Cruise 1986; Gill et al. 1986; Schumann, Janzen and McKinnon 1990; Harland et al. 1991; Schumann, Janzen and McKinnon 1991; Van Koevering et al. 1992; Hill, Gill and Ball 1993; Morck et al. 1993; Lauridsen, Jorgensen and Olsen 1994; Mc-Coy et al. 1994 Gallo and Berg 1995; Galyean, Gunter and Malcolm-Callis 1995; Hughes, Tice and O'Connor 1996; Kreikemeier, Stokka and Marston 1996; Brazle 1997; Klemesrud et al. 1997; McClary and Vogel 1999; Mechor and Vogel 1999; Frank and Duff 2000; Schmidt et al. 2001; Frank et al. 2002; Hibbard et al. 2002; Kato et al. 2003; Lechtenberg and Hanna 2003; Cusack 2004; Skogerboe et al. 2004; Anonymous 2005 Anonymous , 2013 Godinho et al. 2005; Kilgore et al. 2005; Encinias et al. 2006; Bremer et al. 2007; Mart\u00edn et al. 2007; Benton et al. 2008; Catry et al. 2008; Coe et al. 2008; Johnson et al. 2008; Caluwaerts et al. 2009; Heinrichs et al. 2009; Checkley et al. 2010; Sgoifo Rossi et al. 2010; Baggott et al. 2011; Gonz\u00e1lez-Mart\u00edn et al. 2011; Lechtenberg et al. 2011; Bechtol et al. 2012; Hendrick, Bateman and Rosengren 2013; Schlegel et al. 2014; Fazzio et al. 2015; Stanford et al. 2015; Dedonder et al. 2016) .", [["O'Connor 1996; Kreikemeier, Stokka and Marston 1996; Brazle 1997; Klemesrud et al. 1997; McClary and Vogel 1999; Mechor and Vogel 1999; Frank and Duff 2000; Schmidt et al.", "SPECIES", 685, 856], ["Gonz\u00e1lez", "TEST", 1314, 1322], ["Gill", "ANATOMY", 511, 515]]], ["Other sources of publications included proprietary data described in two Freedom of Information Act summaries (3 RCTs), nine university research progress reports (18 RCTs) and four pharmaceutical companies technical bulletins (20 RCTs).", [["proprietary data", "TEST", 39, 55]]], ["Prophylaxis RCTs included 45 publications (27 peerreviewed-77 RCTs + 3 international conferences-9 RCTs + 15 other sources-36 RCTs) (Fig. 1) , and metaphylaxis RCTs included 14 publications (11 peer-reviewed-39 RCTs + 2 international conferences-6 RCTs + 1 other source-2 RCTs) (Fig. 2) .", [["Prophylaxis RCTs", "TREATMENT", 0, 16], ["RCTs", "TEST", 62, 66], ["RCTs", "TEST", 99, 103], ["other sources", "TEST", 109, 122], ["RCTs", "TEST", 126, 130], ["Fig.", "TEST", 133, 137], ["metaphylaxis RCTs", "TREATMENT", 147, 164], ["RCTs", "TEST", 211, 215], ["RCTs", "TEST", 248, 252], ["other source", "TEST", 257, 269]]], ["Two publications assessed both prophylaxis and metaphylaxis.", [["metaphylaxis", "DISEASE", 47, 59], ["both prophylaxis", "TREATMENT", 26, 42], ["metaphylaxis", "TREATMENT", 47, 59], ["prophylaxis", "OBSERVATION", 31, 42]]], ["RCTs in feedlots were described in 51 publications (149 RCTs), four concerning veal/dairy calves (10 RCTs), two cow-calf operations (6 RCTs) and one bull-testing station (5 RCTs).", [["calves", "ORGANISM", 90, 96], ["calves", "SPECIES", 90, 96], ["cow", "SPECIES", 112, 115], ["calf", "SPECIES", 116, 120], ["RCTs in feedlots", "PROBLEM", 0, 16], ["veal/dairy calves", "TREATMENT", 79, 96], ["two cow-calf operations", "TREATMENT", 108, 131], ["dairy calves", "OBSERVATION", 84, 96], ["calf", "ANATOMY", 116, 120], ["operations", "OBSERVATION", 121, 131]]], ["Observation periods for RCTs ranged from 10 to 365 days (<20 days-26 RCTs; 20-39 days-91 RCTs; 40-80 days-40 RCTs; >80 days-11 RCTs).", [["RCTs", "TEST", 24, 28], ["RCTs", "TEST", 89, 93]]], ["The majority of publications described a uniform processing of cattle/calves upon arrival to the test facility, including injections with a variety of vaccines, vitamin products, dewormers and occasionally other products (e.g. growth implants).", [["vitamin products", "CHEMICAL", 161, 177], ["cattle", "ORGANISM", 63, 69], ["calves", "ORGANISM", 70, 76], ["vitamin products", "SIMPLE_CHEMICAL", 161, 177], ["cattle", "SPECIES", 63, 69], ["calves", "SPECIES", 70, 76], ["cattle", "SPECIES", 63, 69], ["cattle/calves", "TREATMENT", 63, 76], ["injections", "TREATMENT", 122, 132], ["a variety of vaccines", "TREATMENT", 138, 159], ["vitamin products", "TREATMENT", 161, 177], ["dewormers", "TREATMENT", 179, 188], ["occasionally other products (e.g. growth implants", "TREATMENT", 193, 242], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["publications", "OBSERVATION", 16, 28], ["uniform", "OBSERVATION_MODIFIER", 41, 48]]], ["Afterwards, cattle were separated into treatment and control groups.", [["cattle", "ORGANISM", 12, 18], ["cattle", "SPECIES", 12, 18], ["cattle", "SPECIES", 12, 18], ["treatment and control groups", "TREATMENT", 39, 67]]], ["These were considered typical field conditions for introduction of calves into feedlots and veal calf operations.RESULTSMost clinical trials described antimicrobial use according to the label dose (prophylaxis-99 RCTs; metaphylaxis-44 RCTs), with a minority over the label dose (prophylaxis-11 RCTs; metaphylaxis-2 RCTs), and under the label dose (prophylaxis-12 RCTs; metaphylaxis-1 RCT).", [["calves", "ORGANISM", 67, 73], ["calf", "ORGANISM_SUBDIVISION", 97, 101], ["calves", "SPECIES", 67, 73], ["calf", "SPECIES", 97, 101], ["veal", "SPECIES", 92, 96], ["introduction of calves", "TREATMENT", 51, 73], ["veal calf operations", "TREATMENT", 92, 112], ["prophylaxis", "TEST", 198, 209], ["metaphylaxis", "TREATMENT", 219, 231], ["the label dose (prophylaxis", "TREATMENT", 263, 290], ["metaphylaxis", "TREATMENT", 300, 312], ["metaphylaxis", "TREATMENT", 369, 381], ["calf", "ANATOMY", 97, 101], ["operations", "OBSERVATION", 102, 112]]], ["Thirteen BRD publications described the initial treatment of the negative control with saline using the same route of administration as the treatment group (45 RCTs), one with a placebo oral bolus (1 RCT), one with same formulation as the treatment group minus the antimicrobial substance (6 RCTs) and 43 publications with no placebo Figure 1 .", [["oral", "ANATOMY", 186, 190], ["saline", "SIMPLE_CHEMICAL", 87, 93], ["oral", "ORGANISM_SUBDIVISION", 186, 190], ["Thirteen BRD publications", "PROBLEM", 0, 25], ["saline", "TREATMENT", 87, 93], ["the treatment group (45 RCTs)", "TREATMENT", 136, 165], ["a placebo oral bolus", "TREATMENT", 176, 196], ["same formulation", "TREATMENT", 215, 231], ["the treatment group minus the antimicrobial substance", "TREATMENT", 235, 288], ["BRD publications", "OBSERVATION", 9, 25]]], ["Forest plot of prophylaxis RCTs morbidity data sorted by antimicrobial class and control group attack rates.", [["prophylaxis RCTs", "TREATMENT", 15, 31], ["morbidity data", "TEST", 32, 46], ["antimicrobial class", "TREATMENT", 57, 76]]], ["Random-effects meta-regression model RR predictions represented as shaded grey and black diamonds.", [["RR predictions", "TEST", 37, 51], ["black diamonds", "PROBLEM", 83, 97], ["black diamonds", "OBSERVATION", 83, 97]]], ["AttRate-control group attack rate % (CER%); antimicrobials investigated included macrolides (tylosin, tilmicosin, tulathromycin, gamithromycin, tildipirosin), tetracyclines (oxytetracyline, chlortetracycline, doxycycline), amphenicols (florfenicol), cephalosporins (ceftiofur), sulfonamides (sulfadimethoxine, sulfamethazine, trimethoprim sulphonamide), and fluoroquinolones (enrofloxacin), tetracycline combinations (oxytetracyline and/or chlortetracycline + neomycin, or sulfadimethoxine and/or sulfamethazine). treatment of the control group (118 RCTs).", [["macrolides", "CHEMICAL", 81, 91], ["tylosin", "CHEMICAL", 93, 100], ["tilmicosin", "CHEMICAL", 102, 112], ["tulathromycin", "CHEMICAL", 114, 127], ["gamithromycin", "CHEMICAL", 129, 142], ["tildipirosin", "CHEMICAL", 144, 156], ["tetracyclines", "CHEMICAL", 159, 172], ["oxytetracyline", "CHEMICAL", 174, 188], ["chlortetracycline", "CHEMICAL", 190, 207], ["doxycycline", "CHEMICAL", 209, 220], ["amphenicols", "CHEMICAL", 223, 234], ["florfenicol", "CHEMICAL", 236, 247], ["cephalosporins", "CHEMICAL", 250, 264], ["ceftiofur", "CHEMICAL", 266, 275], ["sulfonamides", "CHEMICAL", 278, 290], ["sulfadimethoxine", "CHEMICAL", 292, 308], ["sulfamethazine", "CHEMICAL", 310, 324], ["trimethoprim sulphonamide", "CHEMICAL", 326, 351], ["fluoroquinolones", "CHEMICAL", 358, 374], ["enrofloxacin", "CHEMICAL", 376, 388], ["tetracycline", "CHEMICAL", 391, 403], ["oxytetracyline", "CHEMICAL", 418, 432], ["chlortetracycline", "CHEMICAL", 440, 457], ["neomycin", "CHEMICAL", 460, 468], ["sulfadimethoxine", "CHEMICAL", 473, 489], ["sulfamethazine", "CHEMICAL", 497, 511], ["macrolides", "CHEMICAL", 81, 91], ["tylosin", "CHEMICAL", 93, 100], ["tilmicosin", "CHEMICAL", 102, 112], ["tulathromycin", "CHEMICAL", 114, 127], ["gamithromycin", "CHEMICAL", 129, 142], ["tildipirosin", "CHEMICAL", 144, 156], ["tetracyclines", "CHEMICAL", 159, 172], ["oxytetracyline", "CHEMICAL", 174, 188], ["chlortetracycline", "CHEMICAL", 190, 207], ["doxycycline", "CHEMICAL", 209, 220], ["amphenicols", "CHEMICAL", 223, 234], ["florfenicol", "CHEMICAL", 236, 247], ["cephalosporins", "CHEMICAL", 250, 264], ["ceftiofur", "CHEMICAL", 266, 275], ["sulfonamides", "CHEMICAL", 278, 290], ["sulfadimethoxine", "CHEMICAL", 292, 308], ["sulfamethazine", "CHEMICAL", 310, 324], ["trimethoprim sulphonamide", "CHEMICAL", 326, 351], ["fluoroquinolones", "CHEMICAL", 358, 374], ["enrofloxacin", "CHEMICAL", 376, 388], ["tetracycline", "CHEMICAL", 391, 403], ["oxytetracyline", "CHEMICAL", 418, 432], ["chlortetracycline", "CHEMICAL", 440, 457], ["neomycin", "CHEMICAL", 460, 468], ["sulfadimethoxine", "CHEMICAL", 473, 489], ["sulfamethazine", "CHEMICAL", 497, 511], ["macrolides", "SIMPLE_CHEMICAL", 81, 91], ["tylosin", "SIMPLE_CHEMICAL", 93, 100], ["tilmicosin", "SIMPLE_CHEMICAL", 102, 112], ["tulathromycin", "SIMPLE_CHEMICAL", 114, 127], ["gamithromycin", "SIMPLE_CHEMICAL", 129, 142], ["tildipirosin", "SIMPLE_CHEMICAL", 144, 156], ["tetracyclines", "SIMPLE_CHEMICAL", 159, 172], ["oxytetracyline", "SIMPLE_CHEMICAL", 174, 188], ["chlortetracycline", "SIMPLE_CHEMICAL", 190, 207], ["doxycycline", "SIMPLE_CHEMICAL", 209, 220], ["amphenicols", "SIMPLE_CHEMICAL", 223, 234], ["florfenicol", "SIMPLE_CHEMICAL", 236, 247], ["cephalosporins", "SIMPLE_CHEMICAL", 250, 264], ["ceftiofur", "SIMPLE_CHEMICAL", 266, 275], ["sulfonamides", "SIMPLE_CHEMICAL", 278, 290], ["sulfadimethoxine", "SIMPLE_CHEMICAL", 292, 308], ["sulfamethazine", "SIMPLE_CHEMICAL", 310, 324], ["trimethoprim sulphonamide", "SIMPLE_CHEMICAL", 326, 351], ["fluoroquinolones", "SIMPLE_CHEMICAL", 358, 374], ["enrofloxacin", "SIMPLE_CHEMICAL", 376, 388], ["tetracycline", "SIMPLE_CHEMICAL", 391, 403], ["oxytetracyline", "SIMPLE_CHEMICAL", 418, 432], ["chlortetracycline", "SIMPLE_CHEMICAL", 440, 457], ["neomycin", "SIMPLE_CHEMICAL", 460, 468], ["sulfadimethoxine", "SIMPLE_CHEMICAL", 473, 489], ["sulfamethazine", "SIMPLE_CHEMICAL", 497, 511], ["AttRate-control group attack rate", "TREATMENT", 0, 33], ["antimicrobials", "TREATMENT", 44, 58], ["macrolides", "TREATMENT", 81, 91], ["tylosin", "TREATMENT", 93, 100], ["tilmicosin", "TREATMENT", 102, 112], ["tulathromycin", "TREATMENT", 114, 127], ["gamithromycin", "TREATMENT", 129, 142], ["tildipirosin", "TREATMENT", 144, 156], ["tetracyclines", "TREATMENT", 159, 172], ["oxytetracyline", "TREATMENT", 174, 188], ["chlortetracycline", "TREATMENT", 190, 207], ["doxycycline", "TREATMENT", 209, 220], ["amphenicols (florfenicol)", "TREATMENT", 223, 248], ["cephalosporins (ceftiofur)", "TREATMENT", 250, 276], ["sulfonamides", "TREATMENT", 278, 290], ["sulfadimethoxine", "TREATMENT", 292, 308], ["sulfamethazine", "TREATMENT", 310, 324], ["trimethoprim sulphonamide)", "TREATMENT", 326, 352], ["fluoroquinolones", "TREATMENT", 358, 374], ["enrofloxacin", "TREATMENT", 376, 388], ["tetracycline combinations", "TREATMENT", 391, 416], ["oxytetracyline", "TREATMENT", 418, 432], ["chlortetracycline", "TREATMENT", 440, 457], ["neomycin", "TREATMENT", 460, 468], ["sulfadimethoxine", "TREATMENT", 473, 489], ["sulfamethazine", "TREATMENT", 497, 511], ["treatment", "TREATMENT", 514, 523]]], ["The majority of RCTs (150) described two or more visual clinical signs in their BRD assessment (e.g. depression, poor body condition, anorexia, abnormal respiration, cough, oculo-nasal discharge).", [["body", "ANATOMY", 118, 122], ["nasal", "ANATOMY", 179, 184], ["BRD", "DISEASE", 80, 83], ["depression", "DISEASE", 101, 111], ["anorexia", "DISEASE", 134, 142], ["abnormal respiration", "DISEASE", 144, 164], ["cough", "DISEASE", 166, 171], ["body", "ORGANISM_SUBDIVISION", 118, 122], ["nasal", "ORGANISM_SUBDIVISION", 179, 184], ["RCTs", "TEST", 16, 20], ["their BRD assessment", "TEST", 74, 94], ["depression", "PROBLEM", 101, 111], ["poor body condition", "PROBLEM", 113, 132], ["anorexia", "PROBLEM", 134, 142], ["abnormal respiration", "PROBLEM", 144, 164], ["cough", "PROBLEM", 166, 171], ["oculo-nasal discharge", "PROBLEM", 173, 194]]], ["Of these, 118 RCTs also included the presence of fever in the assessment.", [["fever", "DISEASE", 49, 54], ["fever", "PROBLEM", 49, 54], ["the assessment", "TEST", 58, 72], ["fever", "OBSERVATION", 49, 54]]], ["No description was stated for 19 RCTs.RESULTSMethods of randomisation described included 20 publications (prophylaxis-60 RCTs; metaphylaxis-23 RCTs) with random-block design, 19 publications (prophylaxis-17 RCTs; metaphylaxis-20 RCTs) with systematic randomisation, 5 publications (prophylaxis-7 RCTs; metaphylaxis-2 RCTs) describing computer/statistical randomisation and 14 publications (40 RCTs) with no description.", [["randomisation", "TREATMENT", 56, 69], ["prophylaxis", "TEST", 106, 117], ["RCTs", "TEST", 121, 125], ["metaphylaxis", "TEST", 127, 139], ["random-block design", "TREATMENT", 154, 173], ["prophylaxis", "TEST", 192, 203], ["RCTs", "TREATMENT", 207, 211], ["metaphylaxis", "TREATMENT", 213, 225], ["systematic randomisation", "TREATMENT", 240, 264], ["prophylaxis-7 RCTs", "TREATMENT", 282, 300], ["metaphylaxis", "TREATMENT", 302, 314], ["computer/statistical randomisation", "TREATMENT", 334, 368]]], ["Also, 26 publications (prophylaxis-45 RCTs; metaphylaxis-34 RCTs) utilised blinding in the study design, with 4 publications (prophylaxis-2 RCTs; metaphylaxis-8 RCTs) describing the person/s giving the treatments as blinded and 22 publications (prophylaxis-43 RCTs; metaphylaxis-26 RCTs) describing the person/s checking cattle/pens for BRD as blinded.RESULTSMany RCTs demonstrated a benefit in RR for reducing morbidity, with either antimicrobial prophylaxis or metaphylaxis (Figs 1 and 2) , although results varied considerably between studies.", [["BRD", "DISEASE", 337, 340], ["cattle", "ORGANISM", 321, 327], ["person", "SPECIES", 182, 188], ["person", "SPECIES", 303, 309], ["cattle", "SPECIES", 321, 327], ["prophylaxis", "TEST", 23, 34], ["RCTs", "TEST", 38, 42], ["metaphylaxis", "TEST", 44, 56], ["the study", "TEST", 87, 96], ["4 publications", "TREATMENT", 110, 124], ["prophylaxis-2 RCTs", "TREATMENT", 126, 144], ["metaphylaxis", "TREATMENT", 146, 158], ["the treatments", "TREATMENT", 198, 212], ["prophylaxis", "TREATMENT", 245, 256], ["RCTs", "TREATMENT", 260, 264], ["metaphylaxis", "TREATMENT", 266, 278], ["cattle/pens", "TREATMENT", 321, 332], ["BRD", "PROBLEM", 337, 340], ["RR", "TEST", 395, 397], ["reducing morbidity", "PROBLEM", 402, 420], ["antimicrobial prophylaxis", "TREATMENT", 434, 459], ["metaphylaxis", "TREATMENT", 463, 475]]], ["The combined RR estimate (prophylaxis + metaphylaxis) was 0.49 (95% CI = 0.45-0.53).", [["The combined RR estimate", "PROBLEM", 0, 24], ["prophylaxis + metaphylaxis", "TREATMENT", 26, 52], ["CI", "TEST", 68, 70]]], ["Data asymmetry was identified with funnel plots (Fig. 3) .", [["Data asymmetry", "TEST", 0, 14], ["funnel plots", "TEST", 35, 47]]], ["Using the Duval and Tweedie Trim and Fill method, the adjusted combined RR estimate was 0.52 (0.48-0.57).", [["the adjusted combined RR estimate", "TEST", 50, 83]]], ["Funnel plot asymmetry was more evident for RCTs describing metaphylaxis, particularly a lack of small studies reporting poor efficacy (Fig. 3) .", [["metaphylaxis", "DISEASE", 59, 71], ["Funnel plot asymmetry", "PROBLEM", 0, 21], ["RCTs", "PROBLEM", 43, 47], ["metaphylaxis", "PROBLEM", 59, 71], ["small studies", "TEST", 96, 109]]], ["Initially, metaphylaxis RCTs (RR, 95% CI = 0.42, 0.35-0.49) performed significantly better (P = 0.031) in reducing BRD morbidity than prophylaxis (RR, 95% CI = 0.52, 0.47-0.57).", [["BRD", "DISEASE", 115, 118], ["metaphylaxis RCTs", "TEST", 11, 28], ["RR", "TEST", 30, 32], ["CI", "TEST", 38, 40], ["P", "TEST", 92, 93], ["reducing BRD morbidity", "PROBLEM", 106, 128], ["RR", "TEST", 147, 149], ["CI", "TEST", 155, 157]]], ["However, adjusted RR estimates revealed the two types of mass medications performed equally (metaphylaxis RR, 95% CI = 0.53, 0.43-0.64; prophylaxis RR, For prophylaxis RCTs, macrolides performed best in reducing BRD morbidity (RR, 95% CI = 0.43, 0.38-0.48; 28 pubs-50 RCTs), compared to tetracyclines (RR, 95% CI = 0.74, 0.62-0.88; 20 pubs-31 RCTs), tetracycline combinations (RR, 95% CI = 0.49, 0.38-0.63; 10 pubs-18 RCTs), amphenicols (RR, 95% CI = 0.60, 0.41-0.89; 2 pubs-5 RCTs), cephalosporins (RR, 95% CI = 0.57, 0.45-0.73; 7 pubs-10 RCTs), sulfonamides (RR, 95% CI = 0.81, 0.56-1.16; 7 pubs-7 RCTs) and fluoroquinolones (RR, 95% CI = 0.31, 0.13-0.71; 1 pub-1 RCT) (Fig. 1) .", [["macrolides", "CHEMICAL", 174, 184], ["BRD", "DISEASE", 212, 215], ["tetracyclines", "CHEMICAL", 287, 300], ["tetracycline", "CHEMICAL", 350, 362], ["cephalosporins", "CHEMICAL", 484, 498], ["sulfonamides", "CHEMICAL", 547, 559], ["fluoroquinolones", "CHEMICAL", 610, 626], ["macrolides", "CHEMICAL", 174, 184], ["tetracycline", "CHEMICAL", 350, 362], ["cephalosporins", "CHEMICAL", 484, 498], ["sulfonamides", "CHEMICAL", 547, 559], ["fluoroquinolones", "CHEMICAL", 610, 626], ["tetracycline", "SIMPLE_CHEMICAL", 350, 362], ["cephalosporins", "SIMPLE_CHEMICAL", 484, 498], ["sulfonamides", "SIMPLE_CHEMICAL", 547, 559], ["fluoroquinolones", "SIMPLE_CHEMICAL", 610, 626], ["RR estimates", "TEST", 18, 30], ["mass medications", "TREATMENT", 57, 73], ["metaphylaxis", "TEST", 93, 105], ["RR", "TEST", 106, 108], ["CI", "TEST", 114, 116], ["prophylaxis RR", "TREATMENT", 136, 150], ["prophylaxis RCTs", "TREATMENT", 156, 172], ["macrolides", "TREATMENT", 174, 184], ["reducing BRD morbidity", "PROBLEM", 203, 225], ["RR", "TEST", 227, 229], ["CI", "TEST", 235, 237], ["pubs", "TEST", 260, 264], ["tetracyclines", "TEST", 287, 300], ["RR", "TEST", 302, 304], ["CI", "TEST", 310, 312], ["pubs", "TEST", 335, 339], ["RCTs", "TEST", 343, 347], ["tetracycline combinations", "TREATMENT", 350, 375], ["RR", "TEST", 377, 379], ["CI", "TEST", 385, 387], ["pubs", "TEST", 410, 414], ["RCTs", "TEST", 418, 422], ["amphenicols", "TEST", 425, 436], ["RR", "TEST", 438, 440], ["CI", "TEST", 446, 448], ["pubs", "TEST", 470, 474], ["cephalosporins", "TREATMENT", 484, 498], ["RR", "TEST", 500, 502], ["CI", "TEST", 508, 510], ["pubs", "TEST", 532, 536], ["sulfonamides", "TREATMENT", 547, 559], ["RR", "TEST", 561, 563], ["CI", "TEST", 569, 571], ["pubs", "TEST", 593, 597], ["fluoroquinolones", "TREATMENT", 610, 626], ["RR", "TEST", 628, 630], ["CI", "TEST", 636, 638], ["pub", "TEST", 660, 663], ["mass", "OBSERVATION", 57, 61]]], ["For metaphylaxis RCTs, no significant differences were detected between antimicrobial classes (P = 0.86).RESULTSMetaphylaxis definitions included 11 publications (33 RCTs) defined as the BRD morbidity \u226510% within the group; 3 publications (3 RCTs) defined as pyrexia and no other symptoms; 5 pub-lications (11 RCTs) as cattle in-contact within groups with visual BRD cattle.", [["BRD", "DISEASE", 187, 190], ["pyrexia", "DISEASE", 259, 266], ["cattle", "SPECIES", 367, 373], ["cattle", "SPECIES", 319, 325], ["cattle", "SPECIES", 367, 373], ["metaphylaxis RCTs", "TREATMENT", 4, 21], ["significant differences", "PROBLEM", 26, 49], ["P", "TEST", 95, 96], ["the BRD morbidity", "PROBLEM", 183, 200], ["pyrexia", "PROBLEM", 259, 266], ["other symptoms", "PROBLEM", 274, 288], ["pyrexia", "OBSERVATION", 259, 266], ["no", "UNCERTAINTY", 271, 273]]], ["Metaphylaxis definitions demonstrated significantly different results.", [["Metaphylaxis definitions", "TEST", 0, 24]]], ["Best results on BRD morbidity were obtained with a '\u226510%-morbidity' definition (RR, 95% CI = 0.34, 0.28-0.41), compared to an 'in-contact' definition (RR, 95% CI = 0.53, 0.40-0.70; P = 0.011) or 'fever' definition (RR, 95% CI = 1.11, 0.67-1.84; P < 0.001) (Fig. 2) .RESULTSThe majority of RCTs (prophylaxis+metaphylaxis) fitted a correlation of decreasing NNT with increasing control group attack rates (Fig. 4) .", [["BRD", "DISEASE", 16, 19], ["fever", "DISEASE", 196, 201], ["NNT", "CHEMICAL", 356, 359], ["BRD morbidity", "PROBLEM", 16, 29], ["RR", "TEST", 80, 82], ["CI", "TEST", 88, 90], ["RR", "TEST", 151, 153], ["CI", "TEST", 159, 161], ["P", "TEST", 181, 182], ["'fever' definition", "PROBLEM", 195, 213], ["RR", "TEST", 215, 217], ["CI", "TEST", 223, 225], ["P", "TEST", 245, 246], ["RCTs (prophylaxis+metaphylaxis", "TREATMENT", 289, 319], ["decreasing NNT", "PROBLEM", 345, 359], ["increasing control group attack rates", "PROBLEM", 365, 402]]], ["NNT for RCTs dropped below the NNT median at attack rates >25%.", [["NNT", "CHEMICAL", 0, 3], ["RCTs", "TREATMENT", 8, 12], ["rates", "TEST", 52, 57]]], ["Observation periods (duration) of RCTs affected morbidity outcomes with short RCTs (<20 days-RR, 95% CI = 0.35, 0.28-0.42) demonstrating significantly better (P = 0.011) outcomes compared to longer RCTs (20-39 days-RR, 95% CI = 0.50, 0.45-0.56; 40-80 days-RR, 95% CI = 0.58, 0.49-0.67; > 80 days-RR, 95% CI = 0.68, 0.51-0.91).", [["RCTs affected morbidity outcomes", "PROBLEM", 34, 66], ["short RCTs", "TEST", 72, 82], ["RR", "TEST", 93, 95], ["CI", "TEST", 101, 103], ["longer RCTs", "TEST", 191, 202], ["RR", "TEST", 215, 217], ["CI", "TEST", 223, 225], ["RR", "TEST", 256, 258], ["CI", "TEST", 264, 266], ["RR", "TEST", 296, 298], ["CI", "TEST", 304, 306]]], ["Best ARR results on BRD morbidity were clustered to only short RCT durations (e.g. \u226430 days) (Fig. 5a) .", [["BRD", "DISEASE", 20, 23], ["Best ARR", "TEST", 0, 8], ["BRD morbidity", "PROBLEM", 20, 33], ["short RCT durations", "PROBLEM", 57, 76]]], ["Also, best ARR results on BRD morbidity were a feature of small rather than larger RCTs.RESULTSPublications described uniformly that identified BRD cattle were 'pulled' from the pen and treated with a pre-specified treatment protocol for that study, and returned.", [["BRD", "DISEASE", 26, 29], ["cattle", "ORGANISM", 148, 154], ["cattle", "SPECIES", 148, 154], ["cattle", "SPECIES", 148, 154], ["BRD morbidity", "PROBLEM", 26, 39], ["small rather than larger RCTs", "PROBLEM", 58, 87], ["a pre-specified treatment protocol", "TREATMENT", 199, 233], ["that study", "TEST", 238, 248], ["small", "OBSERVATION_MODIFIER", 58, 63]]], ["Thus, mortality data were confounded since all BRD cattle (i.e. treatment and control groups) were treated with antimicrobials, after recorded as morbidity data.", [["cattle", "SPECIES", 51, 57], ["cattle", "SPECIES", 51, 57], ["mortality data", "TEST", 6, 20], ["all BRD cattle", "TREATMENT", 43, 57], ["treatment and control groups", "TREATMENT", 64, 92], ["antimicrobials", "TREATMENT", 112, 126], ["morbidity data", "TEST", 146, 160]]], ["Nevertheless, mortality data were analysed since it represented a treatment-only strategy, without prior mass medication (e.g. control group) compared to a treatment strategy, with prior mass medication (e.g. treatment group).", [["mortality data", "TEST", 14, 28], ["a treatment", "TREATMENT", 64, 75], ["prior mass medication", "TREATMENT", 99, 120], ["a treatment strategy", "TREATMENT", 154, 174], ["prior mass medication", "TREATMENT", 181, 202], ["mass", "OBSERVATION", 187, 191]]], ["From the original publications accepted for the morbidity data analysis, 47 publications (38 prophylaxis-89 RCTs, 11 metaphylaxis-39 RCTs) contained sufficient mortality data.", [["the morbidity data analysis", "TEST", 44, 71], ["prophylaxis", "TEST", 93, 104], ["RCTs", "TEST", 108, 112], ["metaphylaxis", "TEST", 117, 129]]], ["BRD mortality rates were very low, with 37 of 89 (41.5%) prophylaxis RCTs and 32 of 39 (82%) metaphylaxis RCTs reported zero mortality in the control groups.", [["BRD", "DISEASE", 0, 3], ["BRD mortality rates", "TEST", 0, 19], ["very low", "PROBLEM", 25, 33], ["prophylaxis RCTs", "TEST", 57, 73], ["metaphylaxis RCTs", "TREATMENT", 93, 110], ["zero mortality", "PROBLEM", 120, 134], ["low", "OBSERVATION_MODIFIER", 30, 33]]], ["The highest mortality rate was 18% (Fig. 5b) .RESULTSAntimicrobial mass medications (prophylaxis + metaphylaxis) led to a relative reduction in mortality risk (RR, 95% CI = 0.62, 0.54-0.72).", [["The highest mortality rate", "TEST", 0, 26], ["RESULTSAntimicrobial mass medications", "TREATMENT", 46, 83], ["prophylaxis + metaphylaxis)", "TREATMENT", 85, 112], ["a relative reduction in mortality risk", "PROBLEM", 120, 158], ["RR", "TEST", 160, 162], ["CI", "TEST", 168, 170], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["mass", "OBSERVATION", 67, 71], ["reduction", "OBSERVATION_MODIFIER", 131, 140]]], ["This was correlated with control group results, with RR declining with increasing mortality rates.", [["RR", "TEST", 53, 55], ["increasing mortality rates", "PROBLEM", 71, 97]]], ["A subgroup analysis revealed relative risk reductions with a control group mortality above 1.5% (RR, 95% CI = 0.55, 0.45-0.67) compared to below 1.5% (RR, 95% CI = 0.74, 0.57-0.96).", [["A subgroup analysis", "TEST", 0, 19], ["relative risk reductions", "PROBLEM", 29, 53], ["RR", "TEST", 97, 99], ["CI", "TEST", 105, 107], ["RR", "TEST", 151, 153], ["CI", "TEST", 159, 161], ["risk reductions", "OBSERVATION", 38, 53]]], ["However, the majority of RCTs demonstrated only minor effects in ARR (e.g. <5%) (Fig. 5b) .DISCUSSIONTo the authors' knowledge, this is the first critical appraisal of evidence for antimicrobial prophylaxis and metaphylaxis to prevent disease morbidity and mortality in a major food animal species.", [["RCTs", "TEST", 25, 29], ["ARR", "TEST", 65, 68], ["antimicrobial prophylaxis", "TREATMENT", 181, 206], ["metaphylaxis", "TREATMENT", 211, 223], ["disease morbidity", "PROBLEM", 235, 252], ["minor", "OBSERVATION_MODIFIER", 48, 53], ["effects", "OBSERVATION_MODIFIER", 54, 61]]], ["A systematic review and meta-analysis of RCTs concerning antimicrobial mass medications for preventing BRD identified advantages and disadvantages.", [["BRD", "DISEASE", 103, 106], ["BRD", "SPECIES", 103, 106], ["A systematic review", "TEST", 0, 19], ["meta-analysis of RCTs", "TREATMENT", 24, 45], ["antimicrobial mass medications", "TREATMENT", 57, 87], ["BRD", "PROBLEM", 103, 106]]], ["Prophylaxis and metaphylaxis demonstrated moderate, yet highly variable relative risk reductions in BRD morbidity (adjusted combined RR, \u00b195% = 0.52, 0.48-0.57).", [["BRD", "DISEASE", 100, 103], ["BRD", "SPECIES", 100, 103], ["Prophylaxis", "TREATMENT", 0, 11], ["metaphylaxis", "TREATMENT", 16, 28], ["BRD morbidity", "PROBLEM", 100, 113], ["RR", "TEST", 133, 135], ["\u00b1", "TEST", 137, 138], ["moderate", "OBSERVATION_MODIFIER", 42, 50], ["reductions", "OBSERVATION_MODIFIER", 86, 96], ["BRD morbidity", "OBSERVATION", 100, 113]]], ["BRD morbidity reductions were dependent on the antimicrobial classes used (Fig. 1) , metaphylaxis definition criteria (Fig. 2) , BRD attack rates (Fig. 4) and duration of the RCTs Figure 5 .", [["BRD", "DISEASE", 0, 3], ["BRD", "DISEASE", 129, 132], ["BRD morbidity reductions", "PROBLEM", 0, 24], ["the antimicrobial classes", "TREATMENT", 43, 68], ["BRD attack rates", "PROBLEM", 129, 145], ["morbidity", "OBSERVATION", 4, 13]]], ["Plot of absolute risk reductions in (a) morbidity or (b) mortality for each RCT versus the duration of the RCT.", [["absolute risk reductions", "PROBLEM", 8, 32], ["each RCT", "TEST", 71, 79], ["absolute risk", "OBSERVATION_MODIFIER", 8, 21], ["reductions", "OBSERVATION_MODIFIER", 22, 32]]], ["For publications stating a range of duration days for RCTs, then the average value was calculated.", [["RCTs", "TREATMENT", 54, 58], ["the average value", "TEST", 65, 82]]], ["RCTs involving either antimicrobial prophylaxis (red circles) or metaphylaxis (black circles).", [["RCTs", "TREATMENT", 0, 4], ["antimicrobial prophylaxis", "TREATMENT", 22, 47], ["metaphylaxis", "PROBLEM", 65, 77], ["antimicrobial", "OBSERVATION_MODIFIER", 22, 35]]], ["Size of the circles reflects the sample size of the RCT (see the legend).", [["circles", "OBSERVATION", 12, 19], ["sample", "OBSERVATION_MODIFIER", 33, 39], ["size", "OBSERVATION_MODIFIER", 40, 44]]], ["For the purpose of visualisation of the wide range of ARR values for the mortality data, the y-values in (b) are shown on a modified log-scale (sign(y) * log10(10 * y+ 1)).", [["ARR values", "TEST", 54, 64], ["the mortality data", "TEST", 69, 87]]], ["Disadvantages include that best positive RR results were achieved with antimicrobial classes (e.g. macrolides) considered as broad-spectrum critically important antimicrobials (CIAs) to human and veterinary medicine, or combination antimicrobials (Fig. 1) .", [["macrolides", "CHEMICAL", 99, 109], ["macrolides", "CHEMICAL", 99, 109], ["CIAs", "SIMPLE_CHEMICAL", 177, 181], ["human", "ORGANISM", 186, 191], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["antimicrobial classes", "TREATMENT", 71, 92], ["macrolides", "TREATMENT", 99, 109], ["human and veterinary medicine", "TREATMENT", 186, 215], ["combination antimicrobials", "TREATMENT", 220, 246]]], ["Also, the NNT to prevent one BRD case was very high under circumstances of low attack rates and variable when the infection pressure was too high for medication to prevent BRD transmission (Fig. 4) .DISCUSSIONAetiologies for BRD outbreaks are founded in physiological, management and environmental factors in conjunction with viral and bacterial infectious agents.", [["NNT", "CHEMICAL", 10, 13], ["BRD", "DISEASE", 29, 32], ["infection", "DISEASE", 114, 123], ["BRD", "DISEASE", 172, 175], ["BRD", "DISEASE", 225, 228], ["BRD", "SPECIES", 172, 175], ["BRD", "SPECIES", 225, 228], ["one BRD case", "PROBLEM", 25, 37], ["low attack rates", "PROBLEM", 75, 91], ["the infection pressure", "TEST", 110, 132], ["medication", "TREATMENT", 150, 160], ["BRD outbreaks", "PROBLEM", 225, 238], ["environmental factors", "TREATMENT", 284, 305], ["viral and bacterial infectious agents", "TREATMENT", 326, 363], ["low attack", "OBSERVATION_MODIFIER", 75, 85]]], ["Genetic selection has resulted in domesticated cattle with small lungs relative to their metabolic demands, contributing to decreased respiratory compensation, particularly during periods of exertion or disease (Weekly and Veit 1995) .", [["lungs", "ANATOMY", 65, 70], ["respiratory", "ANATOMY", 134, 145], ["respiratory compensation", "DISEASE", 134, 158], ["cattle", "ORGANISM", 47, 53], ["lungs", "ORGAN", 65, 70], ["cattle", "SPECIES", 47, 53], ["cattle", "SPECIES", 47, 53], ["Genetic selection", "TEST", 0, 17], ["small lungs", "PROBLEM", 59, 70], ["decreased respiratory compensation", "PROBLEM", 124, 158], ["disease", "PROBLEM", 203, 210], ["small", "OBSERVATION_MODIFIER", 59, 64], ["lungs", "ANATOMY", 65, 70], ["metabolic demands", "OBSERVATION", 89, 106], ["decreased", "OBSERVATION_MODIFIER", 124, 133], ["respiratory compensation", "OBSERVATION", 134, 158]]], ["Generally, high-risk calves/cattle are typically lightweight, recently weaned, highly co-mingled, or of auction market origin, extended transport times and unknown health/vaccination history.", [["calves", "ORGANISM", 21, 27], ["cattle", "ORGANISM", 28, 34], ["calves", "SPECIES", 21, 27], ["cattle", "SPECIES", 28, 34], ["cattle", "SPECIES", 28, 34]]], ["Despite widespread use of vaccines and antimicrobial mass medications, a sobering picture has suggested limited progress in North America to reduce the impact of BRD over the last 10-20 years (Hilton 2014) .", [["BRD", "DISEASE", 162, 165], ["BRD", "SPECIES", 162, 165], ["vaccines", "TREATMENT", 26, 34], ["antimicrobial mass medications", "TREATMENT", 39, 69], ["a sobering picture", "PROBLEM", 71, 89], ["BRD", "PROBLEM", 162, 165]]], ["National Animal Health Monitoring System data show an increase in BRD feedlot mortality from 1.03% in 1994 to 1.6% in 2011, despite \u223c16% were treated for BRD and up to 31% received prophylactic antimicrobials on arrival.", [["BRD", "DISEASE", 66, 69], ["BRD", "DISEASE", 154, 157], ["BRD", "SPECIES", 66, 69], ["BRD", "SPECIES", 154, 157], ["an increase in BRD feedlot mortality", "PROBLEM", 51, 87], ["BRD", "PROBLEM", 154, 157], ["prophylactic antimicrobials", "TREATMENT", 181, 208], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["BRD feedlot", "OBSERVATION", 66, 77]]], ["Dairy heifer rearing data showed that 18.1% of pre-weaned dairy heifers were treated for BRD, including a BRD mortality of 2.3% (Dargatz 2014) .", [["BRD", "DISEASE", 89, 92], ["BRD", "DISEASE", 106, 109], ["heifers", "ORGANISM", 64, 71], ["BRD", "SPECIES", 89, 92], ["BRD", "PROBLEM", 89, 92], ["a BRD mortality", "PROBLEM", 104, 119]]], ["Other data reveal that feedlot mortality increased by 0.05% per year over the last 13 years (Engler 2014) .", [["Other data", "TEST", 0, 10], ["feedlot mortality", "PROBLEM", 23, 40]]], ["The reaction has been an increasing reliance on antimicrobial prophylaxis and/or metaphylaxis to control BRD, but the need for mass medications is more driven by the antiquated structure of the feedlot and veal calf industries compared to the disease itself.", [["BRD", "DISEASE", 105, 108], ["calf", "ORGANISM_SUBDIVISION", 211, 215], ["calf", "SPECIES", 211, 215], ["veal", "SPECIES", 206, 210], ["The reaction", "PROBLEM", 0, 12], ["antimicrobial prophylaxis", "TREATMENT", 48, 73], ["metaphylaxis", "TREATMENT", 81, 93], ["BRD", "PROBLEM", 105, 108], ["mass medications", "TREATMENT", 127, 143], ["veal calf industries", "TREATMENT", 206, 226], ["the disease itself", "PROBLEM", 239, 257], ["increasing", "OBSERVATION_MODIFIER", 25, 35], ["reliance", "OBSERVATION_MODIFIER", 36, 44], ["veal calf", "ANATOMY", 206, 215], ["disease", "OBSERVATION", 243, 250]]], ["A major obstacle to control BRD remains the segmented infrastructure of these industries, as relatively unchanged for several decades (Ives and Richeson 2015) .", [["BRD", "DISEASE", 28, 31], ["major", "OBSERVATION_MODIFIER", 2, 7], ["obstacle", "OBSERVATION", 8, 16], ["segmented", "OBSERVATION_MODIFIER", 44, 53], ["infrastructure", "OBSERVATION", 54, 68], ["industries", "OBSERVATION", 78, 88], ["relatively", "OBSERVATION_MODIFIER", 93, 103], ["unchanged", "OBSERVATION_MODIFIER", 104, 113]]], ["Calves/cattle progress through the production phase, changing ownership at any and all points, resulting in transporting, co-mingling from various sources, minimal biosecurity and other stressors, providing ample opportunity for immunosuppression and pathogen colonisation of the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 280, 303], ["Calves", "ORGANISM", 0, 6], ["lower", "ORGANISM_SUBDIVISION", 280, 285], ["respiratory tract", "ORGANISM_SUBDIVISION", 286, 303], ["Calves", "SPECIES", 0, 6], ["cattle", "SPECIES", 7, 13], ["cattle", "SPECIES", 7, 13], ["immunosuppression", "TREATMENT", 229, 246], ["pathogen colonisation of the lower respiratory tract", "TREATMENT", 251, 303], ["minimal", "OBSERVATION_MODIFIER", 156, 163], ["pathogen", "OBSERVATION_MODIFIER", 251, 259], ["colonisation", "OBSERVATION", 260, 272], ["lower", "ANATOMY_MODIFIER", 280, 285], ["respiratory tract", "ANATOMY", 286, 303]]], ["It has been estimated the average number of middle men between the cattle rancher and the consumer is 15 (Ives and Richeson 2015) .", [["men", "ORGANISM", 51, 54], ["cattle", "ORGANISM", 67, 73], ["men", "SPECIES", 51, 54], ["cattle", "SPECIES", 67, 73], ["cattle", "SPECIES", 67, 73], ["average", "OBSERVATION_MODIFIER", 26, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["middle", "OBSERVATION_MODIFIER", 44, 50]]], ["Cattle can be transported between two to five times throughout their lifetime, resulting in degrees of dehydration, physiologic stress and environmental/nutritional changes.", [["dehydration", "DISEASE", 103, 114], ["Cattle", "ORGANISM", 0, 6], ["Cattle", "SPECIES", 0, 6], ["dehydration", "PROBLEM", 103, 114], ["physiologic stress", "PROBLEM", 116, 134], ["nutritional changes", "PROBLEM", 153, 172], ["dehydration", "OBSERVATION", 103, 114], ["physiologic stress", "OBSERVATION", 116, 134]]], ["This persistent infrastructure also impedes alternatives to antimicrobial mass medications, since the major BRD predisposition factors are present at the time of arrival to the facilities.DISCUSSIONA BRD field diagnosis has major limitations for accurately identifying all BRD cattle.", [["BRD", "DISEASE", 273, 276], ["major BRD predisposition factors", "PROTEIN", 102, 134], ["cattle", "SPECIES", 277, 283], ["BRD cattle", "SPECIES", 273, 283], ["antimicrobial mass medications", "TREATMENT", 60, 90], ["the major BRD predisposition factors", "PROBLEM", 98, 134], ["persistent", "OBSERVATION_MODIFIER", 5, 15], ["infrastructure", "OBSERVATION", 16, 30]]], ["Common clinical signs (e.g. depression, anorexia, fever) are not pathognomonic.", [["depression", "DISEASE", 28, 38], ["anorexia", "DISEASE", 40, 48], ["fever", "DISEASE", 50, 55], ["Common clinical signs", "PROBLEM", 0, 21], ["depression", "PROBLEM", 28, 38], ["anorexia", "PROBLEM", 40, 48], ["fever", "PROBLEM", 50, 55], ["pathognomonic", "PROBLEM", 65, 78]]], ["A recently published study using a hierarchical Bayesian latent class metaanalysis comparing BRD clinical signs to slaughter lung lesions revealed an estimated predicted diagnostic sensitivity and specificity of 0.27 (95% CI = 0.01-0.96) and 0.92 (0.14-1.00), respectively (Timsit et al. 2016) .", [["lung lesions", "ANATOMY", 125, 137], ["lung lesions", "CANCER", 125, 137], ["A recently published study", "TEST", 0, 26], ["BRD clinical signs", "TEST", 93, 111], ["slaughter lung lesions", "PROBLEM", 115, 137], ["specificity", "TEST", 197, 208], ["CI", "TEST", 222, 224], ["lung", "ANATOMY", 125, 129], ["lesions", "OBSERVATION", 130, 137]]], ["There was much variability between studies due to different criteria for visual BRD diagnosis.", [["studies", "TEST", 35, 42], ["visual BRD diagnosis", "PROBLEM", 73, 93]]], ["This variability is further influenced by the number of cattle to be managed per employee, at large facilities.", [["cattle", "ORGANISM", 56, 62], ["cattle", "SPECIES", 56, 62]]], ["For example, the reported average number of cattle at high risk of developing BRD to be managed per employee at feedlots increased from 2739 to 3464 head between 2009 and 2014, in the USA and Canada (Lee et al. 2015) .", [["head", "ANATOMY", 149, 153], ["BRD", "DISEASE", 78, 81], ["cattle", "ORGANISM", 44, 50], ["head", "ORGAN", 149, 153], ["cattle", "SPECIES", 44, 50], ["BRD", "SPECIES", 78, 81], ["developing BRD", "PROBLEM", 67, 81], ["BRD", "OBSERVATION", 78, 81]]], ["The relevance of the RCTs from this systematic review and meta-analysis also reflects the decisionmaking criteria of producers, since every identified BRD case was further treated with antimicrobials.", [["the RCTs", "TEST", 17, 25], ["this systematic review", "TEST", 31, 53], ["meta-analysis", "TEST", 58, 71], ["antimicrobials", "TREATMENT", 185, 199]]], ["Based on NNT (Fig 4) , antimicrobial mass medications had a minor effect on either reducing BRD morbidity risk or affecting the decision-making process for using further treatment antimicrobials.", [["BRD", "DISEASE", 92, 95], ["NNT (Fig", "TREATMENT", 9, 17], ["antimicrobial mass medications", "TREATMENT", 23, 53], ["reducing BRD morbidity risk", "PROBLEM", 83, 110], ["further treatment antimicrobials", "TREATMENT", 162, 194]]], ["For example, the NNT median was 7.27, or an approximate 14% reduction in ARR.", [["the NNT median", "TEST", 13, 27], ["ARR", "TEST", 73, 76]]], ["Pharmaco-economic benefits only occurred at high attack rates (e.g. \u226550%) where benefits were also variable between RCTs.DISCUSSIONConcerns have been expressed previously about the quality of RCTs for BRD, primarily for treatment trials (O'Connor et al. 2010b) .", [["BRD", "DISEASE", 201, 204], ["BRD", "PROBLEM", 201, 204], ["treatment trials", "TREATMENT", 220, 236]]], ["Generally, veterinary RCTs lag behind human RCTs in quantity and quality study design features (e.g. blinding, description of randomisation, saline-treated placebo).", [["human", "ORGANISM", 38, 43], ["saline", "SIMPLE_CHEMICAL", 141, 147], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["quality study", "TEST", 65, 78], ["saline", "TREATMENT", 141, 147], ["placebo", "TREATMENT", 156, 163]]], ["Other limitations found in this investigation included a lack of RCTs for certain antimicrobial classes and metaphylaxis definitions.", [["this investigation", "TEST", 27, 45], ["certain antimicrobial classes", "PROBLEM", 74, 103], ["metaphylaxis definitions", "PROBLEM", 108, 132]]], ["Certain types of beef production systems were under-represented (e.g. veal calves).", [["calves", "ORGANISM_SUBDIVISION", 75, 81], ["calves", "SPECIES", 75, 81], ["beef", "SPECIES", 17, 21], ["beef production systems", "PROBLEM", 17, 40]]], ["Also, not all types of non-CIAs were represented by RCTs.", [["non-CIAs", "CANCER", 23, 31], ["all types", "OBSERVATION_MODIFIER", 10, 19]]], ["More long-term studies could have better confirmed the declining benefits of initial antimicrobial mass medications.", [["term studies", "TEST", 10, 22], ["initial antimicrobial mass medications", "TREATMENT", 77, 115]]], ["Significant explanatory variables were identified, but heterogeneity remained high in the models, due to the diversity of issues explored.", [["Significant explanatory variables", "PROBLEM", 0, 33], ["the diversity of issues", "PROBLEM", 105, 128], ["high", "OBSERVATION_MODIFIER", 78, 82]]], ["Also, this heterogeneity further reflects the lack of foresight of old fashion practices of antimicrobial mass medication, based on beliefs of non-standardised risks without knowledge of the type/s of pathogens involved or antimicrobial susceptibilities.", [["antimicrobial mass medication", "TREATMENT", 92, 121], ["pathogens", "PROBLEM", 201, 210], ["antimicrobial susceptibilities", "PROBLEM", 223, 253], ["antimicrobial mass", "OBSERVATION", 92, 110]]], ["Like other food animal diseases, BRD is a disease complex encompassing multiple pathogens, and combined with a lack of foresight, will thus attract broad-spectrum antimicrobials for its successful prevention.DISCUSSIONThe results could be viewed further as general observations about antimicrobial mass medications under field conditions, describing cohorts of food animals with similar circumstances (e.g. transport, co-mingling, minimal biosecurity, broad disease definitions).", [["food animal diseases", "DISEASE", 11, 31], ["BRD", "DISEASE", 33, 36], ["BRD", "SPECIES", 33, 36], ["animal diseases", "PROBLEM", 16, 31], ["BRD", "PROBLEM", 33, 36], ["a disease complex", "PROBLEM", 40, 57], ["multiple pathogens", "PROBLEM", 71, 89], ["broad-spectrum antimicrobials", "TREATMENT", 148, 177], ["its successful prevention", "TREATMENT", 182, 207], ["antimicrobial mass medications", "TREATMENT", 284, 314], ["broad disease definitions", "PROBLEM", 452, 477], ["diseases", "OBSERVATION", 23, 31], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["pathogens", "OBSERVATION", 80, 89]]], ["Aspects of these results could fit concepts expressed in mathematical models of infectious disease transmission.", [["infectious disease transmission", "DISEASE", 80, 111], ["infectious disease transmission", "PROBLEM", 80, 111], ["infectious", "OBSERVATION_MODIFIER", 80, 90]]], ["BRD demonstrated disease patterns of low to high morbidity but consistently low mortality.", [["BRD", "DISEASE", 0, 3], ["BRD", "PROBLEM", 0, 3], ["disease patterns", "PROBLEM", 17, 33], ["low to high morbidity", "PROBLEM", 37, 58], ["consistently low mortality", "PROBLEM", 63, 89], ["disease", "OBSERVATION", 17, 24], ["low to high", "OBSERVATION_MODIFIER", 37, 48], ["morbidity", "OBSERVATION", 49, 58], ["low mortality", "OBSERVATION_MODIFIER", 76, 89]]], ["Eventually, saturation (the resulting decline in the number of susceptible individuals to infection) occurs over time (up to 90 days for BRD) with more stable population dynamics (Grassly and Fraser 2008) .", [["infection", "DISEASE", 90, 99], ["saturation", "TEST", 12, 22], ["infection", "PROBLEM", 90, 99], ["BRD", "PROBLEM", 137, 140], ["infection", "OBSERVATION", 90, 99], ["stable", "OBSERVATION_MODIFIER", 152, 158]]], ["The broad range of attack rates from RCTs reflects field variations in infectiousness (characteristics of infected individuals that determines the rate of spread to the susceptible population that can be broken down into biological, behavioural and environmental components) and susceptibility (biological, behavioural and environmental) of cohorts of cattle.", [["cattle", "ORGANISM", 352, 358], ["cattle", "SPECIES", 352, 358], ["cattle", "SPECIES", 352, 358], ["attack rates", "PROBLEM", 19, 31], ["RCTs", "TREATMENT", 37, 41], ["field variations in infectiousness", "PROBLEM", 51, 85], ["infected individuals", "PROBLEM", 106, 126], ["the susceptible population", "PROBLEM", 165, 191], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["range", "OBSERVATION_MODIFIER", 10, 15], ["infected", "OBSERVATION", 106, 114]]], ["For example, at low attack rates (<15%), the basic reproduction number (R o ) (the expected number of secondary infections resulting from infected individual/s in a population.", [["infections", "DISEASE", 112, 122], ["low attack rates", "PROBLEM", 16, 32], ["secondary infections", "PROBLEM", 102, 122], ["infected individual/s", "PROBLEM", 138, 159], ["secondary", "OBSERVATION_MODIFIER", 102, 111], ["infections", "OBSERVATION", 112, 122], ["infected", "OBSERVATION_MODIFIER", 138, 146]]], ["Mathematical models typically incorporate variables that describe the probability of transmission per animal contact, the number of contacts with the infectious animal per unit time and the duration animal/s are infectious.) is sufficiently low (<1) based on a small offspring distribution (the number of secondary infections as a function of infectiousness over time) that does not economically justify prior antimicrobial mass medications (based on NNT).", [["infections", "DISEASE", 315, 325], ["infectious", "PROBLEM", 212, 222], ["a small offspring distribution", "PROBLEM", 259, 289], ["secondary infections", "PROBLEM", 305, 325], ["infectiousness", "PROBLEM", 343, 357], ["prior antimicrobial mass medications", "TREATMENT", 404, 440], ["infectious", "OBSERVATION", 212, 222], ["low", "OBSERVATION_MODIFIER", 241, 244], ["small", "OBSERVATION_MODIFIER", 261, 266], ["offspring", "OBSERVATION_MODIFIER", 267, 276], ["distribution", "OBSERVATION_MODIFIER", 277, 289], ["secondary", "OBSERVATION_MODIFIER", 305, 314], ["infections", "OBSERVATION", 315, 325]]], ["Under these circumstances, the disease could die out (R o < 1) or become endemic (R o = 1), but unlikely to progress to an epidemic (R o > 1).", [["the disease", "PROBLEM", 27, 38], ["endemic", "PROBLEM", 73, 80], ["disease", "OBSERVATION", 31, 38], ["endemic", "OBSERVATION", 73, 80]]], ["A morbidity threshold does exist where antimicrobial mass medications provided more consistent reductions in morbidity risk (Figs 2 and 3) , but negligible effect on mortality (Fig. 5b) .", [["A morbidity threshold", "PROBLEM", 0, 21], ["antimicrobial mass medications", "TREATMENT", 39, 69], ["morbidity risk", "PROBLEM", 109, 123], ["Figs", "TEST", 125, 129], ["morbidity", "OBSERVATION", 2, 11], ["reductions", "OBSERVATION_MODIFIER", 95, 105]]], ["This is broadly consistent with general observations that a disproportionate amount of disease transmission results from a small fraction of infected individuals (Grassly and Fraser 2008) .", [["disease transmission", "PROBLEM", 87, 107], ["infected individuals", "PROBLEM", 141, 161], ["consistent with", "UNCERTAINTY", 16, 31], ["disproportionate", "OBSERVATION_MODIFIER", 60, 76], ["amount", "OBSERVATION_MODIFIER", 77, 83], ["disease", "OBSERVATION", 87, 94], ["small", "OBSERVATION_MODIFIER", 123, 128], ["fraction", "OBSERVATION_MODIFIER", 129, 137], ["infected", "OBSERVATION_MODIFIER", 141, 149]]], ["The random effects among individuals tend to cancel each other out as the number of infected individuals increases, resulting in a more predictable progression to epidemic dynamics.", [["infected individuals", "PROBLEM", 84, 104], ["epidemic dynamics", "PROBLEM", 163, 180], ["infected", "OBSERVATION", 84, 92]]], ["Antimicrobial mass medications represent the main intervention for BRD (i.e. R o -1) to prevent/control an epidemic.", [["BRD", "DISEASE", 67, 70], ["BRD", "SPECIES", 67, 70], ["Antimicrobial mass medications", "TREATMENT", 0, 30], ["the main intervention", "TREATMENT", 41, 62], ["BRD", "PROBLEM", 67, 70], ["an epidemic", "PROBLEM", 104, 115], ["mass", "OBSERVATION", 14, 18], ["epidemic", "OBSERVATION", 107, 115]]], ["The results of this investigation revealed that the impact of this intervention was influenced by the duration of the RCTs.", [["this investigation", "TEST", 15, 33], ["this intervention", "TREATMENT", 62, 79]]], ["For example, the highest impact clustered with only short and small RCTs (\u226430 days) (Fig. 5) , with progressively less impact over longer and larger RCTs.", [["highest", "OBSERVATION_MODIFIER", 17, 24], ["short", "OBSERVATION_MODIFIER", 52, 57], ["small", "OBSERVATION_MODIFIER", 62, 67], ["RCTs", "OBSERVATION", 68, 72], ["progressively", "OBSERVATION_MODIFIER", 100, 113], ["less", "OBSERVATION_MODIFIER", 114, 118], ["impact", "OBSERVATION_MODIFIER", 119, 125], ["larger", "OBSERVATION_MODIFIER", 142, 148], ["RCTs", "OBSERVATION", 149, 153]]], ["Longer RCTs better reflect feedlot/veal facilities, since cattle are typically kept for months.", [["cattle", "ORGANISM", 58, 64], ["cattle", "SPECIES", 58, 64], ["cattle", "SPECIES", 58, 64]]], ["Also, high variability from antimicrobial interventions reflects the complex BRD infectious disease dynamics, where the likelihood of each of three possible outcome population scenarios (endemic, epidemic, disease die out) is dependent on factors, including:DISCUSSIONI.", [["BRD infectious disease", "DISEASE", 77, 99], ["high variability", "PROBLEM", 6, 22], ["antimicrobial interventions", "TREATMENT", 28, 55], ["the complex BRD infectious disease dynamics", "PROBLEM", 65, 108], ["outcome population scenarios", "PROBLEM", 157, 185], ["high variability", "OBSERVATION_MODIFIER", 6, 22], ["complex", "OBSERVATION_MODIFIER", 69, 76], ["BRD", "OBSERVATION_MODIFIER", 77, 80], ["infectious", "OBSERVATION", 81, 91]]], ["Herd immunity-when a significant proportion of the population have immunity (e.g. vaccines, natural acquired or colostral immunity).", [["colostral", "ORGANISM_SUBDIVISION", 112, 121], ["immunity (e.g. vaccines", "TREATMENT", 67, 90]]], ["Thus, more difficult for diseases to spread between individuals if a proportion are already immune, breaking the 'chain of infection'.", [["infection", "DISEASE", 123, 132], ["diseases", "PROBLEM", 25, 33], ["infection'", "PROBLEM", 123, 133], ["infection", "OBSERVATION", 123, 132]]], ["II.", [["II", "CHEMICAL", 0, 2]]], ["Animal stress factors that promote immunosuppression (e.g. weaning, castration, dehorning) III.", [["Animal stress factors", "PROBLEM", 0, 21], ["immunosuppression (e.g. weaning", "TREATMENT", 35, 66], ["castration", "TREATMENT", 68, 78]]], ["Animal husbandry practices that promote contagious diseases (e.g. stocking density, transport of animals, comingling animals from different sources, poor biosecurity).", [["contagious diseases", "PROBLEM", 40, 59], ["contagious", "OBSERVATION_MODIFIER", 40, 50]]], ["IV.", [["IV", "TREATMENT", 0, 2]]], ["Characteristics of the bacterial clone involved in the disease (e.g. virulence factors, antigenicity, previous exposure to the population).DISCUSSIONAlthough RCTs results for BRD mortality were confounded by previous treatment of BRD cattle, it does reveal an interesting aspect.", [["clone", "ANATOMY", 33, 38], ["BRD", "DISEASE", 175, 178], ["BRD", "DISEASE", 230, 233], ["bacterial clone", "CELL", 23, 38], ["virulence factors", "PROTEIN", 69, 86], ["cattle", "SPECIES", 234, 240], ["BRD", "SPECIES", 175, 178], ["BRD", "SPECIES", 230, 233], ["cattle", "SPECIES", 234, 240], ["the bacterial clone", "PROBLEM", 19, 38], ["the disease (e.g. virulence factors", "PROBLEM", 51, 86], ["RCTs", "TEST", 158, 162], ["BRD mortality", "PROBLEM", 175, 188], ["BRD cattle", "PROBLEM", 230, 240], ["bacterial clone", "OBSERVATION", 23, 38], ["disease", "OBSERVATION", 55, 62]]], ["The majority of RCTs reported zero mortality in control groups based on a 'treatment-only' strategy of visual BRD cases, with no prior mass medication, as just an effective method of preventing mortality.CONCLUSIONSPrudent use of antimicrobials is the judicious practice of medical principles, as 'the cost-effective use of antimicrobials which maximises clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance'.", [["visual BRD", "DISEASE", 103, 113], ["toxicity", "DISEASE", 418, 426], ["zero mortality in control groups", "PROBLEM", 30, 62], ["a 'treatment", "TREATMENT", 72, 84], ["visual BRD cases", "PROBLEM", 103, 119], ["prior mass medication", "TREATMENT", 129, 150], ["antimicrobials", "TREATMENT", 230, 244], ["medical principles", "TREATMENT", 274, 292], ["antimicrobials", "TREATMENT", 324, 338], ["related toxicity", "PROBLEM", 410, 426], ["antimicrobial resistance'", "TREATMENT", 450, 475], ["antimicrobial resistance", "OBSERVATION", 450, 474]]], ["This includes an accurate diagnosis, short-term effective first antimicrobial professional prescriptions based on microbial sensitivity or proven efficacy (RCTs, safety, PK/PD, spectrum of activity) and low impact on selecting antimicrobial-resistant bacteria.", [["first antimicrobial professional prescriptions", "TREATMENT", 58, 104], ["microbial sensitivity", "TEST", 114, 135], ["RCTs", "TEST", 156, 160], ["PK/PD", "TREATMENT", 170, 175], ["low impact", "PROBLEM", 203, 213], ["selecting antimicrobial", "TREATMENT", 217, 240], ["resistant bacteria", "PROBLEM", 241, 259]]], ["BRD antimicrobial mass medications fails in aspects of prudent use in that the disease to prevent is poorly distinguishable from primary viral or cases with lung lesions, and without knowledge of inciting pathogen/s or microbial sensitivity.", [["lung lesions", "ANATOMY", 157, 169], ["BRD", "DISEASE", 0, 3], ["lung lesions", "DISEASE", 157, 169], ["lung lesions", "PATHOLOGICAL_FORMATION", 157, 169], ["BRD antimicrobial mass medications", "TREATMENT", 0, 34], ["the disease", "PROBLEM", 75, 86], ["lung lesions", "PROBLEM", 157, 169], ["inciting pathogen/s", "PROBLEM", 196, 215], ["microbial sensitivity", "PROBLEM", 219, 240], ["antimicrobial", "OBSERVATION_MODIFIER", 4, 17], ["mass", "OBSERVATION", 18, 22], ["disease", "OBSERVATION", 79, 86], ["lung", "ANATOMY", 157, 161], ["lesions", "OBSERVATION", 162, 169]]], ["This systematic review and meta-analysis of RCTs revealed that antimicrobial mass medications lead to a mean overall relative reduction in disease burden but did not economically lower the absolute risk for either displaying visual BRD symptoms or being selected for further antimicrobial treatments.", [["visual BRD symptoms", "DISEASE", 225, 244], ["This systematic review", "TEST", 0, 22], ["meta-analysis of RCTs", "TEST", 27, 48], ["antimicrobial mass medications", "TREATMENT", 63, 93], ["disease burden", "PROBLEM", 139, 153], ["visual BRD symptoms", "PROBLEM", 225, 244], ["further antimicrobial treatments", "TREATMENT", 267, 299], ["antimicrobial", "OBSERVATION_MODIFIER", 63, 76], ["mass", "OBSERVATION", 77, 81], ["reduction", "OBSERVATION_MODIFIER", 126, 135], ["disease", "OBSERVATION", 139, 146]]], ["Metaphylaxis has a similar impact as prophylaxis, but the potential for lower antimicrobial consumption with an appropriate morbidity threshold definition that eliminates the least efficient (highest NNT) possibilities and prevents an epidemic.", [["Metaphylaxis", "DISEASE", 0, 12], ["Metaphylaxis", "TREATMENT", 0, 12], ["prophylaxis", "TREATMENT", 37, 48], ["lower antimicrobial consumption", "TREATMENT", 72, 103], ["an epidemic", "PROBLEM", 232, 243], ["epidemic", "OBSERVATION_MODIFIER", 235, 243]]], ["Prophylaxis/metaphylaxis for BRD represents major antimicrobial consumption for highly variable short-term gains in ARR, whereas RCTs of longer duration (e.g. >30 days) show progressive dampened variable ARR.", [["BRD", "DISEASE", 29, 32], ["BRD", "SPECIES", 29, 32], ["Prophylaxis", "TREATMENT", 0, 11], ["metaphylaxis", "TREATMENT", 12, 24], ["BRD", "PROBLEM", 29, 32], ["major antimicrobial consumption", "TREATMENT", 44, 75], ["highly variable short-term gains in ARR", "PROBLEM", 80, 119], ["progressive dampened variable ARR", "PROBLEM", 174, 207], ["progressive", "OBSERVATION_MODIFIER", 174, 185], ["dampened", "OBSERVATION", 186, 194], ["variable ARR", "OBSERVATION", 195, 207]]], ["Antimicrobial mass medications can also be associated with negligible improvements or worsened BRD morbidity/mortality.", [["BRD", "DISEASE", 95, 98], ["Antimicrobial mass medications", "TREATMENT", 0, 30], ["worsened BRD morbidity/mortality", "PROBLEM", 86, 118], ["mass", "OBSERVATION", 14, 18], ["worsened", "OBSERVATION_MODIFIER", 86, 94]]]], "60e7e9768252f36b63720b7ad9a1ffd5b339990e": [["B oth angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have repeatedly, but not consistently, been documented to slow progression of pulmonary complications in vulnerable patients.", [["pulmonary", "ANATOMY", 177, 186], ["angiotensin", "CHEMICAL", 6, 17], ["angiotensin II", "CHEMICAL", 59, 73], ["pulmonary complications", "DISEASE", 177, 200], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 6, 35], ["ACEIs", "SIMPLE_CHEMICAL", 48, 53], ["angiotensin II receptor blockers", "SIMPLE_CHEMICAL", 59, 91], ["ARBs", "SIMPLE_CHEMICAL", 93, 97], ["pulmonary", "ORGAN", 177, 186], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["B oth angiotensin", "TREATMENT", 0, 17], ["enzyme inhibitors", "TREATMENT", 29, 46], ["ACEIs", "TREATMENT", 48, 53], ["angiotensin II receptor blockers", "TREATMENT", 59, 91], ["ARBs", "TEST", 93, 97], ["pulmonary complications", "PROBLEM", 177, 200], ["slow", "OBSERVATION_MODIFIER", 157, 161], ["progression", "OBSERVATION_MODIFIER", 162, 173], ["pulmonary", "ANATOMY", 177, 186], ["complications", "OBSERVATION", 187, 200]]], ["A previously published meta-analysis pointed toward a putative protective role of ACEIs, and to lesser extent of ARBs, in risk of community acquired pneumonia.", [["pneumonia", "DISEASE", 149, 158], ["ACEIs", "SIMPLE_CHEMICAL", 82, 87], ["A previously published meta-analysis", "PROBLEM", 0, 36], ["ACEIs", "TREATMENT", 82, 87], ["ARBs", "TREATMENT", 113, 117], ["community acquired pneumonia", "PROBLEM", 130, 158], ["ACEIs", "OBSERVATION", 82, 87], ["ARBs", "OBSERVATION", 113, 117], ["community acquired", "OBSERVATION", 130, 148], ["pneumonia", "OBSERVATION", 149, 158]]], ["ACEIs in 7 studies were associated with decreased pneumonia mortality compared with control treatment (odds ratio [OR] 0.66 [95% CI, 0.55-0.80]).", [["pneumonia", "DISEASE", 50, 59], ["ACEIs", "TREATMENT", 0, 5], ["decreased pneumonia mortality", "PROBLEM", 40, 69], ["control treatment", "TREATMENT", 84, 101], ["CI", "TEST", 129, 131], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["pneumonia", "OBSERVATION", 50, 59]]], ["ARBs in 1 randomized controlled trial only showed a reduction of borderline significance (OR 0.63 [95% CI, 0.40-1.00]).", [["ARBs", "TEST", 0, 4], ["a reduction of borderline significance", "PROBLEM", 50, 88], ["CI", "TEST", 103, 105], ["reduction", "OBSERVATION_MODIFIER", 52, 61]]], ["1 These seemingly beneficial findings of renin angiotensin system (RAS) blockade on outcomes in pneumonia resurfaced in the recent literature in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), infection.", [["angiotensin", "CHEMICAL", 47, 58], ["pneumonia", "DISEASE", 96, 105], ["acute respiratory syndrome coronavirus", "DISEASE", 164, 202], ["coronavirus disease", "DISEASE", 233, 252], ["COVID-19", "CHEMICAL", 259, 267], ["infection", "DISEASE", 270, 279], ["renin angiotensin system", "GENE_OR_GENE_PRODUCT", 41, 65], ["RAS", "GENE_OR_GENE_PRODUCT", 67, 70], ["SARS-CoV-2", "ORGANISM", 206, 216], ["renin", "PROTEIN", 41, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 157, 202], ["SARS-CoV-2", "SPECIES", 206, 216], ["renin angiotensin system", "TREATMENT", 41, 65], ["RAS) blockade", "TREATMENT", 67, 80], ["pneumonia", "PROBLEM", 96, 105], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 157, 202], ["SARS-CoV", "TEST", 206, 214], ["coronavirus disease", "PROBLEM", 233, 252], ["COVID", "TEST", 259, 264], ["infection", "PROBLEM", 270, 279], ["pneumonia", "OBSERVATION", 96, 105], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["respiratory syndrome", "OBSERVATION", 170, 190], ["coronavirus disease", "OBSERVATION", 233, 252], ["infection", "OBSERVATION", 270, 279]]], ["Several potential therapeutic/preventive approaches to address angiotensin-converting enzyme 2 (ACE2)-mediated COVID-19 have been described, including the suggestion that ARBs could be administered in the form of a nasal spray to treat COVID-19.", [["nasal", "ANATOMY", 215, 220], ["angiotensin", "CHEMICAL", 63, 74], ["ARBs", "CHEMICAL", 171, 175], ["COVID-19", "CHEMICAL", 236, 244], ["COVID-19", "CHEMICAL", 111, 119], ["COVID-19", "CHEMICAL", 236, 244], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 63, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["COVID-19", "GENE_OR_GENE_PRODUCT", 111, 119], ["ARBs", "SIMPLE_CHEMICAL", 171, 175], ["nasal", "ORGANISM_SUBDIVISION", 215, 220], ["angiotensin-converting enzyme 2", "PROTEIN", 63, 94], ["ACE2", "PROTEIN", 96, 100], ["preventive approaches", "TREATMENT", 30, 51], ["angiotensin-converting enzyme", "TREATMENT", 63, 92], ["ACE2)-mediated COVID", "TREATMENT", 96, 116], ["ARBs", "TREATMENT", 171, 175], ["a nasal spray", "TREATMENT", 213, 226], ["COVID", "TEST", 236, 241]]], ["Because pneumonia is a common potentially fatal complication in COVID-19 infection, we wondered whether RAS blockade could exert a favorable effect on pneumonia-related outcomes.EVIDENCE OF ACEI/ARB THERAPY AND VIRAL INFECTIONS OF RESPIRATORY SYSTEMWe systematically reviewed the literature for evidence from animal models and clinical data related to the role of ACEIs/ARBs and viral infections.", [["pneumonia", "DISEASE", 8, 17], ["infection", "DISEASE", 73, 82], ["pneumonia", "DISEASE", 151, 160], ["ACEIs", "CHEMICAL", 364, 369], ["viral infections", "DISEASE", 379, 395], ["COVID-19", "CELL", 64, 72], ["RAS", "GENE_OR_GENE_PRODUCT", 104, 107], ["ACEIs", "GENE_OR_GENE_PRODUCT", 364, 369], ["ARBs", "GENE_OR_GENE_PRODUCT", 370, 374], ["COVID-19", "SPECIES", 64, 72], ["pneumonia", "PROBLEM", 8, 17], ["fatal complication", "PROBLEM", 42, 60], ["COVID-19 infection", "PROBLEM", 64, 82], ["RAS blockade", "TREATMENT", 104, 116], ["pneumonia", "PROBLEM", 151, 160], ["ACEI/ARB THERAPY", "TREATMENT", 190, 206], ["animal models", "PROBLEM", 309, 322], ["clinical data", "TEST", 327, 340], ["ACEIs", "TREATMENT", 364, 369], ["ARBs", "TREATMENT", 370, 374], ["viral infections", "PROBLEM", 379, 395], ["pneumonia", "OBSERVATION", 8, 17], ["common potentially", "UNCERTAINTY", 23, 41], ["fatal", "OBSERVATION_MODIFIER", 42, 47], ["complication", "OBSERVATION", 48, 60], ["infection", "OBSERVATION", 73, 82], ["favorable", "OBSERVATION_MODIFIER", 131, 140], ["pneumonia", "OBSERVATION", 151, 160], ["ACEI", "OBSERVATION", 190, 194], ["ARB THERAPY", "OBSERVATION", 195, 206], ["viral infections", "OBSERVATION", 379, 395]]], ["We searched PubMed and EMBASE for original research on animals or humans investigating the impact of ACEIs/ARBs on viral infections.", [["ACEIs", "CHEMICAL", 101, 106], ["ARBs", "CHEMICAL", 107, 111], ["viral infections", "DISEASE", 115, 131], ["humans", "ORGANISM", 66, 72], ["ACEIs", "SIMPLE_CHEMICAL", 101, 106], ["ARBs", "SIMPLE_CHEMICAL", 107, 111], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["ACEIs", "TREATMENT", 101, 106], ["ARBs", "TREATMENT", 107, 111], ["viral infections", "PROBLEM", 115, 131], ["viral infections", "OBSERVATION", 115, 131]]], ["The following search terms were used: viral, virus, infect, pneumonia, acute respiratory distress syndrome, acute lung injury, and angiotensin.", [["respiratory", "ANATOMY", 77, 88], ["lung", "ANATOMY", 114, 118], ["pneumonia", "DISEASE", 60, 69], ["acute respiratory distress syndrome", "DISEASE", 71, 106], ["acute lung injury", "DISEASE", 108, 125], ["angiotensin", "CHEMICAL", 131, 142], ["lung", "ORGAN", 114, 118], ["angiotensin", "GENE_OR_GENE_PRODUCT", 131, 142], ["viral, virus", "PROBLEM", 38, 50], ["infect", "PROBLEM", 52, 58], ["pneumonia", "PROBLEM", 60, 69], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["acute lung injury", "PROBLEM", 108, 125], ["angiotensin", "PROBLEM", 131, 142], ["pneumonia", "OBSERVATION", 60, 69], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory distress syndrome", "OBSERVATION", 77, 106], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["lung", "ANATOMY", 114, 118], ["injury", "OBSERVATION", 119, 125], ["angiotensin", "OBSERVATION_MODIFIER", 131, 142]]], ["Overall, we identified 4 studies 2-5 evaluating the role of ACEIs/ ARBs in viral infections of respiratory system.", [["respiratory system", "ANATOMY", 95, 113], ["ACEIs", "CHEMICAL", 60, 65], ["ARBs", "CHEMICAL", 67, 71], ["viral infections", "DISEASE", 75, 91], ["ACEIs", "GENE_OR_GENE_PRODUCT", 60, 65], ["ARBs", "SIMPLE_CHEMICAL", 67, 71], ["4 studies", "TEST", 23, 32], ["ACEIs", "TREATMENT", 60, 65], ["ARBs", "TREATMENT", 67, 71], ["viral infections of respiratory system", "PROBLEM", 75, 113], ["viral infections", "OBSERVATION", 75, 91], ["respiratory system", "ANATOMY", 95, 113]]], ["In 3 studies of animal models, 2-4 virusinduced lung injury and the role of losartan was tested; all reported a key role of decreased RAS activation through losartan (Table) .", [["lung", "ANATOMY", 48, 52], ["lung injury", "DISEASE", 48, 59], ["losartan", "CHEMICAL", 76, 84], ["losartan", "CHEMICAL", 157, 165], ["losartan", "CHEMICAL", 76, 84], ["losartan", "CHEMICAL", 157, 165], ["lung", "ORGAN", 48, 52], ["losartan", "SIMPLE_CHEMICAL", 76, 84], ["RAS", "GENE_OR_GENE_PRODUCT", 134, 137], ["losartan", "SIMPLE_CHEMICAL", 157, 165], ["RAS", "PROTEIN", 134, 137], ["animal models", "TEST", 16, 29], ["4 virusinduced lung injury", "PROBLEM", 33, 59], ["losartan", "TREATMENT", 76, 84], ["losartan", "TREATMENT", 157, 165], ["lung", "ANATOMY", 48, 52], ["injury", "OBSERVATION", 53, 59]]], ["In 1 retrospective study, 5 lower rates of death and intubation were noted among patients who continued to be on ACEIs during hospitalization (OR 0.25 [95% CI, 0.09-0.64]).", [["death", "DISEASE", 43, 48], ["ACEIs", "CHEMICAL", 113, 118], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["1 retrospective study", "TEST", 3, 24], ["death", "PROBLEM", 43, 48], ["intubation", "TREATMENT", 53, 63], ["ACEIs", "TREATMENT", 113, 118], ["CI", "TEST", 156, 158]]], ["We did not find evidence supporting the continuation, withdrawal, or de novo initiation of ACEIs/ ARBs in patients with SARS-CoV-2-infection.COVID-19 AND HYPERTENSIONEpidemiological data suggest that patients with cardiovascular disease and hypertension are more susceptible to SARS-CoV-2-infection and that the course of pneumonia is more severe in hypertensive relative to normotensive subjects.COVID-19 AND HYPERTENSIONCOVID-19-associated pneumonia death cases were marked by more comorbidities, such as cardiovascular disease (22.7%) and hypertension (39.7%).", [["cardiovascular", "ANATOMY", 214, 228], ["cardiovascular", "ANATOMY", 507, 521], ["ACEIs/ ARBs", "CHEMICAL", 91, 102], ["SARS-CoV-2-infection", "DISEASE", 120, 140], ["cardiovascular disease", "DISEASE", 214, 236], ["hypertension", "DISEASE", 241, 253], ["SARS", "DISEASE", 278, 282], ["infection", "DISEASE", 289, 298], ["pneumonia", "DISEASE", 322, 331], ["hypertensive", "DISEASE", 350, 362], ["pneumonia", "DISEASE", 442, 451], ["death", "DISEASE", 452, 457], ["cardiovascular disease", "DISEASE", 507, 529], ["hypertension", "DISEASE", 542, 554], ["ACEIs", "SIMPLE_CHEMICAL", 91, 96], ["ARBs", "SIMPLE_CHEMICAL", 98, 102], ["patients", "ORGANISM", 106, 114], ["SARS-CoV-2", "ORGANISM", 120, 130], ["patients", "ORGANISM", 200, 208], ["cardiovascular", "ANATOMICAL_SYSTEM", 214, 228], ["SARS-CoV-2", "ORGANISM", 278, 288], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 200, 208], ["SARS-CoV", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 278, 286], ["withdrawal", "PROBLEM", 54, 64], ["ACEIs", "TREATMENT", 91, 96], ["ARBs", "TREATMENT", 98, 102], ["SARS", "PROBLEM", 120, 124], ["CoV-2", "PROBLEM", 125, 130], ["infection", "PROBLEM", 131, 140], ["COVID", "TEST", 141, 146], ["HYPERTENSIONEpidemiological data", "TEST", 154, 186], ["cardiovascular disease", "PROBLEM", 214, 236], ["hypertension", "PROBLEM", 241, 253], ["SARS", "PROBLEM", 278, 282], ["CoV", "PROBLEM", 283, 286], ["infection", "PROBLEM", 289, 298], ["pneumonia", "PROBLEM", 322, 331], ["hypertensive", "PROBLEM", 350, 362], ["normotensive subjects", "PROBLEM", 375, 396], ["COVID", "TEST", 397, 402], ["HYPERTENSIONCOVID", "TEST", 410, 427], ["pneumonia death cases", "PROBLEM", 442, 463], ["cardiovascular disease", "PROBLEM", 507, 529], ["hypertension", "PROBLEM", 542, 554], ["infection", "OBSERVATION", 131, 140], ["hypertension", "OBSERVATION", 241, 253], ["infection", "OBSERVATION", 289, 298], ["pneumonia", "OBSERVATION", 322, 331], ["more severe", "OBSERVATION_MODIFIER", 335, 346], ["pneumonia", "OBSERVATION", 442, 451], ["cardiovascular", "ANATOMY", 507, 521], ["hypertension", "OBSERVATION", 542, 554]]], ["Considerably higher is the prevalence of these comorbidities in black patients.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["these comorbidities", "PROBLEM", 41, 60], ["higher", "OBSERVATION_MODIFIER", 13, 19]]], ["However, susceptibility for infection and complications may be explained by advanced age and multiple comorbidities in many patients.", [["infection", "DISEASE", 28, 37], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["infection", "PROBLEM", 28, 37], ["complications", "PROBLEM", 42, 55], ["multiple comorbidities", "PROBLEM", 93, 115], ["infection", "OBSERVATION", 28, 37], ["multiple", "OBSERVATION_MODIFIER", 93, 101], ["comorbidities", "OBSERVATION", 102, 115]]], ["Two large independent studies of influenza type A H1N1 have documented a higher prevalence of hypertension and diabetes.", [["influenza type A H1N1", "DISEASE", 33, 54], ["hypertension", "DISEASE", 94, 106], ["diabetes", "DISEASE", 111, 119], ["influenza type A H1N1", "ORGANISM", 33, 54], ["A H1N1", "SPECIES", 48, 54], ["influenza type A H1N1", "SPECIES", 33, 54], ["influenza type A H1N1", "PROBLEM", 33, 54], ["hypertension", "PROBLEM", 94, 106], ["diabetes", "PROBLEM", 111, 119], ["large", "OBSERVATION_MODIFIER", 4, 9], ["influenza", "OBSERVATION", 33, 42], ["hypertension", "OBSERVATION", 94, 106], ["diabetes", "OBSERVATION", 111, 119]]], ["Thus, confounding is likely to be extensive.POSSIBLE MECHANISMSSARS-CoV-2, the recently identified strain responsible for the current COVID-19 epidemic, relies on ACE2 protein as a cellular entry receptor by binding with its spike protein, similar to SARS-CoV.", [["cellular", "ANATOMY", 181, 189], ["SARS", "DISEASE", 251, 255], ["CoV-2", "ORGANISM", 68, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 163, 167], ["cellular", "CELL", 181, 189], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 251, 259], ["ACE2 protein", "PROTEIN", 163, 175], ["cellular entry receptor", "PROTEIN", 181, 204], ["spike protein", "PROTEIN", 225, 238], ["SARS-CoV", "SPECIES", 251, 259], ["MECHANISMSSARS", "TEST", 53, 67], ["strain", "PROBLEM", 99, 105], ["the current COVID", "TEST", 122, 139], ["epidemic", "PROBLEM", 143, 151], ["ACE2 protein", "TREATMENT", 163, 175], ["its spike protein", "PROBLEM", 221, 238], ["is likely to be", "UNCERTAINTY", 18, 33], ["extensive", "OBSERVATION", 34, 43]]], ["ACE2 participates in a pathway that is counter-regulatory to the effects of angiotensin II, and the cardiorenal protective effect of ARBs may be attributable in part to increased metabolism of angiotensin II by ACE2.", [["angiotensin II", "CHEMICAL", 76, 90], ["ARBs", "CHEMICAL", 133, 137], ["angiotensin II", "CHEMICAL", 193, 207], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 76, 90], ["ARBs", "SIMPLE_CHEMICAL", 133, 137], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 193, 207], ["ACE2", "GENE_OR_GENE_PRODUCT", 211, 215], ["ACE2", "PROTEIN", 0, 4], ["angiotensin II", "PROTEIN", 76, 90], ["angiotensin II", "PROTEIN", 193, 207], ["ACE2", "PROTEIN", 211, 215], ["angiotensin II", "TREATMENT", 76, 90], ["ARBs", "TREATMENT", 133, 137], ["angiotensin II", "TREATMENT", 193, 207], ["cardiorenal", "ANATOMY", 100, 111]]], ["Importantly, ACE2 expression protects from lung injury, an action which is downregulated by binding of SARS-CoV via its spike protein.POSSIBLE MECHANISMSExperimentally and in humans, RAS blockade has been shown to upregulate ACE2 activity, thereby potentially antagonizing some effects of COVID-19.", [["lung", "ANATOMY", 43, 47], ["lung injury", "DISEASE", 43, 54], ["COVID-19", "CHEMICAL", 289, 297], ["COVID-19", "CHEMICAL", 289, 297], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["lung", "ORGAN", 43, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["humans", "ORGANISM", 175, 181], ["RAS", "GENE_OR_GENE_PRODUCT", 183, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 225, 229], ["COVID-19", "GENE_OR_GENE_PRODUCT", 289, 297], ["ACE2", "PROTEIN", 13, 17], ["spike protein", "PROTEIN", 120, 133], ["ACE2", "PROTEIN", 225, 229], ["humans", "SPECIES", 175, 181], ["SARS-CoV", "SPECIES", 103, 111], ["humans", "SPECIES", 175, 181], ["lung injury", "PROBLEM", 43, 54], ["SARS", "PROBLEM", 103, 107], ["its spike protein", "PROBLEM", 116, 133], ["MECHANISMSExperimentally", "PROBLEM", 143, 167], ["RAS blockade", "TREATMENT", 183, 195], ["COVID", "TEST", 289, 294], ["lung", "ANATOMY", 43, 47], ["injury", "OBSERVATION", 48, 54]]], ["Injection of SARS-CoV spike protein into mice worsens acute lung failure in vivo that can be attenuated by inhibiting the RAS pathway.", [["lung", "ANATOMY", 60, 64], ["SARS", "DISEASE", 13, 17], ["acute lung failure", "DISEASE", 54, 72], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["mice", "ORGANISM", 41, 45], ["lung", "ORGAN", 60, 64], ["RAS", "GENE_OR_GENE_PRODUCT", 122, 125], ["SARS-CoV spike protein", "PROTEIN", 13, 35], ["RAS", "PROTEIN", 122, 125], ["mice", "SPECIES", 41, 45], ["SARS-CoV", "SPECIES", 13, 21], ["mice", "SPECIES", 41, 45], ["SARS", "PROBLEM", 13, 17], ["CoV spike protein", "TREATMENT", 18, 35], ["acute lung failure", "PROBLEM", 54, 72], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["lung", "ANATOMY", 60, 64], ["failure", "OBSERVATION", 65, 72]]], ["2 Conversely, speculation has been put forward that the enhanced ACE2 expression with RAS antagonists might increase the number of binding sites thereby increasing the odds of infection with SARS-CoV-2.CLINICAL IMPLICATIONSGiven that ACE2 is a cellular entry receptor for SARS-CoV-2, careful evaluation of efficacy and safety of antihypertensive therapy with RAS blockade is needed.", [["cellular", "ANATOMY", 244, 252], ["infection", "DISEASE", 176, 185], ["SARS", "DISEASE", 191, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["RAS antagonists", "GENE_OR_GENE_PRODUCT", 86, 101], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 191, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 234, 238], ["cellular", "CELL", 244, 252], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 272, 282], ["RAS", "GENE_OR_GENE_PRODUCT", 359, 362], ["ACE2", "PROTEIN", 65, 69], ["ACE2", "PROTEIN", 234, 238], ["cellular entry receptor", "PROTEIN", 244, 267], ["SARS-CoV", "SPECIES", 191, 199], ["the enhanced ACE2 expression", "TREATMENT", 52, 80], ["RAS antagonists", "TREATMENT", 86, 101], ["binding sites", "PROBLEM", 131, 144], ["infection", "PROBLEM", 176, 185], ["SARS", "PROBLEM", 272, 276], ["CoV", "TEST", 277, 280], ["careful evaluation", "TEST", 284, 302], ["antihypertensive therapy", "TREATMENT", 329, 353], ["RAS blockade", "TREATMENT", 359, 371], ["infection", "OBSERVATION", 176, 185]]], ["There is experimental and clinical evidence that RAS blockade can mitigate pulmonary outcome in some forms of viral pneumonia.", [["pulmonary", "ANATOMY", 75, 84], ["viral pneumonia", "DISEASE", 110, 125], ["RAS", "GENE_OR_GENE_PRODUCT", 49, 52], ["pulmonary", "ORGAN", 75, 84], ["RAS blockade", "TREATMENT", 49, 61], ["pulmonary outcome", "PROBLEM", 75, 92], ["viral pneumonia", "PROBLEM", 110, 125], ["pulmonary", "ANATOMY", 75, 84], ["viral", "OBSERVATION_MODIFIER", 110, 115], ["pneumonia", "OBSERVATION", 116, 125]]], ["Presently, there are no data regarding a favorable effect of RAS blockade on pulmonary outcome in SARS-CoV-2-infected patients.", [["pulmonary", "ANATOMY", 77, 86], ["SARS-CoV-2-infected", "DISEASE", 98, 117], ["RAS", "GENE_OR_GENE_PRODUCT", 61, 64], ["pulmonary", "ORGAN", 77, 86], ["SARS-CoV-2", "ORGANISM", 98, 108], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["SARS-CoV", "SPECIES", 98, 106], ["RAS blockade", "TREATMENT", 61, 73], ["pulmonary outcome", "PROBLEM", 77, 94], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["pulmonary", "ANATOMY", 77, 86], ["infected", "OBSERVATION", 109, 117]]], ["Whether or not infectivity to viral infection is increased in patients treated with RAS blockers remains unknown.", [["viral infection", "DISEASE", 30, 45], ["patients", "ORGANISM", 62, 70], ["RAS", "GENE_OR_GENE_PRODUCT", 84, 87], ["patients", "SPECIES", 62, 70], ["viral infection", "PROBLEM", 30, 45], ["RAS blockers", "TREATMENT", 84, 96], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45], ["increased", "OBSERVATION_MODIFIER", 49, 58]]], ["However, recent news media coverage of this issue has provoked concern and unfortunately even motivated some patients to discontinue RAS blockers all together.", [["patients", "ORGANISM", 109, 117], ["RAS", "GENE_OR_GENE_PRODUCT", 133, 136], ["patients", "SPECIES", 109, 117], ["recent news media coverage", "TREATMENT", 9, 35], ["RAS blockers", "TREATMENT", 133, 145]]], ["Of note, the RAS effects among available blockers is markedly different.", [["RAS", "GENE_OR_GENE_PRODUCT", 13, 16], ["available blockers", "TREATMENT", 31, 49], ["markedly", "OBSERVATION_MODIFIER", 53, 61], ["different", "OBSERVATION_MODIFIER", 62, 71]]], ["Direct renin inhibitors ACE indicate angiotensin-converting enzyme; ACEI, angiotensin-converting enzyme inhibitor; ALI, acute-lung injury; ARB, angiotensin II receptor blocker; AT1, angiotensin 1; PCR, polymerase chain reaction; RAS, renin-angiotensin system; RSV, respiratory syncytial virus; and SARS-CoV, severe acute respiratory syndromecoronavirus.CLINICAL IMPLICATIONShave been shown to diminish activity of the RAS and also downregulate ACE2 in animal models.", [["lung", "ANATOMY", 126, 130], ["respiratory", "ANATOMY", 321, 332], ["angiotensin", "CHEMICAL", 37, 48], ["ACEI", "CHEMICAL", 68, 72], ["angiotensin", "CHEMICAL", 74, 85], ["ALI", "DISEASE", 115, 118], ["acute-lung injury", "DISEASE", 120, 137], ["ARB", "CHEMICAL", 139, 142], ["angiotensin II", "CHEMICAL", 144, 158], ["angiotensin", "CHEMICAL", 182, 193], ["angiotensin", "CHEMICAL", 240, 251], ["respiratory syncytial virus", "DISEASE", 265, 292], ["SARS-CoV", "DISEASE", 298, 306], ["acute respiratory syndromecoronavirus", "DISEASE", 315, 352], ["renin", "GENE_OR_GENE_PRODUCT", 7, 12], ["ACE", "GENE_OR_GENE_PRODUCT", 24, 27], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 37, 66], ["ACEI", "SIMPLE_CHEMICAL", 68, 72], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 74, 103], ["lung", "ORGAN", 126, 130], ["ARB", "SIMPLE_CHEMICAL", 139, 142], ["angiotensin II receptor blocker", "GENE_OR_GENE_PRODUCT", 144, 175], ["AT1", "GENE_OR_GENE_PRODUCT", 177, 180], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 182, 195], ["RAS", "GENE_OR_GENE_PRODUCT", 229, 232], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 234, 251], ["RSV", "ORGANISM", 260, 263], ["respiratory syncytial virus", "ORGANISM", 265, 292], ["SARS-CoV", "ORGANISM", 298, 306], ["RAS", "GENE_OR_GENE_PRODUCT", 418, 421], ["ACE2", "GENE_OR_GENE_PRODUCT", 444, 448], ["renin", "PROTEIN", 7, 12], ["angiotensin-converting enzyme", "PROTEIN", 37, 66], ["RAS", "PROTEIN", 418, 421], ["ACE2", "PROTEIN", 444, 448], ["respiratory syncytial virus", "SPECIES", 265, 292], ["RSV", "SPECIES", 260, 263], ["respiratory syncytial virus", "SPECIES", 265, 292], ["SARS-CoV", "SPECIES", 298, 306], ["Direct renin inhibitors ACE", "TREATMENT", 0, 27], ["angiotensin", "TEST", 37, 48], ["enzyme", "TEST", 60, 66], ["ACEI", "TREATMENT", 68, 72], ["angiotensin", "TREATMENT", 74, 85], ["converting enzyme inhibitor", "TREATMENT", 86, 113], ["ALI", "PROBLEM", 115, 118], ["acute-lung injury", "PROBLEM", 120, 137], ["ARB", "TREATMENT", 139, 142], ["angiotensin II receptor blocker", "TREATMENT", 144, 175], ["AT1", "TEST", 177, 180], ["angiotensin", "TEST", 182, 193], ["PCR", "TEST", 197, 200], ["polymerase chain reaction", "TEST", 202, 227], ["RAS", "TEST", 229, 232], ["renin-angiotensin system", "TEST", 234, 258], ["RSV", "PROBLEM", 260, 263], ["respiratory syncytial virus", "PROBLEM", 265, 292], ["SARS", "PROBLEM", 298, 302], ["CoV", "PROBLEM", 303, 306], ["severe acute respiratory syndromecoronavirus", "PROBLEM", 308, 352], ["ALI", "ANATOMY", 115, 118], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["lung", "ANATOMY", 126, 130], ["injury", "OBSERVATION", 131, 137], ["RSV", "ANATOMY", 260, 263], ["respiratory syncytial", "ANATOMY", 265, 286], ["severe", "OBSERVATION_MODIFIER", 308, 314], ["acute", "OBSERVATION_MODIFIER", 315, 320], ["respiratory syndromecoronavirus", "OBSERVATION", 321, 352]]], ["Thus with direct renin inhibitors, RAS blockade and cardiopulmonary protection is maintained, but ACE2 seems to be downregulatedCLINICAL IMPLICATIONSIn general, RAS blockers are efficacious and welltolerated drugs with few adverse side effects.", [["renin", "GENE_OR_GENE_PRODUCT", 17, 22], ["RAS", "GENE_OR_GENE_PRODUCT", 35, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["RAS blockers", "SIMPLE_CHEMICAL", 161, 173], ["renin", "PROTEIN", 17, 22], ["ACE2", "PROTEIN", 98, 102], ["direct renin inhibitors", "TREATMENT", 10, 33], ["RAS blockade", "TREATMENT", 35, 47], ["cardiopulmonary protection", "TREATMENT", 52, 78], ["ACE2", "TREATMENT", 98, 102], ["RAS blockers", "TREATMENT", 161, 173], ["efficacious", "PROBLEM", 178, 189], ["welltolerated drugs", "TREATMENT", 194, 213], ["few adverse side effects", "PROBLEM", 219, 243], ["cardiopulmonary", "ANATOMY", 52, 67]]], ["However, once fever and dehydration set in, the RAS will become upregulated to the extent that its blockade can result in profound hypotension, syncope, cardiovascular collapse, renal failure, and shock.", [["cardiovascular", "ANATOMY", 153, 167], ["renal", "ANATOMY", 178, 183], ["fever", "DISEASE", 14, 19], ["dehydration", "DISEASE", 24, 35], ["hypotension", "DISEASE", 131, 142], ["syncope", "DISEASE", 144, 151], ["cardiovascular collapse", "DISEASE", 153, 176], ["renal failure", "DISEASE", 178, 191], ["shock", "DISEASE", 197, 202], ["RAS", "GENE_OR_GENE_PRODUCT", 48, 51], ["renal", "ORGAN", 178, 183], ["fever", "PROBLEM", 14, 19], ["dehydration", "PROBLEM", 24, 35], ["profound hypotension", "PROBLEM", 122, 142], ["syncope", "PROBLEM", 144, 151], ["cardiovascular collapse", "PROBLEM", 153, 176], ["renal failure", "PROBLEM", 178, 191], ["shock", "PROBLEM", 197, 202], ["profound", "OBSERVATION_MODIFIER", 122, 130], ["hypotension", "OBSERVATION", 131, 142], ["cardiovascular", "ANATOMY", 153, 167], ["collapse", "OBSERVATION", 168, 176], ["renal", "ANATOMY", 178, 183], ["failure", "OBSERVATION", 184, 191], ["shock", "OBSERVATION", 197, 202]]], ["More often than not, this sequence of events occurs unexpectedly and is abrupt.RECOMMENDATIONSPresently, all guidelines recommend continuing ACEI/ ARBs in patients diagnosed with COVID-19 infection.", [["ACEI/ ARBs", "CHEMICAL", 141, 151], ["COVID-19", "CHEMICAL", 179, 187], ["infection", "DISEASE", 188, 197], ["ACEI", "SIMPLE_CHEMICAL", 141, 145], ["ARBs", "SIMPLE_CHEMICAL", 147, 151], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["continuing ACEI", "TREATMENT", 130, 145], ["ARBs", "TREATMENT", 147, 151], ["COVID-19 infection", "PROBLEM", 179, 197], ["abrupt", "OBSERVATION_MODIFIER", 72, 78], ["infection", "OBSERVATION", 188, 197]]], ["Until the evidence in aggregate becomes firmer (and it will), we recommend the following with regard to CO-VID-19 and RAS blockade:RECOMMENDATIONS1.", [["CO", "CHEMICAL", 104, 106], ["RAS", "GENE_OR_GENE_PRODUCT", 118, 121], ["CO", "TEST", 104, 106], ["VID", "TEST", 107, 110], ["firmer", "OBSERVATION", 40, 46]]], ["In noninfected patients and patients at risk, there is currently no valid reason to discontinue RAS blockade.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 28, 36], ["RAS", "GENE_OR_GENE_PRODUCT", 96, 99], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 28, 36], ["RAS blockade", "TREATMENT", 96, 108], ["noninfected", "OBSERVATION_MODIFIER", 3, 14]]], ["In healthy subjects at risk, evidence is not (yet?) sufficient to prophylactically recommend RAS blockade.If apprehension about increased infectivity per-sists, patients on ACEIs or ARBs could temporarily be switched to a direct renin inhibitor.", [["ACEIs", "CHEMICAL", 173, 178], ["ARBs", "CHEMICAL", 182, 186], ["RAS", "GENE_OR_GENE_PRODUCT", 93, 96], ["patients", "ORGANISM", 161, 169], ["ACEIs", "SIMPLE_CHEMICAL", 173, 178], ["ARBs", "SIMPLE_CHEMICAL", 182, 186], ["renin", "GENE_OR_GENE_PRODUCT", 229, 234], ["renin", "PROTEIN", 229, 234], ["patients", "SPECIES", 161, 169], ["RAS blockade", "TREATMENT", 93, 105], ["apprehension", "PROBLEM", 109, 121], ["increased infectivity per-sists", "PROBLEM", 128, 159], ["ACEIs", "TREATMENT", 173, 178], ["ARBs", "TREATMENT", 182, 186], ["a direct renin inhibitor", "TREATMENT", 220, 244], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["infectivity", "OBSERVATION", 138, 149]]], ["In COVID-19-positive patients on RAS blockers, the drugs should be continued.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 3, 11], ["patients", "ORGANISM", 21, 29], ["RAS blockers", "SIMPLE_CHEMICAL", 33, 45], ["patients", "SPECIES", 21, 29], ["COVID", "TEST", 3, 8], ["RAS blockers", "TREATMENT", 33, 45], ["the drugs", "TREATMENT", 47, 56]]], ["In febrile patients with pulmonary symptoms on RAS blockers, close monitoring of blood pressure and renal function is advisable; RAS blockers should be discontinued only as clinically indicated.CONCLUSIONSCardiovascular disease in general, and hypertension and diabetes mellitus specifically, are prevalent in SARS-CoV-2-infected patients.", [["pulmonary", "ANATOMY", 25, 34], ["blood", "ANATOMY", 81, 86], ["renal", "ANATOMY", 100, 105], ["febrile", "DISEASE", 3, 10], ["pulmonary symptoms", "DISEASE", 25, 43], ["hypertension", "DISEASE", 244, 256], ["diabetes mellitus", "DISEASE", 261, 278], ["SARS-CoV-2-infected", "DISEASE", 310, 329], ["patients", "ORGANISM", 11, 19], ["pulmonary", "ORGAN", 25, 34], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["renal", "ORGAN", 100, 105], ["RAS blockers", "GENE_OR_GENE_PRODUCT", 129, 141], ["SARS-CoV-2", "ORGANISM", 310, 320], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 11, 19], ["CoV-", "SPECIES", 315, 319], ["patients", "SPECIES", 330, 338], ["SARS-CoV", "SPECIES", 310, 318], ["febrile", "PROBLEM", 3, 10], ["pulmonary symptoms", "PROBLEM", 25, 43], ["RAS blockers", "TREATMENT", 47, 59], ["close monitoring", "TEST", 61, 77], ["blood pressure", "TEST", 81, 95], ["renal function", "TEST", 100, 114], ["RAS blockers", "TREATMENT", 129, 141], [".CONCLUSIONSCardiovascular disease", "PROBLEM", 193, 227], ["hypertension", "PROBLEM", 244, 256], ["diabetes mellitus", "PROBLEM", 261, 278], ["CoV", "TEST", 315, 318], ["febrile", "OBSERVATION_MODIFIER", 3, 10], ["pulmonary", "ANATOMY", 25, 34], ["symptoms", "OBSERVATION", 35, 43], ["renal", "ANATOMY", 100, 105], ["hypertension", "OBSERVATION", 244, 256], ["diabetes mellitus", "OBSERVATION", 261, 278]]], ["RAS blockers are extensively used for cardiovascular disease and hypertension therapy.", [["cardiovascular", "ANATOMY", 38, 52], ["cardiovascular disease", "DISEASE", 38, 60], ["hypertension", "DISEASE", 65, 77], ["RAS blockers", "GENE_OR_GENE_PRODUCT", 0, 12], ["cardiovascular", "ANATOMICAL_SYSTEM", 38, 52], ["RAS blockers", "TREATMENT", 0, 12], ["cardiovascular disease", "PROBLEM", 38, 60], ["hypertension therapy", "TREATMENT", 65, 85], ["hypertension", "OBSERVATION", 65, 77]]], ["There is inconsistent evidence to suggest that RAS blockers exert a favorable effect on pulmonary outcome in viral pneumonia, but no data are available specifically for SARS-CoV-2-infected patients.", [["pulmonary", "ANATOMY", 88, 97], ["viral pneumonia", "DISEASE", 109, 124], ["SARS-CoV-2-infected", "DISEASE", 169, 188], ["RAS blockers", "GENE_OR_GENE_PRODUCT", 47, 59], ["pulmonary", "ORGAN", 88, 97], ["SARS-CoV-2", "ORGANISM", 169, 179], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 169, 177], ["RAS blockers", "TREATMENT", 47, 59], ["pulmonary outcome", "PROBLEM", 88, 105], ["viral pneumonia", "PROBLEM", 109, 124], ["SARS", "TEST", 169, 173], ["CoV", "TEST", 174, 177], ["inconsistent evidence to suggest", "UNCERTAINTY", 9, 41], ["favorable", "OBSERVATION_MODIFIER", 68, 77], ["pulmonary", "ANATOMY", 88, 97], ["viral", "OBSERVATION_MODIFIER", 109, 114], ["pneumonia", "OBSERVATION", 115, 124]]], ["Conversely, patients with cardiovascular disease and hypertension seem to be prone to SARS-CoV-2-infection, although this most likely is attributable to confounding factors.", [["cardiovascular", "ANATOMY", 26, 40], ["cardiovascular disease", "DISEASE", 26, 48], ["hypertension", "DISEASE", 53, 65], ["SARS", "DISEASE", 86, 90], ["infection", "DISEASE", 97, 106], ["patients", "ORGANISM", 12, 20], ["SARS-CoV-2", "ORGANISM", 86, 96], ["patients", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 86, 94], ["cardiovascular disease", "PROBLEM", 26, 48], ["hypertension", "PROBLEM", 53, 65], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["infection", "PROBLEM", 97, 106], ["confounding factors", "PROBLEM", 153, 172], ["cardiovascular", "ANATOMY", 26, 40], ["disease", "OBSERVATION", 41, 48], ["hypertension", "OBSERVATION", 53, 65], ["infection", "OBSERVATION", 97, 106], ["most likely is attributable to", "UNCERTAINTY", 122, 152]]], ["RAS blockade should be continued in infected patients as clinically indicated.", [["RAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["RAS blockade", "TREATMENT", 0, 12], ["blockade", "OBSERVATION", 4, 12]]], ["Present evidence is insufficient to recommend use of RAS blockade prophylactically in subjects at risk or therapeutically in those infected with SARS-CoV-2.", [["SARS", "DISEASE", 145, 149], ["RAS", "GENE_OR_GENE_PRODUCT", 53, 56], ["SARS-CoV-2", "ORGANISM", 145, 155], ["SARS-CoV", "SPECIES", 145, 153], ["RAS blockade prophylactically", "TREATMENT", 53, 82], ["infected", "OBSERVATION", 131, 139]]]], "5be812ecd3a63e7b5e718f17d9ca3a0d0fdb4a70": [["IntroductionVirtually all DNA virus classes including herpesviruses, adenoviruses, hepatitis B virus, parvoviruses and polyomaviruses must deposit and replicate their genomes within the nucleus for transcription, genome replication and subsequent capsid assembly.", [["nucleus", "ANATOMY", 186, 193], ["hepatitis B", "DISEASE", 83, 94], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["herpesviruses", "ORGANISM", 54, 67], ["adenoviruses", "ORGANISM", 69, 81], ["hepatitis B virus", "ORGANISM", 83, 100], ["parvoviruses", "ORGANISM", 102, 114], ["polyomaviruses", "ORGANISM", 119, 133], ["nucleus", "CELLULAR_COMPONENT", 186, 193], ["genome", "CELLULAR_COMPONENT", 213, 219], ["hepatitis B virus", "SPECIES", 83, 100], ["hepatitis B virus", "SPECIES", 83, 100], ["all DNA virus classes", "PROBLEM", 22, 43], ["herpesviruses", "PROBLEM", 54, 67], ["adenoviruses", "PROBLEM", 69, 81], ["hepatitis B virus", "PROBLEM", 83, 100], ["parvoviruses", "PROBLEM", 102, 114], ["polyomaviruses must deposit", "PROBLEM", 119, 146], ["genome replication", "TREATMENT", 213, 231], ["hepatitis", "OBSERVATION", 83, 92], ["nucleus", "ANATOMY", 186, 193]]], ["Genome transport and entry to the nucleus is also a prerequisite for replication of retroviruses, lentiviruses including HIV and certain RNA viruses including e.g., orthomyxoviruses such as influenza virus.", [["nucleus", "ANATOMY", 34, 41], ["influenza virus", "DISEASE", 190, 205], ["nucleus", "CELLULAR_COMPONENT", 34, 41], ["retroviruses", "ORGANISM", 84, 96], ["lentiviruses", "ORGANISM", 98, 110], ["HIV", "ORGANISM", 121, 124], ["orthomyxoviruses", "GENE_OR_GENE_PRODUCT", 165, 181], ["influenza virus", "ORGANISM", 190, 205], ["HIV", "SPECIES", 121, 124], ["influenza virus", "SPECIES", 190, 205], ["HIV", "SPECIES", 121, 124], ["retroviruses", "PROBLEM", 84, 96], ["lentiviruses", "PROBLEM", 98, 110], ["HIV", "PROBLEM", 121, 124], ["certain RNA viruses", "PROBLEM", 129, 148], ["orthomyxoviruses", "PROBLEM", 165, 181], ["influenza virus", "PROBLEM", 190, 205], ["nucleus", "ANATOMY", 34, 41], ["retroviruses", "OBSERVATION", 84, 96]]], ["All these viruses must navigate through the cytoplasm of infected cells, escape or counteract physical host cell barriers and antiviral processes, and engage with the nuclear envelope or nuclear pore for genome import into the nucleus [1] [2] [3] [4] [5] [6] [7] [8] [9] .", [["cytoplasm", "ANATOMY", 44, 53], ["cells", "ANATOMY", 66, 71], ["cell", "ANATOMY", 108, 112], ["nuclear envelope", "ANATOMY", 167, 183], ["nuclear pore", "ANATOMY", 187, 199], ["nucleus", "ANATOMY", 227, 234], ["cytoplasm", "ORGANISM_SUBSTANCE", 44, 53], ["cells", "CELL", 66, 71], ["cell", "CELL", 108, 112], ["nuclear", "CELLULAR_COMPONENT", 167, 174], ["nuclear pore", "CELLULAR_COMPONENT", 187, 199], ["genome", "CELLULAR_COMPONENT", 204, 210], ["nucleus", "CELLULAR_COMPONENT", 227, 234], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 235, 270], ["infected cells", "CELL_TYPE", 57, 71], ["All these viruses", "PROBLEM", 0, 17], ["infected cells", "PROBLEM", 57, 71], ["escape", "PROBLEM", 73, 79], ["antiviral processes", "TREATMENT", 126, 145], ["viruses", "OBSERVATION", 10, 17], ["infected cells", "OBSERVATION", 57, 71]]], ["Despite advances in certain areas [10] [11] [12] [13] [14] [15] [16] much remains to be understood concerning the detailed pathways and mechanisms involved, particularly with regard to the localisation of infecting virus genomes themselves and their regulated (or premature) presentation to the cell environment.", [["cell", "ANATOMY", 295, 299], ["[10] [11] [12] [13] [14] [15] [16", "SIMPLE_CHEMICAL", 34, 67], ["cell", "CELL", 295, 299], ["infecting virus genomes themselves", "PROBLEM", 205, 239]]], ["Quantitative spatiotemporal information at the single particle level on localisation, uncoating and transport of the infecting genome is required for any complete understanding of many critical aspects of virus infection and virus pathogenesis.IntroductionAmong the factors which have limited the quantitative spatiotemporal analysis of genome transport and presentation are the insensitivity or ready tractability of methods to directly visualise and measure virus genomes, the inability to differentiate genomes that are encapsidated from those that have dissociated, the inability to readily differentiate incoming from replicated genomes; and the incompatibility of certain detection methods with immunohistochemistry for parallel detection of host and viral protein components.", [["infection", "DISEASE", 211, 220], ["viral protein components", "PROTEIN", 757, 781], ["the infecting genome", "PROBLEM", 113, 133], ["virus infection", "PROBLEM", 205, 220], ["virus pathogenesis", "PROBLEM", 225, 243], ["the insensitivity", "PROBLEM", 375, 392], ["virus genomes", "PROBLEM", 460, 473], ["immunohistochemistry", "TEST", 701, 721], ["parallel detection", "TEST", 726, 744], ["host and viral protein components", "PROBLEM", 748, 781], ["encapsidated", "OBSERVATION", 523, 535], ["viral protein components", "OBSERVATION", 757, 781]]], ["FISH inherently cannot discriminate input from replicated genomes nor, due to the harsh conditions frequently incompatible with immunofluorescence, does FISH discriminate between encapsidated genomes versus released genomes.", [["encapsidated genomes", "DNA", 179, 199], ["the harsh conditions", "PROBLEM", 78, 98], ["immunofluorescence", "TEST", 128, 146]]], ["Other routes such as the incorporation of multimerised binding sites for fluorescent DNA binding proteins, e.g. YFP-TetR [17] offer possibilities for live cell imaging but require specialised recombinant viruses or cell lines and can still be highly limited in detecting infecting genomes.", [["cell", "ANATOMY", 155, 159], ["cell lines", "ANATOMY", 215, 225], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["YFP", "GENE_OR_GENE_PRODUCT", 112, 115], ["cell", "CELL", 155, 159], ["cell lines", "CELL", 215, 225], ["multimerised binding sites", "DNA", 42, 68], ["fluorescent DNA binding proteins", "PROTEIN", 73, 105], ["YFP", "PROTEIN", 112, 115], ["TetR", "PROTEIN", 116, 120], ["cell lines", "CELL_LINE", 215, 225], ["multimerised binding sites", "TREATMENT", 42, 68], ["fluorescent DNA binding proteins", "TEST", 73, 105], ["live cell imaging", "TEST", 150, 167], ["specialised recombinant viruses", "TREATMENT", 180, 211], ["cell lines", "TREATMENT", 215, 225], ["cell lines", "OBSERVATION", 215, 225]]], ["Such limitations and issues of sensitivity or tractability have meant that many studies on aspects of virus infection have almost invariably relied on indirect, surrogate measures of detection of virus genomes.", [["infection", "DISEASE", 108, 117], ["virus genomes", "DNA", 196, 209], ["sensitivity", "PROBLEM", 31, 42], ["many studies", "TEST", 75, 87], ["virus infection", "PROBLEM", 102, 117], ["virus genomes", "PROBLEM", 196, 209], ["virus genomes", "OBSERVATION", 196, 209]]], ["Reports, e.g., on the effect of inhibitors on DNA entry or analysis of DNA sensing have inferred effects on genome localisation from protein localisation.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["inhibitors", "TREATMENT", 32, 42], ["DNA entry", "TREATMENT", 46, 55], ["DNA sensing", "PROBLEM", 71, 82], ["protein localisation", "OBSERVATION", 133, 153]]], ["Clearly genomes not bound by surrogate markers will not be detected for any number of reasons including unknown but specific differences between genomes, occlusion by other factors, spatial segregation dictating differential protein association, repression by chromatin, non-nuclear localisations where surrogate markers may not co-localise and many others factors.", [["chromatin", "ANATOMY", 260, 269], ["chromatin", "CELLULAR_COMPONENT", 260, 269], ["chromatin", "DNA", 260, 269], ["occlusion", "PROBLEM", 154, 163], ["surrogate markers", "TEST", 303, 320], ["occlusion", "OBSERVATION", 154, 163]]], ["Such assays also give little information on other aspects of uncoating and the morphological state of infecting genomes.", [["infecting genomes", "OBSERVATION", 102, 119]]], ["These and other considerations limit our understanding of genome entry, uncoating, nuclear translocation and physical transitions, all of which are necessary for a true understanding of the earliest processes governing virus infection and host responses.IntroductionIn this regard, the development of bioorthogonal metabolic precursors combined with cycloaddition to corresponding capture reagents is increasingly being exploited in various approaches to biological processes and to mechanisms in infection and immunity [16, [18] [19] [20] [21] .", [["nuclear", "ANATOMY", 83, 90], ["infection", "DISEASE", 225, 234], ["infection", "DISEASE", 497, 506], ["genome", "CELLULAR_COMPONENT", 58, 64], ["nuclear", "CELLULAR_COMPONENT", 83, 90], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 525, 544], ["virus infection", "PROBLEM", 219, 234], ["bioorthogonal metabolic precursors", "PROBLEM", 301, 335], ["cycloaddition", "TREATMENT", 350, 363], ["corresponding capture reagents", "TREATMENT", 367, 397], ["infection", "PROBLEM", 497, 506], ["infection", "OBSERVATION", 497, 506]]], ["Analysis of DNA synthesis by labelling with alkyne-derivatised nucleosides and cycloaddition to azide-coupled fluorochromes has been evaluated in several systems [20, 22, 23] and used in spatial, biochemical, and systems approaches to investigate DNA replication and the cell cycle.", [["cell", "ANATOMY", 271, 275], ["alkyne-derivatised nucleosides", "CHEMICAL", 44, 74], ["azide", "CHEMICAL", 96, 101], ["alkyne", "CHEMICAL", 44, 50], ["nucleosides", "CHEMICAL", 63, 74], ["azide", "CHEMICAL", 96, 101], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["alkyne-derivatised nucleosides", "SIMPLE_CHEMICAL", 44, 74], ["azide", "SIMPLE_CHEMICAL", 96, 101], ["fluorochromes", "SIMPLE_CHEMICAL", 110, 123], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["cell", "CELL", 271, 275], ["DNA synthesis", "PROBLEM", 12, 25], ["alkyne", "TREATMENT", 44, 50], ["nucleosides", "TREATMENT", 63, 74], ["cycloaddition", "TREATMENT", 79, 92], ["azide", "TREATMENT", 96, 101], ["coupled fluorochromes", "TREATMENT", 102, 123], ["DNA replication", "TREATMENT", 247, 262], ["cell cycle", "OBSERVATION", 271, 281]]], ["These techniques have recently been exploited by the Greber laboratory for analysis of adenovirus (Adv) infection [16] using viruses incorporating the alkyne-derivatised nucleosides EdC (ethynyl-deoxycytidine) or EdU (ethynyl-deoxyuridine) in their genomes for the spatiotemporal investigation of genome trafficking at the single particle level.", [["infection", "DISEASE", 104, 113], ["alkyne", "CHEMICAL", 151, 157], ["EdC", "CHEMICAL", 182, 185], ["ethynyl-deoxycytidine", "CHEMICAL", 187, 208], ["EdU", "CHEMICAL", 213, 216], ["ethynyl-deoxyuridine", "CHEMICAL", 218, 238], ["alkyne", "CHEMICAL", 151, 157], ["nucleosides", "CHEMICAL", 170, 181], ["EdC", "CHEMICAL", 182, 185], ["ethynyl-deoxycytidine", "CHEMICAL", 187, 208], ["EdU", "CHEMICAL", 213, 216], ["ethynyl-deoxyuridine", "CHEMICAL", 218, 238], ["adenovirus", "ORGANISM", 87, 97], ["Adv", "GENE_OR_GENE_PRODUCT", 99, 102], ["alkyne", "SIMPLE_CHEMICAL", 151, 157], ["EdC", "SIMPLE_CHEMICAL", 182, 185], ["ethynyl-deoxycytidine", "SIMPLE_CHEMICAL", 187, 208], ["EdU", "SIMPLE_CHEMICAL", 213, 216], ["ethynyl-deoxyuridine", "SIMPLE_CHEMICAL", 218, 238], ["adenovirus", "SPECIES", 87, 97], ["adenovirus (Adv) infection", "PROBLEM", 87, 113], ["viruses", "TREATMENT", 125, 132], ["the alkyne", "TREATMENT", 147, 157], ["derivatised nucleosides EdC", "TREATMENT", 158, 185], ["ethynyl-deoxycytidine)", "TREATMENT", 187, 209], ["EdU (ethynyl-deoxyuridine)", "TREATMENT", 213, 239]]], ["We also recently showed that EdC was efficiently incorporated into HSV replication compartments and that incubation with EdC had no significant effect on HSV plaque forming ability or spread, reflected in plaque size [24] .", [["plaque", "ANATOMY", 158, 164], ["plaque", "ANATOMY", 205, 211], ["EdC", "CHEMICAL", 29, 32], ["EdC", "CHEMICAL", 121, 124], ["EdC", "CHEMICAL", 121, 124], ["EdC", "GENE_OR_GENE_PRODUCT", 29, 32], ["HSV", "ORGANISM", 67, 70], ["EdC", "SIMPLE_CHEMICAL", 121, 124], ["HSV", "ORGANISM", 154, 157], ["plaque", "PATHOLOGICAL_FORMATION", 205, 211], ["EdC", "PROTEIN", 29, 32], ["HSV", "SPECIES", 67, 70], ["HSV", "SPECIES", 154, 157], ["HSV replication compartments", "TREATMENT", 67, 95], ["HSV plaque", "PROBLEM", 154, 164], ["no significant", "UNCERTAINTY", 129, 143], ["HSV", "OBSERVATION_MODIFIER", 154, 157], ["plaque", "OBSERVATION", 158, 164], ["spread", "OBSERVATION_MODIFIER", 184, 190], ["plaque", "OBSERVATION_MODIFIER", 205, 211], ["size", "OBSERVATION_MODIFIER", 212, 216]]], ["De novo HSV DNA synthesis has also been analysed using EdC incorporation [25] .IntroductionHere we expand on these methods to produce infectious HSV containing EdC incorporating genomes, (termed HSV EdC ).", [["EdC", "CHEMICAL", 55, 58], ["HSV", "ORGANISM", 8, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["EdC", "SIMPLE_CHEMICAL", 55, 58], ["HSV", "ORGANISM", 145, 148], ["EdC", "GENE_OR_GENE_PRODUCT", 160, 163], ["HSV", "ORGANISM", 195, 198], ["EdC", "ORGANISM", 199, 202], ["EdC", "DNA", 160, 163], ["HSV", "SPECIES", 8, 11], ["HSV", "SPECIES", 145, 148], ["HSV", "SPECIES", 195, 198], ["De novo HSV DNA synthesis", "PROBLEM", 0, 25], ["these methods", "TREATMENT", 109, 122], ["infectious HSV", "PROBLEM", 134, 148], ["infectious", "OBSERVATION_MODIFIER", 134, 144]]], ["Using an in vitro uncoating assay on solid supports [26, 27] , we show that the vast majority of particles contained bioorthogonally-tagged genomes, detectable by cycloaddition to azide-linked fluorescent probes.", [["azide", "CHEMICAL", 180, 185], ["azide", "CHEMICAL", 180, 185], ["azide", "SIMPLE_CHEMICAL", 180, 185], ["bioorthogonally-tagged genomes", "DNA", 117, 147]]], ["Remarkably, if HSV EdC virions were also heat treated on the support prior to cycloaddition, virus DNA ejected from the capsid could be coupled to azide-linked fluorochromes and detectable as filamentous strands.", [["azide", "CHEMICAL", 147, 152], ["azide", "CHEMICAL", 147, 152], ["HSV EdC virions", "ORGANISM", 15, 30], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["azide", "SIMPLE_CHEMICAL", 147, 152], ["fluorochromes", "SIMPLE_CHEMICAL", 160, 173], ["virus DNA", "DNA", 93, 102], ["HSV", "SPECIES", 15, 18], ["HSV EdC virions", "TREATMENT", 15, 30], ["the support", "TREATMENT", 57, 68], ["cycloaddition", "TREATMENT", 78, 91], ["virus DNA", "PROBLEM", 93, 102], ["the capsid", "PROBLEM", 116, 126], ["filamentous strands", "OBSERVATION", 192, 211]]], ["Genomes were not detectable in virions in solution nor on cell surfaces at +4\u02daC, where numerous capsids could readily be observed but without genome accessibility.", [["virions", "ANATOMY", 31, 38], ["cell surfaces", "ANATOMY", 58, 71], ["cell", "CELL", 58, 62], ["+4\u02daC", "CELL", 75, 79]]], ["When infection was initiated by raising the temperature to 37\u02daC, DNA uncoating and transport in the nucleus could be observed within 30 mins and prior to synthesis and recruitment of the major immediate-early (IE) regulator ICP4.", [["nucleus", "ANATOMY", 100, 107], ["infection", "DISEASE", 5, 14], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["nucleus", "CELLULAR_COMPONENT", 100, 107], ["ICP4", "GENE_OR_GENE_PRODUCT", 224, 228], ["major immediate-early (IE) regulator", "PROTEIN", 187, 223], ["ICP4", "PROTEIN", 224, 228], ["infection", "PROBLEM", 5, 14], ["the temperature", "TEST", 40, 55], ["DNA uncoating", "PROBLEM", 65, 78], ["synthesis", "TREATMENT", 154, 163], ["infection", "OBSERVATION", 5, 14], ["nucleus", "ANATOMY", 100, 107]]], ["Using these assays we undertake a comprehensive quantitative spatiotemporal analysis of genome trafficking and uncoating, including analysis by three-dimensional structured illumination microscopy.", [["these assays", "TEST", 6, 18], ["analysis", "TEST", 132, 140]]], ["Together with additional data reported here, this work provides the first direct quantitative spatiotemporal analysis of HSV genome transport and presentation to the cellular environment, revealing new processes in genome dynamics not previously appreciated and advancing our understanding of these crucial early steps in infection.DNA synthesis in uninfected and HSV infected cells analysed by ethynylnucleoside incorporationlocalisation of nascent replicating DNA with virus replication proteins using combined clickchemistry and immunofluorescence approaches.", [["cellular", "ANATOMY", 166, 174], ["cells", "ANATOMY", 377, 382], ["infection", "DISEASE", 322, 331], ["ethynylnucleoside", "CHEMICAL", 395, 412], ["ethynylnucleoside", "CHEMICAL", 395, 412], ["HSV", "ORGANISM", 121, 124], ["cellular", "CELL", 166, 174], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["HSV", "ORGANISM", 364, 367], ["cells", "CELL", 377, 382], ["ethynylnucleoside", "SIMPLE_CHEMICAL", 395, 412], ["DNA", "CELLULAR_COMPONENT", 462, 465], ["uninfected and HSV infected cells", "CELL_TYPE", 349, 382], ["virus replication proteins", "PROTEIN", 471, 497], ["HSV", "SPECIES", 121, 124], ["HSV", "SPECIES", 364, 367], ["new processes in genome dynamics", "PROBLEM", 198, 230], ["infection", "PROBLEM", 322, 331], ["DNA synthesis in uninfected and HSV infected cells", "PROBLEM", 332, 382], ["nascent replicating DNA", "PROBLEM", 442, 465], ["virus replication proteins", "TREATMENT", 471, 497], ["combined clickchemistry", "TREATMENT", 504, 527], ["immunofluorescence approaches", "TREATMENT", 532, 561], ["new", "OBSERVATION_MODIFIER", 198, 201], ["infection", "OBSERVATION", 322, 331], ["infected cells", "OBSERVATION", 368, 382]]], ["We found that EdC (ethynyl-deoxycytidine) was more sensitive for detection of HSV replication centres than EdU (ethynyl-deoxyuridine), consistent with the high GC content of HSV DNA [24] .", [["EdC (ethynyl-deoxycytidine", "CHEMICAL", 14, 40], ["EdU", "CHEMICAL", 107, 110], ["ethynyl-deoxyuridine", "CHEMICAL", 112, 132], ["EdC (ethynyl-deoxycytidine", "CHEMICAL", 14, 40], ["EdU", "CHEMICAL", 107, 110], ["ethynyl-deoxyuridine", "CHEMICAL", 112, 132], ["EdC", "SIMPLE_CHEMICAL", 14, 17], ["ethynyl-deoxycytidine", "SIMPLE_CHEMICAL", 19, 40], ["HSV", "ORGANISM", 78, 81], ["EdU", "SIMPLE_CHEMICAL", 107, 110], ["ethynyl-deoxyuridine", "SIMPLE_CHEMICAL", 112, 132], ["HSV", "ORGANISM", 174, 177], ["DNA", "CELLULAR_COMPONENT", 178, 181], ["HSV", "SPECIES", 78, 81], ["HSV", "SPECIES", 174, 177], ["EdC (ethynyl-deoxycytidine", "TREATMENT", 14, 40], ["HSV replication centres", "TREATMENT", 78, 101], ["EdU (ethynyl-deoxyuridine", "TREATMENT", 107, 132], ["HSV DNA", "PROBLEM", 174, 181]]], ["In this work, optimising conditions for the production of HSV EdC we found no significant effect of EdC even over relatively prolonged times (72 hrs) on uninfected cell growth or morphology (S1 Fig) and no significant effect on the efficiency of virus plaque formation nor plaque spread (Fig 1A) , consistent with previous data [24] .", [["cell", "ANATOMY", 164, 168], ["plaque", "ANATOMY", 252, 258], ["plaque", "ANATOMY", 273, 279], ["EdC", "CHEMICAL", 100, 103], ["plaque", "DISEASE", 252, 258], ["HSV", "ORGANISM", 58, 61], ["EdC", "GENE_OR_GENE_PRODUCT", 62, 65], ["EdC", "SIMPLE_CHEMICAL", 100, 103], ["cell", "CELL", 164, 168], ["plaque", "PATHOLOGICAL_FORMATION", 252, 258], ["HSV EdC", "PROTEIN", 58, 65], ["HSV", "SPECIES", 58, 61], ["HSV EdC", "TEST", 58, 65], ["significant effect of EdC", "PROBLEM", 78, 103], ["uninfected cell growth", "PROBLEM", 153, 175], ["significant effect", "PROBLEM", 206, 224], ["virus plaque formation", "PROBLEM", 246, 268], ["plaque spread", "PROBLEM", 273, 286], ["no", "UNCERTAINTY", 203, 205], ["significant", "OBSERVATION_MODIFIER", 206, 217], ["virus plaque", "OBSERVATION", 246, 258], ["plaque", "OBSERVATION_MODIFIER", 273, 279]]], ["In analysis of both single step ( Fig 1B) and multi-step replication (Fig 1C) , we found at most a minor effect (3-4-fold reduction) in overall yields.", [["multi-step replication (Fig 1C", "TREATMENT", 46, 76], ["4-fold reduction", "TREATMENT", 115, 131]]], ["The particle/pfu ratio of HSV EdC produced from multi-round virus replication and normal HSV produced in the absence of precursor were compared by particle counts using normalised amounts of pfu.", [["HSV", "ORGANISM", 26, 29], ["EdC", "GENE_OR_GENE_PRODUCT", 30, 33], ["multi-round virus", "ORGANISM", 48, 65], ["HSV", "ORGANISM", 89, 92], ["HSV EdC", "PROTEIN", 26, 33], ["HSV", "SPECIES", 26, 29], ["HSV", "SPECIES", 89, 92], ["The particle/pfu ratio", "TEST", 0, 22], ["HSV EdC", "PROBLEM", 26, 33], ["multi-round virus replication", "TREATMENT", 48, 77], ["particle counts", "TEST", 147, 162], ["particle", "OBSERVATION_MODIFIER", 4, 12]]], ["The results show a modest increase for HSV EdC (Fig 1D) .", [["HSV", "ORGANISM", 39, 42], ["HSV EdC", "PROTEIN", 39, 46], ["HSV", "SPECIES", 39, 42], ["HSV EdC", "TREATMENT", 39, 46], ["modest", "OBSERVATION_MODIFIER", 19, 25], ["increase", "OBSERVATION_MODIFIER", 26, 34]]], ["We do not know the precise explanation for this slight increase though the value was within the range of particle/pfu we have found for normal HSV stocks (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .", [["HSV", "ORGANISM", 143, 146], ["this slight increase", "PROBLEM", 43, 63], ["the value", "TEST", 71, 80], ["HSV stocks", "OBSERVATION", 143, 153]]], ["Overall even prolonged incubation with EdC at concentrations at least up to 10 \u03bcM was well tolerated, with minimal effect of virus replication and the progression of infection.DNA synthesis in uninfected and HSV infected cells analysed by ethynylnucleoside incorporationEdC incorporation in uninfected cells (4 hrs) showed DNA synthesis in approximately 25-30% of cells ( These patterns are consistent with previous spatial analysis of cellular DNA synthesis and reflect approximate stage within S-phase [20, 22] .", [["cells", "ANATOMY", 221, 226], ["cells", "ANATOMY", 302, 307], ["cells", "ANATOMY", 364, 369], ["cellular", "ANATOMY", 436, 444], ["EdC", "CHEMICAL", 39, 42], ["infection", "DISEASE", 166, 175], ["ethynylnucleoside", "CHEMICAL", 239, 256], ["EdC", "CHEMICAL", 39, 42], ["ethynylnucleoside", "CHEMICAL", 239, 256], ["EdC", "SIMPLE_CHEMICAL", 39, 42], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["HSV", "ORGANISM", 208, 211], ["cells", "CELL", 221, 226], ["ethynylnucleoside incorporationEdC", "SIMPLE_CHEMICAL", 239, 273], ["cells", "CELL", 302, 307], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["cells", "CELL", 364, 369], ["cellular", "CELL", 436, 444], ["DNA", "CELLULAR_COMPONENT", 445, 448], ["uninfected and HSV infected cells", "CELL_TYPE", 193, 226], ["uninfected cells", "CELL_TYPE", 291, 307], ["HSV", "SPECIES", 208, 211], ["prolonged incubation", "TREATMENT", 13, 33], ["EdC at concentrations", "TREATMENT", 39, 60], ["virus replication", "TREATMENT", 125, 142], ["infection", "PROBLEM", 166, 175], ["DNA synthesis in uninfected and HSV infected cells", "PROBLEM", 176, 226], ["DNA synthesis", "PROBLEM", 323, 336], ["cellular DNA synthesis", "PROBLEM", 436, 458], ["virus", "OBSERVATION", 125, 130], ["progression", "OBSERVATION_MODIFIER", 151, 162], ["infection", "OBSERVATION", 166, 175], ["uninfected", "OBSERVATION_MODIFIER", 193, 203], ["infected cells", "OBSERVATION", 212, 226], ["uninfected cells", "OBSERVATION", 291, 307], ["consistent with", "UNCERTAINTY", 391, 406], ["cellular DNA synthesis", "OBSERVATION", 436, 458]]], ["In HSV infected cells, the percentage of positive cells increased to approximately 55% by 5 hpi (hours post infection) and virtually all cells were positive for EdC incorporation by 8 hpi (Fig 2A, summarised panel b) .DNA synthesis in uninfected and HSV infected cells analysed by ethynylnucleoside incorporationFrom higher resolution spatial analysis of active DNA synthesis and localisation of the major DNA replication protein ICP8, several distinct patterns were observed (Fig 3) .", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 263, 268], ["HSV infected", "DISEASE", 3, 15], ["infection", "DISEASE", 108, 117], ["ethynylnucleoside", "CHEMICAL", 281, 298], ["EdC", "CHEMICAL", 161, 164], ["ethynylnucleoside", "CHEMICAL", 281, 298], ["HSV", "ORGANISM", 3, 6], ["cells", "CELL", 16, 21], ["cells", "CELL", 50, 55], ["cells", "CELL", 137, 142], ["EdC", "SIMPLE_CHEMICAL", 161, 164], ["DNA", "CELLULAR_COMPONENT", 218, 221], ["HSV", "ORGANISM", 250, 253], ["cells", "CELL", 263, 268], ["ethynylnucleoside", "SIMPLE_CHEMICAL", 281, 298], ["DNA", "CELLULAR_COMPONENT", 362, 365], ["DNA", "CELLULAR_COMPONENT", 406, 409], ["ICP8", "GENE_OR_GENE_PRODUCT", 430, 434], ["HSV infected cells", "CELL_TYPE", 3, 21], ["positive cells", "CELL_TYPE", 41, 55], ["EdC", "PROTEIN", 161, 164], ["uninfected and HSV infected cells", "CELL_TYPE", 235, 268], ["major DNA replication protein", "PROTEIN", 400, 429], ["ICP8", "PROTEIN", 430, 434], ["HSV", "SPECIES", 3, 6], ["HSV", "SPECIES", 250, 253], ["HSV infected cells", "PROBLEM", 3, 21], ["positive cells", "PROBLEM", 41, 55], ["infection", "PROBLEM", 108, 117], ["virtually all cells", "PROBLEM", 123, 142], ["EdC incorporation", "PROBLEM", 161, 178], ["DNA synthesis in uninfected and HSV infected cells", "PROBLEM", 218, 268], ["active DNA synthesis", "PROBLEM", 355, 375], ["the major DNA replication protein ICP8", "TREATMENT", 396, 434], ["infected cells", "OBSERVATION", 7, 21], ["percentage", "OBSERVATION_MODIFIER", 27, 37], ["positive cells", "OBSERVATION", 41, 55], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["infected cells", "OBSERVATION", 254, 268], ["active", "OBSERVATION_MODIFIER", 355, 361], ["DNA synthesis", "OBSERVATION", 362, 375]]], ["By 5 hpi, in those cells positive for DNA synthesis, the majority of cells showed discrete replication foci, colocalising with ICP8 (Fig 3, panels ii, iii) and reflecting the previously documented features of HSV DNA replication compartments [28] [29] [30] .", [["cells", "ANATOMY", 19, 24], ["cells", "ANATOMY", 69, 74], ["foci", "ANATOMY", 103, 107], ["cells", "CELL", 19, 24], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["cells", "CELL", 69, 74], ["ICP8", "GENE_OR_GENE_PRODUCT", 127, 131], ["HSV", "ORGANISM", 209, 212], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["ICP8", "PROTEIN", 127, 131], ["HSV", "SPECIES", 209, 212], ["DNA synthesis", "PROBLEM", 38, 51], ["discrete replication foci", "PROBLEM", 82, 107], ["ICP8", "TEST", 127, 131], ["Fig", "TEST", 133, 136], ["HSV DNA replication compartments", "PROBLEM", 209, 241], ["discrete", "OBSERVATION_MODIFIER", 82, 90], ["replication", "OBSERVATION_MODIFIER", 91, 102], ["foci", "OBSERVATION", 103, 107]]], ["We also observed populations of infected cells wherein multiple intense focal clusters of nascent DNA synthesis were observed, but in this case without any clear colocalisation with ICP8, which nevertheless still formed in distinct smaller (Fig 3, iv) or larger (Fig 3, v,vii) lobules.", [["cells", "ANATOMY", 41, 46], ["lobules", "ANATOMY", 277, 284], ["cells", "CELL", 41, 46], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["ICP8", "GENE_OR_GENE_PRODUCT", 182, 186], ["infected cells", "CELL_TYPE", 32, 46], ["ICP8", "PROTEIN", 182, 186], ["infected cells", "PROBLEM", 32, 46], ["nascent DNA synthesis", "PROBLEM", 90, 111], ["ICP8", "PROBLEM", 182, 186], ["Fig", "TEST", 241, 244], ["Fig", "TEST", 263, 266], ["populations", "OBSERVATION_MODIFIER", 17, 28], ["infected cells", "OBSERVATION", 32, 46], ["multiple", "OBSERVATION_MODIFIER", 55, 63], ["intense", "OBSERVATION_MODIFIER", 64, 71], ["focal", "OBSERVATION_MODIFIER", 72, 77], ["clusters", "OBSERVATION_MODIFIER", 78, 86], ["nascent DNA synthesis", "OBSERVATION", 90, 111], ["ICP8", "OBSERVATION", 182, 186], ["distinct", "OBSERVATION_MODIFIER", 223, 231], ["smaller", "OBSERVATION_MODIFIER", 232, 239], ["larger", "OBSERVATION_MODIFIER", 255, 261], ["lobules", "ANATOMY", 277, 284]]], ["These latter patterns likely represent infection of cells which were in S-phase (or committed to S-phase and not prevented from doing so).", [["cells", "ANATOMY", 52, 57], ["infection", "DISEASE", 39, 48], ["cells", "CELL", 52, 57], ["infection of cells", "PROBLEM", 39, 57], ["likely represent", "UNCERTAINTY", 22, 38], ["infection", "OBSERVATION", 39, 48]]], ["The localisation of ICP8 likely represents some level of ongoing viral DNA synthesis in such Sphase cells, in the background of prominent cellular DNA synthesis.", [["Sphase cells", "ANATOMY", 93, 105], ["cellular", "ANATOMY", 138, 146], ["ICP8", "GENE_OR_GENE_PRODUCT", 20, 24], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["Sphase cells", "CELL", 93, 105], ["cellular DNA", "CELLULAR_COMPONENT", 138, 150], ["ICP8", "PROTEIN", 20, 24], ["Sphase cells", "CELL_TYPE", 93, 105], ["The localisation of ICP8", "PROBLEM", 0, 24], ["ongoing viral DNA synthesis in such Sphase cells", "PROBLEM", 57, 105], ["prominent cellular DNA synthesis", "PROBLEM", 128, 160], ["ICP8", "OBSERVATION", 20, 24], ["likely represents", "UNCERTAINTY", 25, 42], ["ongoing", "OBSERVATION_MODIFIER", 57, 64], ["viral DNA synthesis", "OBSERVATION", 65, 84], ["Sphase cells", "OBSERVATION", 93, 105], ["prominent", "OBSERVATION_MODIFIER", 128, 137], ["cellular DNA synthesis", "OBSERVATION", 138, 160]]], ["Again these results are entirely consistent with previous data [31] .Production and genome detection in HSV virions containing EdCWe carried out a series of experiments to optimise conditions for the production of HSV EdC and then scaled up (see materials and methods) with multi-round infection initiated at low multiplicity of infection (moi; 0.005 pfu/cell) and two pulse-labelling intervals in the presence of 5 \u03bcM EdC.", [["cell", "ANATOMY", 355, 359], ["infection", "DISEASE", 286, 295], ["infection", "DISEASE", 329, 338], ["HSV virions", "ORGANISM", 104, 115], ["HSV", "ORGANISM", 214, 217], ["cell", "CELL", 355, 359], ["HSV EdC", "PROTEIN", 214, 221], ["HSV", "SPECIES", 104, 107], ["HSV", "SPECIES", 214, 217], ["genome detection", "TEST", 84, 100], ["HSV virions", "PROBLEM", 104, 115], ["HSV EdC", "PROBLEM", 214, 221], ["multi-round infection", "PROBLEM", 274, 295], ["infection", "PROBLEM", 329, 338], ["HSV virions", "OBSERVATION", 104, 115], ["infection", "OBSERVATION", 286, 295], ["low multiplicity", "OBSERVATION_MODIFIER", 309, 325], ["infection", "OBSERVATION", 329, 338]]], ["Overall yields of HSV EdC virus produced were virtually unchanged from normal virus production.Production and genome detection in HSV virions containing EdCThe lack of any pronounced effect of EdC on HSV yield and its incorporation into replication compartments does not necessarily mean that it will be efficiently incorporated or detectable in capsids.", [["EdC", "CHEMICAL", 193, 196], ["HSV EdC virus", "ORGANISM", 18, 31], ["HSV virions", "ORGANISM", 130, 141], ["EdC", "SIMPLE_CHEMICAL", 193, 196], ["HSV", "ORGANISM", 200, 203], ["EdC", "PROTEIN", 193, 196], ["HSV EdC virus", "SPECIES", 18, 31], ["HSV EdC virus", "SPECIES", 18, 31], ["HSV", "SPECIES", 130, 133], ["HSV", "SPECIES", 200, 203], ["HSV EdC virus", "PROBLEM", 18, 31], ["genome detection", "TEST", 110, 126], ["HSV virions", "PROBLEM", 130, 141], ["HSV yield", "TREATMENT", 200, 209], ["HSV", "OBSERVATION", 18, 21], ["unchanged", "OBSERVATION_MODIFIER", 56, 65], ["virus production", "OBSERVATION", 78, 94], ["HSV virions", "OBSERVATION", 130, 141]]], ["Therefore to examine the efficiency of detection of genomes in capsids we exploited an in vitro assay reported by Newcomb et al., [26, 27] which showed that HSV capsids, after absorption onto solid surfaces, underwent some form of structural rearrangement(s) such that with moderately elevated temperatures, genome expulsion from the capsids could be observed.", [["HSV", "ORGANISM", 157, 160], ["HSV", "SPECIES", 157, 160], ["genomes in capsids", "PROBLEM", 52, 70], ["an in vitro assay", "TEST", 84, 101], ["HSV capsids", "PROBLEM", 157, 168], ["structural rearrangement", "PROBLEM", 231, 255], ["moderately elevated temperatures", "PROBLEM", 274, 306], ["genome expulsion", "PROBLEM", 308, 324], ["the capsids", "PROBLEM", 330, 341], ["HSV capsids", "OBSERVATION", 157, 168], ["structural rearrangement", "OBSERVATION", 231, 255], ["genome expulsion", "OBSERVATION", 308, 324]]], ["Although the precise mechanism was unknown, these observations indicate that attachment to a solid surface perturbs the capsid, (or transmits a structural change to the portal) facilitating DNA release.Production and genome detection in HSV virions containing EdCSamples of HSV EdC or unlabelled HSV-1 [17] were adsorbed onto borosilicate coverslips, fixed and processed for the simultaneous detection of genomes (green channel) and capsids (using anti-VP5 antibody, red channel).", [["solid surface", "ANATOMY", 93, 106], ["borosilicate", "CHEMICAL", 326, 338], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["HSV virions", "ORGANISM", 237, 248], ["HSV EdC", "ORGANISM", 274, 281], ["HSV-1", "ORGANISM", 296, 301], ["anti-VP5 antibody", "GENE_OR_GENE_PRODUCT", 448, 465], ["HSV EdC", "PROTEIN", 274, 281], ["borosilicate coverslips", "DNA", 326, 349], ["green channel", "PROTEIN", 414, 427], ["anti-VP5 antibody", "PROTEIN", 448, 465], ["red channel", "PROTEIN", 467, 478], ["HSV-1", "SPECIES", 296, 301], ["HSV", "SPECIES", 237, 240], ["HSV", "SPECIES", 274, 277], ["HSV-1", "SPECIES", 296, 301], ["a solid surface perturbs the capsid", "PROBLEM", 91, 126], ["genome detection", "TEST", 217, 233], ["HSV virions", "TREATMENT", 237, 248], ["HSV EdC", "TEST", 274, 281], ["unlabelled HSV", "TEST", 285, 299], ["borosilicate coverslips", "TREATMENT", 326, 349], ["the simultaneous detection", "TEST", 375, 401], ["capsids", "TREATMENT", 433, 440], ["anti-VP5 antibody", "TREATMENT", 448, 465], ["portal", "ANATOMY", 169, 175]]], ["Typical results showing the merged image for HSV EdC [17] and incubated in the presence of EdC at various concentrations (added at 2 hpi).", [["EdC", "CHEMICAL", 91, 94], ["EdC", "CHEMICAL", 91, 94], ["HSV", "ORGANISM", 45, 48], ["EdC", "SIMPLE_CHEMICAL", 91, 94], ["HSV", "SPECIES", 45, 48], ["HSV EdC", "TEST", 45, 52]]], ["Plaques were fixed and stained at 48 hr (scale bar 1 mm).", [["Plaques", "ANATOMY", 0, 7], ["Plaques", "PROBLEM", 0, 7], ["fixed", "OBSERVATION_MODIFIER", 13, 18]]], ["Plaque area (approximately 40 plaques) and plaque numbers at each EdC concentration were quantitated relative to untreated cells (set to 100%). (b) Single-step growth yield assay of HSV-1 [17] in the presence of EdC.", [["Plaque area", "ANATOMY", 0, 11], ["plaques", "ANATOMY", 30, 37], ["plaque", "ANATOMY", 43, 49], ["cells", "ANATOMY", 123, 128], ["Plaque", "PATHOLOGICAL_FORMATION", 0, 6], ["plaque", "PATHOLOGICAL_FORMATION", 43, 49], ["EdC", "SIMPLE_CHEMICAL", 66, 69], ["cells", "CELL", 123, 128], ["HSV-1", "ORGANISM", 182, 187], ["EdC", "PROTEIN", 66, 69], ["untreated cells", "CELL_TYPE", 113, 128], ["HSV-1", "SPECIES", 182, 187], ["EdC.", "SPECIES", 212, 216], ["Plaque area", "PROBLEM", 0, 11], ["40 plaques", "PROBLEM", 27, 37], ["plaque numbers", "TEST", 43, 57], ["each EdC concentration", "TEST", 61, 83], ["Single-step growth", "TEST", 148, 166], ["HSV", "TEST", 182, 185], ["approximately", "OBSERVATION_MODIFIER", 13, 26], ["40 plaques", "OBSERVATION_MODIFIER", 27, 37], ["plaque", "OBSERVATION_MODIFIER", 43, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["untreated cells", "OBSERVATION", 113, 128]]], ["Cells were infected (moi 5) and incubated with EdC (added at 2 hpi).", [["Cells", "ANATOMY", 0, 5], ["EdC", "CHEMICAL", 47, 50], ["EdC", "CHEMICAL", 47, 50], ["Cells", "CELL", 0, 5], ["EdC", "SIMPLE_CHEMICAL", 47, 50]]], ["Supernatant and cell-associated virus was harvested at 20 hpi and titrated on RPE-1 cells. (c) Multi-step growth yield assay.", [["Supernatant", "ANATOMY", 0, 11], ["cell", "ANATOMY", 16, 20], ["RPE-1 cells", "ANATOMY", 78, 89], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["cell", "CELL", 16, 20], ["RPE-1 cells", "CELL", 78, 89], ["RPE-1 cells", "CELL_LINE", 78, 89], ["Supernatant and cell-associated virus", "PROBLEM", 0, 37], ["RPE", "TEST", 78, 81], ["Multi-step growth yield assay", "TEST", 95, 124], ["cell", "ANATOMY", 16, 20], ["virus", "OBSERVATION", 32, 37]]], ["Cells were infected (moi 0.005) and incubated with EdC added at 2 hpi.", [["Cells", "ANATOMY", 0, 5], ["EdC", "CHEMICAL", 51, 54], ["EdC", "CHEMICAL", 51, 54], ["Cells", "CELL", 0, 5], ["EdC", "SIMPLE_CHEMICAL", 51, 54]]], ["Virus was harvested at 72 hpi and titrated on RPE-1 cells. (d) Particles/pfu ratios of HSV and HSV EdC .", [["RPE-1 cells", "ANATOMY", 46, 57], ["Virus", "ORGANISM", 0, 5], ["RPE-1 cells", "CELL", 46, 57], ["HSV", "ORGANISM", 87, 90], ["HSV", "ORGANISM", 95, 98], ["EdC", "ORGANISM", 99, 102], ["RPE-1 cells", "CELL_LINE", 46, 57], ["HSV", "SPECIES", 87, 90], ["HSV", "SPECIES", 95, 98], ["Virus", "PROBLEM", 0, 5], ["RPE", "TEST", 46, 49], ["(d) Particles/pfu ratios", "TEST", 59, 83], ["HSV", "PROBLEM", 87, 90], ["HSV EdC", "TREATMENT", 95, 102]]], ["Virus released into the medium and purified by ultracentrifugation was titrated and equal pfu applied to a defined area on coverslips and stained for VP5+ve particles.", [["Virus", "ORGANISM", 0, 5], ["VP5", "GENE_OR_GENE_PRODUCT", 150, 153], ["VP5", "PROTEIN", 150, 153], ["Virus", "PROBLEM", 0, 5], ["ultracentrifugation", "TREATMENT", 47, 66], ["coverslips", "TEST", 123, 133], ["VP5", "TEST", 150, 153]]], ["Multiple fields were imaged and tiled so that all particles in the samples were quantified.", [["samples", "ANATOMY", 67, 74], ["the samples", "TEST", 63, 74]]], ["The graph indicates total particle counts from the accumulated individual fields and the SD of particle counts within individual fields. and HSV-1 [17] are illustrated in Fig 4, panels I and IV respectively.", [["HSV-1", "ORGANISM", 141, 146], ["HSV-1", "SPECIES", 141, 146], ["The graph", "TEST", 0, 9], ["total particle counts", "PROBLEM", 20, 41], ["particle counts", "TEST", 95, 110], ["HSV", "TEST", 141, 144], ["total", "OBSERVATION_MODIFIER", 20, 25], ["particle counts", "OBSERVATION", 26, 41], ["accumulated", "OBSERVATION_MODIFIER", 51, 62], ["individual", "OBSERVATION_MODIFIER", 63, 73], ["fields", "OBSERVATION_MODIFIER", 74, 80], ["SD", "OBSERVATION_MODIFIER", 89, 91], ["particle counts", "OBSERVATION", 95, 110], ["fields", "OBSERVATION_MODIFIER", 129, 135]]], ["The individual channels for genome detection are shown in corresponding panels II and V for each virus.", [["genome detection", "TEST", 28, 44], ["each virus", "PROBLEM", 92, 102]]], ["Using an ImageJ plugin, capsids were enumerated and the signals quantitated in each channel (see materials and methods).", [["an ImageJ plugin", "TEST", 6, 22], ["capsids", "TREATMENT", 24, 31]]], ["Particles are categorised as a positive red particle or positive green particle, requiring positive particles to be not only above the background ROI but 1 standard deviation (SD) above the background ROI.", [["a positive red particle", "PROBLEM", 29, 52], ["positive green particle", "PROBLEM", 56, 79], ["positive particles", "PROBLEM", 91, 109], ["1 standard deviation (SD) above the background ROI", "PROBLEM", 154, 204], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["red particle", "OBSERVATION_MODIFIER", 40, 52], ["positive", "OBSERVATION_MODIFIER", 56, 64], ["green particle", "OBSERVATION", 65, 79], ["positive particles", "OBSERVATION_MODIFIER", 91, 109]]], ["The macro produces a colour-coded overlay (panels III and VI) in which particles containing both signals are coded yellow, particles that are capsid positive but lacking a genome signal above threshold are indicated in red, and particles with a (a) RPE-1 cells were infected (moi 10) and pulsed with 5 \u03bcM EdC for 4 hrs at the times indicated.", [["RPE-1 cells", "ANATOMY", 249, 260], ["EdC", "CHEMICAL", 305, 308], ["RPE-1 cells", "CELL", 249, 260], ["RPE-1 cells", "CELL_LINE", 249, 260], ["a colour", "TEST", 19, 27], ["capsid positive", "PROBLEM", 142, 157], ["5 \u03bcM EdC", "TREATMENT", 300, 308]]], ["Cells were fixed and processed for EdC incorporation together with immunofluorescence for ICP8 and counterstained with DAPI staining for total DNA (DAPI).", [["Cells", "ANATOMY", 0, 5], ["DAPI", "CHEMICAL", 119, 123], ["Cells", "CELL", 0, 5], ["EdC", "SIMPLE_CHEMICAL", 35, 38], ["ICP8", "GENE_OR_GENE_PRODUCT", 90, 94], ["DAPI", "SIMPLE_CHEMICAL", 119, 123], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["DAPI", "SIMPLE_CHEMICAL", 148, 152], ["EdC", "PROTEIN", 35, 38], ["ICP8", "PROTEIN", 90, 94], ["EdC incorporation", "TREATMENT", 35, 52], ["immunofluorescence", "TEST", 67, 85], ["ICP8", "PROBLEM", 90, 94], ["DAPI staining", "TEST", 119, 132], ["total DNA (DAPI", "TREATMENT", 137, 152]]], ["Individual channels are shown in grey scale and the merged images in colour. (b) Using the DAPI channel as a mask, images were then quantified for EdC or ICP8 and the percentage +ve plotted against total cell nuclei count.", [["cell nuclei", "ANATOMY", 204, 215], ["DAPI", "CHEMICAL", 91, 95], ["DAPI", "SIMPLE_CHEMICAL", 91, 95], ["EdC", "GENE_OR_GENE_PRODUCT", 147, 150], ["ICP8", "GENE_OR_GENE_PRODUCT", 154, 158], ["cell nuclei", "CELL", 204, 215], ["DAPI channel", "PROTEIN", 91, 103], ["EdC", "PROTEIN", 147, 150], ["ICP8", "PROTEIN", 154, 158], ["grey scale", "TEST", 33, 43], ["the DAPI channel", "TREATMENT", 87, 103], ["a mask", "TREATMENT", 107, 113], ["images", "TEST", 115, 121], ["ICP8", "TEST", 154, 158], ["the percentage", "TEST", 163, 177], ["total cell nuclei count", "TEST", 198, 221], ["cell", "OBSERVATION", 204, 208], ["nuclei count", "OBSERVATION", 209, 221]]], ["Images were taken at 10x magnification (scale bar 100 \u03bcm).Production and genome detection in HSV virions containing EdChttps://doi.org/10.1371/journal.ppat.1006721.g002Production and genome detection in HSV virions containing EdCTransport and nuclear entry of the HSV genome genome signal but lacking a capsid signal are coloured in green.", [["nuclear", "ANATOMY", 243, 250], ["HSV virions", "ORGANISM", 93, 104], ["HSV virions", "ORGANISM", 203, 214], ["EdCTransport", "GENE_OR_GENE_PRODUCT", 226, 238], ["nuclear", "CELLULAR_COMPONENT", 243, 250], ["HSV", "ORGANISM", 264, 267], ["HSV genome genome", "DNA", 264, 281], ["HSV", "SPECIES", 93, 96], ["HSV", "SPECIES", 203, 206], ["HSV", "SPECIES", 264, 267], ["Images", "TEST", 0, 6], ["genome detection", "TEST", 73, 89], ["HSV virions", "PROBLEM", 93, 104], ["genome detection", "TEST", 183, 199], ["HSV virions", "TREATMENT", 203, 214], ["HSV virions", "OBSERVATION", 93, 104], ["HSV genome genome", "OBSERVATION", 264, 281]]], ["Quantitation is shown in the right-hand panels.", [["right-hand", "ANATOMY", 29, 39], ["Quantitation", "TEST", 0, 12], ["right", "ANATOMY_MODIFIER", 29, 34], ["hand panels", "ANATOMY", 35, 46]]], ["Approximately 700 HSV EdC capsid particles were identified in this representative field of which 95% were positive for genome detection.", [["HSV", "ORGANISM", 18, 21], ["EdC", "GENE_OR_GENE_PRODUCT", 22, 25], ["HSV", "SPECIES", 18, 21], ["HSV EdC capsid particles", "PROBLEM", 18, 42], ["genome detection", "TEST", 119, 135], ["capsid particles", "OBSERVATION", 26, 42]]], ["The small percentage of particles that do not contain a genome signal above threshold could be due to low detection signal, low EdC incorporation, defective particles, or genome release (see below).", [["EdC", "CHEMICAL", 128, 131], ["EdC", "SIMPLE_CHEMICAL", 128, 131], ["EdC", "PROTEIN", 128, 131], ["The small percentage of particles", "PROBLEM", 0, 33], ["low detection signal", "PROBLEM", 102, 122], ["low EdC incorporation", "PROBLEM", 124, 145], ["defective particles", "PROBLEM", 147, 166], ["small", "OBSERVATION_MODIFIER", 4, 9], ["percentage", "OBSERVATION_MODIFIER", 10, 20], ["particles", "OBSERVATION", 24, 33], ["low", "OBSERVATION_MODIFIER", 102, 105], ["defective particles", "OBSERVATION", 147, 166]]], ["The extremely small numbers of green particles that were not detectable by VP5 immunofluorescence could also be due to defective particles or released DNA.", [["VP5", "GENE_OR_GENE_PRODUCT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["VP5", "PROTEIN", 75, 78], ["The extremely small numbers of green particles", "PROBLEM", 0, 46], ["VP5 immunofluorescence", "TEST", 75, 97], ["defective particles", "PROBLEM", 119, 138], ["released DNA", "PROBLEM", 142, 154], ["extremely", "OBSERVATION_MODIFIER", 4, 13], ["small", "OBSERVATION_MODIFIER", 14, 19], ["numbers", "OBSERVATION_MODIFIER", 20, 27], ["green particles", "OBSERVATION", 31, 46], ["could also be due to", "UNCERTAINTY", 98, 118], ["defective particles", "OBSERVATION", 119, 138], ["DNA", "OBSERVATION", 151, 154]]], ["However clearly the vast majority of HSV EdC capsids contained detectable EdC containing genomes.", [["HSV", "ORGANISM", 37, 40], ["EdC capsids", "ORGANISM", 41, 52], ["EdC", "GENE_OR_GENE_PRODUCT", 74, 77], ["EdC containing genomes", "DNA", 74, 96], ["HSV", "SPECIES", 37, 40], ["HSV EdC capsids", "TREATMENT", 37, 52]]], ["The control HSV-1 [17] had essentially no Cells were processed by cycloaddition for EdC incorporation together with immunofluorescence for ICP8 and counterstained by DAPI staining for total DNA (DAPI).", [["Cells", "ANATOMY", 42, 47], ["EdC", "CHEMICAL", 84, 87], ["DAPI", "CHEMICAL", 166, 170], ["HSV-1", "ORGANISM", 12, 17], ["Cells", "CELL", 42, 47], ["EdC", "SIMPLE_CHEMICAL", 84, 87], ["ICP8", "GENE_OR_GENE_PRODUCT", 139, 143], ["DAPI", "SIMPLE_CHEMICAL", 166, 170], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["DAPI", "SIMPLE_CHEMICAL", 195, 199], ["EdC", "PROTEIN", 84, 87], ["ICP8", "PROTEIN", 139, 143], ["HSV-1", "SPECIES", 12, 17], ["The control HSV", "TEST", 0, 15], ["Cells", "PROBLEM", 42, 47], ["EdC incorporation", "TREATMENT", 84, 101], ["immunofluorescence", "TEST", 116, 134], ["ICP8", "PROBLEM", 139, 143], ["DAPI staining", "TEST", 166, 179], ["total DNA", "TEST", 184, 193], ["DAPI staining", "OBSERVATION", 166, 179]]], ["Individual channels are shown in grey scale and the merged images in colour.", [["grey scale", "TEST", 33, 43]]], ["Images were acquired with an x63 objective (scale bar 10 \u03bcm).", [["Images", "TEST", 0, 6]]], ["Patterns of localisation are as discussed in the text. detectable genomes above background (Fig 4, IV-VI and panel), demonstrating the extreme specificity of the reaction.", [["Fig", "TEST", 92, 95], ["the reaction", "PROBLEM", 158, 170], ["localisation", "OBSERVATION", 12, 24]]], ["From our analysis, the percentage of HSV EdC particles with detectable genomes was comparable if not slightly greater than that for similarly labelled Adv (using a combination of EdA and EdC), where approximately 90% of capsids applied to coverslips contained detectable genomes [16] .", [["HSV", "ORGANISM", 37, 40], ["EdC", "GENE_OR_GENE_PRODUCT", 41, 44], ["EdA", "GENE_OR_GENE_PRODUCT", 179, 182], ["Adv", "PROTEIN", 151, 154], ["EdA", "PROTEIN", 179, 182], ["EdC", "PROTEIN", 187, 190], ["HSV", "SPECIES", 37, 40], ["our analysis", "TEST", 5, 17], ["HSV EdC particles", "PROBLEM", 37, 54], ["detectable genomes", "PROBLEM", 60, 78], ["a combination of EdA and EdC", "TREATMENT", 162, 190], ["capsids", "TREATMENT", 220, 227]]], ["This information is important since if incorporation efficiency was low, e.g., only 10% of particles were detected or the efficiency was unknown, then subsequent studies examining genome localisation may give an incomplete picture.Production and genome detection in HSV virions containing EdCFurther quantitation of HSV EdC is given in S3 Fig, including the comparative distributions and variance for VP5 detected by immunofluorescence and genomes detected by cycloaddition.", [["HSV", "ORGANISM", 266, 269], ["virions", "ORGANISM", 270, 277], ["EdCFurther", "GENE_OR_GENE_PRODUCT", 289, 299], ["HSV", "ORGANISM", 316, 319], ["EdC", "ORGANISM", 320, 323], ["VP5", "GENE_OR_GENE_PRODUCT", 401, 404], ["HSV EdC", "PROTEIN", 316, 323], ["VP5", "PROTEIN", 401, 404], ["HSV", "SPECIES", 266, 269], ["HSV", "SPECIES", 316, 319], ["incorporation efficiency", "PROBLEM", 39, 63], ["subsequent studies", "TEST", 151, 169], ["an incomplete picture", "PROBLEM", 209, 230], ["genome detection", "TEST", 246, 262], ["HSV virions", "TREATMENT", 266, 277], ["HSV EdC", "PROBLEM", 316, 323], ["VP5", "PROBLEM", 401, 404], ["immunofluorescence", "TEST", 417, 435], ["HSV virions", "OBSERVATION", 266, 277]]], ["Gaussian distributions were fitted to each channels' frequency data using Image J curve fitter.", [["Gaussian distributions", "PROBLEM", 0, 22], ["Image J curve fitter", "TREATMENT", 74, 94]]], ["We used the coefficient of variation (CV, (\u03c3/\u03bc) x 100) as a measure of variance.", [["CV", "TEST", 38, 40]]], ["The goodness of fit to a normal distribution of VP5 intensities exceeded 0.95 with a CV of 23.75 (S3 Fig).", [["VP5", "GENE_OR_GENE_PRODUCT", 48, 51], ["VP5", "PROTEIN", 48, 51], ["VP5 intensities", "TEST", 48, 63], ["a CV", "TEST", 83, 87], ["normal", "OBSERVATION", 25, 31]]], ["This variance in particle intensity is very similar to analogous types of HSV single particle analysis using either GFP-fusion proteins or antibody to capsid protein [32, 33] .", [["HSV", "ORGANISM", 74, 77], ["GFP", "GENE_OR_GENE_PRODUCT", 116, 119], ["GFP", "PROTEIN", 116, 119], ["fusion proteins", "PROTEIN", 120, 135], ["antibody", "PROTEIN", 139, 147], ["capsid protein", "PROTEIN", 151, 165], ["HSV", "SPECIES", 74, 77], ["This variance in particle intensity", "PROBLEM", 0, 35], ["HSV single particle analysis", "TEST", 74, 102], ["GFP-fusion proteins", "TEST", 116, 135], ["capsid protein", "TEST", 151, 165], ["particle intensity", "OBSERVATION_MODIFIER", 17, 35]]], ["With this as a benchmark, we found the distribution genome signal detected by cycloaddition to have only marginally increased variance with a CV of 34.", [["marginally increased variance", "PROBLEM", 105, 134], ["a CV", "TEST", 140, 144], ["marginally", "OBSERVATION_MODIFIER", 105, 115], ["increased", "OBSERVATION", 116, 125]]], ["[17] at 1x10 8 pfu/ml were adsorbed onto glass coverslips prior to detection by cycloaddition and immunofluorescence for VP5.", [["VP5", "GENE_OR_GENE_PRODUCT", 121, 124], ["VP5", "PROTEIN", 121, 124], ["immunofluorescence", "TEST", 98, 116], ["VP5", "PROBLEM", 121, 124]]], ["Panels I and IV show the merged channel images for each virus (scale bar 10 \u03bcm).", [["I and IV", "PROTEIN", 7, 15]]], ["The inset in panel I shows a magnified section.", [["The inset in panel I", "TEST", 0, 20], ["a magnified section", "TREATMENT", 27, 46]]], ["Panels II and V show only the green channel (genome detection) for each virus.", [["green channel", "PROTEIN", 30, 43], ["Panels II", "TEST", 0, 9], ["each virus", "PROBLEM", 67, 77]]], ["Panels III and VI show the colour-coded outline overlay produced by the ImageJ plugin used for particle analysis (described in materials and methods); yellow indicates particles containing both VP5 capsid protein and EdC genome signal; red indicates VP5+ve particles lacking detectable EdC; green indicates particles with detectable EdC but no VP5.", [["VP5", "GENE_OR_GENE_PRODUCT", 194, 197], ["EdC", "GENE_OR_GENE_PRODUCT", 217, 220], ["VP5", "GENE_OR_GENE_PRODUCT", 250, 253], ["EdC", "GENE_OR_GENE_PRODUCT", 333, 336], ["VP5", "GENE_OR_GENE_PRODUCT", 344, 347], ["VP5 capsid protein", "PROTEIN", 194, 212], ["EdC", "PROTEIN", 217, 220], ["VP5", "PROTEIN", 250, 253], ["EdC", "PROTEIN", 286, 289], ["EdC", "PROTEIN", 333, 336], ["VP5", "PROTEIN", 344, 347], ["the colour", "TEST", 23, 33], ["the ImageJ plugin", "TEST", 68, 85], ["particle analysis", "TEST", 95, 112], ["yellow indicates particles", "PROBLEM", 151, 177], ["both VP5 capsid protein", "TEST", 189, 212], ["EdC genome signal", "TEST", 217, 234], ["VP5", "TEST", 250, 253], ["VP5", "PROBLEM", 344, 347], ["VP5 capsid protein", "OBSERVATION", 194, 212], ["no", "UNCERTAINTY", 341, 343]]], ["The data for approximately 700 particles are quantified in the right panels for each virus. particles having a genome signal below threshold.", [["each virus", "PROBLEM", 80, 90], ["right", "ANATOMY_MODIFIER", 63, 68], ["virus", "OBSERVATION", 85, 90]]], ["HSV w/t exhibited a single focus above background, likely an artefact of detection.", [["HSV", "ORGANISM", 0, 3], ["HSV", "TEST", 0, 3], ["likely", "UNCERTAINTY", 51, 57], ["artefact", "OBSERVATION", 61, 69]]], ["Taken altogether, these results demonstrate that EdC is efficiently incorporated into HSV replication compartments and subsequently into genomes in mature HSV particles, that the yields and infectivity of such particles are minimally affected and that the genomes of the majority of such particles can be detected in vitro by cycloaddition reaction.Capsid ejection and detection of genomes by cycloadditionOur results by definition detect HSV EdC genomes by cycloaddition after virions are adsorbed onto coverslips.", [["EdC", "CHEMICAL", 49, 52], ["EdC", "GENE_OR_GENE_PRODUCT", 49, 52], ["HSV", "ORGANISM", 86, 89], ["HSV", "ORGANISM", 155, 158], ["HSV", "ORGANISM", 439, 442], ["EdC", "GENE_OR_GENE_PRODUCT", 443, 446], ["EdC", "PROTEIN", 49, 52], ["HSV EdC genomes", "DNA", 439, 454], ["HSV", "SPECIES", 86, 89], ["HSV", "SPECIES", 155, 158], ["HSV", "SPECIES", 439, 442], ["HSV replication compartments", "TREATMENT", 86, 114], ["the yields and infectivity of such particles", "PROBLEM", 175, 219], ["minimally affected", "PROBLEM", 224, 242], ["such particles", "PROBLEM", 283, 297], ["Capsid ejection", "TEST", 349, 364], ["HSV EdC genomes", "TREATMENT", 439, 454], ["virions", "TREATMENT", 478, 485], ["HSV replication", "OBSERVATION", 86, 101], ["mature", "OBSERVATION_MODIFIER", 148, 154], ["HSV particles", "OBSERVATION", 155, 168], ["ejection", "OBSERVATION", 356, 364]]], ["We also found in additional control experiments that the vast majority of HSV EdC genomes (99%) were not detectable if the cycloaddition reaction was performed on virions in physiological buffer, prior to adsorption to the coverslips (S5A and S5B Fig) .Capsid ejection and detection of genomes by cycloadditionIn the original observations using purified capsids, Newcomb and colleagues observed that DNA was realised as elongated strands with progressively increasing ejection at elevated temperatures [26, 27] .", [["HSV", "ORGANISM", 74, 77], ["EdC", "GENE_OR_GENE_PRODUCT", 78, 81], ["DNA", "CELLULAR_COMPONENT", 400, 403], ["HSV EdC genomes", "DNA", 74, 89], ["HSV", "SPECIES", 74, 77], ["HSV EdC genomes", "PROBLEM", 74, 89], ["the cycloaddition reaction", "PROBLEM", 119, 145], ["virions in physiological buffer", "TREATMENT", 163, 194], ["Capsid ejection", "TREATMENT", 253, 268], ["purified capsids", "TREATMENT", 345, 361], ["DNA", "PROBLEM", 400, 403], ["elongated strands", "PROBLEM", 420, 437], ["progressively increasing ejection at elevated temperatures", "PROBLEM", 443, 501], ["ejection", "OBSERVATION", 260, 268]]], ["Although there was considerable heterogeneity between particles, release could be substantially prevented if the capsids were first cross-linked with PFA.", [["PFA", "CHEMICAL", 150, 153], ["PFA", "SIMPLE_CHEMICAL", 150, 153], ["considerable heterogeneity between particles", "PROBLEM", 19, 63], ["the capsids", "PROBLEM", 109, 120], ["PFA", "PROBLEM", 150, 153], ["considerable", "OBSERVATION_MODIFIER", 19, 31], ["heterogeneity", "OBSERVATION", 32, 45], ["particles", "OBSERVATION_MODIFIER", 54, 63]]], ["We detected genomes within virions as punctate foci, but we did not observe elongated genome release.", [["virions", "ANATOMY", 27, 34], ["punctate foci", "ANATOMY", 38, 51], ["genome", "CELLULAR_COMPONENT", 86, 92], ["punctate foci", "PROBLEM", 38, 51], ["punctate", "OBSERVATION_MODIFIER", 38, 46], ["foci", "OBSERVATION", 47, 51], ["genome release", "OBSERVATION", 86, 100]]], ["However our analysis was on extracellular virions and not capsids.", [["extracellular virions", "ANATOMY", 28, 49], ["extracellular virions", "CELLULAR_COMPONENT", 28, 49], ["capsids", "CELLULAR_COMPONENT", 58, 65], ["our analysis", "TEST", 8, 20], ["extracellular virions", "TREATMENT", 28, 49]]], ["To examine the detection and possible ejection of HSV EdC genomes further, we analysed virions that had been adsorbed onto coverslips and then subject to elevated heat treatment.", [["virions", "ANATOMY", 87, 94], ["HSV", "ORGANISM", 50, 53], ["HSV EdC genomes", "DNA", 50, 65], ["HSV", "SPECIES", 50, 53], ["the detection", "TEST", 11, 24], ["ejection of HSV EdC genomes", "TREATMENT", 38, 65], ["elevated heat treatment", "TREATMENT", 154, 177]]], ["Whereas adsorption of virions at room temperature resulted in detection of genomes colocalised within capsids (e.g. panel a, also Fig 4) , elevated temperature resulted in numerous elongated filamentous stands ejected from virions (panel c).", [["virions", "ANATOMY", 223, 230], ["genomes colocalised within capsids", "PROBLEM", 75, 109], ["Fig", "TEST", 130, 133], ["elevated temperature", "PROBLEM", 139, 159], ["numerous elongated filamentous stands", "PROBLEM", 172, 209], ["numerous", "OBSERVATION_MODIFIER", 172, 180], ["elongated", "OBSERVATION_MODIFIER", 181, 190], ["filamentous stands", "OBSERVATION", 191, 209]]], ["This was accompanied by an increase in the numbers of capsids in which genomes were not detected as well as an increase in the numbers of punctate genome foci that were not detected by immunofluorescence.", [["foci", "ANATOMY", 154, 158], ["an increase in the numbers of capsids", "PROBLEM", 24, 61], ["punctate genome foci", "PROBLEM", 138, 158], ["immunofluorescence", "TEST", 185, 203], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["numbers", "OBSERVATION_MODIFIER", 43, 50], ["capsids", "OBSERVATION_MODIFIER", 54, 61], ["increase", "OBSERVATION_MODIFIER", 111, 119], ["numbers", "OBSERVATION_MODIFIER", 127, 134], ["punctate", "OBSERVATION_MODIFIER", 138, 146], ["genome", "OBSERVATION_MODIFIER", 147, 153], ["foci", "OBSERVATION", 154, 158]]], ["Our results are entirely consistent with the previous data obtained by electron microscopy and demonstrate that HSV EdC genomes when released from heat-disrupted virions could readily be detected on coverslips by the cycloaddition reaction.", [["HSV", "ORGANISM", 112, 115], ["EdC", "GENE_OR_GENE_PRODUCT", 116, 119], ["HSV EdC genomes", "DNA", 112, 127], ["HSV", "SPECIES", 112, 115], ["electron microscopy", "TEST", 71, 90], ["HSV EdC genomes", "PROBLEM", 112, 127], ["disrupted virions", "PROBLEM", 152, 169], ["the cycloaddition reaction", "PROBLEM", 213, 239], ["entirely consistent with", "UNCERTAINTY", 16, 40]]], ["Furthermore, they indicate that when absorbed onto solid supports at lower temperatures, the genome is available for the cycloaddition reaction, presumably due to some conformational perturbation of the virion/capsid, but maintained in the confines of the capsid or virion.Genome trafficking and nuclear transportWe next investigated HSV EdC genome transport and uncoating in cells in vivo.", [["nuclear", "ANATOMY", 296, 303], ["cells", "ANATOMY", 376, 381], ["virion", "CELLULAR_COMPONENT", 203, 209], ["capsid", "CELLULAR_COMPONENT", 256, 262], ["virion", "CELLULAR_COMPONENT", 266, 272], ["nuclear", "CELLULAR_COMPONENT", 296, 303], ["HSV", "ORGANISM", 334, 337], ["EdC", "GENE_OR_GENE_PRODUCT", 338, 341], ["cells", "CELL", 376, 381], ["virion/capsid", "PROTEIN", 203, 216], ["capsid", "PROTEIN", 256, 262], ["HSV EdC genome", "DNA", 334, 348], ["HSV", "SPECIES", 334, 337], ["the cycloaddition reaction", "PROBLEM", 117, 143], ["some conformational perturbation of the virion/capsid", "PROBLEM", 163, 216], ["HSV EdC genome transport", "TREATMENT", 334, 358]]], ["Virus (moi 10) was adsorbed onto cells at 4\u02daC for 45 min and then either washed and processed directly or shifted to 37\u02daC to allow fusion and virus entry and then processed 2 hrs later (Fig 5) .", [["cells", "ANATOMY", 33, 38], ["Virus", "ORGANISM", 0, 5], ["moi 10", "ORGANISM", 7, 13], ["cells", "CELL", 33, 38], ["Virus", "PROBLEM", 0, 5], ["fusion", "TREATMENT", 131, 137]]], ["At 4\u02daC for both HSV EdC and HSV (Fig 5A and 5B respectively), numerous virus particles could be detected on cells (VP5, panels I).", [["cells", "ANATOMY", 108, 113], ["C", "GENE_OR_GENE_PRODUCT", 5, 6], ["HSV", "ORGANISM", 16, 19], ["EdC", "ORGANISM", 20, 23], ["HSV (Fig 5A", "ORGANISM", 28, 39], ["cells", "CELL", 108, 113], ["VP5", "GENE_OR_GENE_PRODUCT", 115, 118], ["VP5", "PROTEIN", 115, 118], ["panels I", "PROTEIN", 120, 128], ["HSV", "SPECIES", 16, 19], ["HSV", "SPECIES", 28, 31], ["both HSV EdC", "TEST", 11, 23], ["HSV (Fig 5A and 5B respectively", "TEST", 28, 59], ["numerous virus particles", "PROBLEM", 62, 86]]], ["In contrast to adsorption onto coverslips, there was no significant genome signal for HSV EdC particles adsorbed onto cells (Fig 5A, 4\u02daC , EdC channel, panel II).", [["cells", "ANATOMY", 118, 123], ["HSV", "ORGANISM", 86, 89], ["cells", "CELL", 118, 123], ["EdC", "GENE_OR_GENE_PRODUCT", 139, 142], ["EdC channel", "PROTEIN", 139, 150], ["panel II", "PROTEIN", 152, 160], ["HSV", "SPECIES", 86, 89], ["significant genome signal", "PROBLEM", 56, 81], ["HSV EdC particles", "PROBLEM", 86, 103], ["Fig 5A", "TEST", 125, 131], ["no", "UNCERTAINTY", 53, 55]]], ["This is consistent with the lack of genome detection in physiological buffer and supports the proposal from this and previous work [26, 27] for a conformational perturbation upon adsorption to artificial surfaces which is registered by the cycloaddition reaction.", [["a conformational perturbation", "PROBLEM", 144, 173], ["artificial surfaces", "TREATMENT", 193, 212], ["the cycloaddition reaction", "PROBLEM", 236, 262], ["consistent with", "UNCERTAINTY", 8, 23], ["cycloaddition reaction", "OBSERVATION", 240, 262]]], ["After shift to 37\u02daC for 2 hrs, numerous capsids could be detected within the cytoplasm but with only infrequent detection of genomes ( Fig 5A, panels IV-VI, see also below).", [["cytoplasm", "ANATOMY", 77, 86], ["cytoplasm", "ORGANISM_SUBSTANCE", 77, 86], ["IV-VI", "GENE_OR_GENE_PRODUCT", 150, 155], ["numerous capsids", "PROBLEM", 31, 47], ["IV", "TEST", 150, 152]]], ["In contrast, distinct genome foci were now readily observed in the nucleus (Fig 5A, panels V and merged VI).", [["foci", "ANATOMY", 29, 33], ["nucleus", "ANATOMY", 67, 74], ["nucleus", "CELLULAR_COMPONENT", 67, 74], ["distinct genome foci", "PROBLEM", 13, 33], ["distinct", "OBSERVATION_MODIFIER", 13, 21], ["genome", "OBSERVATION_MODIFIER", 22, 28], ["foci", "OBSERVATION", 29, 33], ["nucleus", "ANATOMY", 67, 74]]], ["We frequently observed smaller genome foci in close proximity to capsids (panel VI, small angled arrows) together with larger nuclear foci (arrowheads).", [["foci", "ANATOMY", 38, 42], ["nuclear foci", "ANATOMY", 126, 138], ["smaller genome foci", "PROBLEM", 23, 42], ["small angled arrows)", "PROBLEM", 84, 104], ["larger nuclear foci", "PROBLEM", 119, 138], ["smaller", "OBSERVATION_MODIFIER", 23, 30], ["genome", "OBSERVATION_MODIFIER", 31, 37], ["foci", "OBSERVATION", 38, 42], ["small", "OBSERVATION_MODIFIER", 84, 89], ["larger", "OBSERVATION_MODIFIER", 119, 125], ["nuclear", "OBSERVATION_MODIFIER", 126, 133], ["foci", "OBSERVATION", 134, 138]]], ["Low but detectable numbers of foci could be observed in a minority of cells in the cytoplasm (e.g., panel VI, vertical arrows).", [["foci", "ANATOMY", 30, 34], ["cells", "ANATOMY", 70, 75], ["cytoplasm", "ANATOMY", 83, 92], ["cells", "CELL", 70, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 83, 92], ["foci", "PROBLEM", 30, 34], ["detectable", "OBSERVATION_MODIFIER", 8, 18], ["numbers", "OBSERVATION_MODIFIER", 19, 26], ["foci", "OBSERVATION", 30, 34], ["cytoplasm", "ANATOMY_MODIFIER", 83, 92]]], ["The HSV EdC foci detected within the nucleus were somewhat heterogeneous in size at this time (2 hrs) and distinctly larger than the few foci detected within the cytoplasm (see below).", [["EdC foci", "ANATOMY", 8, 16], ["nucleus", "ANATOMY", 37, 44], ["foci", "ANATOMY", 137, 141], ["cytoplasm", "ANATOMY", 162, 171], ["HSV", "ORGANISM", 4, 7], ["EdC", "GENE_OR_GENE_PRODUCT", 8, 11], ["nucleus", "CELLULAR_COMPONENT", 37, 44], ["cytoplasm", "ORGANISM_SUBSTANCE", 162, 171], ["HSV", "SPECIES", 4, 7], ["The HSV EdC foci", "PROBLEM", 0, 16], ["HSV", "OBSERVATION_MODIFIER", 4, 7], ["EdC", "OBSERVATION_MODIFIER", 8, 11], ["foci", "OBSERVATION", 12, 16], ["nucleus", "ANATOMY_MODIFIER", 37, 44], ["somewhat", "OBSERVATION_MODIFIER", 50, 58], ["heterogeneous", "OBSERVATION_MODIFIER", 59, 72], ["size", "OBSERVATION_MODIFIER", 76, 80], ["distinctly", "OBSERVATION_MODIFIER", 106, 116], ["larger", "OBSERVATION_MODIFIER", 117, 123], ["few", "OBSERVATION_MODIFIER", 133, 136], ["foci", "OBSERVATION", 137, 141], ["cytoplasm", "OBSERVATION_MODIFIER", 162, 171]]], ["No specific genome signal was observed for the control HSV-1 [17] (Fig 5B, panels V-VI).", [["HSV-1", "ORGANISM", 55, 60], ["V-VI", "GENE_OR_GENE_PRODUCT", 82, 86], ["HSV-1", "SPECIES", 55, 60], ["specific genome signal", "TEST", 3, 25], ["the control HSV", "TEST", 43, 58], ["Fig 5B", "TEST", 67, 73]]], ["In further control experiments the appearance of nuclear genome foci after HSV EdC infection was completely dependent upon the copper-catalysed cycloaddition reaction, was blocked by incubation with neutralising antibody prior to infection and was not prevented by prior treatment of HSV EdC virions with DNAse (S6 Fig) .Genome trafficking and nuclear transportAltogether these data provide robust support for the proposal that the nuclear foci represent uncoated HSV EdC genomes that have reached nuclear pores, uncoated and have been transported into the nucleus, with infrequent (though detectable) presence in the cytoplasm of some cells.", [["nuclear genome foci", "ANATOMY", 49, 68], ["nuclear", "ANATOMY", 344, 351], ["nuclear foci", "ANATOMY", 432, 444], ["nuclear pores", "ANATOMY", 498, 511], ["nucleus", "ANATOMY", 557, 564], ["cytoplasm", "ANATOMY", 618, 627], ["cells", "ANATOMY", 636, 641], ["infection", "DISEASE", 83, 92], ["copper", "CHEMICAL", 127, 133], ["infection", "DISEASE", 230, 239], ["copper", "CHEMICAL", 127, 133], ["nuclear", "CELLULAR_COMPONENT", 49, 56], ["HSV EdC", "ORGANISM", 75, 82], ["copper", "SIMPLE_CHEMICAL", 127, 133], ["HSV", "ORGANISM", 284, 287], ["EdC", "GENE_OR_GENE_PRODUCT", 288, 291], ["DNAse", "GENE_OR_GENE_PRODUCT", 305, 310], ["nuclear", "CELLULAR_COMPONENT", 344, 351], ["nuclear", "CELLULAR_COMPONENT", 432, 439], ["HSV", "ORGANISM", 464, 467], ["EdC", "GENE_OR_GENE_PRODUCT", 468, 471], ["nuclear pores", "CELLULAR_COMPONENT", 498, 511], ["nucleus", "CELLULAR_COMPONENT", 557, 564], ["cytoplasm", "ORGANISM_SUBSTANCE", 618, 627], ["cells", "CELL", 636, 641], ["neutralising antibody", "PROTEIN", 199, 220], ["DNAse", "PROTEIN", 305, 310], ["S6", "PROTEIN", 312, 314], ["uncoated HSV EdC genomes", "DNA", 455, 479], ["HSV", "SPECIES", 75, 78], ["HSV", "SPECIES", 284, 287], ["HSV", "SPECIES", 464, 467], ["nuclear genome foci", "PROBLEM", 49, 68], ["HSV EdC infection", "PROBLEM", 75, 92], ["the copper-catalysed cycloaddition reaction", "PROBLEM", 123, 166], ["neutralising antibody", "PROBLEM", 199, 220], ["infection", "PROBLEM", 230, 239], ["HSV EdC virions", "TREATMENT", 284, 299], ["DNAse (S6 Fig", "TREATMENT", 305, 318], ["robust support", "TREATMENT", 391, 405], ["the nuclear foci", "PROBLEM", 428, 444], ["uncoated HSV EdC genomes", "PROBLEM", 455, 479], ["genome", "OBSERVATION_MODIFIER", 57, 63], ["foci", "OBSERVATION", 64, 68], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 230, 239], ["foci", "OBSERVATION", 440, 444], ["uncoated", "OBSERVATION_MODIFIER", 455, 463], ["HSV EdC genomes", "OBSERVATION", 464, 479], ["pores", "OBSERVATION_MODIFIER", 506, 511], ["nucleus", "ANATOMY", 557, 564], ["some cells", "OBSERVATION", 631, 641]]], ["[17] at moi 10 at 4\u02daC and incubated for 45 min.", [["C", "GENE_OR_GENE_PRODUCT", 20, 21]]], ["Cells were then either fixed immediately (4\u02daC), or the temperature was raised to 37\u02daC for 2 hr (4\u02daC ! 37\u02daC).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the temperature", "TEST", 51, 66]]], ["Genomes were detected by cycloaddition and capsids by anti-VP5 immunofluorescence (scale bar 10 \u03bcm).", [["anti-VP5", "PROTEIN", 54, 62]]], ["In each of (a) and (b), panels I and IV show detection of VP5, II and V show detection of EdC labelled genomes, with panels III and VI show the merged image.Genome trafficking and nuclear transporthttps://doi.org/10.1371/journal.ppat.1006721.g005Genome trafficking and nuclear transportTransport and nuclear entry of the HSV genome Temporal alteration in genome compaction state We next undertook a quantitative examination (Fig 6) of the relationship of moi to the numbers of genomic foci, evaluated at 30 min after shift to 37\u02daC, in this case co-staining with anti-VP5 to detect infecting capsids.", [["nuclear", "ANATOMY", 180, 187], ["nuclear", "ANATOMY", 269, 276], ["nuclear", "ANATOMY", 300, 307], ["foci", "ANATOMY", 485, 489], ["VP5", "GENE_OR_GENE_PRODUCT", 58, 61], ["EdC", "GENE_OR_GENE_PRODUCT", 90, 93], ["nuclear", "CELLULAR_COMPONENT", 180, 187], ["nuclear", "CELLULAR_COMPONENT", 269, 276], ["nuclear", "CELLULAR_COMPONENT", 300, 307], ["HSV", "ORGANISM", 321, 324], ["anti-VP5", "GENE_OR_GENE_PRODUCT", 562, 570], ["VP5", "PROTEIN", 58, 61], ["EdC labelled genomes", "DNA", 90, 110], ["HSV genome", "DNA", 321, 331], ["anti-VP5", "PROTEIN", 562, 570], ["VP5", "TEST", 58, 61], ["a quantitative examination", "TEST", 397, 423], ["genomic foci", "PROBLEM", 477, 489], ["anti-VP5", "TREATMENT", 562, 570], ["infecting capsids", "PROBLEM", 581, 598], ["Temporal", "OBSERVATION_MODIFIER", 332, 340], ["alteration", "OBSERVATION", 341, 351], ["genome compaction", "OBSERVATION", 355, 372], ["foci", "OBSERVATION", 485, 489]]], ["We used 30 min to quantitate the relationship with moi since foci became more difficult to quantitate accurately at later times because of the changing morphology at 2-3 hpi (see below) and because immediate early protein synthesis had almost invariably already occurred by 2 hpi.", [["foci", "PROBLEM", 61, 65], ["the changing morphology", "PROBLEM", 139, 162], ["immediate early protein synthesis", "PROBLEM", 198, 231], ["foci", "OBSERVATION", 61, 65]]], ["Fig 6A panel I shows a representative maximum projection image of cells 30 min after HSV EdC infection, illustrating the frequent occurrence of genomes at a consistent and close proximity to capsids, most likely representing recent uncoating events where the genome had not yet physically moved far from the capsids from which they emanated (Fig 6A, inset) .", [["cells", "ANATOMY", 66, 71], ["infection", "DISEASE", 93, 102], ["cells", "CELL", 66, 71], ["HSV", "ORGANISM", 85, 88], ["6A panel I", "PROTEIN", 4, 14], ["HSV", "SPECIES", 85, 88], ["HSV EdC infection", "PROBLEM", 85, 102], ["recent uncoating events", "PROBLEM", 225, 248], ["infection", "OBSERVATION", 93, 102], ["most likely", "UNCERTAINTY", 200, 211], ["uncoating events", "OBSERVATION", 232, 248]]], ["At this early stage, HSV EdC nuclear genomic foci were comparatively homogeneous in size and shape and generally spherical.", [["foci", "ANATOMY", 45, 49], ["HSV", "ORGANISM", 21, 24], ["EdC", "GENE_OR_GENE_PRODUCT", 25, 28], ["HSV", "SPECIES", 21, 24], ["HSV EdC nuclear genomic foci", "PROBLEM", 21, 49], ["genomic", "OBSERVATION_MODIFIER", 37, 44], ["foci", "OBSERVATION", 45, 49], ["comparatively", "OBSERVATION_MODIFIER", 55, 68], ["homogeneous", "OBSERVATION_MODIFIER", 69, 80], ["size", "OBSERVATION_MODIFIER", 84, 88], ["shape", "OBSERVATION_MODIFIER", 93, 98], ["generally", "OBSERVATION_MODIFIER", 103, 112], ["spherical", "OBSERVATION_MODIFIER", 113, 122]]], ["Mean numbers of genomes per nucleus observed at different mois (approximately 200 cells at each moi) are illustrated in Fig 6B ( summarised in panel d), with frequency distributions indicated in Fig 6C.", [["nucleus", "ANATOMY", 28, 35], ["cells", "ANATOMY", 82, 87], ["nucleus", "CELLULAR_COMPONENT", 28, 35], ["cells", "CELL", 82, 87], ["Mean numbers", "TEST", 0, 12], ["genomes", "OBSERVATION", 16, 23], ["nucleus", "ANATOMY", 28, 35]]], ["With increasing moi there was an increasing trend of genome foci in the nucleus, but this was not directly proportionate, with for example an average of 4-5 foci at moi 10, 6 at moi 20 and 10 at moi 50.", [["foci", "ANATOMY", 60, 64], ["nucleus", "ANATOMY", 72, 79], ["nucleus", "CELLULAR_COMPONENT", 72, 79], ["increasing moi", "PROBLEM", 5, 19], ["genome foci in the nucleus", "PROBLEM", 53, 79], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["moi", "OBSERVATION", 16, 19], ["increasing", "OBSERVATION_MODIFIER", 33, 43], ["trend", "OBSERVATION_MODIFIER", 44, 49], ["genome", "OBSERVATION_MODIFIER", 53, 59], ["foci", "OBSERVATION", 60, 64], ["nucleus", "ANATOMY", 72, 79]]], ["Moreover, while representing minority populations high numbers of foci could be observed in some nuclei (example, panel a, ii) with maximum numbers for moi 10, 20, and 50 being 21, 27 and 34 respectively (Fig 6B and 6D ).", [["foci", "ANATOMY", 66, 70], ["nuclei", "ANATOMY", 97, 103], ["nuclei", "CELLULAR_COMPONENT", 97, 103], ["foci", "PROBLEM", 66, 70], ["maximum numbers", "TEST", 132, 147], ["moi", "TEST", 152, 155], ["Fig 6B", "TEST", 205, 211], ["minority", "OBSERVATION_MODIFIER", 29, 37], ["populations", "OBSERVATION_MODIFIER", 38, 49], ["high", "OBSERVATION_MODIFIER", 50, 54], ["numbers", "OBSERVATION_MODIFIER", 55, 62], ["foci", "OBSERVATION", 66, 70]]], ["Later in infection while there was a trend of increased numbers of nuclear foci, this was generally less than a 50% increase but more difficult to quantitate as indicated above.", [["nuclear foci", "ANATOMY", 67, 79], ["infection", "DISEASE", 9, 18], ["nuclear", "CELLULAR_COMPONENT", 67, 74], ["infection", "PROBLEM", 9, 18], ["increased numbers of nuclear foci", "PROBLEM", 46, 79], ["infection", "OBSERVATION", 9, 18], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["numbers", "OBSERVATION_MODIFIER", 56, 63], ["nuclear", "OBSERVATION_MODIFIER", 67, 74], ["foci", "OBSERVATION", 75, 79], ["less", "OBSERVATION_MODIFIER", 100, 104]]], ["Capsid-free cytoplasmic foci (example, Fig 6E, vertical arrows) were infrequently observed though at higher mois these could represent 7-8% of the total foci ( Fig 6E) .", [["cytoplasmic foci", "ANATOMY", 12, 28], ["foci", "ANATOMY", 153, 157], ["Capsid", "GENE_OR_GENE_PRODUCT", 0, 6], ["cytoplasmic", "ORGANISM_SUBSTANCE", 12, 23], ["Capsid", "TEST", 0, 6], ["free cytoplasmic foci", "PROBLEM", 7, 28], ["Fig 6E", "TEST", 39, 45], ["free", "OBSERVATION_MODIFIER", 7, 11], ["cytoplasmic foci", "OBSERVATION", 12, 28], ["total", "OBSERVATION_MODIFIER", 147, 152], ["foci", "OBSERVATION", 153, 157]]], ["While these were a minor population, such cells could be relevant e.g., to overall cellular responses (see discussion).Genome trafficking and nuclear transportStandard wide field microscopy is limited by diffraction and additional inherent limitations in optical imaging and capture.", [["cells", "ANATOMY", 42, 47], ["cellular", "ANATOMY", 83, 91], ["nuclear", "ANATOMY", 142, 149], ["cells", "CELL", 42, 47], ["cellular", "CELL", 83, 91], ["nuclear", "CELLULAR_COMPONENT", 142, 149], ["a minor population", "PROBLEM", 17, 35], ["such cells", "PROBLEM", 37, 47], ["Standard wide field microscopy", "TEST", 159, 189], ["optical imaging", "TEST", 255, 270], ["minor", "OBSERVATION_MODIFIER", 19, 24], ["population", "OBSERVATION", 25, 35]]], ["To examine the genomes in more detail, we pursued super-resolution microscopy using 3D structured illumination microscopy (3D-SIM) [34] .Genome trafficking and nuclear transportWe first extended the analysis of virions on coverslips combining capsid and genome detection followed by 3D-SIM, as described in materials and methods.", [["nuclear", "ANATOMY", 160, 167], ["nuclear", "CELLULAR_COMPONENT", 160, 167], ["3D structured illumination microscopy", "TEST", 84, 121], ["virions on coverslips", "TREATMENT", 211, 232], ["capsid and genome detection", "TREATMENT", 243, 270]]], ["Further particle analysis (approximately 800 particles) was performed via 2D-Gaussian fitting in each channel to calculate dimensions at full width half maxima (FWHM, summarised in table of Fig 7A) .", [["Further particle analysis", "TEST", 0, 25], ["2D-Gaussian fitting", "TREATMENT", 74, 93]]], ["For the capsid and genome signals the mean FWHM were 144 nm and 131 nm respectively.", [["capsid", "CELLULAR_COMPONENT", 8, 14], ["the mean FWHM", "TEST", 34, 47]]], ["Although the mean genome signal was slightly smaller than the mean capsid signal, we do not take this as a significant difference between capsid dimension and packaged genome dimensions, the resolution of which is beyond the limits of these techniques.", [["the mean genome signal", "TEST", 9, 31], ["slightly", "OBSERVATION_MODIFIER", 36, 44], ["smaller", "OBSERVATION_MODIFIER", 45, 52], ["capsid dimension", "OBSERVATION_MODIFIER", 138, 154], ["genome", "OBSERVATION_MODIFIER", 168, 174], ["dimensions", "OBSERVATION_MODIFIER", 175, 185], ["resolution", "OBSERVATION_MODIFIER", 191, 201]]], ["On the other hand 3D-SIM combined with quantitative object analysis allowed a better resolved spatiotemporal analysis of nuclear entry in the cell.Genome trafficking and nuclear transportWe examined genome presentation in the nucleus at early times of infection (0.5 hpi).", [["nuclear", "ANATOMY", 121, 128], ["cell", "ANATOMY", 142, 146], ["nuclear", "ANATOMY", 170, 177], ["nucleus", "ANATOMY", 226, 233], ["infection", "DISEASE", 252, 261], ["nuclear", "CELLULAR_COMPONENT", 121, 128], ["cell", "CELL", 142, 146], ["nuclear", "CELLULAR_COMPONENT", 170, 177], ["nucleus", "CELLULAR_COMPONENT", 226, 233], ["quantitative object analysis", "TEST", 39, 67], ["infection", "PROBLEM", 252, 261], ["nuclear entry", "OBSERVATION", 121, 134], ["cell", "ANATOMY", 142, 146], ["nucleus", "ANATOMY", 226, 233], ["infection", "OBSERVATION", 252, 261]]], ["Cells were imaged by 3D-SIM and the data processed using the Object analyser module of Huygens image processing software in which after 3D segmentation, geometrical and spatial localisation data can be calculated for individual objects.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["3D segmentation", "TEST", 136, 151], ["spatial localisation data", "TEST", 169, 194]]], ["This field shows capsids in the red channel, genomes in green and DAPI stained nucleus in blue, with transparencies applied.", [["nucleus", "ANATOMY", 79, 86], ["DAPI", "CHEMICAL", 66, 70], ["DAPI", "SIMPLE_CHEMICAL", 66, 70], ["nucleus", "CELLULAR_COMPONENT", 79, 86], ["red channel", "PROTEIN", 32, 43], ["capsids in the red channel", "PROBLEM", 17, 43], ["green and DAPI stained nucleus in blue", "PROBLEM", 56, 94], ["transparencies", "TREATMENT", 101, 115], ["capsids", "OBSERVATION", 17, 24], ["red channel", "ANATOMY", 32, 43], ["green", "OBSERVATION_MODIFIER", 56, 61], ["DAPI stained nucleus", "OBSERVATION", 66, 86], ["blue", "OBSERVATION_MODIFIER", 90, 94]]], ["An accompanying 3D video animation is shown in S7 Fig. The inherent lower optical resolution in the z-dimension than x/y-dimensions results in slightly oblong capsids.", [["slightly oblong capsids", "PROBLEM", 143, 166], ["S7 Fig", "OBSERVATION", 47, 53], ["inherent", "OBSERVATION_MODIFIER", 59, 67], ["lower", "OBSERVATION_MODIFIER", 68, 73], ["optical", "OBSERVATION_MODIFIER", 74, 81], ["resolution", "OBSERVATION_MODIFIER", 82, 92], ["slightly", "OBSERVATION_MODIFIER", 143, 151], ["oblong capsids", "OBSERVATION", 152, 166]]], ["This optical limitation applies also to the genomic foci but does not affect the main conclusions on comparative volume between genomes.", [["foci", "ANATOMY", 52, 56], ["the genomic foci", "PROBLEM", 40, 56], ["genomic", "OBSERVATION_MODIFIER", 44, 51], ["foci", "OBSERVATION", 52, 56], ["main", "OBSERVATION_MODIFIER", 81, 85]]], ["We compared virions on coverslips versus infected cell nuclear genomic foci at 0.5 hpi and 2 hpi (Fig 7C) .", [["virions", "ANATOMY", 12, 19], ["coverslips", "ANATOMY", 23, 33], ["cell", "ANATOMY", 50, 54], ["foci", "ANATOMY", 71, 75], ["cell", "CELL", 50, 54], ["foci", "CELL", 71, 75], ["coverslips", "TREATMENT", 23, 33], ["infected cell nuclear genomic foci", "PROBLEM", 41, 75], ["infected", "OBSERVATION_MODIFIER", 41, 49], ["cell nuclear genomic foci", "OBSERVATION", 50, 75]]], ["For clarity in the infected cell nuclei only the genome signal is shown.", [["cell nuclei", "ANATOMY", 28, 39], ["cell nuclei", "CELL", 28, 39], ["infected cell nuclei", "OBSERVATION", 19, 39], ["genome signal", "OBSERVATION", 49, 62]]], ["The 3D genome objects were quantified for volume ( Fig 7D) and shape (Fig 7E) , the latter measured as proximity to a sphere (sphericity).", [["3D genome objects", "DNA", 4, 21], ["volume", "TEST", 42, 48], ["shape (Fig 7E", "TEST", 63, 76], ["sphere", "OBSERVATION_MODIFIER", 118, 124]]], ["The results demonstrate a substantial increase (approximately 3-fold) in mean volume of the nuclear genomic foci compared to those in virions (Fig 7C panels I, II; Fig 7D) .", [["nuclear genomic foci", "ANATOMY", 92, 112], ["virions", "ANATOMY", 134, 141], ["nuclear", "CELLULAR_COMPONENT", 92, 99], ["a substantial increase", "PROBLEM", 24, 46], ["mean volume", "TEST", 73, 84], ["the nuclear genomic foci", "PROBLEM", 88, 112], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["approximately", "OBSERVATION_MODIFIER", 48, 61], ["3-fold", "OBSERVATION_MODIFIER", 62, 68], ["mean", "OBSERVATION_MODIFIER", 73, 77], ["volume", "OBSERVATION_MODIFIER", 78, 84], ["nuclear genomic", "OBSERVATION", 92, 107], ["foci", "OBSERVATION", 108, 112]]], ["Nuclear foci at 0.5 hpi were comparatively homogeneous and with only marginal differences in sphericity (Fig 7D and 7E ).", [["Nuclear foci", "ANATOMY", 0, 12], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["Nuclear foci", "TEST", 0, 12], ["foci", "OBSERVATION", 8, 12], ["homogeneous", "OBSERVATION_MODIFIER", 43, 54], ["marginal", "OBSERVATION_MODIFIER", 69, 77], ["differences", "OBSERVATION_MODIFIER", 78, 89], ["sphericity", "OBSERVATION_MODIFIER", 93, 103]]], ["The linear length of the HSV genome is approximately 50 \u03bcm and would stretch across a typical cell several times.", [["cell", "ANATOMY", 94, 98], ["HSV", "ORGANISM", 25, 28], ["cell", "CELL", 94, 98], ["HSV genome", "DNA", 25, 35], ["HSV", "SPECIES", 25, 28], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["HSV genome", "OBSERVATION", 25, 35], ["approximately", "OBSERVATION_MODIFIER", 39, 52], ["50 \u03bcm", "OBSERVATION_MODIFIER", 53, 58], ["typical cell", "OBSERVATION", 86, 98]]], ["Our results demonstrate that while HSV genomes clearly expand, they Transport and nuclear entry of the HSV genome are initially constrained and condensed to a comparatively consistent compact, roughly spherical volume.", [["nuclear", "ANATOMY", 82, 89], ["HSV", "ORGANISM", 35, 38], ["nuclear", "CELLULAR_COMPONENT", 82, 89], ["HSV", "ORGANISM", 103, 106], ["HSV genomes", "DNA", 35, 46], ["HSV genome", "DNA", 103, 113], ["HSV", "SPECIES", 35, 38], ["HSV", "SPECIES", 103, 106], ["the HSV genome", "PROBLEM", 99, 113], ["HSV genome", "OBSERVATION", 103, 113], ["spherical volume", "OBSERVATION", 201, 217]]], ["By 2 hpi, the mean volume of the foci had increased further (by another 2-4 fold), and examined at 0.5 hpi.", [["foci", "ANATOMY", 33, 37], ["the foci", "PROBLEM", 29, 37], ["foci", "OBSERVATION", 33, 37], ["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["Red objects denote VP5 capsids, while green objects denote EdC-labelled genomes.", [["VP5", "GENE_OR_GENE_PRODUCT", 19, 22], ["EdC", "GENE_OR_GENE_PRODUCT", 59, 62], ["VP5 capsids", "PROTEIN", 19, 30], ["EdC-labelled genomes", "DNA", 59, 79], ["Red objects", "PROBLEM", 0, 11], ["VP5 capsids", "PROBLEM", 19, 30], ["VP5 capsids", "OBSERVATION", 19, 30], ["green objects", "OBSERVATION", 38, 51], ["labelled genomes", "OBSERVATION", 63, 79]]], ["Blue object is nuclear DAPI staining. (c) 3D-SIM data of HSV-1 EdC genomes on coverslips compared to infected cells at 0.5 hpi and 2 hpi visualised after 3D-SIM by isorendering in Huygens analysis software (scale bar 1 \u03bcm).", [["nuclear", "ANATOMY", 15, 22], ["cells", "ANATOMY", 110, 115], ["DAPI", "CHEMICAL", 23, 27], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["DAPI", "SIMPLE_CHEMICAL", 23, 27], ["HSV", "ORGANISM", 57, 60], ["cells", "CELL", 110, 115], ["HSV-1 EdC genomes", "DNA", 57, 74], ["infected cells", "CELL_TYPE", 101, 115], ["HSV-1", "SPECIES", 57, 62], ["nuclear DAPI staining", "PROBLEM", 15, 36], ["HSV", "TEST", 57, 60], ["coverslips", "TEST", 78, 88], ["infected cells", "PROBLEM", 101, 115], ["3D", "TEST", 154, 156], ["nuclear", "OBSERVATION", 15, 22], ["DAPI staining", "OBSERVATION", 23, 36]]], ["Quantitative analysis of genome volume (d) and sphericity (e) is shown as box and whisker plots.", [["Quantitative analysis", "TEST", 0, 21]]], ["Boxes show 2 nd and 3 rd quartiles with a horizontal bar in the middle showing the median, while whiskers show up to 5-95% of the total population.", [["middle", "ANATOMY_MODIFIER", 64, 70]]], ["Unpaired two-tailed t-tests were used for statistical results (** = p<0.005, *** = p<0.0001).Genome trafficking and nuclear transporthttps://doi.org/10.1371/journal.ppat.1006721.g007Genome trafficking and nuclear transportTransport and nuclear entry of the HSV genome but there was also a marked increase in irregularity as the foci became more decondensed and dissipated.", [["nuclear", "ANATOMY", 116, 123], ["nuclear", "ANATOMY", 205, 212], ["nuclear", "ANATOMY", 236, 243], ["foci", "ANATOMY", 328, 332], ["nuclear", "CELLULAR_COMPONENT", 116, 123], ["nuclear", "CELLULAR_COMPONENT", 205, 212], ["nuclear", "CELLULAR_COMPONENT", 236, 243], ["HSV", "ORGANISM", 257, 260], ["HSV genome", "DNA", 257, 267], ["HSV", "SPECIES", 257, 260], ["tailed t-tests", "TEST", 13, 27], ["a marked increase in irregularity", "PROBLEM", 287, 320], ["the foci", "PROBLEM", 324, 332], ["HSV genome", "OBSERVATION", 257, 267], ["marked", "OBSERVATION_MODIFIER", 289, 295], ["increase", "OBSERVATION_MODIFIER", 296, 304], ["irregularity", "OBSERVATION", 308, 320], ["foci", "OBSERVATION_MODIFIER", 328, 332], ["more decondensed", "OBSERVATION_MODIFIER", 340, 356]]], ["As infection progressed beyond 2 hrs, the genome signal became more difficult to quantitate evolving into diffuse, dissipated aggregates of lower intensity, but frequently with smaller, more condensed foci remaining (see below), usually on the perimeter of the decondensed material.Genome trafficking and nuclear transportTo examine this alteration in genome compaction further we extended the analysis to investigate the relationship between localisation of ICP4, the major HSV IE regulator of transcription and genome morphology.", [["foci", "ANATOMY", 201, 205], ["nuclear", "ANATOMY", 305, 312], ["infection", "DISEASE", 3, 12], ["nuclear", "CELLULAR_COMPONENT", 305, 312], ["ICP4", "GENE_OR_GENE_PRODUCT", 459, 463], ["HSV", "ORGANISM", 475, 478], ["ICP4", "PROTEIN", 459, 463], ["major HSV IE regulator", "PROTEIN", 469, 491], ["HSV", "SPECIES", 475, 478], ["infection", "PROBLEM", 3, 12], ["the genome signal", "TEST", 38, 55], ["diffuse, dissipated aggregates of lower intensity", "PROBLEM", 106, 155], ["smaller, more condensed foci", "PROBLEM", 177, 205], ["the analysis", "TEST", 390, 402], ["ICP4", "TREATMENT", 459, 463], ["infection", "OBSERVATION", 3, 12], ["diffuse", "OBSERVATION_MODIFIER", 106, 113], ["dissipated", "OBSERVATION_MODIFIER", 115, 125], ["aggregates", "OBSERVATION_MODIFIER", 126, 136], ["lower intensity", "OBSERVATION_MODIFIER", 140, 155], ["smaller", "OBSERVATION_MODIFIER", 177, 184], ["more", "OBSERVATION_MODIFIER", 186, 190], ["condensed", "OBSERVATION_MODIFIER", 191, 200], ["foci", "OBSERVATION", 201, 205], ["decondensed material", "OBSERVATION", 261, 281]]], ["As shown above, within 30 min after shift to 37\u02daC, new discrete nuclear foci (green channel) were readily observed.", [["nuclear foci", "ANATOMY", 64, 76], ["green channel", "PROTEIN", 78, 91], ["new discrete nuclear foci", "PROBLEM", 51, 76], ["new", "OBSERVATION_MODIFIER", 51, 54], ["discrete", "OBSERVATION_MODIFIER", 55, 63], ["nuclear", "OBSERVATION_MODIFIER", 64, 71], ["foci", "OBSERVATION", 72, 76], ["green channel", "OBSERVATION_MODIFIER", 78, 91]]], ["These were detectable prior to the accumulation of ICP4 (Fig 8, 0 .5 hpi).", [["ICP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["ICP4", "PROTEIN", 51, 55], ["ICP4 (Fig", "TREATMENT", 51, 60]]], ["By 1 hr, together with the progressive increase in size of genome foci, as ICP4 became detectable we observed several patterns of localisation.", [["foci", "ANATOMY", 66, 70], ["ICP4", "GENE_OR_GENE_PRODUCT", 75, 79], ["ICP4", "PROTEIN", 75, 79], ["the progressive increase in size of genome foci", "PROBLEM", 23, 70], ["ICP4", "PROBLEM", 75, 79], ["progressive", "OBSERVATION_MODIFIER", 27, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["size", "OBSERVATION_MODIFIER", 51, 55], ["genome foci", "OBSERVATION", 59, 70]]], ["These included cells with ICP4 recruitment to a subset of genomes with several foci still having undetectable levels (e.g., panel V); cells with most foci accumulating ICP4 at some level (panels VI-VII) and cells with virtual quantitative accumulation of ICP4 on all genomic foci (panel VIII).", [["cells", "ANATOMY", 15, 20], ["foci", "ANATOMY", 79, 83], ["cells", "ANATOMY", 134, 139], ["foci", "ANATOMY", 150, 154], ["cells", "ANATOMY", 207, 212], ["foci", "ANATOMY", 275, 279], ["cells", "CELL", 15, 20], ["ICP4", "GENE_OR_GENE_PRODUCT", 26, 30], ["cells", "CELL", 134, 139], ["ICP4", "GENE_OR_GENE_PRODUCT", 168, 172], ["VI-VII", "GENE_OR_GENE_PRODUCT", 195, 201], ["cells", "CELL", 207, 212], ["ICP4", "GENE_OR_GENE_PRODUCT", 255, 259], ["panel VIII", "GENE_OR_GENE_PRODUCT", 281, 291], ["ICP4", "PROTEIN", 26, 30], ["ICP4", "PROTEIN", 168, 172], ["ICP4", "PROTEIN", 255, 259], ["ICP4 recruitment", "TREATMENT", 26, 42], ["several foci", "PROBLEM", 71, 83], ["undetectable levels (e.g., panel V); cells", "PROBLEM", 97, 139], ["most foci accumulating ICP4", "PROBLEM", 145, 172], ["virtual quantitative accumulation of ICP4", "PROBLEM", 218, 259], ["all genomic foci", "PROBLEM", 263, 279], ["ICP4 recruitment", "OBSERVATION", 26, 42], ["several", "OBSERVATION_MODIFIER", 71, 78], ["foci", "OBSERVATION", 79, 83], ["ICP4", "OBSERVATION", 168, 172], ["accumulation of ICP4", "OBSERVATION", 239, 259], ["foci", "OBSERVATION", 275, 279]]], ["At this time there was comparatively little diffuse ICP4 with the majority co-located with genome foci.", [["foci", "ANATOMY", 98, 102], ["ICP4", "GENE_OR_GENE_PRODUCT", 52, 56], ["ICP4", "PROTEIN", 52, 56], ["comparatively little diffuse ICP4", "PROBLEM", 23, 56], ["genome foci", "PROBLEM", 91, 102], ["little", "OBSERVATION_MODIFIER", 37, 43], ["diffuse", "OBSERVATION_MODIFIER", 44, 51], ["ICP4", "OBSERVATION", 52, 56], ["majority", "OBSERVATION_MODIFIER", 66, 74], ["genome", "OBSERVATION_MODIFIER", 91, 97], ["foci", "OBSERVATION", 98, 102]]], ["By 2-3 hrs a qualitative change was observed in this association.", [["a qualitative change", "PROBLEM", 11, 31]]], ["As discussed above, the infecting genomic foci appeared as increasingly heterogeneous dispersed aggregates of lower intensity, together with residual punctate foci frequently on the periphery of the dispersed pattern ( Fig 8A, 3 hpi) .", [["foci", "ANATOMY", 42, 46], ["punctate foci", "ANATOMY", 150, 163], ["the infecting genomic foci", "PROBLEM", 20, 46], ["residual punctate foci", "PROBLEM", 141, 163], ["infecting", "OBSERVATION_MODIFIER", 24, 33], ["genomic", "OBSERVATION_MODIFIER", 34, 41], ["foci", "OBSERVATION", 42, 46], ["increasingly", "OBSERVATION_MODIFIER", 59, 71], ["heterogeneous", "OBSERVATION_MODIFIER", 72, 85], ["dispersed", "OBSERVATION_MODIFIER", 86, 95], ["aggregates", "OBSERVATION_MODIFIER", 96, 106], ["lower intensity", "OBSERVATION_MODIFIER", 110, 125], ["residual", "OBSERVATION_MODIFIER", 141, 149], ["punctate", "OBSERVATION_MODIFIER", 150, 158], ["foci", "OBSERVATION", 159, 163]]], ["However while ICP4 exhibited quite precise co-localisation with the genome foci at 1 hr, by 3 hrs ICP4 was observed more within the dispersed areas of genome labelling, lacking any distinct enrichment in the remaining punctate foci.", [["foci", "ANATOMY", 75, 79], ["punctate foci", "ANATOMY", 218, 231], ["ICP4", "GENE_OR_GENE_PRODUCT", 14, 18], ["ICP4", "GENE_OR_GENE_PRODUCT", 98, 102], ["punctate foci", "CELLULAR_COMPONENT", 218, 231], ["ICP4", "PROTEIN", 14, 18], ["ICP4", "PROTEIN", 98, 102], ["ICP4", "PROBLEM", 14, 18], ["the remaining punctate foci", "PROBLEM", 204, 231], ["foci", "OBSERVATION", 75, 79], ["dispersed", "OBSERVATION_MODIFIER", 132, 141], ["areas", "OBSERVATION_MODIFIER", 142, 147], ["genome labelling", "OBSERVATION", 151, 167], ["distinct", "OBSERVATION_MODIFIER", 181, 189], ["enrichment", "OBSERVATION_MODIFIER", 190, 200], ["remaining", "OBSERVATION_MODIFIER", 208, 217], ["punctate", "OBSERVATION_MODIFIER", 218, 226], ["foci", "OBSERVATION", 227, 231]]], ["This was a distinct qualitative feature wherein foci remaining at later times on the periphery of the diffuse areas either completely lacked or were not enriched in ICP4, while foci at earlier times selectively recruited ICP4.", [["foci", "ANATOMY", 48, 52], ["foci", "ANATOMY", 177, 181], ["ICP4", "GENE_OR_GENE_PRODUCT", 165, 169], ["ICP4", "GENE_OR_GENE_PRODUCT", 221, 225], ["ICP4", "PROTEIN", 165, 169], ["ICP4", "PROTEIN", 221, 225], ["a distinct qualitative feature wherein foci", "PROBLEM", 9, 52], ["the diffuse areas", "PROBLEM", 98, 115], ["distinct", "OBSERVATION_MODIFIER", 11, 19], ["qualitative", "OBSERVATION_MODIFIER", 20, 31], ["foci", "OBSERVATION", 48, 52], ["periphery", "OBSERVATION_MODIFIER", 85, 94], ["diffuse", "OBSERVATION_MODIFIER", 102, 109], ["areas", "OBSERVATION_MODIFIER", 110, 115], ["foci", "OBSERVATION", 177, 181], ["ICP4", "OBSERVATION", 221, 225]]], ["This distinction of ICP4 localisation on earlier condensed (1 hr, panel VIII) versus later more decondensed foci (3 hrs, panel XII) is shown in expanded form (Fig 8B) with each channel separate and merged.", [["foci", "ANATOMY", 108, 112], ["ICP4", "GENE_OR_GENE_PRODUCT", 20, 24], ["ICP4", "PROTEIN", 20, 24], ["panel VIII", "PROTEIN", 66, 76], ["ICP4 localisation", "PROBLEM", 20, 37], ["panel VIII", "TEST", 66, 76], ["later more decondensed foci", "PROBLEM", 85, 112], ["panel XII", "TEST", 121, 130], ["ICP4 localisation", "OBSERVATION", 20, 37], ["decondensed", "OBSERVATION_MODIFIER", 96, 107], ["foci", "OBSERVATION", 108, 112]]], ["A separate analysis by 3D-SIM is shown in Fig 8C, (2 hpi) , illustrating a more condensed genomic signal (arrowed) on the edge of extended decondensed area, with ICP4 localised preferentially within the decondensed material and virtually excluded from remaining punctate focus.Transcription and translation coupled transitions in infecting genome compaction stateTo examine the relationship between metabolic processes acting in the infected cell nucleus and virus genome localisation and compaction, we next investigated the effect of inhibition of transcription, viral DNA synthesis, or translation on genome localisation to the nucleus and the morphological condensation state.", [["area", "ANATOMY", 151, 155], ["cell nucleus", "ANATOMY", 442, 454], ["nucleus", "ANATOMY", 631, 638], ["ICP4", "GENE_OR_GENE_PRODUCT", 162, 166], ["cell nucleus", "CELLULAR_COMPONENT", 442, 454], ["DNA", "CELLULAR_COMPONENT", 571, 574], ["nucleus", "CELLULAR_COMPONENT", 631, 638], ["ICP4", "PROTEIN", 162, 166], ["A separate analysis", "TEST", 0, 19], ["a more condensed genomic signal", "PROBLEM", 73, 104], ["ICP4", "PROBLEM", 162, 166], ["Transcription", "TREATMENT", 277, 290], ["the infected cell nucleus", "PROBLEM", 429, 454], ["inhibition of transcription", "TREATMENT", 536, 563], ["viral DNA synthesis", "TREATMENT", 565, 584], ["more condensed", "OBSERVATION_MODIFIER", 75, 89], ["genomic signal", "OBSERVATION", 90, 104], ["edge", "OBSERVATION_MODIFIER", 122, 126], ["extended", "OBSERVATION_MODIFIER", 130, 138], ["decondensed", "OBSERVATION", 139, 150], ["ICP4 localised", "OBSERVATION", 162, 176], ["decondensed material", "OBSERVATION", 203, 223], ["virtually excluded", "UNCERTAINTY", 228, 246], ["remaining", "OBSERVATION_MODIFIER", 252, 261], ["punctate", "OBSERVATION_MODIFIER", 262, 270], ["focus", "OBSERVATION", 271, 276], ["infecting genome", "OBSERVATION", 330, 346], ["infected cell nucleus", "OBSERVATION", 433, 454], ["virus genome", "OBSERVATION", 459, 471], ["nucleus", "ANATOMY", 631, 638], ["morphological", "OBSERVATION", 647, 660], ["condensation state", "OBSERVATION", 661, 679]]], ["Cells were infected (moi 10) either untreated or in the presence of a series of inhibitors each added 1 hr prior to infection; actinomycin D (Act D, 5 \u03bcg/ml), acyclovir (ACV, 500 \u03bcM), phosphonoacetic acid (PAA, 400 \u03bcg/ml), or cycloheximide (CHX, 100 \u03bcg/ml) to inhibit transcription, virus DNA replication and protein synthesis.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 116, 125], ["actinomycin D", "CHEMICAL", 127, 140], ["Act D", "CHEMICAL", 142, 147], ["acyclovir", "CHEMICAL", 159, 168], ["ACV", "CHEMICAL", 170, 173], ["phosphonoacetic acid", "CHEMICAL", 184, 204], ["PAA", "CHEMICAL", 206, 209], ["cycloheximide", "CHEMICAL", 226, 239], ["CHX", "CHEMICAL", 241, 244], ["actinomycin D", "CHEMICAL", 127, 140], ["Act D", "CHEMICAL", 142, 147], ["acyclovir", "CHEMICAL", 159, 168], ["ACV", "CHEMICAL", 170, 173], ["phosphonoacetic acid", "CHEMICAL", 184, 204], ["PAA", "CHEMICAL", 206, 209], ["cycloheximide", "CHEMICAL", 226, 239], ["CHX", "CHEMICAL", 241, 244], ["Cells", "CELL", 0, 5], ["actinomycin D", "SIMPLE_CHEMICAL", 127, 140], ["Act D", "SIMPLE_CHEMICAL", 142, 147], ["acyclovir", "SIMPLE_CHEMICAL", 159, 168], ["ACV", "SIMPLE_CHEMICAL", 170, 173], ["phosphonoacetic acid", "SIMPLE_CHEMICAL", 184, 204], ["PAA", "SIMPLE_CHEMICAL", 206, 209], ["cycloheximide", "SIMPLE_CHEMICAL", 226, 239], ["CHX", "SIMPLE_CHEMICAL", 241, 244], ["DNA", "CELLULAR_COMPONENT", 289, 292], ["a series of inhibitors", "TREATMENT", 68, 90], ["infection", "PROBLEM", 116, 125], ["actinomycin D (Act D", "TREATMENT", 127, 147], ["acyclovir (ACV", "TREATMENT", 159, 173], ["phosphonoacetic acid (PAA", "TREATMENT", 184, 209], ["cycloheximide (CHX", "TREATMENT", 226, 244], ["virus DNA replication", "TREATMENT", 283, 304], ["protein synthesis", "TREATMENT", 309, 326]]], ["Control experiments confirmed activity of the drugs e.g., ICP4 protein synthesis was completely blocked by Act D and CHX but not by PAA or ACV (S8A Fig).", [["CHX", "CHEMICAL", 117, 120], ["PAA", "CHEMICAL", 132, 135], ["ACV", "CHEMICAL", 139, 142], ["CHX", "CHEMICAL", 117, 120], ["PAA", "CHEMICAL", 132, 135], ["ACV", "CHEMICAL", 139, 142], ["ICP4", "GENE_OR_GENE_PRODUCT", 58, 62], ["Act D", "SIMPLE_CHEMICAL", 107, 112], ["CHX", "SIMPLE_CHEMICAL", 117, 120], ["PAA", "SIMPLE_CHEMICAL", 132, 135], ["ACV", "SIMPLE_CHEMICAL", 139, 142], ["ICP4", "PROTEIN", 58, 62], ["the drugs", "TREATMENT", 42, 51], ["ICP4 protein synthesis", "TREATMENT", 58, 80], ["CHX", "TREATMENT", 117, 120]]], ["Representative results for genome uncoating and morphology for each inhibitor at each of four early time points are shown in Fig 9.", [["genome uncoating", "PROBLEM", 27, 43], ["each inhibitor", "TREATMENT", 63, 77]]], ["In the absence of drug treatment, genome foci were observed in the nucleus by 0.5 hpi together with the temporal increase in volume, irregular morphology (1, 2 hpi), progressive decondensation and dissipation (3 hpi) described above.", [["foci", "ANATOMY", 41, 45], ["nucleus", "ANATOMY", 67, 74], ["nucleus", "CELLULAR_COMPONENT", 67, 74], ["drug treatment", "TREATMENT", 18, 32], ["genome foci", "PROBLEM", 34, 45], ["the temporal increase in volume", "PROBLEM", 100, 131], ["irregular morphology", "PROBLEM", 133, 153], ["progressive decondensation and dissipation", "PROBLEM", 166, 208], ["drug treatment", "OBSERVATION", 18, 32], ["foci", "OBSERVATION", 41, 45], ["nucleus", "ANATOMY_MODIFIER", 67, 74], ["temporal", "OBSERVATION_MODIFIER", 104, 112], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["volume", "OBSERVATION_MODIFIER", 125, 131], ["irregular", "OBSERVATION_MODIFIER", 133, 142], ["morphology", "OBSERVATION_MODIFIER", 143, 153], ["progressive", "OBSERVATION_MODIFIER", 166, 177], ["decondensation", "OBSERVATION", 178, 192]]], ["Two significant conclusions could be made from results of inhibition of transcription.", [["inhibition of transcription", "TREATMENT", 58, 85]]], ["Firstly there was no significant effect on either the average initial numbers or morphology of uncoated nuclear genome foci, indicating that transcription per se (for example, by a transcription-coupled ratcheting process) played no discernible role in genome uncoating and transport into the nucleus (Fig 9 , + Act D).", [["nuclear genome foci", "ANATOMY", 104, 123], ["nucleus", "ANATOMY", 293, 300], ["nuclear", "CELLULAR_COMPONENT", 104, 111], ["genome", "CELLULAR_COMPONENT", 253, 259], ["nucleus", "CELLULAR_COMPONENT", 293, 300], ["significant effect", "PROBLEM", 21, 39], ["uncoated nuclear genome foci", "PROBLEM", 95, 123], ["no", "UNCERTAINTY", 18, 20], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["effect", "OBSERVATION_MODIFIER", 33, 39], ["uncoated", "OBSERVATION_MODIFIER", 95, 103], ["nuclear genome foci", "OBSERVATION", 104, 123], ["no discernible", "UNCERTAINTY", 230, 244], ["genome uncoating", "OBSERVATION", 253, 269], ["nucleus", "ANATOMY", 293, 300]]], ["Secondly however it was clear that inhibition of transcription did have a significant effect on the progressive increase in genome volume and eventual decompaction, which were almost completely inhibited (cf, 3 hpi, untreated versus +Act D).Transcription and translation coupled transitions in infecting genome compaction stateThese results were distinct from those obtained after inhibition of virus DNA synthesis.", [["+Act D", "SIMPLE_CHEMICAL", 233, 239], ["DNA", "CELLULAR_COMPONENT", 401, 404], ["the progressive increase in genome volume", "PROBLEM", 96, 137], ["eventual decompaction", "PROBLEM", 142, 163], ["Transcription", "TREATMENT", 241, 254], ["virus DNA synthesis", "TREATMENT", 395, 414], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["progressive", "OBSERVATION_MODIFIER", 100, 111], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["genome volume", "OBSERVATION", 124, 137], ["infecting genome", "OBSERVATION", 294, 310]]], ["Similar numbers of uncoated infecting genome foci were initially observed, not unexpectedly.", [["foci", "ANATOMY", 45, 49], ["uncoated infecting genome foci", "PROBLEM", 19, 49], ["numbers", "OBSERVATION_MODIFIER", 8, 15], ["uncoated", "OBSERVATION_MODIFIER", 19, 27], ["infecting", "OBSERVATION_MODIFIER", 28, 37], ["genome foci", "OBSERVATION", 38, 49]]], ["In this case however, a progressive increase in foci volume was observed, with a clear difference especially by 3 hpi for the ACV/PAA treated cells versus the Act D treated cells (cf, small arrowed foci in Act D versus larger foci in PAA/ACV panels).", [["foci", "ANATOMY", 48, 52], ["cells", "ANATOMY", 142, 147], ["cells", "ANATOMY", 173, 178], ["foci", "ANATOMY", 198, 202], ["foci", "ANATOMY", 226, 230], ["ACV", "CHEMICAL", 126, 129], ["PAA", "CHEMICAL", 130, 133], ["ACV", "CHEMICAL", 126, 129], ["PAA", "CHEMICAL", 130, 133], ["PAA", "CHEMICAL", 234, 237], ["ACV", "CHEMICAL", 238, 241], ["cells", "CELL", 142, 147], ["Act D", "SIMPLE_CHEMICAL", 159, 164], ["cells", "CELL", 173, 178], ["ACV/PAA treated cells", "CELL_LINE", 126, 147], ["Act D treated cells", "CELL_LINE", 159, 178], ["a progressive increase in foci volume", "PROBLEM", 22, 59], ["the ACV/PAA treated cells", "TREATMENT", 122, 147], ["the Act D treated cells", "PROBLEM", 155, 178], ["small arrowed foci", "PROBLEM", 184, 202], ["larger foci", "PROBLEM", 219, 230], ["PAA/ACV panels", "TREATMENT", 234, 248], ["progressive", "OBSERVATION_MODIFIER", 24, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["foci volume", "OBSERVATION", 48, 59], ["clear", "OBSERVATION", 81, 86], ["small", "OBSERVATION_MODIFIER", 184, 189], ["arrowed", "OBSERVATION_MODIFIER", 190, 197], ["foci", "OBSERVATION", 198, 202], ["larger", "OBSERVATION_MODIFIER", 219, 225], ["foci", "OBSERVATION", 226, 230]]], ["On the other hand, inhibition of DNA replication clearly had an effect, preventing the later dissipation and decrease in intensity seen in untreated cells (cf, 3 hpi, untreated versus ACV/PAA), indicating that these latter events were likely related to genome replication or other coupled events.", [["cells", "ANATOMY", 149, 154], ["ACV", "CHEMICAL", 184, 187], ["ACV", "CHEMICAL", 184, 187], ["PAA", "CHEMICAL", 188, 191], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["cells", "CELL", 149, 154], ["untreated cells", "CELL_TYPE", 139, 154], ["DNA replication", "PROBLEM", 33, 48], ["the later dissipation", "PROBLEM", 83, 104], ["decrease in intensity", "PROBLEM", 109, 130], ["untreated cells", "PROBLEM", 139, 154], ["ACV/PAA", "TREATMENT", 184, 191], ["these latter events", "PROBLEM", 210, 229], ["genome replication", "PROBLEM", 253, 271], ["other coupled events", "PROBLEM", 275, 295], ["decrease", "OBSERVATION_MODIFIER", 109, 117], ["untreated cells", "OBSERVATION", 139, 154]]], ["The smaller genome foci size and tighter morphology in the presence of Act D compared to that observed in the presence of ACV or PAA also indicates that events linked to or downstream of transcription per se, but not requiring DNA replication, are reflected in increasing volume and irregularity and decreased compaction of the uncoated genomic foci.", [["foci", "ANATOMY", 19, 23], ["foci", "ANATOMY", 345, 349], ["ACV", "CHEMICAL", 122, 125], ["PAA", "CHEMICAL", 129, 132], ["ACV", "CHEMICAL", 122, 125], ["PAA", "CHEMICAL", 129, 132], ["Act D", "GENE_OR_GENE_PRODUCT", 71, 76], ["ACV", "GENE_OR_GENE_PRODUCT", 122, 125], ["PAA", "GENE_OR_GENE_PRODUCT", 129, 132], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["Act D", "PROTEIN", 71, 76], ["The smaller genome foci size", "PROBLEM", 0, 28], ["Act D", "PROBLEM", 71, 76], ["DNA replication", "TREATMENT", 227, 242], ["increasing volume", "PROBLEM", 261, 278], ["irregularity", "PROBLEM", 283, 295], ["decreased compaction of the uncoated genomic foci", "PROBLEM", 300, 349], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["genome", "OBSERVATION_MODIFIER", 12, 18], ["foci", "OBSERVATION_MODIFIER", 19, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["tighter", "OBSERVATION_MODIFIER", 33, 40], ["morphology", "OBSERVATION_MODIFIER", 41, 51], ["increasing", "OBSERVATION_MODIFIER", 261, 271], ["volume", "OBSERVATION_MODIFIER", 272, 278], ["irregularity", "OBSERVATION_MODIFIER", 283, 295], ["decreased", "OBSERVATION_MODIFIER", 300, 309], ["compaction", "OBSERVATION_MODIFIER", 310, 320], ["uncoated", "OBSERVATION_MODIFIER", 328, 336], ["genomic", "OBSERVATION_MODIFIER", 337, 344], ["foci", "OBSERVATION", 345, 349]]], ["We repeated this analysis for Act D including relatively late times (8 hpi), comparing the fate of infecting virus genomes during normal progression of infection or when transcription was inhibited (Fig 10A) .", [["infection", "DISEASE", 152, 161], ["Act D", "SIMPLE_CHEMICAL", 30, 35], ["this analysis", "TEST", 12, 25], ["infecting virus genomes", "PROBLEM", 99, 122], ["infection", "PROBLEM", 152, 161], ["progression", "OBSERVATION_MODIFIER", 137, 148], ["infection", "OBSERVATION", 152, 161]]], ["Under normal conditions, the temporal trend to increasing dissipation and decreased signal intensity continued so that by 8 hpi, the diffuse dispersed signal from incoming genomes was extremely low (Fig 10A) .", [["increasing dissipation", "PROBLEM", 47, 69], ["decreased signal intensity", "PROBLEM", 74, 100], ["the diffuse dispersed signal from incoming genomes", "PROBLEM", 129, 179], ["normal conditions", "OBSERVATION", 6, 23], ["increasing", "OBSERVATION_MODIFIER", 47, 57], ["dissipation", "OBSERVATION", 58, 69], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["signal", "OBSERVATION_MODIFIER", 84, 90], ["intensity", "OBSERVATION_MODIFIER", 91, 100], ["diffuse", "OBSERVATION_MODIFIER", 133, 140]]], ["In distinct contrast, in the presence of Act D, not only were genomes maintained in more condensed foci, they were maintained until at least 8 hpi, with minimal changes in numbers or morphology (Fig 10A, + Act D) .Transcription and translation coupled transitions in infecting genome compaction stateWe also examined genome localisation in the presence of cycloheximide.", [["foci", "ANATOMY", 99, 103], ["cycloheximide", "CHEMICAL", 356, 369], ["cycloheximide", "CHEMICAL", 356, 369], ["Act D", "GENE_OR_GENE_PRODUCT", 41, 46], ["foci", "CELL", 99, 103], ["cycloheximide", "SIMPLE_CHEMICAL", 356, 369], ["Act D", "PROTEIN", 41, 46], ["minimal changes in numbers", "PROBLEM", 153, 179], ["Transcription", "TREATMENT", 214, 227], ["cycloheximide", "TREATMENT", 356, 369], ["distinct", "OBSERVATION_MODIFIER", 3, 11], ["contrast", "OBSERVATION", 12, 20], ["more condensed", "OBSERVATION_MODIFIER", 84, 98], ["foci", "OBSERVATION", 99, 103], ["minimal", "OBSERVATION_MODIFIER", 153, 160], ["changes", "OBSERVATION", 161, 168], ["infecting genome", "OBSERVATION", 267, 283]]], ["Abundant accumulated data has shown that, unlike in the presence of Act D, in the presence of CHX transcription occurs but, in the absence of HSV protein synthesis, is limited to IE loci with little or no DE transcription nor DNA replication.", [["CHX", "CHEMICAL", 94, 97], ["CHX", "CHEMICAL", 94, 97], ["Act D", "GENE_OR_GENE_PRODUCT", 68, 73], ["CHX", "SIMPLE_CHEMICAL", 94, 97], ["HSV", "ORGANISM", 142, 145], ["DNA", "CELLULAR_COMPONENT", 226, 229], ["Act D", "PROTEIN", 68, 73], ["HSV protein", "PROTEIN", 142, 153], ["IE loci", "DNA", 179, 186], ["HSV", "SPECIES", 142, 145], ["CHX transcription", "TREATMENT", 94, 111], ["HSV protein synthesis", "PROBLEM", 142, 163], ["DNA replication", "PROBLEM", 226, 241], ["CHX", "OBSERVATION", 94, 97]]], ["CHX did not block uncoating and the numbers of nuclear genome foci at 0.5 hpi were similar in CHX treated to untreated and to each of the other inhibitors (Fig 9, CHX) .", [["nuclear genome foci", "ANATOMY", 47, 66], ["CHX", "CHEMICAL", 0, 3], ["CHX", "CHEMICAL", 94, 97], ["CHX", "CHEMICAL", 163, 166], ["CHX", "CHEMICAL", 0, 3], ["CHX", "CHEMICAL", 94, 97], ["CHX", "CHEMICAL", 163, 166], ["CHX", "SIMPLE_CHEMICAL", 0, 3], ["nuclear", "CELLULAR_COMPONENT", 47, 54], ["CHX", "SIMPLE_CHEMICAL", 94, 97], ["CHX", "SIMPLE_CHEMICAL", 163, 166], ["CHX", "TREATMENT", 0, 3], ["block uncoating", "PROBLEM", 12, 27], ["nuclear genome foci", "PROBLEM", 47, 66], ["the other inhibitors", "TREATMENT", 134, 154], ["numbers", "OBSERVATION_MODIFIER", 36, 43], ["nuclear", "OBSERVATION_MODIFIER", 47, 54], ["genome", "OBSERVATION_MODIFIER", 55, 61], ["foci", "OBSERVATION_MODIFIER", 62, 66]]], ["However, we observed a distinct feature in genome morphology at subsequent times with CHX treatment.", [["CHX", "CHEMICAL", 86, 89], ["CHX", "CHEMICAL", 86, 89], ["CHX", "SIMPLE_CHEMICAL", 86, 89], ["CHX treatment", "TREATMENT", 86, 99], ["distinct", "OBSERVATION_MODIFIER", 23, 31], ["genome morphology", "OBSERVATION", 43, 60]]], ["Thus whereas inhibition of transcription resulted in the maintenance of tighter more condensed and largely singular foci (Figs 9 and 10A and 10B), genome localisation in the presence of CHX resulted in a distinct congregation and clustering of genomic foci (Fig 9, CHX, circled clusters) .", [["foci", "ANATOMY", 116, 120], ["foci", "ANATOMY", 252, 256], ["CHX", "CHEMICAL", 186, 189], ["CHX", "CHEMICAL", 186, 189], ["genome", "CELLULAR_COMPONENT", 147, 153], ["CHX", "SIMPLE_CHEMICAL", 186, 189], ["transcription", "TREATMENT", 27, 40], ["tighter more condensed and largely singular foci", "PROBLEM", 72, 120], ["Figs", "TEST", 122, 126], ["CHX", "PROBLEM", 186, 189], ["a distinct congregation", "PROBLEM", 202, 225], ["genomic foci", "PROBLEM", 244, 256], ["tighter", "OBSERVATION_MODIFIER", 72, 79], ["more condensed", "OBSERVATION_MODIFIER", 80, 94], ["largely", "OBSERVATION_MODIFIER", 99, 106], ["singular", "OBSERVATION_MODIFIER", 107, 115], ["foci", "OBSERVATION", 116, 120], ["CHX", "OBSERVATION", 186, 189], ["distinct", "OBSERVATION_MODIFIER", 204, 212], ["congregation", "OBSERVATION", 213, 225], ["genomic foci", "OBSERVATION", 244, 256]]], ["While individual singular foci could still be observed in CHX treated cells, this was a noticeable qualitative change in genome presentation especially at later times (see Fig 10B, comparison at 3 hpi of untreated, Act D treated and CHX treated).", [["foci", "ANATOMY", 26, 30], ["cells", "ANATOMY", 70, 75], ["CHX", "CHEMICAL", 58, 61], ["CHX", "CHEMICAL", 233, 236], ["CHX", "CHEMICAL", 58, 61], ["CHX", "CHEMICAL", 233, 236], ["foci", "CELL", 26, 30], ["CHX", "SIMPLE_CHEMICAL", 58, 61], ["cells", "CELL", 70, 75], ["CHX", "SIMPLE_CHEMICAL", 233, 236], ["CHX treated cells", "CELL_LINE", 58, 75], ["individual singular foci", "PROBLEM", 6, 30], ["CHX treated cells", "PROBLEM", 58, 75], ["CHX", "TREATMENT", 233, 236], ["singular", "OBSERVATION_MODIFIER", 17, 25], ["foci", "OBSERVATION", 26, 30]]], ["Transport and nuclear entry of the HSV genome To examine this difference in an unbiased quantitative manner, we used the spatial statistics and focus clustering algorithm in ImageJ [35] .", [["nuclear", "ANATOMY", 14, 21], ["nuclear", "CELLULAR_COMPONENT", 14, 21], ["HSV", "ORGANISM", 35, 38], ["HSV genome", "DNA", 35, 45], ["HSV", "SPECIES", 35, 38]]], ["This algorithm (see materials and methods) examines the positions of objects within a reference structure (nuclei in this case) and assesses clustering using a normalized measure of the difference between the observed distribution of inter-point nearest neighbour distances and a completely random one.", [["nuclei", "ANATOMY", 107, 113], ["nuclei", "CELLULAR_COMPONENT", 107, 113], ["This algorithm", "TEST", 0, 14]]], ["This difference is termed the Spatial Distribution Index (SDI).", [["Spatial", "OBSERVATION_MODIFIER", 30, 37], ["Distribution", "OBSERVATION_MODIFIER", 38, 50]]], ["S9 Fig shows a schematic illustration of the The SDI distribution among populations of Act D and CHX treated cells were calculated as discussed in the text and materials and methods.", [["cells", "ANATOMY", 109, 114], ["CHX", "CHEMICAL", 97, 100], ["CHX", "CHEMICAL", 97, 100], ["Act D", "SIMPLE_CHEMICAL", 87, 92], ["CHX", "SIMPLE_CHEMICAL", 97, 100], ["cells", "CELL", 109, 114], ["CHX treated cells", "CELL_LINE", 97, 114], ["Act D and CHX treated cells", "TREATMENT", 87, 114]]], ["SDIs close to 1 indicate a tendency to dispersion while closer to 0 indicates clustering.", [["SDIs", "TEST", 0, 4], ["a tendency to dispersion", "PROBLEM", 25, 49]]], ["The differences in SDI frequency distributions between Act D and CHX were highly significant with that of CHX reflecting a clear trend to clustering.", [["CHX", "CHEMICAL", 65, 68], ["CHX", "CHEMICAL", 106, 109], ["CHX", "CHEMICAL", 65, 68], ["CHX", "CHEMICAL", 106, 109], ["Act D", "SIMPLE_CHEMICAL", 55, 60], ["CHX", "SIMPLE_CHEMICAL", 65, 68], ["CHX", "SIMPLE_CHEMICAL", 106, 109], ["The differences in SDI frequency distributions", "PROBLEM", 0, 46], ["CHX", "TREATMENT", 65, 68], ["CHX", "TREATMENT", 106, 109]]], ["Histograms of the SDI were calculated from 50 nuclei from each group and the difference in distributions calculated using the Kolmogorov-Smirnoff test (p < 0.0001, D = 0.52). (d) Independent estimation of clustering by calculation of the K-function at increasing length of test radii.", [["nuclei", "ANATOMY", 46, 52], ["nuclei", "CELLULAR_COMPONENT", 46, 52], ["the SDI", "TEST", 14, 21], ["the Kolmogorov", "TEST", 122, 136], ["Smirnoff test", "TEST", 137, 150], ["D", "TEST", 164, 165]]], ["Data shown are the mean +/-sem of the K function for radii between 0.11\u03bcm and 6 \u03bcm, with corresponding low and high quantiles (0.01 and 0.99 respectively) for 47 cells treated with Act D and 52 cells treated with CHX.", [["cells", "ANATOMY", 162, 167], ["cells", "ANATOMY", 194, 199], ["CHX", "CHEMICAL", 213, 216], ["CHX", "CHEMICAL", 213, 216], ["cells", "CELL", 162, 167], ["Act D", "SIMPLE_CHEMICAL", 181, 186], ["cells", "CELL", 194, 199], ["CHX", "SIMPLE_CHEMICAL", 213, 216], ["the K function", "TEST", 34, 48], ["radii", "TEST", 53, 58], ["Act D and 52 cells", "TREATMENT", 181, 199], ["CHX", "TREATMENT", 213, 216], ["low", "OBSERVATION_MODIFIER", 103, 106]]], ["The tendency towards clustering is highly significant for the CHX treated cells.Transcription and translation coupled transitions in infecting genome compaction statehttps://doi.org/10.1371/journal.ppat.1006721.g010Transcription and translation coupled transitions in infecting genome compaction stateTransport and nuclear entry of the HSV genome analysis of the SDI.", [["cells", "ANATOMY", 74, 79], ["nuclear", "ANATOMY", 315, 322], ["CHX", "CHEMICAL", 62, 65], ["CHX", "CHEMICAL", 62, 65], ["CHX", "SIMPLE_CHEMICAL", 62, 65], ["cells", "CELL", 74, 79], ["nuclear", "CELLULAR_COMPONENT", 315, 322], ["HSV", "ORGANISM", 336, 339], ["CHX treated cells", "CELL_LINE", 62, 79], ["HSV genome", "DNA", 336, 346], ["SDI", "DNA", 363, 366], ["HSV", "SPECIES", 336, 339], ["the CHX treated cells", "PROBLEM", 58, 79], ["Transcription", "TREATMENT", 80, 93], ["infecting genome compaction statehttps://doi.org/10.1371/journal.ppat.1006721.g010Transcription", "TREATMENT", 133, 228], ["the HSV genome analysis", "TEST", 332, 355], ["infecting genome compaction", "OBSERVATION", 268, 295]]], ["Panel a illustrates theoretical nuclei with random, clustered or dispersed patterns.", [["nuclei", "ANATOMY", 32, 38], ["nuclei", "CELLULAR_COMPONENT", 32, 38], ["Panel", "TEST", 0, 5]]], ["The algorithm compares the cumulative inter-point distance frequencies (CDFs) for a truly completely random distribution (panel b, black lines in each graph; 95% confidence limits in grey lines) with the actual cumulative distribution obtained for foci in each example pattern (panel b, red lines in each graph).", [["red lines", "CELL_LINE", 287, 296], ["black lines", "TREATMENT", 131, 142], ["each graph", "TEST", 146, 156], ["foci", "PROBLEM", 248, 252], ["red lines in each graph", "TREATMENT", 287, 310], ["foci", "OBSERVATION", 248, 252], ["red lines", "OBSERVATION", 287, 296]]], ["An actual random distribution (left cell) will show a distribution overlapping the theoretical random distribution while clustered (middle cell) or dispersed (right cell) distributions deviate significantly to the left or right respectively (cf, red and black CDFs in each panel).", [["left cell", "ANATOMY", 31, 40], ["middle cell", "ANATOMY", 132, 143], ["right cell", "ANATOMY", 159, 169], ["cell", "CELL", 36, 40], ["cell", "CELL", 139, 143], ["right cell", "CELL", 159, 169], ["left", "ANATOMY_MODIFIER", 31, 35], ["cell", "ANATOMY", 36, 40], ["theoretical", "OBSERVATION_MODIFIER", 83, 94], ["random", "OBSERVATION_MODIFIER", 95, 101], ["distribution", "OBSERVATION_MODIFIER", 102, 114], ["middle cell", "OBSERVATION_MODIFIER", 132, 143], ["dispersed", "OBSERVATION_MODIFIER", 148, 157], ["right", "ANATOMY_MODIFIER", 159, 164], ["cell", "ANATOMY_MODIFIER", 165, 169], ["distributions", "OBSERVATION_MODIFIER", 171, 184], ["deviate", "OBSERVATION_MODIFIER", 185, 192], ["significantly", "OBSERVATION_MODIFIER", 193, 206], ["left", "ANATOMY_MODIFIER", 214, 218], ["right", "ANATOMY_MODIFIER", 222, 227]]], ["SDIs are then calculated as a probability index with a SDI close to 0 indicating a more clustered pattern, while SDIs closer to 1 indicate a pattern that is more evenly spread out.", [["a SDI", "TEST", 53, 58], ["more clustered", "OBSERVATION_MODIFIER", 83, 97], ["more evenly", "OBSERVATION_MODIFIER", 157, 168], ["spread", "OBSERVATION_MODIFIER", 169, 175]]], ["The theoretical overall distributions of SDIs for populations of cells is then calculated (S9C Fig bottom panels) .", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["populations of cells", "PROBLEM", 50, 70], ["theoretical", "OBSERVATION_MODIFIER", 4, 15], ["overall", "OBSERVATION_MODIFIER", 16, 23], ["distributions", "OBSERVATION_MODIFIER", 24, 37]]], ["A truly random pattern will show approximately even distributions of SDI values between 0 and 1 while clustered SDI distributions will show a distinct leftward shift towards lower values and evenly spaced distributions show a shift towards 1.", [["A truly random pattern", "TEST", 0, 22], ["SDI values", "PROBLEM", 69, 79], ["a distinct leftward shift", "PROBLEM", 140, 165], ["distinct", "OBSERVATION_MODIFIER", 142, 150], ["leftward", "OBSERVATION_MODIFIER", 151, 159], ["shift", "OBSERVATION", 160, 165]]], ["We validated this approach using the completely random pattern of spots when viruses were applied to coverslips (S9E Fig).", [["this approach", "TREATMENT", 13, 26], ["viruses", "PROBLEM", 77, 84]]], ["The CDF function of these capsid foci (S9F Fig, red line) directly overlapped with the theoretical random distribution pattern for the image (black line).", [["these capsid foci", "PROBLEM", 20, 37], ["S9F Fig, red line", "TREATMENT", 39, 56], ["the image (black line", "TREATMENT", 131, 152], ["capsid", "OBSERVATION_MODIFIER", 26, 32], ["foci", "OBSERVATION", 33, 37], ["Fig", "OBSERVATION_MODIFIER", 43, 46], ["red line", "OBSERVATION", 48, 56]]], ["Note while clusters can be observed in the distributed capsids, such clusters will occur by definition, but there is no significant difference between the overall distribution and a random pattern (S9F Fig) .Transcription and translation coupled transitions in infecting genome compaction stateWe applied this nearest neighbour analysis to virus genomes in infected cells for individual nuclei (approximately 50 nuclei, 3 hpi) in the presence of Act D or CHX.", [["cells", "ANATOMY", 366, 371], ["nuclei", "ANATOMY", 387, 393], ["nuclei", "ANATOMY", 412, 418], ["CHX", "CHEMICAL", 455, 458], ["CHX", "CHEMICAL", 455, 458], ["cells", "CELL", 366, 371], ["nuclei", "CELLULAR_COMPONENT", 387, 393], ["Act D", "SIMPLE_CHEMICAL", 446, 451], ["CHX", "SIMPLE_CHEMICAL", 455, 458], ["virus genomes", "DNA", 340, 353], ["infected cells", "CELL_TYPE", 357, 371], ["Transcription", "TREATMENT", 208, 221], ["infecting genome compaction", "TREATMENT", 261, 288], ["individual nuclei", "PROBLEM", 376, 393], ["no", "UNCERTAINTY", 117, 119], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["difference", "OBSERVATION", 132, 142], ["overall", "OBSERVATION_MODIFIER", 155, 162], ["distribution", "OBSERVATION_MODIFIER", 163, 175], ["infected cells", "OBSERVATION", 357, 371]]], ["SDIs were calculated for the foci in each nucleus and compiled into a distribution of SDIs across the cells for each condition.", [["foci", "ANATOMY", 29, 33], ["nucleus", "ANATOMY", 42, 49], ["cells", "ANATOMY", 102, 107], ["SDIs", "SIMPLE_CHEMICAL", 0, 4], ["nucleus", "CELLULAR_COMPONENT", 42, 49], ["cells", "CELL", 102, 107], ["SDIs", "TEST", 0, 4], ["the foci in each nucleus", "PROBLEM", 25, 49], ["foci", "OBSERVATION", 29, 33], ["each nucleus", "ANATOMY", 37, 49]]], ["Consistent with the indication from visual inspection (Figs 9 and 10B) , the results indicate a clear difference in the population distribution of inter-foci distances in Act D versus CHX treated cells (Fig 10C) .", [["cells", "ANATOMY", 196, 201], ["CHX", "CHEMICAL", 184, 187], ["CHX", "CHEMICAL", 184, 187], ["Act D", "SIMPLE_CHEMICAL", 171, 176], ["CHX", "SIMPLE_CHEMICAL", 184, 187], ["cells", "CELL", 196, 201], ["Act D", "CELL_LINE", 171, 176], ["CHX treated cells", "CELL_LINE", 184, 201], ["visual inspection", "TEST", 36, 53], ["Figs", "TEST", 55, 59], ["inter-foci distances", "PROBLEM", 147, 167], ["CHX treated cells", "TREATMENT", 184, 201], ["clear", "OBSERVATION_MODIFIER", 96, 101], ["difference", "OBSERVATION", 102, 112]]], ["While the Act D pattern deviates from random to some degree across the population, this was bordering on statistical significance (p-value = 0.056; D statistic = 0.26).", [["p-value", "TEST", 131, 138], ["D statistic", "TEST", 148, 159], ["some degree", "OBSERVATION_MODIFIER", 48, 59]]], ["What was clear was the distinctly different trends for CHX versus Act D, indicating a highly significant change in relative localisation and clustering of genomes in the presence of CHX versus Act D (p-value < 0.0001; D statistic = 0.52).Transcription and translation coupled transitions in infecting genome compaction stateIn a second approach to support these conclusions we examined clustering by an independent method, the distance-based K function (Ripley function).", [["CHX", "CHEMICAL", 55, 58], ["CHX", "CHEMICAL", 182, 185], ["CHX", "CHEMICAL", 55, 58], ["CHX", "CHEMICAL", 182, 185], ["CHX", "SIMPLE_CHEMICAL", 55, 58], ["Act D", "SIMPLE_CHEMICAL", 66, 71], ["CHX", "SIMPLE_CHEMICAL", 182, 185], ["Act D", "SIMPLE_CHEMICAL", 193, 198], ["CHX", "PROBLEM", 55, 58], ["a highly significant change", "PROBLEM", 84, 111], ["CHX", "PROBLEM", 182, 185], ["Act D (p-value", "TEST", 193, 207], ["D statistic", "TEST", 218, 229], ["Transcription", "TREATMENT", 238, 251], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["change", "OBSERVATION", 105, 111], ["infecting genome", "OBSERVATION", 291, 307]]], ["In this method (see materials and methods) using the BioImage Analysis platform ICY [36] , nuclei are segmented and EdC labelled genomes located similarly to the approach above.", [["nuclei", "ANATOMY", 91, 97], ["nuclei", "CELLULAR_COMPONENT", 91, 97], ["EdC labelled genomes", "DNA", 116, 136]]], ["Regions of interest (circles) with increasing radii are drawn around each detected spot and other spots located within the circles are identified.", [["increasing radii", "PROBLEM", 35, 51], ["interest", "OBSERVATION_MODIFIER", 11, 19], ["circles", "OBSERVATION_MODIFIER", 21, 28], ["increasing", "OBSERVATION_MODIFIER", 35, 45], ["radii", "OBSERVATION_MODIFIER", 46, 51], ["spot", "OBSERVATION_MODIFIER", 83, 87], ["spots", "OBSERVATION_MODIFIER", 98, 103], ["circles", "OBSERVATION_MODIFIER", 123, 130]]], ["The K-function, K(r), is based on the average number of points inside a circle of radius r, calculated for the increasing radii and has an expectant value of zero for a random distribution of spots.", [["The K-function", "TEST", 0, 14], ["K", "TEST", 16, 17], ["the increasing radii", "PROBLEM", 107, 127], ["a random distribution of spots", "PROBLEM", 167, 197], ["radius", "ANATOMY_MODIFIER", 82, 88], ["increasing", "OBSERVATION_MODIFIER", 111, 121], ["radii", "OBSERVATION_MODIFIER", 122, 127], ["spots", "OBSERVATION", 192, 197]]], ["The amplitude of the K-function can then be compared to corresponding low and high quantiles of completely random distributions (0.01 and 0.99 here).", [["amplitude", "OBSERVATION_MODIFIER", 4, 13], ["low", "OBSERVATION_MODIFIER", 70, 73], ["high", "OBSERVATION_MODIFIER", 78, 82], ["completely", "OBSERVATION_MODIFIER", 96, 106], ["random", "OBSERVATION_MODIFIER", 107, 113], ["distributions", "OBSERVATION_MODIFIER", 114, 127]]], ["When K(r) is higher than the high quantile for a certain radius, the foci are significantly organised in clusters.", [["foci", "ANATOMY", 69, 73], ["K", "CHEMICAL", 5, 6], ["K(r)", "GENE_OR_GENE_PRODUCT", 5, 9], ["K(r)", "TEST", 5, 9], ["a certain radius", "PROBLEM", 47, 63], ["the foci", "PROBLEM", 65, 73], ["foci", "OBSERVATION", 69, 73], ["significantly", "OBSERVATION_MODIFIER", 78, 91]]], ["Conversely, when K is lower than the low quantile, the foci are dispersed.", [["foci", "ANATOMY", 55, 59], ["K", "CHEMICAL", 17, 18], ["K", "TEST", 17, 18], ["foci", "OBSERVATION", 55, 59]]], ["The results were very clear and indicated a distinct statistical significance for clustering of genomes in CHX treated cells with search radii from 1-4 \u03bcm and a tailing off as the radii became too large to attribute significance (Fig 10D) .", [["cells", "ANATOMY", 119, 124], ["CHX", "CHEMICAL", 107, 110], ["CHX", "CHEMICAL", 107, 110], ["CHX", "SIMPLE_CHEMICAL", 107, 110], ["cells", "CELL", 119, 124], ["CHX treated cells", "CELL_LINE", 107, 124], ["genomes in CHX treated cells", "PROBLEM", 96, 124], ["search radii", "TEST", 130, 142]]], ["In contrast the spatial distribution of genomes in Act D treated cells could not be attributed any distinct pattern.", [["cells", "ANATOMY", 65, 70], ["Act D", "SIMPLE_CHEMICAL", 51, 56], ["cells", "CELL", 65, 70], ["Act D treated cells", "CELL_LINE", 51, 70], ["genomes in Act D treated cells", "PROBLEM", 40, 70], ["spatial", "OBSERVATION_MODIFIER", 16, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["genomes", "OBSERVATION", 40, 47]]], ["Altogether from the spatial analysis of the images and clustering analysis based on independent methods, the results strongly support the conclusions for a distinct difference between Act D and CHX treated cells and the proposal that transcription is recognised in the host cell and results in distinct events we have termed genome congregation (see discussion).HSV genome transport is independent of proteasome and nuclear export activityIn a previous report using an indirect surrogate measure (i.e., \u03b2-galactosidase enzyme activity from a recombinant virus or capsid localisation), it was concluded that proteasome inhibition, which suppressed \u03b2-galactosidase activity, did so by preventing HSV genome transport to the nucleus [37] .", [["cells", "ANATOMY", 206, 211], ["cell", "ANATOMY", 274, 278], ["nuclear", "ANATOMY", 416, 423], ["nucleus", "ANATOMY", 722, 729], ["CHX", "CHEMICAL", 194, 197], ["CHX", "CHEMICAL", 194, 197], ["Act D", "SIMPLE_CHEMICAL", 184, 189], ["CHX", "SIMPLE_CHEMICAL", 194, 197], ["cells", "CELL", 206, 211], ["host cell", "CELL", 269, 278], ["HSV", "ORGANISM", 362, 365], ["nuclear", "CELLULAR_COMPONENT", 416, 423], ["\u03b2-galactosidase enzyme", "GENE_OR_GENE_PRODUCT", 503, 525], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 647, 662], ["HSV", "ORGANISM", 694, 697], ["nucleus", "CELLULAR_COMPONENT", 722, 729], ["Act D", "CELL_LINE", 184, 189], ["CHX treated cells", "CELL_LINE", 194, 211], ["proteasome", "PROTEIN", 401, 411], ["\u03b2-galactosidase enzyme", "PROTEIN", 503, 525], ["proteasome", "PROTEIN", 607, 617], ["\u03b2-galactosidase", "PROTEIN", 647, 662], ["HSV", "SPECIES", 362, 365], ["HSV", "SPECIES", 694, 697], ["the spatial analysis", "TEST", 16, 36], ["the images", "TEST", 40, 50], ["clustering analysis", "TEST", 55, 74], ["Act D and CHX treated cells", "TREATMENT", 184, 211], ["proteasome", "TREATMENT", 401, 411], ["an indirect surrogate measure", "TEST", 466, 495], ["\u03b2-galactosidase enzyme activity", "PROBLEM", 503, 534], ["a recombinant virus", "PROBLEM", 540, 559], ["proteasome inhibition", "TREATMENT", 607, 628], ["host cell", "OBSERVATION", 269, 278], ["nucleus", "ANATOMY", 722, 729]]], ["Having established a direct assay, we addressed whether proteasome inhibition had any detectable effect for genome uncoating and nuclear import.", [["nuclear", "ANATOMY", 129, 136], ["genome", "CELLULAR_COMPONENT", 108, 114], ["nuclear", "CELLULAR_COMPONENT", 129, 136], ["proteasome", "PROTEIN", 56, 66], ["a direct assay", "TEST", 19, 33], ["proteasome inhibition", "TREATMENT", 56, 77], ["genome uncoating", "PROBLEM", 108, 124]]], ["MG132 (10 \u03bcM) was added to cells 1 hr prior to infection with HSV EdC at moi 10, and genome localisation assessed at 0.5 hpi compared to untreated cells.", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 147, 152], ["MG132", "CHEMICAL", 0, 5], ["infection", "DISEASE", 47, 56], ["MG132", "CHEMICAL", 0, 5], ["MG132", "SIMPLE_CHEMICAL", 0, 5], ["cells", "CELL", 27, 32], ["HSV", "ORGANISM", 62, 65], ["cells", "CELL", 147, 152], ["untreated cells", "CELL_TYPE", 137, 152], ["HSV", "SPECIES", 62, 65], ["MG132", "TREATMENT", 0, 5], ["infection", "PROBLEM", 47, 56], ["HSV EdC", "PROBLEM", 62, 69], ["genome localisation", "TEST", 85, 104], ["infection", "OBSERVATION", 47, 56]]], ["The distribution of numbers of nuclear genome foci in individual cells was assessed for at least 50 cells in each condition (Fig 11A, insets show representative individual nuclei).", [["nuclear genome foci", "ANATOMY", 31, 50], ["cells", "ANATOMY", 65, 70], ["cells", "ANATOMY", 100, 105], ["nuclei", "ANATOMY", 172, 178], ["nuclear", "CELLULAR_COMPONENT", 31, 38], ["cells", "CELL", 65, 70], ["cells", "CELL", 100, 105], ["nuclei", "CELLULAR_COMPONENT", 172, 178], ["nuclear genome foci in individual cells", "PROBLEM", 31, 70], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["numbers", "OBSERVATION_MODIFIER", 20, 27], ["nuclear genome foci", "OBSERVATION", 31, 50], ["individual cells", "OBSERVATION", 54, 70]]], ["Overall there was no significant effect of MG132 on either total numbers or distribution of HSV genomes transported to the nucleus.", [["nucleus", "ANATOMY", 123, 130], ["MG132", "CHEMICAL", 43, 48], ["MG132", "CHEMICAL", 43, 48], ["MG132", "SIMPLE_CHEMICAL", 43, 48], ["HSV", "ORGANISM", 92, 95], ["nucleus", "CELLULAR_COMPONENT", 123, 130], ["HSV genomes", "DNA", 92, 103], ["HSV", "SPECIES", 92, 95], ["significant effect of MG132", "PROBLEM", 21, 48], ["HSV genomes", "PROBLEM", 92, 103], ["no", "UNCERTAINTY", 18, 20], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["effect", "OBSERVATION_MODIFIER", 33, 39], ["HSV genomes", "OBSERVATION", 92, 103], ["nucleus", "ANATOMY", 123, 130]]], ["Inhibition of CRM1-dependent nuclear export by Leptomycin B treatment has previously been shown to inhibit Adv genome nuclear entry [16] .", [["nuclear", "ANATOMY", 29, 36], ["nuclear", "ANATOMY", 118, 125], ["Leptomycin B", "CHEMICAL", 47, 59], ["Leptomycin B", "CHEMICAL", 47, 59], ["CRM1", "GENE_OR_GENE_PRODUCT", 14, 18], ["nuclear", "CELLULAR_COMPONENT", 29, 36], ["Leptomycin B", "SIMPLE_CHEMICAL", 47, 59], ["Adv", "GENE_OR_GENE_PRODUCT", 107, 110], ["nuclear", "CELLULAR_COMPONENT", 118, 125], ["CRM1", "PROTEIN", 14, 18], ["Adv genome", "DNA", 107, 117], ["Inhibition of CRM1", "PROBLEM", 0, 18], ["Leptomycin B treatment", "TREATMENT", 47, 69]]], ["We also examined the effect of Leptomycin B (as used in the previous studies).", [["Leptomycin B", "CHEMICAL", 31, 43], ["Leptomycin B", "CHEMICAL", 31, 43], ["Leptomycin B", "GENE_OR_GENE_PRODUCT", 31, 43], ["Leptomycin B", "TREATMENT", 31, 43]]], ["In contrast to the effects on Adv, we observed no significant effect on HSV EdC genome uncoating and import.", [["Adv", "GENE_OR_GENE_PRODUCT", 30, 33], ["HSV", "ORGANISM", 72, 75], ["EdC", "GENE_OR_GENE_PRODUCT", 76, 79], ["Adv", "PROTEIN", 30, 33], ["HSV EdC genome", "DNA", 72, 86], ["HSV", "SPECIES", 72, 75], ["significant effect", "PROBLEM", 50, 68], ["no", "UNCERTAINTY", 47, 49], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["effect", "OBSERVATION_MODIFIER", 62, 68]]], ["By comparison, when we examined nocodazole treatment, a drug which depolymerises microtubules and has been previously shown in many studies to inhibit HSV infection and capsid transport [38] [39] [40] , we observed a very striking inhibition of the appearance of nuclear genomes.", [["microtubules", "ANATOMY", 81, 93], ["nuclear genomes", "ANATOMY", 263, 278], ["nocodazole", "CHEMICAL", 32, 42], ["HSV infection", "DISEASE", 151, 164], ["nocodazole", "CHEMICAL", 32, 42], ["nocodazole", "SIMPLE_CHEMICAL", 32, 42], ["microtubules", "CELLULAR_COMPONENT", 81, 93], ["HSV", "ORGANISM", 151, 154], ["nuclear", "CELLULAR_COMPONENT", 263, 270], ["nuclear genomes", "DNA", 263, 278], ["HSV", "SPECIES", 151, 154], ["nocodazole treatment", "TREATMENT", 32, 52], ["HSV infection", "PROBLEM", 151, 164], ["capsid transport", "TEST", 169, 185], ["nuclear genomes", "OBSERVATION", 263, 278]]], ["Control experiments for the activities of MG132 and Leptomycin B using known targets and effects confirmed their action (S8B Fig).", [["MG132", "CHEMICAL", 42, 47], ["Leptomycin B", "CHEMICAL", 52, 64], ["MG132", "CHEMICAL", 42, 47], ["Leptomycin B", "CHEMICAL", 52, 64], ["MG132", "SIMPLE_CHEMICAL", 42, 47], ["Leptomycin B", "SIMPLE_CHEMICAL", 52, 64], ["MG132", "TREATMENT", 42, 47], ["Leptomycin B", "TREATMENT", 52, 64]]], ["Taken together with the positive control for the suppression of genome nuclear entry by nocodazole, we conclude that neither proteasome function nor nuclear export are required for the initial stages of HSV nuclear transport, uncoating and nuclear import.DiscussionPrevious work has helped elucidate many aspects of the key processes of capsid transport within the cytoplasm, engagement with the nuclear pore, uncoating and genome transport into the nucleus [1, [4] [5] [6] [7] [8] [9] [41] [42] [43] [44] .", [["nuclear", "ANATOMY", 71, 78], ["nuclear", "ANATOMY", 149, 156], ["nuclear", "ANATOMY", 207, 214], ["nuclear", "ANATOMY", 240, 247], ["cytoplasm", "ANATOMY", 365, 374], ["nuclear pore", "ANATOMY", 396, 408], ["nucleus", "ANATOMY", 450, 457], ["nocodazole", "CHEMICAL", 88, 98], ["1, [4] [5] [6] [7] [8] [9] [41] [42] [43", "CHEMICAL", 459, 499], ["nocodazole", "CHEMICAL", 88, 98], ["nuclear", "CELLULAR_COMPONENT", 71, 78], ["nocodazole", "SIMPLE_CHEMICAL", 88, 98], ["nuclear", "CELLULAR_COMPONENT", 149, 156], ["HSV", "ORGANISM", 203, 206], ["nuclear", "CELLULAR_COMPONENT", 207, 214], ["nuclear", "CELLULAR_COMPONENT", 240, 247], ["cytoplasm", "ORGANISM_SUBSTANCE", 365, 374], ["nuclear pore", "CELLULAR_COMPONENT", 396, 408], ["genome", "CELLULAR_COMPONENT", 424, 430], ["nucleus", "CELLULAR_COMPONENT", 450, 457], ["[4] [5] [6] [7] [8] [9] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 462, 505], ["proteasome", "PROTEIN", 125, 135], ["HSV", "SPECIES", 203, 206], ["the positive control", "TREATMENT", 20, 40], ["nocodazole", "TREATMENT", 88, 98], ["HSV nuclear transport", "PROBLEM", 203, 224]]], ["Moreover for some viruses including HSV, the nature of the infecting genome has been extensively pursued by biochemical analyses, e.g., micrococcal nuclease (MCN) digestion [45] [46] [47] [48] [49] [50] [51] or by chromatin immunoprecipitation (ChiP) with antibodies to specific host cell histones or histone isoforms [52] [53] [54] [55] , Nevertheless altogether these studies give an incomplete understanding of infecting genome dynamics, at times difficult to reconcile [56] and with little insight into spatial aspects of transport, uncoating and organisation of the genome itself during the progressive stages or early infection.", [["chromatin", "ANATOMY", 214, 223], ["cell", "ANATOMY", 284, 288], ["[45] [46] [47] [48] [49] [50]", "CHEMICAL", 173, 202], ["infection", "DISEASE", 624, 633], ["HSV", "ORGANISM", 36, 39], ["micrococcal nuclease", "GENE_OR_GENE_PRODUCT", 136, 156], ["46] [47] [48] [49] [50] [51]", "SIMPLE_CHEMICAL", 179, 207], ["chromatin", "CELLULAR_COMPONENT", 214, 223], ["cell", "CELL", 284, 288], ["histone", "GENE_OR_GENE_PRODUCT", 301, 308], ["genome", "CELLULAR_COMPONENT", 571, 577], ["infecting genome", "DNA", 59, 75], ["micrococcal nuclease", "PROTEIN", 136, 156], ["ChiP", "PROTEIN", 245, 249], ["antibodies", "PROTEIN", 256, 266], ["host cell histones", "PROTEIN", 279, 297], ["histone isoforms", "PROTEIN", 301, 317], ["HSV", "SPECIES", 36, 39], ["some viruses", "PROBLEM", 13, 25], ["HSV", "PROBLEM", 36, 39], ["the infecting genome", "PROBLEM", 55, 75], ["biochemical analyses", "TEST", 108, 128], ["chromatin immunoprecipitation", "TEST", 214, 243], ["ChiP", "TEST", 245, 249], ["antibodies", "TEST", 256, 266], ["host cell histones", "TEST", 279, 297], ["histone isoforms", "TEST", 301, 317], ["these studies", "TEST", 364, 377], ["early infection", "PROBLEM", 618, 633], ["viruses", "OBSERVATION", 18, 25], ["infecting genome", "OBSERVATION", 59, 75], ["host cell histones", "OBSERVATION", 279, 297], ["genome", "OBSERVATION", 571, 577], ["progressive", "OBSERVATION_MODIFIER", 596, 607], ["stages", "OBSERVATION_MODIFIER", 608, 614], ["early", "OBSERVATION_MODIFIER", 618, 623], ["infection", "OBSERVATION", 624, 633]]], ["Thus many fundamental aspects of early genome dynamics remain poorly understood.", [["early", "OBSERVATION_MODIFIER", 33, 38], ["genome dynamics", "OBSERVATION", 39, 54]]], ["In this work we focus on spatial aspects of genome dynamics during HSV infection with results which yield new insight into intracellular transport and organisation of the genome and help complement biochemical analyses to inform or qualify their interpretation.", [["intracellular", "ANATOMY", 123, 136], ["HSV infection", "DISEASE", 67, 80], ["HSV", "ORGANISM", 67, 70], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["HSV", "SPECIES", 67, 70], ["genome dynamics", "PROBLEM", 44, 59], ["HSV infection", "PROBLEM", 67, 80]]], ["A summary of key conclusions and their implications from different aspects of this work is illustrated in Fig 12 and discussed below.Genome detection within HSV EdC virionsWe demonstrate the efficient incorporation of EdC into virus replication compartments, colocalisation with the major virus DNA binding protein, ICP8 and features of virus DNA replication in relation to the cell cycle that are entirely consistent with previous work [28] [29] [30] .", [["cell", "ANATOMY", 378, 382], ["EdC", "CHEMICAL", 218, 221], ["HSV", "ORGANISM", 157, 160], ["EdC virions", "ORGANISM", 161, 172], ["EdC", "GENE_OR_GENE_PRODUCT", 218, 221], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["ICP8", "GENE_OR_GENE_PRODUCT", 316, 320], ["DNA", "CELLULAR_COMPONENT", 343, 346], ["cell", "CELL", 378, 382], ["EdC", "PROTEIN", 218, 221], ["major virus DNA binding protein", "PROTEIN", 283, 314], ["ICP8", "PROTEIN", 316, 320], ["HSV", "SPECIES", 157, 160], ["Genome detection", "TEST", 133, 149], ["HSV EdC virions", "PROBLEM", 157, 172], ["EdC into virus replication compartments", "PROBLEM", 218, 257], ["the major virus DNA binding protein", "PROBLEM", 279, 314], ["ICP8", "PROBLEM", 316, 320], ["virus DNA replication", "TREATMENT", 337, 358], ["the cell cycle", "TEST", 374, 388], ["cell cycle", "OBSERVATION", 378, 388]]], ["However, results demonstrating the incorporation of EdC into replication compartments and its minimal effect on virus yields do not necessarily mean that it would be incorporated into Inhibitors were added to cells for 1 hr prior to infection with HSV EdC (moi 10).", [["cells", "ANATOMY", 209, 214], ["EdC", "CHEMICAL", 52, 55], ["infection", "DISEASE", 233, 242], ["EdC", "GENE_OR_GENE_PRODUCT", 52, 55], ["cells", "CELL", 209, 214], ["HSV", "ORGANISM", 248, 251], ["moi 10", "ORGANISM", 257, 263], ["EdC", "PROTEIN", 52, 55], ["HSV EdC (moi 10", "SPECIES", 248, 263], ["EdC into replication compartments", "TREATMENT", 52, 85], ["virus yields", "TREATMENT", 112, 124], ["infection", "PROBLEM", 233, 242], ["HSV EdC", "TREATMENT", 248, 255], ["minimal", "OBSERVATION_MODIFIER", 94, 101]]], ["Cells were analysed at 0.5 hpi for the localisation of EdC-labeled genomes as described for other figures.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["EdC", "GENE_OR_GENE_PRODUCT", 55, 58], ["EdC-labeled genomes", "DNA", 55, 74], ["Cells", "TEST", 0, 5]]], ["For MG132 we also analysed genome localisation at 1 hr. (a) Each panels shows a representative image at high magnification (x63 objective) together with histograms of quantitative evaluation of the frequency of numbers of genomes/nucleus observed for each condition (at least 200 nuclei for each). (b) Box and whisker plots for data in (a).", [["nucleus", "ANATOMY", 230, 237], ["MG132", "CHEMICAL", 4, 9], ["MG132", "CHEMICAL", 4, 9], ["MG132", "SIMPLE_CHEMICAL", 4, 9], ["nucleus", "CELLULAR_COMPONENT", 230, 237], ["nuclei", "CELLULAR_COMPONENT", 280, 286], ["MG132", "TREATMENT", 4, 9], ["Each panels", "TEST", 60, 71], ["quantitative evaluation", "TEST", 167, 190], ["genomes/nucleus", "PROBLEM", 222, 237], ["nucleus", "ANATOMY", 230, 237]]], ["Box shows 2 nd and 3 rd quartiles with a horizontal bar in the middle showing the median, while whiskers show up to 5-95% of the total population. '+' denotes the mean value.", [["a horizontal bar", "TREATMENT", 39, 55], ["2 nd", "OBSERVATION_MODIFIER", 10, 14], ["middle", "ANATOMY_MODIFIER", 63, 69]]], ["Unpaired two-tailed t-tests were used for statistical results (ns = not statistically significant, *** = p<0.0001).", [["tailed t-tests", "TEST", 13, 27], ["ns", "TEST", 63, 65]]], ["In this experiment infection even in the untreated sample was somewhat less efficient than standard, but there was no significant difference with either MG132 or Leptomycin B at 30 min and no diference for MG132 at 1 hr.", [["sample", "ANATOMY", 51, 57], ["infection", "DISEASE", 19, 28], ["MG132", "CHEMICAL", 153, 158], ["Leptomycin B", "CHEMICAL", 162, 174], ["MG132", "CHEMICAL", 206, 211], ["MG132", "CHEMICAL", 153, 158], ["Leptomycin B", "CHEMICAL", 162, 174], ["MG132", "CHEMICAL", 206, 211], ["MG132", "SIMPLE_CHEMICAL", 153, 158], ["Leptomycin B", "SIMPLE_CHEMICAL", 162, 174], ["MG132", "SIMPLE_CHEMICAL", 206, 211], ["this experiment infection", "PROBLEM", 3, 28], ["MG132", "TREATMENT", 153, 158], ["Leptomycin B", "TREATMENT", 162, 174], ["MG132", "TREATMENT", 206, 211], ["infection", "OBSERVATION", 19, 28], ["less efficient", "OBSERVATION_MODIFIER", 71, 85], ["no", "UNCERTAINTY", 115, 117], ["significant", "OBSERVATION_MODIFIER", 118, 129]]], ["In contrast, Nocodazole treatment resulted in a substantial and significant reduction in accumulation of uncoated nuclear genomes as discussed in the text.Genome detection within HSV EdC virionshttps://doi.org/10.1371/journal.ppat.1006721.g011Genome detection within HSV EdC virionsTransport and nuclear entry of the HSV genome mature infectious virions.", [["nuclear genomes", "ANATOMY", 114, 129], ["nuclear", "ANATOMY", 296, 303], ["virions", "ANATOMY", 346, 353], ["Nocodazole", "CHEMICAL", 13, 23], ["Nocodazole", "CHEMICAL", 13, 23], ["Nocodazole", "SIMPLE_CHEMICAL", 13, 23], ["nuclear", "CELLULAR_COMPONENT", 114, 121], ["HSV", "ORGANISM", 179, 182], ["HSV", "ORGANISM", 267, 270], ["nuclear", "CELLULAR_COMPONENT", 296, 303], ["HSV", "ORGANISM", 317, 320], ["uncoated nuclear genomes", "DNA", 105, 129], ["HSV genome", "DNA", 317, 327], ["HSV", "SPECIES", 179, 182], ["HSV", "SPECIES", 267, 270], ["HSV", "SPECIES", 317, 320], ["Nocodazole treatment", "TREATMENT", 13, 33], ["uncoated nuclear genomes", "PROBLEM", 105, 129], ["Genome detection", "TEST", 155, 171], ["HSV", "PROBLEM", 179, 182], ["substantial", "OBSERVATION_MODIFIER", 48, 59], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["accumulation", "OBSERVATION_MODIFIER", 89, 101], ["uncoated nuclear genomes", "OBSERVATION", 105, 129], ["HSV genome", "OBSERVATION", 317, 327], ["mature", "OBSERVATION_MODIFIER", 328, 334], ["infectious virions", "OBSERVATION", 335, 353]]], ["Information on the efficiency and proportion of particles that contain detectable EdC is necessary for subsequent analyses and we exploited an in vitro assay described by Newcomb et al., who showed that HSV genomes are ejected from the capsid upon attachment to solid supports due to undefined structural perturbation(s) [26, 27] .", [["EdC", "GENE_OR_GENE_PRODUCT", 82, 85], ["HSV", "ORGANISM", 203, 206], ["EdC", "PROTEIN", 82, 85], ["HSV genomes", "DNA", 203, 214], ["HSV", "SPECIES", 203, 206], ["an in vitro assay", "TEST", 140, 157], ["HSV genomes", "PROBLEM", 203, 214]]], ["Consistent with this, we show that adsorption on glass induces a structural change in the capsid permitting access to the catalytic molecules involved in cycloaddition, including the azidefluorochrome.", [["azidefluorochrome", "CHEMICAL", 183, 200], ["azidefluorochrome", "CHEMICAL", 183, 200], ["azidefluorochrome", "SIMPLE_CHEMICAL", 183, 200], ["catalytic molecules", "PROTEIN", 122, 141], ["a structural change", "PROBLEM", 63, 82], ["cycloaddition", "TREATMENT", 154, 167], ["the azidefluorochrome", "TREATMENT", 179, 200]]], ["In our analysis with virions the genome was retained within the particle while with purified capsids the genome was readily released [26] .", [["genome", "CELLULAR_COMPONENT", 33, 39], ["genome", "CELLULAR_COMPONENT", 105, 111]]], ["We propose that while there is some structural change in the virion capsid allowing the coupling reaction to the DNA, the genome is nevertheless retained in the confines of the particle due to surrounding components.", [["DNA", "CELLULAR_COMPONENT", 113, 116], ["genome", "CELLULAR_COMPONENT", 122, 128], ["virion capsid", "PROTEIN", 61, 74], ["some structural change in the virion capsid", "PROBLEM", 31, 74], ["the coupling reaction", "PROBLEM", 84, 105], ["the DNA", "PROBLEM", 109, 116], ["structural", "OBSERVATION_MODIFIER", 36, 46], ["change", "OBSERVATION", 47, 53], ["virion capsid", "OBSERVATION", 61, 74], ["genome", "OBSERVATION", 122, 128], ["retained", "OBSERVATION_MODIFIER", 145, 153], ["particle", "OBSERVATION_MODIFIER", 177, 185]]], ["It was also previously demonstrated that when the genome was released from purified capsids, it was ejected in a polarised manner likely from the portal and that the proposed structural alteration may impact directly or indirectly on portal integrity [26] .", [["portal", "ANATOMY", 234, 240], ["genome", "CELLULAR_COMPONENT", 50, 56], ["portal", "MULTI-TISSUE_STRUCTURE", 146, 152], ["portal", "MULTI-TISSUE_STRUCTURE", 234, 240], ["purified capsids", "PROBLEM", 75, 91], ["portal", "ANATOMY", 146, 152], ["portal", "ANATOMY", 234, 240]]], ["A portal-specific alteration is possible but not necessary to explain our observations and it could be that some more global perturbation around the capsid shell could allow access to the components of the cycloaddition reaction, the largest being the azide-fluorochrome (mol wt 861).", [["azide", "CHEMICAL", 252, 257], ["azide", "CHEMICAL", 252, 257], ["azide", "SIMPLE_CHEMICAL", 252, 257], ["fluorochrome", "SIMPLE_CHEMICAL", 258, 270], ["the capsid shell", "TREATMENT", 145, 161], ["the cycloaddition reaction", "PROBLEM", 202, 228], ["the azide-fluorochrome", "TREATMENT", 248, 270], ["portal", "ANATOMY", 2, 8], ["alteration", "OBSERVATION", 18, 28], ["global", "OBSERVATION_MODIFIER", 118, 124], ["perturbation", "OBSERVATION", 125, 137], ["capsid shell", "OBSERVATION", 149, 161], ["cycloaddition reaction", "OBSERVATION", 206, 228], ["largest", "OBSERVATION_MODIFIER", 234, 241]]], ["Indeed there Transport and nuclear entry of the HSV genome could be distinct perturbations with one type allowing access to small compounds and another involving changes including at the portal, promoting genome release.", [["nuclear", "ANATOMY", 27, 34], ["nuclear", "CELLULAR_COMPONENT", 27, 34], ["HSV", "ORGANISM", 48, 51], ["genome", "CELLULAR_COMPONENT", 205, 211], ["HSV genome", "DNA", 48, 58], ["HSV", "SPECIES", 48, 51], ["the HSV genome", "PROBLEM", 44, 58], ["small compounds", "PROBLEM", 124, 139], ["HSV genome", "OBSERVATION", 48, 58], ["small", "OBSERVATION_MODIFIER", 124, 129], ["compounds", "OBSERVATION", 130, 139], ["portal", "ANATOMY", 187, 193], ["genome release", "OBSERVATION", 205, 219]]], ["Nevertheless the ability to identify the genome within the capsid might be exploited for other types of analysis e.g. in vitro biophysical analysis of genome transitions [57] or the identification of specific host components that may promote release.", [["analysis", "TEST", 104, 112]]], ["It is also interesting to compare these results with similar analyses of Adv on solid supports [16] .", [["Adv", "CHEMICAL", 73, 76], ["Adv", "SIMPLE_CHEMICAL", 73, 76], ["Adv on solid supports", "TREATMENT", 73, 94]]], ["In the case of Adv, EdC-labelled genomes were not detected upon initial adsorption of the virus to coverslips but were observed after heat disruption.", [["EdC", "CHEMICAL", 20, 23], ["EdC", "CHEMICAL", 20, 23], ["Adv", "GENE_OR_GENE_PRODUCT", 15, 18], ["EdC", "GENE_OR_GENE_PRODUCT", 20, 23], ["Adv", "DNA", 15, 18], ["EdC-labelled genomes", "DNA", 20, 40], ["the virus", "PROBLEM", 86, 95], ["heat disruption", "PROBLEM", 134, 149], ["disruption", "OBSERVATION", 139, 149]]], ["Heat treatment revealed internal protein VII (by immunofluorescence) and allowed cycloaddition labelling of the genome, which nevertheless remained tightly associated with the capsid [16] .", [["internal protein VII", "GENE_OR_GENE_PRODUCT", 24, 44], ["internal protein VII", "PROTEIN", 24, 44], ["Heat treatment", "TREATMENT", 0, 14], ["internal protein VII", "PROBLEM", 24, 44], ["immunofluorescence", "TEST", 49, 67], ["internal", "ANATOMY", 24, 32], ["protein VII", "OBSERVATION", 33, 44]]], ["The ejection of the HSV genome (from capsids or heated virions) versus the maintained association of the Adv genome (from heated capsids) most likely reflects differences in the pressurisation status of genomes within capsids [58] and the lack of DNA packaging proteins within HSV compared to Adv where the genome is associated with several core proteins, in particular protein VII [59] .", [["HSV", "ORGANISM", 20, 23], ["Adv", "GENE_OR_GENE_PRODUCT", 105, 108], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["HSV", "ORGANISM", 277, 280], ["Adv", "GENE_OR_GENE_PRODUCT", 293, 296], ["genome", "CELLULAR_COMPONENT", 307, 313], ["protein VII [59]", "GENE_OR_GENE_PRODUCT", 370, 386], ["HSV genome", "DNA", 20, 30], ["Adv genome", "DNA", 105, 115], ["DNA packaging proteins", "PROTEIN", 247, 269], ["Adv", "PROTEIN", 293, 296], ["core proteins", "PROTEIN", 341, 354], ["protein VII", "PROTEIN", 370, 381], ["HSV", "SPECIES", 20, 23], ["HSV", "SPECIES", 277, 280], ["the HSV genome", "PROBLEM", 16, 30], ["capsids or heated virions", "TREATMENT", 37, 62], ["the Adv genome", "PROBLEM", 101, 115], ["heated capsids", "TREATMENT", 122, 136], ["DNA packaging proteins", "PROBLEM", 247, 269], ["HSV", "PROBLEM", 277, 280], ["several core proteins", "PROBLEM", 333, 354], ["ejection", "OBSERVATION", 4, 12], ["HSV genome", "OBSERVATION", 20, 30], ["Adv genome", "OBSERVATION", 105, 115], ["most likely reflects", "UNCERTAINTY", 138, 158], ["genome", "OBSERVATION", 307, 313]]], ["Such differences in internal pressure and protein-genome association are likely reflected in differences in mechanism in nuclear pore engagement and genome import.HSV genome entryUncoated nuclear genomes could be detected within 30 min of infection at 37\u02daC with HSV EdC .", [["nuclear pore", "ANATOMY", 121, 133], ["nuclear genomes", "ANATOMY", 188, 203], ["infection", "DISEASE", 239, 248], ["nuclear pore", "CELLULAR_COMPONENT", 121, 133], ["genome", "CELLULAR_COMPONENT", 149, 155], ["HSV", "ORGANISM", 163, 166], ["HSV", "ORGANISM", 262, 265], ["HSV genome entryUncoated nuclear genomes", "DNA", 163, 203], ["HSV", "SPECIES", 163, 166], ["HSV", "SPECIES", 262, 265], ["internal pressure", "TEST", 20, 37], ["HSV genome entryUncoated nuclear genomes", "PROBLEM", 163, 203], ["infection", "PROBLEM", 239, 248], ["HSV EdC", "TREATMENT", 262, 269], ["internal", "ANATOMY_MODIFIER", 20, 28], ["pressure", "OBSERVATION_MODIFIER", 29, 37], ["protein-genome", "OBSERVATION", 42, 56], ["likely reflected", "UNCERTAINTY", 73, 89], ["nuclear pore", "OBSERVATION_MODIFIER", 121, 133], ["nuclear genomes", "OBSERVATION", 188, 203], ["infection", "OBSERVATION", 239, 248]]], ["Using similar methods to examine Adv infection, genomes could not be detected in the nucleus at 30 min and quantitative analysis on nuclear entry was performed at 2.5 hrs, a comparatively late point in our analyses, when genomes were already uncoated, decondensed and in many cases beginning to replicate.", [["nucleus", "ANATOMY", 85, 92], ["nuclear", "ANATOMY", 132, 139], ["infection", "DISEASE", 37, 46], ["Adv", "GENE_OR_GENE_PRODUCT", 33, 36], ["nucleus", "CELLULAR_COMPONENT", 85, 92], ["nuclear", "CELLULAR_COMPONENT", 132, 139], ["similar methods", "TREATMENT", 6, 21], ["Adv infection", "PROBLEM", 33, 46], ["quantitative analysis", "TEST", 107, 128], ["nuclear entry", "TEST", 132, 145], ["nucleus", "ANATOMY", 85, 92]]], ["This does not necessarily indicate that HSV genome import is more rapid than adenovirus.", [["HSV", "ORGANISM", 40, 43], ["adenovirus", "ORGANISM", 77, 87], ["HSV", "SPECIES", 40, 43], ["adenovirus", "SPECIES", 77, 87], ["HSV genome import", "PROBLEM", 40, 57], ["adenovirus", "PROBLEM", 77, 87], ["not necessarily indicate", "UNCERTAINTY", 10, 34]]], ["This would require a direct parallel comparison with similarly labelled viruses in the same cells and on identical imaging systems and even then would be a qualified comparison.", [["cells", "ANATOMY", 92, 97], ["cells", "CELL", 92, 97], ["similarly labelled viruses", "PROBLEM", 53, 79], ["identical imaging systems", "TEST", 105, 130]]], ["Nonetheless for the majority of Adv capsids, their genomes become rapidly accessible to click detection in the cytoplasm, reflecting the initial stages of uncoating [12, 16, 59, 60] .", [["cytoplasm", "ANATOMY", 111, 120], ["Adv", "GENE_OR_GENE_PRODUCT", 32, 35], ["cytoplasm", "ORGANISM_SUBSTANCE", 111, 120], ["Adv capsids", "TREATMENT", 32, 43], ["click detection", "TEST", 88, 103]]], ["Given differences in entry processes it is perhaps not unsurprising that unlike Adv, HSV genome entry is not sensitive to Leptomycin B inhibition of nuclear export.", [["nuclear", "ANATOMY", 149, 156], ["Leptomycin B", "CHEMICAL", 122, 134], ["Leptomycin B", "CHEMICAL", 122, 134], ["Adv", "GENE_OR_GENE_PRODUCT", 80, 83], ["HSV", "ORGANISM", 85, 88], ["Leptomycin B", "GENE_OR_GENE_PRODUCT", 122, 134], ["nuclear", "CELLULAR_COMPONENT", 149, 156], ["Adv", "PROTEIN", 80, 83], ["Leptomycin B", "PROTEIN", 122, 134], ["HSV", "SPECIES", 85, 88], ["HSV genome entry", "PROBLEM", 85, 101], ["Leptomycin B inhibition", "TREATMENT", 122, 145], ["perhaps not", "UNCERTAINTY", 43, 54]]], ["For HSV EdC while uncoated cytoplasmic genomes could be detected this was a minor population of the total genomes, mostly in a subpopulation of cells.", [["cytoplasmic genomes", "ANATOMY", 27, 46], ["cells", "ANATOMY", 144, 149], ["HSV", "ORGANISM", 4, 7], ["EdC", "GENE_OR_GENE_PRODUCT", 8, 11], ["cytoplasmic", "ORGANISM_SUBSTANCE", 27, 38], ["cells", "CELL", 144, 149], ["HSV EdC", "DNA", 4, 11], ["uncoated cytoplasmic genomes", "DNA", 18, 46], ["HSV", "SPECIES", 4, 7], ["HSV EdC", "PROBLEM", 4, 11], ["uncoated cytoplasmic genomes", "PROBLEM", 18, 46], ["a minor population of the total genomes", "PROBLEM", 74, 113], ["cytoplasmic genomes", "OBSERVATION", 27, 46], ["minor", "OBSERVATION_MODIFIER", 76, 81], ["population", "OBSERVATION_MODIFIER", 82, 92], ["total genomes", "OBSERVATION", 100, 113], ["subpopulation of cells", "OBSERVATION", 127, 149]]], ["Although unlikely to contribute to the nuclear genome pool, such genomes may play a distinct role in the cell population as a whole, including host responses from subsets of cells that might elicit paracrine effectors to other cells.", [["nuclear", "ANATOMY", 39, 46], ["cell", "ANATOMY", 105, 109], ["cells", "ANATOMY", 174, 179], ["cells", "ANATOMY", 227, 232], ["nuclear", "CELLULAR_COMPONENT", 39, 46], ["cell", "CELL", 105, 109], ["cells", "CELL", 174, 179], ["cells", "CELL", 227, 232], ["the nuclear genome pool", "PROBLEM", 35, 58], ["subsets of cells", "PROBLEM", 163, 179], ["paracrine effectors to other cells", "PROBLEM", 198, 232], ["unlikely to contribute", "UNCERTAINTY", 9, 31]]], ["We conclude that for HSV, most capsids do not undergo structural transitions that perturb access (at least resolvable by cycloaddition labelling with azide-fluorochromes), such transitions likely being tightly coupled to engagement with the nuclear pore.", [["nuclear pore", "ANATOMY", 241, 253], ["azide", "CHEMICAL", 150, 155], ["azide", "CHEMICAL", 150, 155], ["HSV", "ORGANISM", 21, 24], ["azide", "SIMPLE_CHEMICAL", 150, 155], ["nuclear pore", "CELLULAR_COMPONENT", 241, 253], ["HSV", "SPECIES", 21, 24], ["HSV", "PROBLEM", 21, 24], ["perturb access", "TREATMENT", 82, 96], ["azide-fluorochromes", "TREATMENT", 150, 169]]], ["However other factors including cell type could influence capsid integrity and genome accessibility, e.g., differences in entry by fusion at the plasma membrane versus endocytosis.", [["cell", "ANATOMY", 32, 36], ["plasma membrane", "ANATOMY", 145, 160], ["cell type", "CELL", 32, 41], ["plasma membrane", "CELLULAR_COMPONENT", 145, 160], ["cell type", "PROBLEM", 32, 41], ["endocytosis", "PROBLEM", 168, 179], ["cell type", "OBSERVATION", 32, 41], ["capsid integrity", "OBSERVATION", 58, 74], ["genome accessibility", "OBSERVATION", 79, 99]]], ["The ability to positively identify genomes associated with perturbed capsids will be useful in future studies including investigation of capsid integrity as a function of cell type and the influence of prior immune stimulation by different pathways.HSV genome entryWe found no significant qualitative or quantitative difference in the presence of MG132 and conclude that proteasome function is not required for transport of the relevant capsid population or genome import per se.", [["cell", "ANATOMY", 171, 175], ["MG132", "CHEMICAL", 347, 352], ["MG132", "CHEMICAL", 347, 352], ["cell type", "CELL", 171, 180], ["HSV", "ORGANISM", 249, 252], ["MG132", "SIMPLE_CHEMICAL", 347, 352], ["genome", "CELLULAR_COMPONENT", 458, 464], ["HSV genome", "DNA", 249, 259], ["proteasome", "PROTEIN", 371, 381], ["HSV", "SPECIES", 249, 252], ["perturbed capsids", "PROBLEM", 59, 76], ["future studies", "TEST", 95, 109], ["capsid integrity", "PROBLEM", 137, 153], ["cell type", "PROBLEM", 171, 180], ["prior immune stimulation", "TREATMENT", 202, 226], ["MG132", "TREATMENT", 347, 352], ["proteasome function", "TEST", 371, 390], ["capsid integrity", "OBSERVATION", 137, 153], ["cell type", "OBSERVATION", 171, 180], ["entry", "OBSERVATION_MODIFIER", 260, 265], ["no", "UNCERTAINTY", 274, 276], ["significant", "OBSERVATION_MODIFIER", 277, 288]]], ["This is in contrast to a previous publication which indicated that proteasome function was required post-entry for efficient delivery of incoming HSV capsids to the nucleus and subsequent gene expression [37] .", [["nucleus", "ANATOMY", 165, 172], ["HSV", "ORGANISM", 146, 149], ["nucleus", "CELLULAR_COMPONENT", 165, 172], ["proteasome", "PROTEIN", 67, 77], ["HSV", "SPECIES", 146, 149], ["proteasome function", "PROBLEM", 67, 86], ["incoming HSV capsids", "TREATMENT", 137, 157], ["nucleus", "ANATOMY", 165, 172]]], ["While there could be several explanations for the difference, in our analyses we directly measure genome import while previous conclusions were based on measurements of gene expression (\u03b2-galactosidase) at 6 hpi or on measure of capsid localisation of a fluorescent virus at 2.5 hpi.", [["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 186, 201], ["\u03b2-galactosidase", "PROTEIN", 186, 201], ["gene expression", "PROBLEM", 169, 184], ["a fluorescent virus", "PROBLEM", 252, 271]]], ["Proteasome inhibition could have inhibited a number of processes involved in surrogate read-out later in infection or inhibited bulk capsid dynamics that were not important for early genome delivery.HSV genome entryAs summarised (Fig 12) , at the earliest time detectable (stage 1, within 0.5 hpi) uncoated nuclear genomes were in a comparatively homogeneous, roughly spherical form that had expanded to approximately 3-fold the volume within virions.", [["nuclear genomes", "ANATOMY", 307, 322], ["virions", "ANATOMY", 443, 450], ["infection", "DISEASE", 105, 114], ["Proteasome", "GENE_OR_GENE_PRODUCT", 0, 10], ["HSV", "ORGANISM", 199, 202], ["nuclear", "CELLULAR_COMPONENT", 307, 314], ["HSV genome entryAs", "DNA", 199, 217], ["uncoated nuclear genomes", "DNA", 298, 322], ["HSV", "SPECIES", 199, 202], ["Proteasome inhibition", "TREATMENT", 0, 21], ["infection", "PROBLEM", 105, 114], ["early genome delivery", "TREATMENT", 177, 198], ["HSV genome entryAs", "TEST", 199, 217], ["infection", "OBSERVATION", 105, 114]]], ["Thus while there is a distinct genome decompaction after nuclear import, this is constrained in a relatively regular manner.", [["nuclear", "ANATOMY", 57, 64], ["nuclear", "CELLULAR_COMPONENT", 57, 64], ["a distinct genome decompaction", "PROBLEM", 20, 50], ["distinct", "OBSERVATION_MODIFIER", 22, 30], ["genome decompaction", "OBSERVATION", 31, 50]]], ["The distribution of the numbers of genomes appearing in the nucleus and the relationship to moi bear similarity to those from physical analysis of adenovirus genome entry [16] and are relevant also to conclusions from other studies on the numbers of herpesvirus nuclear genomes that participate in transcription and replication [61] [62] [63] .", [["nucleus", "ANATOMY", 60, 67], ["nucleus", "CELLULAR_COMPONENT", 60, 67], ["adenovirus", "ORGANISM", 147, 157], ["herpesvirus", "ORGANISM", 250, 261], ["adenovirus genome", "DNA", 147, 164], ["herpesvirus nuclear genomes", "DNA", 250, 277], ["physical analysis", "TEST", 126, 143], ["other studies", "TEST", 218, 231], ["herpesvirus nuclear genomes", "PROBLEM", 250, 277], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["numbers", "OBSERVATION_MODIFIER", 24, 31], ["genomes", "OBSERVATION", 35, 42], ["nucleus", "ANATOMY", 60, 67]]], ["We observed that at a standard moi of 10 pfu/cell (100-200 particles coating a cell) , although a small percentage of nuclei could contain relatively high numbers, the mean numbers of nuclear genome foci was approximately 5 and around 90% of cells had fewer than 10.", [["cell", "ANATOMY", 45, 49], ["cell", "ANATOMY", 79, 83], ["nuclei", "ANATOMY", 118, 124], ["nuclear genome foci", "ANATOMY", 184, 203], ["cells", "ANATOMY", 242, 247], ["cell", "CELL", 45, 49], ["cell", "CELL", 79, 83], ["nuclei", "CELLULAR_COMPONENT", 118, 124], ["nuclear", "CELLULAR_COMPONENT", 184, 191], ["cells", "CELL", 242, 247], ["a small percentage of nuclei", "PROBLEM", 96, 124], ["small", "OBSERVATION_MODIFIER", 98, 103], ["relatively", "OBSERVATION_MODIFIER", 139, 149], ["high", "OBSERVATION_MODIFIER", 150, 154], ["numbers", "OBSERVATION_MODIFIER", 155, 162], ["mean", "OBSERVATION_MODIFIER", 168, 172], ["numbers", "OBSERVATION_MODIFIER", 173, 180], ["nuclear", "OBSERVATION_MODIFIER", 184, 191], ["genome", "OBSERVATION_MODIFIER", 192, 198], ["foci", "OBSERVATION", 199, 203]]], ["Increasing moi by 5-fold did not increase nuclear genome numbers 5-fold indicating the operation of some form of limit(s) on infection (though this could be at a number of stages) and a decreasing efficiency of nuclear import at higher mois.", [["nuclear", "ANATOMY", 42, 49], ["nuclear", "ANATOMY", 211, 218], ["infection", "DISEASE", 125, 134], ["nuclear", "CELLULAR_COMPONENT", 42, 49], ["nuclear", "CELLULAR_COMPONENT", 211, 218], ["Increasing moi", "PROBLEM", 0, 14], ["the operation", "TREATMENT", 83, 96], ["infection", "PROBLEM", 125, 134], ["a decreasing efficiency of nuclear import", "PROBLEM", 184, 225], ["operation", "OBSERVATION", 87, 96], ["infection", "OBSERVATION", 125, 134], ["decreasing", "OBSERVATION_MODIFIER", 186, 196], ["efficiency", "OBSERVATION_MODIFIER", 197, 207]]], ["Similar conclusions were made for Adv nuclear entry [16] .", [["nuclear", "ANATOMY", 38, 45], ["Adv", "PROTEIN", 34, 37]]], ["We currently cannot discriminate the fate of capsids which do not uncoat at the nuclear pore, while for Adv genomes appear to be lost from the capsid.", [["nuclear pore", "ANATOMY", 80, 92], ["nuclear pore", "CELLULAR_COMPONENT", 80, 92], ["Adv", "GENE_OR_GENE_PRODUCT", 104, 107], ["capsid", "CELLULAR_COMPONENT", 143, 149], ["Adv genomes", "DNA", 104, 115], ["Adv genomes", "TREATMENT", 104, 115], ["capsid", "OBSERVATION", 143, 149]]], ["Based on mathematical modelling of simultaneous infections with strains of pseudorabies virus expressing individual fluorophores, it has also been estimated that an average of approximately five infecting genomes are expressed per cell at a moi of 10 and that even at moi 100 the mean is no more than 7-8 genomes [61] .", [["cell", "ANATOMY", 231, 235], ["infections", "DISEASE", 48, 58], ["pseudorabies virus", "ORGANISM", 75, 93], ["cell", "CELL", 231, 235], ["pseudorabies virus", "SPECIES", 75, 93], ["pseudorabies virus", "SPECIES", 75, 93], ["simultaneous infections", "PROBLEM", 35, 58], ["pseudorabies virus expressing individual fluorophores", "PROBLEM", 75, 128], ["simultaneous", "OBSERVATION_MODIFIER", 35, 47], ["infections", "OBSERVATION", 48, 58], ["average", "OBSERVATION_MODIFIER", 165, 172], ["infecting genomes", "OBSERVATION", 195, 212]]], ["Clearly, at the more extreme ends of distributions from our analyses, high numbers of genomes can enter the nucleus.", [["nucleus", "ANATOMY", 108, 115], ["nucleus", "CELLULAR_COMPONENT", 108, 115], ["our analyses", "TEST", 56, 68], ["distributions", "OBSERVATION_MODIFIER", 37, 50], ["high", "OBSERVATION_MODIFIER", 70, 74], ["numbers", "OBSERVATION_MODIFIER", 75, 82], ["nucleus", "ANATOMY", 108, 115]]], ["However, at a standard moi of 10, the mean numbers of physical nuclear genomes are of the same approximation as the numbers of genomes that have been proposed to express or replicate [61] .", [["physical nuclear genomes", "DNA", 54, 78], ["nuclear genomes", "OBSERVATION", 63, 78]]], ["One implication from this is that once imported into the nucleus, the efficiency of transcription may be relatively high.", [["nucleus", "ANATOMY", 57, 64], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["nucleus", "ANATOMY", 57, 64], ["high", "OBSERVATION_MODIFIER", 116, 120]]], ["Indeed at early times, many of the physical genomes were associated with ICP4 (see below), though this does not necessarily mean such genomes are indeed transcribed.", [["ICP4", "GENE_OR_GENE_PRODUCT", 73, 77], ["physical genomes", "DNA", 35, 51], ["ICP4", "PROTEIN", 73, 77], ["ICP4", "PROBLEM", 73, 77]]], ["Such conclusions will require the ability to simultaneously visualise genomes and nascent transcripts or accumulating RNA.", [["nascent transcripts", "RNA", 82, 101], ["RNA", "RNA", 118, 121], ["accumulating RNA", "PROBLEM", 105, 121], ["accumulating RNA", "OBSERVATION", 105, 121]]], ["We are currently developing bioorthogonal approaches [64] with distinct chemical moieties on DNA versus RNA that allow copper-dependent and independent coupling of distinct fluorochromes to examine these questions in virus infected cells.Genome compaction state transitions during infectionAfter nuclear import, the HSV genome initially expands and continues to decondense in a series of transitions that could be delimited using chemical inhibitors.", [["cells", "ANATOMY", 232, 237], ["nuclear", "ANATOMY", 296, 303], ["copper", "CHEMICAL", 119, 125], ["copper", "CHEMICAL", 119, 125], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["copper", "SIMPLE_CHEMICAL", 119, 125], ["cells", "CELL", 232, 237], ["nuclear", "CELLULAR_COMPONENT", 296, 303], ["HSV", "ORGANISM", 316, 319], ["virus infected cells", "CELL_TYPE", 217, 237], ["HSV genome", "DNA", 316, 326], ["HSV", "SPECIES", 316, 319], ["distinct chemical moieties", "PROBLEM", 63, 89], ["DNA versus RNA", "PROBLEM", 93, 107], ["copper-dependent", "PROBLEM", 119, 135], ["distinct fluorochromes", "PROBLEM", 164, 186], ["virus infected cells", "PROBLEM", 217, 237], ["Genome compaction state transitions", "PROBLEM", 238, 273], ["the HSV genome", "PROBLEM", 312, 326], ["chemical inhibitors", "TREATMENT", 430, 449], ["chemical moieties", "OBSERVATION", 72, 89]]], ["In the absence of transcription, genomes remained relatively compact and were maintained in that form in the nucleus for at least 8 hrs.", [["nucleus", "ANATOMY", 109, 116], ["nucleus", "CELLULAR_COMPONENT", 109, 116], ["nucleus", "ANATOMY", 109, 116]]], ["De novo virus protein synthesis is therefore not required for the initial compact state of the genome, the nature of which is discussed further below.", [["De novo virus protein synthesis", "PROBLEM", 0, 31], ["virus protein synthesis", "OBSERVATION", 8, 31]]], ["Allowing transcription but in the absence of de novo translation revealed a distinct feature, which we termed genome congregation, not observed when transcription was blocked.", [["a distinct feature", "PROBLEM", 74, 92], ["genome congregation", "OBSERVATION", 110, 129]]], ["Several mechanisms could contribute to this process.", [["this process", "PROBLEM", 39, 51], ["could contribute to", "UNCERTAINTY", 19, 38]]], ["Transcription on the viral genomes themselves, i.e., the templates for transcription, could directly contribute to congregation, even if not all genomes were transcribing.", [["viral genomes", "DNA", 21, 34]]], ["This could be via components of the transcription/splicing apparatus somehow progressively capturing multiple genomes in a spatially restricted manner.", [["the transcription/splicing apparatus", "PROBLEM", 32, 68], ["progressively", "OBSERVATION_MODIFIER", 77, 90], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["genomes", "OBSERVATION", 110, 117]]], ["It could also be that genome congregation is a host response to infection (with no viral proteins yet made), specifically recognising the process of transcription and sequestering genomes as a result.", [["infection", "DISEASE", 64, 73], ["viral proteins", "PROTEIN", 83, 97], ["genome congregation", "PROBLEM", 22, 41], ["infection", "PROBLEM", 64, 73], ["viral proteins", "PROBLEM", 83, 97], ["could also be", "UNCERTAINTY", 3, 16], ["infection", "OBSERVATION", 64, 73]]], ["Further explanations are possible but understanding the process of genome congregation will be important for any full understanding of genome dynamics, competency for transcription and host responses to infection (see below).Genome compaction state transitions during infectionDuring normal infection, genomes underwent further progressive decondensation, eventually becoming difficult to discriminate and dissipating within DNA replication compartments.", [["infection", "DISEASE", 203, 212], ["infection", "DISEASE", 291, 300], ["DNA", "CELLULAR_COMPONENT", 425, 428], ["infection", "PROBLEM", 203, 212], ["Genome compaction state transitions", "PROBLEM", 225, 260], ["infectionDuring normal infection", "PROBLEM", 268, 300], ["further progressive decondensation", "PROBLEM", 320, 354], ["infection", "OBSERVATION", 291, 300], ["progressive", "OBSERVATION_MODIFIER", 328, 339], ["decondensation", "OBSERVATION", 340, 354]]], ["We frequently observed longer lived residual condensed foci usually at the periphery of replication compartments (Fig 12, stages 2-4) .", [["foci", "ANATOMY", 55, 59], ["compartments", "ANATOMY", 100, 112], ["longer lived residual condensed foci", "PROBLEM", 23, 59], ["longer lived", "OBSERVATION_MODIFIER", 23, 35], ["residual", "OBSERVATION_MODIFIER", 36, 44], ["condensed", "OBSERVATION_MODIFIER", 45, 54], ["foci", "OBSERVATION", 55, 59], ["periphery", "ANATOMY_MODIFIER", 75, 84]]], ["The intermediate stages of these genome transitions did not require DNA replication per se, with the enlarged and decondensed morphology of infecting genomes in the presence of DNA replication inhibitors being distinct from that observed in the presence of Act D or CHX (Fig 12, summary schematic view, shaded sectors) .", [["CHX", "CHEMICAL", 266, 269], ["CHX", "CHEMICAL", 266, 269], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["CHX", "SIMPLE_CHEMICAL", 266, 269], ["DNA replication", "TREATMENT", 68, 83], ["infecting genomes", "PROBLEM", 140, 157], ["DNA replication inhibitors", "TREATMENT", 177, 203], ["intermediate", "OBSERVATION_MODIFIER", 4, 16], ["stages", "OBSERVATION_MODIFIER", 17, 23], ["genome transitions", "OBSERVATION", 33, 51], ["enlarged", "OBSERVATION_MODIFIER", 101, 109], ["decondensed", "OBSERVATION_MODIFIER", 114, 125], ["morphology", "OBSERVATION_MODIFIER", 126, 136], ["infecting genomes", "OBSERVATION", 140, 157], ["DNA replication inhibitors", "OBSERVATION", 177, 203]]], ["We conclude that recruitment of regulatory and/or replication factors combined with the more extensive early transcription, results in further changes and decondensation of the genome while downstream DNA replication and associated processes e.g., recombination, branching and extensive late transcription, [65, 66] results in more complete decondensation of input genomes at later times.", [["genome", "CELLULAR_COMPONENT", 177, 183], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["replication factors", "PROTEIN", 50, 69], ["replication factors", "PROBLEM", 50, 69], ["decondensation of the genome", "PROBLEM", 155, 183], ["downstream DNA replication", "TREATMENT", 190, 216], ["input genomes", "OBSERVATION", 359, 372]]], ["It is possible that the longer lived condensed foci remaining on the periphery of replication compartments represent either replicated parental strands that remain as foci, or potentially a subset of parental genomes that were not acted upon by either replication or transcription.", [["foci", "ANATOMY", 47, 51], ["foci", "ANATOMY", 167, 171], ["the longer lived condensed foci", "PROBLEM", 20, 51], ["foci", "PROBLEM", 167, 171], ["longer", "OBSERVATION_MODIFIER", 24, 30], ["lived", "OBSERVATION_MODIFIER", 31, 36], ["condensed", "OBSERVATION_MODIFIER", 37, 46], ["foci", "OBSERVATION", 47, 51], ["periphery", "ANATOMY_MODIFIER", 69, 78], ["parental strands", "OBSERVATION", 135, 151], ["foci", "OBSERVATION", 167, 171]]], ["Rolling circle replication [65, 67, 68] acting on HSV EdC would result in one labelled parental strand remaining at the replication fork, while the other parental strand would progressively move away as replication and unlabelled progeny DNA accumulates.", [["HSV", "ORGANISM", 50, 53], ["EdC", "GENE_OR_GENE_PRODUCT", 54, 57], ["DNA", "CELLULAR_COMPONENT", 238, 241], ["HSV EdC", "DNA", 50, 57], ["HSV", "SPECIES", 50, 53]]], ["It is not currently technically possible to discriminate between these possibilities and other explanations are also possible but in this regard the pattern of genome association with ICP4 warrants discussion.ICP4 association with infecting HSV genomesWhile there was heterogeneity at an individual genome level with some genomes not accumulating ICP4, the majority of condensed genomes recruited and were enriched for ICP4 by 1-2 hrs.", [["ICP4", "GENE_OR_GENE_PRODUCT", 184, 188], ["ICP4", "GENE_OR_GENE_PRODUCT", 209, 213], ["HSV", "ORGANISM", 241, 244], ["ICP4", "GENE_OR_GENE_PRODUCT", 347, 351], ["ICP4", "GENE_OR_GENE_PRODUCT", 419, 423], ["ICP4", "PROTEIN", 184, 188], ["ICP4", "PROTEIN", 209, 213], ["infecting HSV genomes", "DNA", 231, 252], ["ICP4", "PROTEIN", 347, 351], ["ICP4", "PROTEIN", 419, 423], ["HSV", "SPECIES", 241, 244], ["ICP4", "TREATMENT", 184, 188], ["infecting HSV genomes", "PROBLEM", 231, 252], ["heterogeneity at an individual genome level", "PROBLEM", 268, 311], ["ICP4", "TREATMENT", 419, 423], ["infecting", "OBSERVATION_MODIFIER", 231, 240], ["HSV genomes", "OBSERVATION", 241, 252], ["heterogeneity", "OBSERVATION", 268, 281], ["not", "UNCERTAINTY", 330, 333], ["accumulating", "OBSERVATION_MODIFIER", 334, 346], ["ICP4", "OBSERVATION", 347, 351], ["majority", "OBSERVATION_MODIFIER", 357, 365], ["condensed genomes", "OBSERVATION", 369, 386]]], ["However as infection progressed there was a clear distinction in this association.", [["infection", "DISEASE", 11, 20], ["infection", "PROBLEM", 11, 20], ["infection", "OBSERVATION", 11, 20], ["clear", "OBSERVATION_MODIFIER", 44, 49], ["distinction", "OBSERVATION", 50, 61]]], ["Those genomes that remained as condensed foci (found mainly on the periphery of replication compartments) were selectively depleted for ICP4 and frequently devoid of the protein altogether.", [["foci", "ANATOMY", 41, 45], ["compartments", "ANATOMY", 92, 104], ["ICP4", "GENE_OR_GENE_PRODUCT", 136, 140], ["ICP4", "PROTEIN", 136, 140], ["condensed foci", "PROBLEM", 31, 45], ["ICP4", "PROBLEM", 136, 140], ["condensed", "OBSERVATION_MODIFIER", 31, 40], ["foci", "OBSERVATION", 41, 45], ["periphery", "ANATOMY_MODIFIER", 67, 76]]], ["One possible explanation is that these foci never accumulated ICP4, in which case they exhibit significant selectivity since ICP4 would clearly have been initially recruited to certain other foci and ICP4 was also present in adjacent decondensed replication centres in the same nuclei.", [["foci", "ANATOMY", 39, 43], ["foci", "ANATOMY", 191, 195], ["nuclei", "ANATOMY", 278, 284], ["ICP4", "GENE_OR_GENE_PRODUCT", 62, 66], ["ICP4", "GENE_OR_GENE_PRODUCT", 125, 129], ["ICP4", "GENE_OR_GENE_PRODUCT", 200, 204], ["nuclei", "CELLULAR_COMPONENT", 278, 284], ["ICP4", "PROTEIN", 62, 66], ["ICP4", "PROTEIN", 125, 129], ["ICP4", "PROTEIN", 200, 204], ["these foci", "PROBLEM", 33, 43], ["ICP4", "PROBLEM", 125, 129], ["ICP4", "PROBLEM", 200, 204], ["possible explanation is", "UNCERTAINTY", 4, 27], ["foci", "OBSERVATION", 39, 43], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["selectivity", "OBSERVATION", 107, 118], ["foci", "OBSERVATION", 191, 195], ["decondensed", "OBSERVATION_MODIFIER", 234, 245], ["replication centres", "OBSERVATION", 246, 265], ["same nuclei", "ANATOMY", 273, 284]]], ["Alternatively it could have been that ICP4 was recruited to many foci but different downstream pathways dictate either maintenance of a more condensed state coupled with displacement of ICP4 or progressive decondensation (and associated replication/transcription) and association with ICP4.", [["foci", "ANATOMY", 65, 69], ["ICP4", "GENE_OR_GENE_PRODUCT", 38, 42], ["ICP4", "GENE_OR_GENE_PRODUCT", 186, 190], ["ICP4", "GENE_OR_GENE_PRODUCT", 285, 289], ["ICP4", "PROTEIN", 38, 42], ["ICP4", "PROTEIN", 186, 190], ["ICP4", "PROTEIN", 285, 289], ["ICP4", "PROBLEM", 38, 42], ["many foci", "PROBLEM", 60, 69], ["displacement of ICP4", "PROBLEM", 170, 190], ["progressive decondensation", "PROBLEM", 194, 220], ["replication/transcription", "TREATMENT", 237, 262], ["ICP4", "TREATMENT", 285, 289], ["ICP4", "OBSERVATION", 38, 42], ["many", "OBSERVATION_MODIFIER", 60, 64], ["foci", "OBSERVATION", 65, 69], ["more condensed", "OBSERVATION_MODIFIER", 136, 150], ["progressive", "OBSERVATION_MODIFIER", 194, 205], ["decondensation", "OBSERVATION", 206, 220]]], ["Future work developing methods for the simultaneous visualisation of infecting genome localisation and condensation, active transcription and protein localisation will help address the nature of these relationships revealed in this work.ICP4 association with infecting HSV genomesFinally, our results on spatial analyses are relevant to the interpretation of the many previous biochemical analyses on the nature of the infecting HSV genome.", [["ICP4", "GENE_OR_GENE_PRODUCT", 237, 241], ["HSV", "ORGANISM", 269, 272], ["HSV", "ORGANISM", 429, 432], ["ICP4", "PROTEIN", 237, 241], ["infecting HSV genomes", "DNA", 259, 280], ["infecting HSV genome", "DNA", 419, 439], ["HSV", "SPECIES", 269, 272], ["HSV", "SPECIES", 429, 432], ["infecting genome localisation", "PROBLEM", 69, 98], ["condensation", "PROBLEM", 103, 115], ["active transcription", "TREATMENT", 117, 137], ["protein localisation", "TEST", 142, 162], ["infecting HSV genomes", "PROBLEM", 259, 280], ["spatial analyses", "TEST", 304, 320], ["the infecting HSV genome", "PROBLEM", 415, 439], ["infecting genome", "OBSERVATION", 69, 85], ["infecting", "OBSERVATION_MODIFIER", 259, 268], ["HSV genomes", "OBSERVATION", 269, 280], ["infecting", "OBSERVATION_MODIFIER", 419, 428], ["HSV genome", "OBSERVATION", 429, 439]]], ["MCN digestion experiments of the bulk virus genome population strongly indicate that the considerable majority of infecting genomes released from the capsid are randomly digested and not assembled into any conventional nucleosomal organisation [45] [46] [47] [48] [49] [50] 69] .", [["capsid", "CELLULAR_COMPONENT", 150, 156], ["[45] [46] [47] [48] [49] [50] 69", "SIMPLE_CHEMICAL", 244, 276], ["MCN digestion experiments", "PROBLEM", 0, 25], ["the bulk virus genome population", "PROBLEM", 29, 61], ["infecting genomes", "PROBLEM", 114, 131]]], ["On the other hand ChiP analyses, which usually address a minor fraction of the total DNA, suggests that histones in some form are associated with at least a population of genomes [52, 53, 55, 70, 71] .", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["histones", "CELLULAR_COMPONENT", 104, 112], ["ChiP", "PROTEIN", 18, 22], ["histones", "PROTEIN", 104, 112], ["the other hand ChiP analyses", "TEST", 3, 31], ["the total DNA", "PROBLEM", 75, 88], ["histones", "PROBLEM", 104, 112], ["total DNA", "OBSERVATION_MODIFIER", 79, 88], ["histones", "OBSERVATION", 104, 112]]], ["One model attempting to integrate results from different approaches proposes that infecting genomes associate with some form of nucleoprotein complex that includes histones but in a non-conventional highly distributive, rapidly associating/dissociating organisation [56, 69] .", [["histones", "GENE_OR_GENE_PRODUCT", 164, 172], ["nucleoprotein complex", "PROTEIN", 128, 149], ["histones", "PROTEIN", 164, 172], ["infecting genomes", "PROBLEM", 82, 99], ["nucleoprotein complex", "PROBLEM", 128, 149], ["histones", "PROBLEM", 164, 172], ["nucleoprotein complex", "OBSERVATION", 128, 149]]], ["We show that after capsid exit and nuclear import, genomes expand but in a constrained and distinct state and then further decondenses in a discernible fashion prior to replication, and that replication and potentially associated transcription result in further extensive dissipation within the nucleus.", [["nuclear", "ANATOMY", 35, 42], ["nucleus", "ANATOMY", 295, 302], ["nuclear", "CELLULAR_COMPONENT", 35, 42], ["nucleus", "CELLULAR_COMPONENT", 295, 302], ["further extensive dissipation within the nucleus", "PROBLEM", 254, 302], ["extensive", "OBSERVATION_MODIFIER", 262, 271], ["dissipation", "OBSERVATION", 272, 283], ["nucleus", "ANATOMY", 295, 302]]], ["In addition to heterogeneity arising from overlapping temporal transitions, heterogeneity arises from subpopulations of genomes that may not associate with e.g. ICP4, or which at later times remain in a more condensed configuration.", [["ICP4", "GENE_OR_GENE_PRODUCT", 161, 165], ["ICP4", "PROTEIN", 161, 165], ["overlapping temporal transitions", "PROBLEM", 42, 74], ["ICP4", "PROBLEM", 161, 165], ["heterogeneity", "OBSERVATION", 15, 28], ["overlapping", "OBSERVATION_MODIFIER", 42, 53], ["temporal transitions", "OBSERVATION", 54, 74], ["subpopulations", "OBSERVATION_MODIFIER", 102, 116], ["may not", "UNCERTAINTY", 133, 140], ["ICP4", "OBSERVATION", 161, 165], ["more condensed", "OBSERVATION_MODIFIER", 203, 217], ["configuration", "OBSERVATION_MODIFIER", 218, 231]]], ["Thus certain proteins may be selectively associated with specific subpopulations of these genome, as an example the longer lived condensed foci, and thus antibodies to such proteins sample only those genome populations.", [["foci", "ANATOMY", 139, 143], ["genome", "CELLULAR_COMPONENT", 90, 96], ["foci", "CELL", 139, 143], ["antibodies", "PROTEIN", 154, 164], ["the longer lived condensed foci", "PROBLEM", 112, 143], ["genome", "OBSERVATION", 90, 96], ["foci", "OBSERVATION", 139, 143]]], ["Future work combining bioorthogonal chemistry for spatial analyses of genomes and ongoing transcription and replication together with immunofluorescence analysis to localise viral and host cell proteins will be necessary to resolve these questions.ICP4 association with infecting HSV genomesIn conclusion, using compatible bioorthogonal nucleoside precursors for genome labelling in HSV infected cells and quantitative individual particle analysis, we demonstrate extremely efficient precursor incorporation resulting in virtually quantitative detection on an individual particle basis in the population of progeny virus.", [["cell", "ANATOMY", 189, 193], ["cells", "ANATOMY", 396, 401], ["nucleoside", "CHEMICAL", 337, 347], ["nucleoside", "CHEMICAL", 337, 347], ["host cell", "CELL", 184, 193], ["ICP4", "GENE_OR_GENE_PRODUCT", 248, 252], ["HSV", "ORGANISM", 280, 283], ["nucleoside", "SIMPLE_CHEMICAL", 337, 347], ["HSV", "ORGANISM", 383, 386], ["cells", "CELL", 396, 401], ["progeny virus", "ORGANISM", 607, 620], ["viral and host cell proteins", "PROTEIN", 174, 202], ["ICP4", "PROTEIN", 248, 252], ["infecting HSV genomes", "DNA", 270, 291], ["HSV infected cells", "CELL_TYPE", 383, 401], ["HSV", "SPECIES", 280, 283], ["HSV", "SPECIES", 383, 386], ["bioorthogonal chemistry", "TEST", 22, 45], ["spatial analyses of genomes", "PROBLEM", 50, 77], ["ongoing transcription", "TREATMENT", 82, 103], ["replication", "TREATMENT", 108, 119], ["immunofluorescence analysis", "TEST", 134, 161], ["viral and host cell proteins", "PROBLEM", 174, 202], ["infecting HSV genomes", "PROBLEM", 270, 291], ["compatible bioorthogonal nucleoside precursors", "TREATMENT", 312, 358], ["genome labelling in HSV infected cells", "PROBLEM", 363, 401], ["quantitative individual particle analysis", "TEST", 406, 447], ["extremely efficient precursor incorporation", "PROBLEM", 464, 507], ["progeny virus", "PROBLEM", 607, 620], ["host cell", "OBSERVATION", 184, 193], ["infecting", "OBSERVATION_MODIFIER", 270, 279], ["HSV genomes", "OBSERVATION", 280, 291], ["infected cells", "OBSERVATION", 387, 401], ["precursor incorporation", "OBSERVATION", 484, 507], ["progeny virus", "OBSERVATION", 607, 620]]], ["We then report a comprehensive analysis in infected cells of genome dynamics during capsid exit and nuclear import in which we; demonstrate qualitative transitions in genome condensation state linked to transcription and replication; reveal novel processes in genome congregation dependent upon transcription and show the temporal switching in regulatory protein recruitment (represented by ICP4) to distinct genome compartments.", [["cells", "ANATOMY", 52, 57], ["nuclear", "ANATOMY", 100, 107], ["genome compartments", "ANATOMY", 409, 428], ["cells", "CELL", 52, 57], ["nuclear", "CELLULAR_COMPONENT", 100, 107], ["ICP4", "GENE_OR_GENE_PRODUCT", 391, 395], ["ICP4", "PROTEIN", 391, 395], ["a comprehensive analysis", "TEST", 15, 39], ["qualitative transitions in genome condensation state", "PROBLEM", 140, 192], ["novel processes in genome congregation dependent", "PROBLEM", 241, 289], ["the temporal switching in regulatory protein recruitment", "PROBLEM", 318, 374], ["infected cells", "OBSERVATION", 43, 57], ["genome congregation", "OBSERVATION", 260, 279], ["temporal", "OBSERVATION_MODIFIER", 322, 330], ["protein recruitment", "OBSERVATION", 355, 374], ["genome compartments", "OBSERVATION", 409, 428]]], ["Altogether our results reveal novel aspects of the spatiotemporal dynamics of HSV genome uncoating, transport and organisation that can be integrated with previous biochemically based analyses and provide a framework for future investigation in distinct fields of host cell-virus genome.Materials and methodsCell culture, viruses and infections RPE-1 cells, a human telomerase immortalised retinal pigment epithelial cell line, (kindly provided by Dr Andrew McAinsh University of Warwick, UK) were grown in Dulbecco's modified minimal essential medium (DMEM/F12, Sigma-Aldrich) supplemented with 200 mM glutamine, 10% newborn bovine serum (NCS; Gibco) and penicillin/streptomycin.", [["cell", "ANATOMY", 269, 273], ["Cell", "ANATOMY", 308, 312], ["RPE-1 cells", "ANATOMY", 345, 356], ["retinal pigment epithelial cell line", "ANATOMY", 390, 426], ["serum", "ANATOMY", 633, 638], ["infections", "DISEASE", 334, 344], ["glutamine", "CHEMICAL", 603, 612], ["penicillin", "CHEMICAL", 656, 666], ["streptomycin", "CHEMICAL", 667, 679], ["glutamine", "CHEMICAL", 603, 612], ["penicillin", "CHEMICAL", 656, 666], ["streptomycin", "CHEMICAL", 667, 679], ["HSV", "ORGANISM", 78, 81], ["host cell", "CELL", 264, 273], ["Cell", "CELL", 308, 312], ["RPE-1 cells", "CELL", 345, 356], ["human", "ORGANISM", 360, 365], ["telomerase", "CELL", 366, 376], ["retinal pigment epithelial cell line", "CELL", 390, 426], ["UK", "GENE_OR_GENE_PRODUCT", 489, 491], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 563, 576], ["glutamine", "AMINO_ACID", 603, 612], ["bovine", "ORGANISM", 626, 632], ["serum", "ORGANISM_SUBSTANCE", 633, 638], ["Gibco", "ORGANISM_SUBSTANCE", 645, 650], ["penicillin", "SIMPLE_CHEMICAL", 656, 666], ["streptomycin", "SIMPLE_CHEMICAL", 667, 679], ["host cell-virus genome", "DNA", 264, 286], ["human telomerase immortalised retinal pigment epithelial cell line", "CELL_LINE", 360, 426], ["human", "SPECIES", 360, 365], ["bovine", "SPECIES", 626, 632], ["HSV", "SPECIES", 78, 81], ["human", "SPECIES", 360, 365], ["bovine", "SPECIES", 626, 632], ["HSV genome uncoating", "PROBLEM", 78, 98], ["future investigation", "TEST", 221, 241], ["host cell-virus genome", "PROBLEM", 264, 286], ["Cell culture", "TEST", 308, 320], ["viruses", "PROBLEM", 322, 329], ["infections RPE", "TEST", 334, 348], ["200 mM glutamine", "TREATMENT", 596, 612], ["10% newborn bovine serum (NCS", "TREATMENT", 614, 643], ["Gibco", "TEST", 645, 650], ["penicillin", "TREATMENT", 656, 666], ["streptomycin", "TREATMENT", 667, 679], ["HSV genome uncoating", "OBSERVATION", 78, 98], ["host cell", "OBSERVATION", 264, 273], ["virus genome", "OBSERVATION", 274, 286], ["viruses", "OBSERVATION", 322, 329], ["retinal", "ANATOMY", 390, 397], ["pigment epithelial cell line", "OBSERVATION", 398, 426]]], ["The wildtype (w/t) parental strain was HSV-1 [17] .", [["HSV-1", "ORGANISM", 39, 44], ["HSV-1", "SPECIES", 39, 44], ["The wildtype (w/t) parental strain", "PROBLEM", 0, 34], ["HSV", "TEST", 39, 42]]], ["Routine plaque assays were performed in RPE cells in the presence of pooled neutralising human serum (Sigma-Aldrich) at 2% or clinical grade purified human immunoglobulin (IVIg, Carimune NF, Nanofiltered, human immune globulin, CSL Behring) at 2 mg/ml, having demonstrated complete neutralisation of extracellular virus at this dose (>6 log reduction in virus titre).", [["plaque", "ANATOMY", 8, 14], ["RPE cells", "ANATOMY", 40, 49], ["serum", "ANATOMY", 95, 100], ["extracellular", "ANATOMY", 300, 313], ["RPE cells", "CELL", 40, 49], ["human", "ORGANISM", 89, 94], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 102, 115], ["human", "ORGANISM", 150, 155], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 156, 170], ["IVIg", "SIMPLE_CHEMICAL", 172, 176], ["human", "ORGANISM", 205, 210], ["immune globulin", "GENE_OR_GENE_PRODUCT", 211, 226], ["CSL Behring", "ORGANISM", 228, 239], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 300, 313], ["virus", "ORGANISM", 314, 319], ["RPE cells", "CELL_TYPE", 40, 49], ["human immunoglobulin", "PROTEIN", 150, 170], ["IVIg", "PROTEIN", 172, 176], ["Carimune NF, Nanofiltered, human immune globulin", "PROTEIN", 178, 226], ["CSL", "PROTEIN", 228, 231], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 205, 210], ["Routine plaque assays", "TEST", 0, 21], ["RPE cells", "TEST", 40, 49], ["pooled neutralising human serum", "PROBLEM", 69, 100], ["human immunoglobulin", "TREATMENT", 150, 170], ["IVIg", "TREATMENT", 172, 176], ["Carimune NF", "TREATMENT", 178, 189], ["Nanofiltered", "TREATMENT", 191, 203], ["human immune globulin", "TREATMENT", 205, 226], ["extracellular virus", "PROBLEM", 300, 319], ["plaque", "OBSERVATION", 8, 14], ["extracellular virus", "OBSERVATION", 300, 319]]], ["High multiplicity infections were performed at multiplicities of infection stated in the experiments and for routine experiments usually at a moi of 10.", [["infections", "DISEASE", 18, 28], ["infection", "DISEASE", 65, 74], ["High multiplicity infections", "PROBLEM", 0, 28], ["infection", "PROBLEM", 65, 74], ["multiplicity", "OBSERVATION_MODIFIER", 5, 17], ["infections", "OBSERVATION", 18, 28], ["infection", "OBSERVATION", 65, 74]]], ["In control experiments for genome uncoating, the inoculum was treated with 500 U/ml DNase I (Roche) for 1 hr at 4\u02daC, or 10 mg/ml IVIg for 0.5 hr at room temperature.", [["IVIg", "CHEMICAL", 129, 133], ["DNase I", "GENE_OR_GENE_PRODUCT", 84, 91], ["IVIg", "SIMPLE_CHEMICAL", 129, 133], ["DNase I", "PROTEIN", 84, 91], ["genome uncoating", "PROBLEM", 27, 43], ["the inoculum", "TREATMENT", 45, 57], ["500 U/ml DNase I (Roche)", "TREATMENT", 75, 99], ["IVIg", "TREATMENT", 129, 133]]], ["Inhibitors were used at the following final concentrations; acycloguanosine (ACV, Thermo Scientific, 500 \u03bcM); phosphonoacetic acid (PAA, 400 \u03bcg/ml); actinomycin D (Sigma-Aldrich, 5 \u03bcg/ ml); MG132 (Calbiochem, 10 \u03bcM); Leptomycin B (Sigma-Aldrich, 20 nM); nocodazole (Sigma-Aldrich, 2 \u03bcM).", [["acycloguanosine", "CHEMICAL", 60, 75], ["ACV", "CHEMICAL", 77, 80], ["phosphonoacetic acid", "CHEMICAL", 110, 130], ["PAA", "CHEMICAL", 132, 135], ["actinomycin D", "CHEMICAL", 149, 162], ["MG132", "CHEMICAL", 190, 195], ["Calbiochem", "CHEMICAL", 197, 207], ["Leptomycin B", "CHEMICAL", 217, 229], ["nocodazole", "CHEMICAL", 254, 264], ["acycloguanosine", "CHEMICAL", 60, 75], ["ACV", "CHEMICAL", 77, 80], ["phosphonoacetic acid", "CHEMICAL", 110, 130], ["PAA", "CHEMICAL", 132, 135], ["actinomycin D", "CHEMICAL", 149, 162], ["Sigma-Aldrich", "CHEMICAL", 164, 177], ["MG132", "CHEMICAL", 190, 195], ["Leptomycin B", "CHEMICAL", 217, 229], ["nocodazole", "CHEMICAL", 254, 264], ["acycloguanosine", "SIMPLE_CHEMICAL", 60, 75], ["ACV", "SIMPLE_CHEMICAL", 77, 80], ["phosphonoacetic acid", "SIMPLE_CHEMICAL", 110, 130], ["PAA", "SIMPLE_CHEMICAL", 132, 135], ["actinomycin D", "SIMPLE_CHEMICAL", 149, 162], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 164, 177], ["MG132", "SIMPLE_CHEMICAL", 190, 195], ["Calbiochem", "SIMPLE_CHEMICAL", 197, 207], ["Leptomycin B", "SIMPLE_CHEMICAL", 217, 229], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 231, 244], ["nocodazole", "SIMPLE_CHEMICAL", 254, 264], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 266, 279], ["Inhibitors", "TREATMENT", 0, 10], ["acycloguanosine (ACV", "TREATMENT", 60, 80], ["Thermo Scientific", "TREATMENT", 82, 99], ["phosphonoacetic acid (PAA", "TREATMENT", 110, 135], ["actinomycin D (Sigma-Aldrich", "TREATMENT", 149, 177], ["MG132 (Calbiochem", "TREATMENT", 190, 207], ["Leptomycin B (Sigma-Aldrich, 20 nM)", "TREATMENT", 217, 252], ["nocodazole (Sigma-Aldrich", "TREATMENT", 254, 279]]], ["Inhibitors were added to cells for 1 hr prior to infection.Assessment of EdC labelling on cell viability and virus yieldTo examine the effects of EdC on cell growth, RPE-1 cells were pulsed with increasing concentrations of EdC (Sigma-Aldrich, #T511307) for 48 hr and examined by phase-contrast microscopy either live or after fixation and staining with crystal violet.", [["cells", "ANATOMY", 25, 30], ["cell", "ANATOMY", 90, 94], ["cell", "ANATOMY", 153, 157], ["RPE-1 cells", "ANATOMY", 166, 177], ["infection", "DISEASE", 49, 58], ["EdC", "CHEMICAL", 146, 149], ["EdC", "CHEMICAL", 224, 227], ["EdC", "CHEMICAL", 224, 227], ["cells", "CELL", 25, 30], ["EdC", "SIMPLE_CHEMICAL", 73, 76], ["cell", "CELL", 90, 94], ["EdC", "SIMPLE_CHEMICAL", 146, 149], ["cell", "CELL", 153, 157], ["RPE-1 cells", "CELL", 166, 177], ["EdC", "SIMPLE_CHEMICAL", 224, 227], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 229, 242], ["EdC", "PROTEIN", 73, 76], ["EdC", "PROTEIN", 146, 149], ["RPE-1 cells", "CELL_LINE", 166, 177], ["Inhibitors", "TREATMENT", 0, 10], ["infection", "PROBLEM", 49, 58], ["cell viability", "TREATMENT", 90, 104], ["cell growth", "TEST", 153, 164], ["RPE", "TEST", 166, 169], ["contrast microscopy", "TEST", 286, 305], ["fixation", "TREATMENT", 327, 335], ["crystal violet", "TREATMENT", 354, 368], ["infection", "OBSERVATION", 49, 58]]], ["Viability was determined by trypan blue exclusion using an automated cell counter.", [["cell", "ANATOMY", 69, 73], ["trypan blue", "CHEMICAL", 28, 39], ["trypan blue", "CHEMICAL", 28, 39], ["trypan blue", "SIMPLE_CHEMICAL", 28, 39], ["cell", "CELL", 69, 73], ["an automated cell counter", "TREATMENT", 56, 81]]], ["For the examination of the effects of EdC pulse-labelling on viral plaque development, RPE cells were infected at 50 pfu/ well, the inoculum was then neutralised with 2% human serum after 1 hpi, and EdC was then added 2 hpi for the remainder of the assay.", [["plaque", "ANATOMY", 67, 73], ["RPE cells", "ANATOMY", 87, 96], ["serum", "ANATOMY", 176, 181], ["EdC", "CHEMICAL", 38, 41], ["EdC", "CHEMICAL", 199, 202], ["EdC", "CHEMICAL", 38, 41], ["EdC", "SIMPLE_CHEMICAL", 38, 41], ["RPE cells", "CELL", 87, 96], ["human", "ORGANISM", 170, 175], ["serum", "ORGANISM_SUBSTANCE", 176, 181], ["EdC", "SIMPLE_CHEMICAL", 199, 202], ["RPE cells", "CELL_TYPE", 87, 96], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["the examination", "TEST", 4, 19], ["EdC pulse", "TEST", 38, 47], ["viral plaque development", "PROBLEM", 61, 85], ["RPE cells", "PROBLEM", 87, 96], ["the inoculum", "TREATMENT", 128, 140], ["viral plaque", "OBSERVATION", 61, 73]]], ["Plaque sizes and numbers were measured at 48 hpi using Image Pro Plus 7 software.", [["Plaque", "ANATOMY", 0, 6], ["Plaque", "PATHOLOGICAL_FORMATION", 0, 6], ["Plaque sizes", "TEST", 0, 12], ["numbers", "TEST", 17, 24], ["sizes", "OBSERVATION_MODIFIER", 7, 12], ["numbers", "OBSERVATION_MODIFIER", 17, 24]]], ["For the effects of EdC on virus yield, RPE-1 cells were infected at moi 5 for single-step growth or moi 0.005 for multi-step growth.", [["RPE-1 cells", "ANATOMY", 39, 50], ["EdC", "CHEMICAL", 19, 22], ["EdC", "SIMPLE_CHEMICAL", 19, 22], ["RPE-1 cells", "CELL", 39, 50], ["RPE-1 cells", "CELL_LINE", 39, 50], ["virus yield", "TREATMENT", 26, 37], ["RPE", "TEST", 39, 42], ["multi-step growth", "PROBLEM", 114, 131]]], ["Inocula were neutralised at 1 hpi with a 40 mM citric acid wash.", [["citric acid", "CHEMICAL", 47, 58], ["citric acid", "CHEMICAL", 47, 58], ["Inocula", "SIMPLE_CHEMICAL", 0, 7], ["citric acid", "SIMPLE_CHEMICAL", 47, 58], ["a 40 mM citric acid wash", "TREATMENT", 39, 63]]], ["Cells were then incubated in the presence of various concentrations of EdC (added at 2 hpi) for the duration of the experiment.", [["Cells", "ANATOMY", 0, 5], ["EdC", "CHEMICAL", 71, 74], ["EdC", "CHEMICAL", 71, 74], ["Cells", "CELL", 0, 5], ["EdC", "SIMPLE_CHEMICAL", 71, 74], ["various concentrations of EdC", "TREATMENT", 45, 74]]], ["Supernatant and cell-associated virus was harvested at 20 hpi (single-step) and 72 hpi (multi-step) and yield assessed by plaque titration on RPE-1 cells.Assessment of EdC labelling on cell viability and virus yieldProduction of HSV-1 containing EdC-labelled genomes (HSV 1EdC) RPE-1 cells were grown in roller bottles (850 cm 2 surface area) to~80% confluency.", [["Supernatant", "ANATOMY", 0, 11], ["cell", "ANATOMY", 16, 20], ["plaque", "ANATOMY", 122, 128], ["RPE-1 cells", "ANATOMY", 142, 153], ["cell", "ANATOMY", 185, 189], ["RPE-1 cells", "ANATOMY", 278, 289], ["surface area", "ANATOMY", 329, 341], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["cell", "CELL", 16, 20], ["RPE-1 cells", "CELL", 142, 153], ["EdC", "SIMPLE_CHEMICAL", 168, 171], ["cell", "CELL", 185, 189], ["HSV-1", "ORGANISM", 229, 234], ["EdC", "GENE_OR_GENE_PRODUCT", 246, 249], ["HSV", "ORGANISM", 268, 271], ["RPE-1 cells", "CELL", 278, 289], ["RPE-1 cells", "CELL_LINE", 142, 153], ["EdC", "PROTEIN", 168, 171], ["EdC-labelled genomes", "DNA", 246, 266], ["HSV 1EdC) RPE-1 cells", "CELL_LINE", 268, 289], ["HSV-1", "SPECIES", 229, 234], ["HSV-1", "SPECIES", 229, 234], ["HSV", "SPECIES", 268, 271], ["Supernatant and cell-associated virus", "PROBLEM", 0, 37], ["RPE", "TEST", 142, 145], ["cell viability", "TEST", 185, 199], ["HSV", "TEST", 229, 232], ["EdC", "TEST", 246, 249], ["HSV", "TEST", 268, 271], ["RPE", "TEST", 278, 281], ["cell", "ANATOMY", 16, 20], ["virus", "OBSERVATION", 32, 37], ["plaque", "OBSERVATION", 122, 128]]], ["The cells were infected with HSV-1 [17] at a moi of 0.025 in 25 ml medium without serum and made to 2% NCS at 1 hpi.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 82, 87], ["cells", "CELL", 4, 9], ["HSV-1", "ORGANISM", 29, 34], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["HSV-1", "SPECIES", 29, 34], ["HSV-1", "SPECIES", 29, 34], ["HSV", "TEST", 29, 32], ["serum", "TEST", 82, 87], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["EdC was added to a final concentration of 5 \u03bcM at 6 hpi and again at 24 hpi.", [["EdC", "CHEMICAL", 0, 3], ["EdC", "SIMPLE_CHEMICAL", 0, 3]]], ["Virus was harvested at approximately 48 hpi, separating cell associated and supernatant virus by low speed centrifugation (3000 rpm, 4\u02daC for 15 min).", [["cell", "ANATOMY", 56, 60], ["supernatant", "ANATOMY", 76, 87], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 56, 60], ["Virus", "PROBLEM", 0, 5], ["supernatant virus", "PROBLEM", 76, 93], ["supernatant virus", "OBSERVATION", 76, 93], ["low speed", "OBSERVATION_MODIFIER", 97, 106]]], ["Supernatant virus was transferred into Oakridge tubes and pelleted in a Sorvall centrifuge RC5B using a SS34 rotor at 19,000 rpm at 4\u02daC for 90 min.", [["Supernatant virus", "PROBLEM", 0, 17], ["Oakridge tubes", "TREATMENT", 39, 53], ["a Sorvall centrifuge RC5B", "TREATMENT", 70, 95], ["a SS34 rotor", "TREATMENT", 102, 114], ["virus", "OBSERVATION", 12, 17]]], ["For cell-associated virus, the virus pellet was first clarified of cell debris, pelleted by high speed centrifugation as above, resuspended in PBS and applied to the top of 0.5 ml 35% sucrose cushion in polyallomer tubes and centrifuged at 25,000 rpm in a SW55Ti rotor for 1 hr.", [["cell", "ANATOMY", 4, 8], ["cell", "ANATOMY", 67, 71], ["sucrose", "CHEMICAL", 184, 191], ["sucrose", "CHEMICAL", 184, 191], ["cell", "CELL", 4, 8], ["cell debris", "CELL", 67, 78], ["polyallomer tubes", "ORGANISM_SUBSTANCE", 203, 220], ["cell-associated virus", "PROBLEM", 4, 25], ["the virus pellet", "PROBLEM", 27, 43], ["cell debris", "PROBLEM", 67, 78], ["high speed centrifugation", "TREATMENT", 92, 117], ["PBS", "TREATMENT", 143, 146], ["sucrose cushion in polyallomer tubes", "TREATMENT", 184, 220], ["virus", "OBSERVATION", 20, 25], ["virus pellet", "OBSERVATION", 31, 43], ["cell debris", "OBSERVATION", 67, 78], ["high speed centrifugation", "OBSERVATION_MODIFIER", 92, 117], ["polyallomer tubes", "OBSERVATION", 203, 220]]], ["The virus pellet was resuspended and stored in PBS.", [["The virus pellet", "TREATMENT", 0, 16], ["virus pellet", "OBSERVATION", 4, 16]]], ["Virus titres were determined on RPE-1 cells.", [["RPE-1 cells", "ANATOMY", 32, 43], ["Virus", "ORGANISM", 0, 5], ["RPE-1 cells", "CELL", 32, 43], ["RPE-1 cells", "CELL_LINE", 32, 43], ["Virus titres", "TEST", 0, 12], ["RPE", "TEST", 32, 35]]], ["Particle/pfu ratios were calculated by diluting control stocks of HSV or HSV EdC to equal pfu titres, spotting standardised aliquots onto coverslips and enumerating total VP5 capsid-containing virions by automated immunofluorescence microscopy and multi-tiled image acquisition to capture and quantify the entire population.", [["virions", "ANATOMY", 193, 200], ["HSV", "ORGANISM", 66, 69], ["HSV", "ORGANISM", 73, 76], ["EdC", "ORGANISM", 77, 80], ["VP5", "GENE_OR_GENE_PRODUCT", 171, 174], ["VP5 capsid", "PROTEIN", 171, 181], ["HSV", "SPECIES", 66, 69], ["HSV", "SPECIES", 73, 76], ["Particle/pfu ratios", "TREATMENT", 0, 19], ["HSV", "PROBLEM", 66, 69], ["HSV EdC", "TREATMENT", 73, 80], ["spotting standardised aliquots onto coverslips", "TREATMENT", 102, 148], ["total VP5 capsid", "TREATMENT", 165, 181], ["automated immunofluorescence microscopy", "TEST", 204, 243], ["multi-tiled image acquisition", "TEST", 248, 277]]], ["Total VP5-positive/pfu particle numbers could then be evaluated for each stock.", [["VP5", "GENE_OR_GENE_PRODUCT", 6, 9], ["VP5", "PROTEIN", 6, 9], ["Total VP5", "TEST", 0, 9]]], ["Alternatively we examined protein profiles of standardised amounts of purified virus and quantified the amounts of the major capsid protein as previously described [72] .", [["major capsid protein", "PROTEIN", 119, 139], ["purified virus", "PROBLEM", 70, 84]]], ["Similar results were obtained in comparing HSV and HSV EdC particle/pfu ratios by the two methods.", [["HSV", "ORGANISM", 43, 46], ["HSV", "ORGANISM", 51, 54], ["HSV", "SPECIES", 43, 46], ["HSV", "SPECIES", 51, 54], ["HSV", "TEST", 43, 46]]], ["The 'Mock EdC' inoculum used for control experiments was prepared by pulsing uninfected RPE-1 cells for 48 hr with 5 \u03bcM EdC, harvesting the supernatant and concentrating exactly as if preparing virus from infected cells.Cycloaddition of labelled fluorochromes and immunofluorescenceCells grown on borosilicate coverslips, infected and labelled with EdC under the variety of experimental conditions discussed, were fixed in 4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS) for 10 min, quenched in 100 mM glycine in PBS for 5 min, and permeabilised with 0.5% Triton X-100 for 5 min.", [["RPE-1 cells", "ANATOMY", 88, 99], ["supernatant", "ANATOMY", 140, 151], ["cells", "ANATOMY", 214, 219], ["Cells", "ANATOMY", 282, 287], ["coverslips", "ANATOMY", 310, 320], ["EdC", "CHEMICAL", 120, 123], ["EdC", "CHEMICAL", 349, 352], ["glycine", "CHEMICAL", 514, 521], ["Triton X-100", "CHEMICAL", 568, 580], ["EdC", "CHEMICAL", 120, 123], ["borosilicate", "CHEMICAL", 297, 309], ["paraformaldehyde", "CHEMICAL", 426, 442], ["PFA", "CHEMICAL", 444, 447], ["glycine", "CHEMICAL", 514, 521], ["RPE-1 cells", "CELL", 88, 99], ["EdC", "SIMPLE_CHEMICAL", 120, 123], ["cells", "CELL", 214, 219], ["fluorochromes", "SIMPLE_CHEMICAL", 246, 259], ["Cells", "CELL", 282, 287], ["borosilicate coverslips", "CELL", 297, 320], ["paraformaldehyde", "SIMPLE_CHEMICAL", 426, 442], ["PFA", "SIMPLE_CHEMICAL", 444, 447], ["phosphatebuffered saline", "SIMPLE_CHEMICAL", 452, 476], ["glycine", "SIMPLE_CHEMICAL", 514, 521], ["Triton X-100", "SIMPLE_CHEMICAL", 568, 580], ["RPE-1 cells", "CELL_LINE", 88, 99], ["infected cells", "CELL_TYPE", 205, 219], ["The 'Mock EdC' inoculum", "TREATMENT", 0, 23], ["control experiments", "TREATMENT", 33, 52], ["5 \u03bcM EdC", "TREATMENT", 115, 123], ["harvesting the supernatant", "TREATMENT", 125, 151], ["preparing virus from infected cells", "PROBLEM", 184, 219], ["Cycloaddition of labelled fluorochromes", "TREATMENT", 220, 259], ["immunofluorescence", "TEST", 264, 282], ["borosilicate coverslips", "TREATMENT", 297, 320], ["4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS", "TREATMENT", 423, 481], ["100 mM glycine in PBS", "TREATMENT", 507, 528], ["0.5% Triton", "TREATMENT", 563, 574], ["infected cells", "OBSERVATION", 205, 219], ["labelled fluorochromes", "OBSERVATION", 237, 259], ["borosilicate coverslips", "OBSERVATION", 297, 320], ["infected", "OBSERVATION_MODIFIER", 322, 330]]], ["Samples were then processed by cycloaddition with azide-linked fluorochromes and then blocked with 10% FBS in PBS where immunofluorescence was required.", [["Samples", "ANATOMY", 0, 7], ["FBS", "ANATOMY", 103, 106], ["azide", "CHEMICAL", 50, 55], ["azide", "CHEMICAL", 50, 55], ["azide", "SIMPLE_CHEMICAL", 50, 55], ["fluorochromes", "SIMPLE_CHEMICAL", 63, 76], ["FBS", "ORGANISM_SUBSTANCE", 103, 106], ["Samples", "TEST", 0, 7], ["azide-linked fluorochromes", "TREATMENT", 50, 76], ["10% FBS in PBS", "TREATMENT", 99, 113], ["immunofluorescence", "TEST", 120, 138]]], ["Cycloaddition and immunofluorescence were essentially as described previously [24] .", [["Cycloaddition", "TREATMENT", 0, 13], ["immunofluorescence", "TEST", 18, 36]]], ["Briefly for the cycloaddition reaction to detect EdC labelled DNA, PFA fixed and washed coverslips were incubated in freshly prepared reaction buffer containing 1 mM CuSO 4 ; 10 mM sodium ascorbate; 10 mM amino-guanidine and 1 mM Tris(3-hydroxypropyltriazolylmethyl)-amine (THPTA, Sigma-Aldrich) and 10 \u03bcM Alexa 488-azide (Thermofisher) in PBS pH 7.4.", [["EdC", "CHEMICAL", 49, 52], ["CuSO 4", "CHEMICAL", 166, 172], ["sodium ascorbate", "CHEMICAL", 181, 197], ["amino-guanidine", "CHEMICAL", 205, 220], ["Tris(3-hydroxypropyltriazolylmethyl)-amine", "CHEMICAL", 230, 272], ["THPTA", "CHEMICAL", 274, 279], ["Alexa 488-azide", "CHEMICAL", 306, 321], ["EdC", "CHEMICAL", 49, 52], ["PFA", "CHEMICAL", 67, 70], ["CuSO 4", "CHEMICAL", 166, 172], ["sodium ascorbate", "CHEMICAL", 181, 197], ["amino-guanidine", "CHEMICAL", 205, 220], ["Tris(3-hydroxypropyltriazolylmethyl)-amine", "CHEMICAL", 230, 272], ["THPTA", "CHEMICAL", 274, 279], ["Alexa 488-azide", "CHEMICAL", 306, 321], ["EdC", "SIMPLE_CHEMICAL", 49, 52], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["PFA", "SIMPLE_CHEMICAL", 67, 70], ["sodium ascorbate", "SIMPLE_CHEMICAL", 181, 197], ["amino-guanidine", "SIMPLE_CHEMICAL", 205, 220], ["Tris(3-hydroxypropyltriazolylmethyl)-amine", "SIMPLE_CHEMICAL", 230, 272], ["THPTA", "SIMPLE_CHEMICAL", 274, 279], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 281, 294], ["Alexa 488-azide", "SIMPLE_CHEMICAL", 306, 321], ["Thermofisher", "SIMPLE_CHEMICAL", 323, 335], ["EdC", "PROTEIN", 49, 52], ["the cycloaddition reaction", "PROBLEM", 12, 38], ["EdC labelled DNA", "PROBLEM", 49, 65], ["PFA fixed", "TREATMENT", 67, 76], ["washed coverslips", "TREATMENT", 81, 98], ["10 mM sodium ascorbate", "TREATMENT", 175, 197], ["amino-guanidine", "TREATMENT", 205, 220], ["1 mM Tris", "TREATMENT", 225, 234], ["hydroxypropyltriazolylmethyl)", "TREATMENT", 237, 266], ["amine (THPTA, Sigma-Aldrich)", "TREATMENT", 267, 295], ["PBS pH", "TEST", 340, 346]]], ["Reactions were performed for 2 hr in the dark, the reaction cocktail then removed and the samples washed with PBS, dried and mounted.", [["samples", "ANATOMY", 90, 97], ["the reaction cocktail", "TREATMENT", 47, 68], ["PBS", "TREATMENT", 110, 113]]], ["For subsequent immunofluorescence, cells were blocked and stained for 45 min with primary antibodies and 45 min with secondary antibodies by standard methods and mounted in ProLong Gold Antifade Mountant (Molecular Probes).", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["primary antibodies", "PROTEIN", 82, 100], ["secondary antibodies", "PROTEIN", 117, 137], ["subsequent immunofluorescence", "TEST", 4, 33], ["primary antibodies", "TEST", 82, 100], ["secondary antibodies", "PROBLEM", 117, 137]]], ["Images were acquired with Zeiss Axiovert 135 TV microscope using Zeiss x63 lens (Plan-APOCHROMAT, 1.4 numerical aperture) and Retiga 2000R camera with Image Pro Plus 7.0 software.Antibodies for immunofluorescence studiesThe following antibodies were used: mouse anti-VP5 (Virusys, HA018; 1:300); mouse anti-ICP8 11E2 (Abcam, #20194; 1:100); mouse anti-ICP4 (Virusys, H1A021; 1:400); mouse anti-\u03b1tubulin (Sigma-Aldrich, #T6074; 1:1000); rabbit anti-PML [73] (1:300); mouse anti-cyclin B1 (Abcam, ab18221; 1:500); Alexa-594 Goat anti-mouse IgG (Thermofisher; 1:750).HSV EdC genome detection in virionsSamples of HSV-1 [17] wild-type or HSV EdC at 1x10 8 pfu/ml were applied to borosilicate coverslips, adsorbed for 15 min, fixed with PFA and processed as above to detect genomes and immunofluorescence using anti-VP5 antibody to detect capsids.", [["PFA", "CHEMICAL", 732, 735], ["mouse", "ORGANISM", 256, 261], ["anti-VP5", "GENE_OR_GENE_PRODUCT", 262, 270], ["mouse", "ORGANISM", 296, 301], ["anti-ICP8 11E2", "ORGANISM", 302, 316], ["Abcam", "GENE_OR_GENE_PRODUCT", 318, 323], ["mouse", "ORGANISM", 341, 346], ["anti-ICP4", "GENE_OR_GENE_PRODUCT", 347, 356], ["Virusys", "ORGANISM", 358, 365], ["mouse", "ORGANISM", 383, 388], ["anti-\u03b1tubulin", "SIMPLE_CHEMICAL", 389, 402], ["Sigma-Aldrich", "ORGANISM", 404, 417], ["1:1000", "ORGANISM", 427, 433], ["rabbit", "ORGANISM", 436, 442], ["anti-PML [73]", "ORGANISM", 443, 456], ["1:300", "ORGANISM", 458, 463], ["mouse", "ORGANISM", 466, 471], ["anti-cyclin B1", "GENE_OR_GENE_PRODUCT", 472, 486], ["Abcam", "GENE_OR_GENE_PRODUCT", 488, 493], ["Alexa-594", "SIMPLE_CHEMICAL", 512, 521], ["HSV", "ORGANISM", 564, 567], ["HSV-1 [17", "ORGANISM", 610, 619], ["HSV", "ORGANISM", 634, 637], ["EdC", "ORGANISM", 638, 641], ["PFA", "SIMPLE_CHEMICAL", 732, 735], ["anti-VP5 antibody", "GENE_OR_GENE_PRODUCT", 806, 823], ["Zeiss Axiovert 135 TV microscope", "DNA", 26, 58], ["Zeiss x63 lens", "DNA", 65, 79], ["Retiga 2000R camera", "DNA", 126, 145], ["mouse anti-VP5", "PROTEIN", 256, 270], ["mouse anti-ICP8 11E2", "PROTEIN", 296, 316], ["Abcam", "PROTEIN", 318, 323], ["mouse anti-ICP4", "PROTEIN", 341, 356], ["mouse anti-\u03b1tubulin", "PROTEIN", 383, 402], ["rabbit anti-PML", "PROTEIN", 436, 451], ["1:300", "PROTEIN", 458, 463], ["mouse anti-cyclin B1", "PROTEIN", 466, 486], ["Abcam, ab18221; 1:500", "PROTEIN", 488, 509], ["Alexa-594 Goat anti-mouse IgG", "PROTEIN", 512, 541], ["Thermofisher", "PROTEIN", 543, 555], ["1:750", "PROTEIN", 557, 562], ["HSV EdC genome", "DNA", 564, 578], ["anti-VP5 antibody", "PROTEIN", 806, 823], ["mouse", "SPECIES", 256, 261], ["mouse", "SPECIES", 296, 301], ["mouse", "SPECIES", 341, 346], ["mouse", "SPECIES", 383, 388], ["rabbit", "SPECIES", 436, 442], ["mouse", "SPECIES", 466, 471], ["Goat", "SPECIES", 522, 526], ["anti-mouse", "SPECIES", 527, 537], ["HSV-1", "SPECIES", 610, 615], ["mouse", "SPECIES", 256, 261], ["mouse", "SPECIES", 296, 301], ["mouse", "SPECIES", 341, 346], ["mouse", "SPECIES", 383, 388], ["rabbit", "SPECIES", 436, 442], ["mouse", "SPECIES", 466, 471], ["Alexa-594 Goat", "SPECIES", 512, 526], ["HSV", "SPECIES", 564, 567], ["HSV-1", "SPECIES", 610, 615], ["HSV", "SPECIES", 634, 637], ["Images", "TEST", 0, 6], ["APOCHROMAT", "TEST", 86, 96], ["Antibodies", "TEST", 179, 189], ["immunofluorescence studies", "TEST", 194, 220], ["HSV", "TEST", 564, 567], ["virionsSamples", "TEST", 592, 606], ["HSV", "TEST", 610, 613], ["HSV EdC", "TREATMENT", 634, 641], ["borosilicate coverslips", "TREATMENT", 675, 698], ["PFA", "TREATMENT", 732, 735], ["immunofluorescence", "TEST", 781, 799], ["anti-VP5 antibody", "TREATMENT", 806, 823]]], ["For experiments examining genome exit we used procedures as previously reported [26, 27] where virions absorbed onto the coverslips were subject to heat treatment (70\u02daC for 2 min) either before or after PFA fixation.", [["virions", "ANATOMY", 95, 102], ["PFA", "CHEMICAL", 203, 206], ["PFA", "SIMPLE_CHEMICAL", 203, 206], ["the coverslips", "TREATMENT", 117, 131], ["heat treatment", "TREATMENT", 148, 162], ["PFA fixation", "TREATMENT", 203, 215]]], ["Samples were then processed for detection of the genome and capsids as before.", [["Samples", "ANATOMY", 0, 7], ["genome", "CELLULAR_COMPONENT", 49, 55], ["Samples", "TEST", 0, 7], ["the genome and capsids", "PROBLEM", 45, 67]]], ["In parallel experiments, viruses were subject to the cycloaddition reaction in PBS containing the appropriate concentrations of reagents.", [["PBS", "SIMPLE_CHEMICAL", 79, 82], ["viruses", "PROBLEM", 25, 32], ["the cycloaddition reaction in PBS", "TREATMENT", 49, 82], ["viruses", "OBSERVATION", 25, 32]]], ["After the reaction, samples were made to 1 mM EDTA to stop any further reaction, then adsorbed onto coverslips and processed for immunofluorescence.", [["samples", "ANATOMY", 20, 27], ["EDTA", "CHEMICAL", 46, 50], ["EDTA", "SIMPLE_CHEMICAL", 46, 50], ["the reaction", "PROBLEM", 6, 18], ["any further reaction", "PROBLEM", 59, 79], ["immunofluorescence", "TEST", 129, 147]]], ["For quantitative analysis maximum projections were captured using the Image Pro Plus Stage-Pro function and Z-stacks were obtained with 10 slices at 0.2 \u03bcm intervals.", [["Z", "PROTEIN", 108, 109], ["quantitative analysis", "TEST", 4, 25], ["Z-stacks", "TEST", 108, 116]]], ["We used Image J and a customised plugin based on the find maxima protocol.", [["Image J", "TREATMENT", 8, 15], ["a customised plugin", "TREATMENT", 20, 39]]], ["The plugin uses find maxima and places an identical sized ROI centred on the maxima with user configurable diameter to encompass virus particles.", [["an identical sized ROI", "PROBLEM", 39, 61], ["encompass virus particles", "PROBLEM", 119, 144], ["plugin", "OBSERVATION", 4, 10], ["sized", "OBSERVATION_MODIFIER", 52, 57], ["ROI", "OBSERVATION", 58, 61], ["virus particles", "OBSERVATION", 129, 144]]], ["Maxima with too close a spatial overlap or at an image edge are excluded by the protocol and can be further excluded manually before quantitation.", [["the protocol", "TEST", 76, 88], ["quantitation", "TEST", 133, 145]]], ["In practice this had a limited effect given the largely monodisperse nature of analysed particles.", [["monodisperse", "OBSERVATION", 56, 68]]], ["Red (capsid) and green (DNA) intensities were measured for each ROI.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["Red (capsid)", "PROBLEM", 0, 12], ["green (DNA) intensities", "TEST", 17, 40]]], ["Mean and standard deviation (SD) background intensities were calculated separately for the red and green channels from the area outside the identified ROIs and normalised for ROI area.", [["red and green channels", "PROTEIN", 91, 113], ["Mean", "TEST", 0, 4], ["standard deviation (SD) background intensities", "PROBLEM", 9, 55], ["the red and green channels", "PROBLEM", 87, 113], ["standard deviation", "OBSERVATION", 9, 27], ["green channels", "OBSERVATION", 99, 113]]], ["Maxima-based ROIs were then compared separately against the mean background for each channel and categorised using a threshold the default of which was the mean channel background plus 1 SD.", [["Maxima-based ROIs", "TEST", 0, 17]]], ["Thus, to be categorised as a red (capsid) positive particle, that particle ROI must be not only be above the mean background ROI in the red channel but at least 1 SD above that background.", [["a red (capsid) positive particle", "PROBLEM", 27, 59], ["red channel", "ANATOMY", 136, 147]]], ["Frequency distributions of individual identified particle ROIs were then quantitated, calculating the bin width using the Friedman-Diaconis criteria for interquartile-ranges [74, 75] .", [["individual identified particle ROIs", "PROBLEM", 27, 62], ["particle ROIs", "OBSERVATION", 49, 62]]], ["The same bin width was used for both channels in the figure for ease of comparison of the distributions.", [["The same bin width", "TREATMENT", 0, 18]]], ["Gaussian distributions were fitted to each channel frequency data using Image J curve fitter.Analysis of intracellular genome uncoatingCells grown on coverslips were mock-infected or infected with parental HSV-1 [17] or HSV EdC by normal procedures (moi 10) at 4\u02daC for 45 min to allow virus adsorption to the cell surface.", [["intracellular", "ANATOMY", 105, 118], ["Cells", "ANATOMY", 135, 140], ["cell surface", "ANATOMY", 309, 321], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 118], ["Cells", "CELL", 135, 140], ["HSV-1", "ORGANISM", 206, 211], ["HSV", "ORGANISM", 220, 223], ["EdC", "ORGANISM", 224, 227], ["cell surface", "CELLULAR_COMPONENT", 309, 321], ["HSV-1", "SPECIES", 206, 211], ["HSV-1", "SPECIES", 206, 211], ["HSV", "SPECIES", 220, 223], ["Gaussian distributions", "PROBLEM", 0, 22], ["Image J curve fitter", "TREATMENT", 72, 92], ["intracellular genome uncoatingCells", "PROBLEM", 105, 140], ["coverslips", "TEST", 150, 160], ["parental HSV", "TEST", 197, 209], ["HSV EdC", "TREATMENT", 220, 227], ["intracellular genome", "OBSERVATION", 105, 125], ["uncoatingCells", "OBSERVATION", 126, 140], ["cell surface", "OBSERVATION", 309, 321]]], ["Cultures were then either washed and fixed immediately for analysis of adsorbed virus or shifted to 37\u02daC to allow the infection to proceed.", [["infection", "DISEASE", 118, 127], ["Cultures", "TEST", 0, 8], ["analysis", "TEST", 59, 67], ["adsorbed virus", "PROBLEM", 71, 85], ["the infection", "PROBLEM", 114, 127], ["infection", "OBSERVATION", 118, 127]]], ["For analysis of infected cells at very early times i.e., 30 mins, the inoculum was then removed and cells washed and fixed.", [["cells", "ANATOMY", 25, 30], ["cells", "ANATOMY", 100, 105], ["cells", "CELL", 25, 30], ["cells", "CELL", 100, 105], ["infected cells", "CELL_TYPE", 16, 30], ["infected cells", "PROBLEM", 16, 30], ["the inoculum", "TREATMENT", 66, 78], ["infected cells", "OBSERVATION", 16, 30], ["inoculum", "OBSERVATION", 70, 78]]], ["For longer times, the inoculum was removed and replaced with pre-warmed medium containing 2% NCS.", [["the inoculum", "TREATMENT", 18, 30], ["pre-warmed medium", "TREATMENT", 61, 78], ["2% NCS", "TREATMENT", 90, 96], ["inoculum", "OBSERVATION", 22, 30]]], ["Cultures were washed and fixed at various times thereafter as indicated in the text and figure legends and processed for genome detection by cycloaddition reaction and immunofluorescence as described above.", [["Cultures", "TEST", 0, 8], ["genome detection", "TEST", 121, 137], ["cycloaddition reaction", "PROBLEM", 141, 163], ["immunofluorescence", "TEST", 168, 186]]], ["Infected cells were co-stained with DAPI to allow outlining of nuclei.", [["cells", "ANATOMY", 9, 14], ["nuclei", "ANATOMY", 63, 69], ["DAPI", "CHEMICAL", 36, 40], ["cells", "CELL", 9, 14], ["DAPI", "SIMPLE_CHEMICAL", 36, 40], ["nuclei", "CELLULAR_COMPONENT", 63, 69], ["Infected cells", "PROBLEM", 0, 14], ["DAPI", "TREATMENT", 36, 40], ["nuclei", "ANATOMY", 63, 69]]], ["Images were acquired by standard wide-field microscopy (described above) or 3Dstructured illumination microscopy (3D-SIM).", [["Images", "TEST", 0, 6], ["standard wide-field microscopy", "TEST", 24, 54], ["3Dstructured illumination microscopy", "TEST", 76, 112]]], ["Images were then processed using Image J denoise plugin and corrected for background.", [["Images", "TEST", 0, 6], ["Image J denoise plugin", "TEST", 33, 55]]], ["For quantitative evaluation of genome foci, images were imported into Image Pro Plus and then subject to thresholding and segmentation modules to define object masks which were quantified for various parameters.", [["foci", "ANATOMY", 38, 42], ["quantitative evaluation", "TEST", 4, 27], ["genome foci", "PROBLEM", 31, 42], ["images", "TEST", 44, 50], ["object masks", "TREATMENT", 153, 165], ["foci", "OBSERVATION", 38, 42]]], ["Using the DAPI outlines and the population analysis tool, the number of genomes within approximately 200 nuclei was calculated for each condition under study, differing mois, times and various drug treatments.3D-SIMSuper-resolution imaging was performed on Elyra PS1 system (Carl Zeiss) with an Apochromat 63x 1.4 NA oil objective lens, 488nm and 561nm excitation lasers and images were captured on a sCMOS PCO Edge camera.", [["nuclei", "ANATOMY", 105, 111], ["nuclei", "CELLULAR_COMPONENT", 105, 111], ["PS1", "PROTEIN", 263, 266], ["the population analysis tool", "TEST", 28, 56], ["various drug treatments", "TREATMENT", 185, 208], ["resolution imaging", "TEST", 221, 239], ["an Apochromat", "TEST", 292, 305], ["nm excitation lasers", "TREATMENT", 350, 370], ["images", "TEST", 375, 381], ["a sCMOS PCO Edge camera", "TREATMENT", 399, 422]]], ["The camera pixel size is 6.5 \u03bcm and with 63x objective and additional 1.6x tube lens, this corresponds to 64 nm in the object plane.", [["The camera pixel size", "TEST", 0, 21], ["additional 1.6x tube lens", "TREATMENT", 59, 84], ["size", "OBSERVATION_MODIFIER", 17, 21], ["6.5 \u03bcm", "OBSERVATION_MODIFIER", 25, 31], ["1.6x", "OBSERVATION_MODIFIER", 70, 74], ["tube lens", "OBSERVATION", 75, 84], ["64 nm", "OBSERVATION_MODIFIER", 106, 111]]], ["For analysis of infected cells, image stacks (2 \u03bcm) were acquired in Frame Fast mode (single multiband cube) with a z-step of 110 nm and 15 raw images (five phases, three angles) per plane.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["infected cells", "CELL_TYPE", 16, 30], ["infected cells", "PROBLEM", 16, 30], ["image stacks", "TEST", 32, 44], ["infected cells", "OBSERVATION", 16, 30]]], ["Raw data was then computationally reconstructed using the ZEN software to obtain a super-resolution 3D image stack with a pixel size of 32 nm in xy and 105 nm in z.", [["a pixel size", "TEST", 120, 132], ["32 nm", "OBSERVATION_MODIFIER", 136, 141]]], ["The SIMCheck ImageJ/Fiji plugin [76] was used to perform quality control on both raw and reconstructed data and to estimate lateral (x-y) resolution (approximately 120 nm) and axial (z) resolution (approximately 300 nm).", [["reconstructed data", "TEST", 89, 107], ["axial (z) resolution", "TREATMENT", 176, 196]]], ["Images from the different colour channels were registered in ZEN with alignment parameters obtained from calibration measurements with either virus capsids simultaneously labelled in both red and green channels or with TetraSpeck calibration beads 0.1 \u03bcm diameter (Thermofisher).", [["ZEN", "CHEMICAL", 61, 64], ["ZEN", "SIMPLE_CHEMICAL", 61, 64], ["red and green channels", "PROTEIN", 188, 210], ["Images", "TEST", 0, 6], ["alignment parameters", "TEST", 70, 90], ["calibration measurements", "TEST", 105, 129], ["virus capsids", "TREATMENT", 142, 155], ["TetraSpeck calibration beads", "TREATMENT", 219, 247], ["green channels", "ANATOMY", 196, 210]]], ["2D Gaussian fitting was done using the PALM analysis function in Zen with 30 pixel image window or 'GaussFit on spot' plugin in ImageJ.", [["2D Gaussian fitting", "TREATMENT", 0, 19], ["the PALM analysis", "TEST", 35, 52]]], ["The Gaussian 1/ sqrt (e) radii were converted to full width at half maximum (FWHM) values by multiplying with 2x sqrt (2 \u00c3 ln (2)).3D-SIMFor analysis of HSV EdC capsid and genome dimensions by immunofluorescence and cycloaddition reactions, the expected dimensions can be estimated by a convolution of the SIM resolution (120 nm and 138 nm for 488 nm and 561 nm excitations respectively) with the known sizes of capsid diameter (125 nm) and genome space (100 nm) [77] .", [["HSV", "ORGANISM", 153, 156], ["HSV EdC capsid", "PROTEIN", 153, 167], ["HSV", "SPECIES", 153, 156], ["3D-SIMFor analysis", "TEST", 131, 149], ["HSV", "PROBLEM", 153, 156], ["immunofluorescence", "TEST", 193, 211], ["cycloaddition reactions", "PROBLEM", 216, 239], ["nm excitations", "TEST", 359, 373], ["genome space", "TEST", 441, 453], ["full width", "OBSERVATION_MODIFIER", 49, 59], ["cycloaddition reactions", "OBSERVATION", 216, 239], ["sizes", "OBSERVATION_MODIFIER", 403, 408], ["capsid diameter", "OBSERVATION", 412, 427]]], ["In case of the capsid by immunofluorescence, based on previous analyses [78] we estimated and additional 35 nm for the primary/secondary antibody bringing the estimated dimensions of the capsid to 160 nm.", [["primary/secondary antibody", "PROTEIN", 119, 145], ["previous analyses", "TEST", 54, 71], ["the primary/secondary antibody", "TEST", 115, 145], ["secondary antibody", "OBSERVATION", 127, 145], ["160 nm", "OBSERVATION_MODIFIER", 197, 203]]], ["The convolutions of the SIM resolution and these sizes results in an estimated size of 200 nm and 170 nm for the capsid and genome respectively.", [["an estimated size", "TEST", 66, 83], ["sizes", "OBSERVATION_MODIFIER", 49, 54], ["size", "OBSERVATION_MODIFIER", 79, 83], ["200 nm", "OBSERVATION_MODIFIER", 87, 93]]], ["Our measured average size is about 26% smaller than the estimate size.", [["average", "OBSERVATION_MODIFIER", 13, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["26%", "OBSERVATION_MODIFIER", 35, 38], ["smaller", "OBSERVATION_MODIFIER", 39, 46], ["size", "OBSERVATION_MODIFIER", 65, 69]]], ["This was in line with measurements of calibration measurements with standard fluorescent beads of different sizes where the FWHM sizes were found to be 22% smaller than expected.3D-SIMVolume analysis was performed the object analyser module of the Huygens image processing suite (SVI, The Netherlands).", [["calibration measurements", "TEST", 38, 62], ["the FWHM sizes", "TEST", 120, 134], ["3D-SIMVolume analysis", "TEST", 178, 199], ["beads", "OBSERVATION_MODIFIER", 89, 94], ["different", "OBSERVATION_MODIFIER", 98, 107], ["sizes", "OBSERVATION_MODIFIER", 108, 113], ["FWHM", "OBSERVATION_MODIFIER", 124, 128], ["sizes", "OBSERVATION_MODIFIER", 129, 134], ["22%", "OBSERVATION_MODIFIER", 152, 155], ["smaller", "OBSERVATION_MODIFIER", 156, 163]]], ["The image is segmented into defined objects by the seedthreshold level adjustment, and connection process.", [["the seedthreshold level adjustment", "TREATMENT", 47, 81]]], ["Introduction of a watershed increases segmentation reliability further.", [["a watershed increases segmentation reliability", "PROBLEM", 16, 62], ["watershed", "OBSERVATION_MODIFIER", 18, 27], ["increases", "OBSERVATION_MODIFIER", 28, 37]]], ["Detected objects are automatically labelled and submitted to a continuous Iso Surface renderer.", [["a continuous Iso Surface renderer", "TREATMENT", 61, 94]]], ["The segmented image is shown as a coloured iso-surface image.", [["The segmented image", "TEST", 0, 19], ["a coloured iso-surface image", "TEST", 32, 60]]], ["Object statistics are reported for each object, including geometrical data and spatial location.", [["geometrical data", "TEST", 58, 74]]], ["A simulated fluorescence process (SFP) computing algorithm allows visualization of the 3D data and production of the rendered image as an animation.", [["A simulated fluorescence process", "PROBLEM", 0, 32], ["the 3D data", "TEST", 83, 94]]], ["Using this method we estimated volume and sphericity for genomic foci from visions on coverslips versus after entry to the nucleus.Spatial analysis and clusteringSpatial clustering analysis of EdC labelled genomes was carried out using the Spatial Statistics 2D/3D ImageJ plugin [35] .", [["foci", "ANATOMY", 65, 69], ["nucleus", "ANATOMY", 123, 130], ["nucleus", "CELLULAR_COMPONENT", 123, 130], ["EdC labelled genomes", "DNA", 193, 213], ["this method", "TREATMENT", 6, 17], ["genomic foci", "PROBLEM", 57, 69], ["visions on coverslips", "TREATMENT", 75, 96], ["Spatial analysis", "TEST", 131, 147], ["EdC labelled genomes", "PROBLEM", 193, 213], ["foci", "OBSERVATION", 65, 69], ["nucleus", "ANATOMY", 123, 130]]], ["The plugin analyses the overall distribution of inter-point distances including any local clusters and calculates whether there is evidence for a non-random distribution in the population of cells.", [["cells", "ANATOMY", 191, 196], ["cells", "CELL", 191, 196], ["inter-point distances", "PROBLEM", 48, 69], ["a non-random distribution in the population of cells", "PROBLEM", 144, 196], ["plugin", "OBSERVATION", 4, 10], ["overall", "OBSERVATION_MODIFIER", 24, 31], ["distribution", "OBSERVATION_MODIFIER", 32, 44], ["inter-point distances", "OBSERVATION", 48, 69], ["local clusters", "OBSERVATION", 84, 98], ["evidence for", "UNCERTAINTY", 131, 143], ["non-random", "OBSERVATION_MODIFIER", 146, 156], ["distribution", "OBSERVATION_MODIFIER", 157, 169]]], ["A binary mask of each nucleus is generated together with a mask of the genomes using the 'Find Maxima' function.", [["nucleus", "ANATOMY", 22, 29], ["nucleus", "CELLULAR_COMPONENT", 22, 29], ["A binary mask", "TREATMENT", 0, 13], ["a mask of the genomes", "TREATMENT", 57, 78], ["binary mask", "OBSERVATION", 2, 13]]], ["The plugin calculates for every nucleus, the distances between every point and its nearest neighbour and generates a cumulative distribution function (CDF) of those distances (the G-function).", [["nucleus", "ANATOMY", 32, 39], ["nucleus", "CELLULAR_COMPONENT", 32, 39], ["plugin", "OBSERVATION", 4, 10]]], ["To compute this function, first the average CDF of a completely random distribution is estimated over a set (500 iterations) of randomly generated point patterns, specific to each reference structure (nucleus) and the number of points (genomes) in that structure.", [["nucleus", "ANATOMY", 201, 208], ["nucleus", "CELLULAR_COMPONENT", 201, 208], ["nucleus", "ANATOMY", 201, 208]]], ["Second, the expected variation of CDFs around their average is estimated using a second set of randomly generated binomial point patterns.", [["CDFs", "CANCER", 34, 38], ["CDFs", "DNA", 34, 38], ["CDFs", "PROBLEM", 34, 38], ["variation", "OBSERVATION_MODIFIER", 21, 30], ["CDFs", "OBSERVATION", 34, 38], ["binomial point", "OBSERVATION", 114, 128]]], ["The relative position of the observed CDF for the actual test set within this range of variation is used to assign a p-value to the observed pattern, termed the 'Spatial Distribution Index' (SDI).", [["CDF", "GENE_OR_GENE_PRODUCT", 38, 41], ["CDF", "DNA", 38, 41], ["the actual test", "TEST", 46, 61], ["position", "OBSERVATION_MODIFIER", 13, 21]]], ["Point patterns that tend to clustering have an SDI closer to 0 while patterns tending to even spacing have an SDI close to 1.", [["Point patterns", "PROBLEM", 0, 14]]], ["The CDFs of SDIs of two different populations are compared using the Kolmogorov-Smirnoff (KS) test, which is non-parametric and distribution free.", [["the Kolmogorov", "TEST", 65, 79], ["two", "OBSERVATION_MODIFIER", 20, 23], ["different", "OBSERVATION_MODIFIER", 24, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["distribution", "OBSERVATION_MODIFIER", 128, 140], ["free", "OBSERVATION_MODIFIER", 141, 145]]], ["A p-value for the difference between the two populations is calculated, as well as the D statistic which is the largest deviation between the two CDFs.Spatial analysis and clusteringAn independent clustering analysis was performed by calculating the Ripley function (K) using the BioImage Analysis platform ICY (http://icy.bioimageanalysis.org) as described [79] .", [["A p-value", "TEST", 0, 9], ["Spatial analysis", "TEST", 151, 167], ["An independent clustering analysis", "TEST", 182, 216], ["the BioImage Analysis", "TEST", 276, 297], ["largest", "OBSERVATION_MODIFIER", 112, 119]]], ["Nuclei were segmented using the DAPI signal as above and a binary mask created.", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 32, 36], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["the DAPI signal", "TEST", 28, 43], ["a binary mask", "TREATMENT", 57, 70], ["segmented", "OBSERVATION_MODIFIER", 12, 21], ["DAPI signal", "OBSERVATION", 32, 43]]], ["The ICY Spot Detector plugin identifies the EdC genomes contained within the nuclear mask.", [["nuclear", "ANATOMY", 77, 84], ["nuclear", "CELLULAR_COMPONENT", 77, 84], ["ICY Spot Detector plugin", "DNA", 4, 28], ["EdC genomes", "DNA", 44, 55], ["nuclear mask", "OBSERVATION", 77, 89]]], ["These were used to calculate the K function using the Spatial Analysis plugin [36] .", [["the K function", "TEST", 29, 43]]], ["In this approach regions of interest (circles) with increasing radii are drawn around every detected spot and other spots located within the circles are identified in the overall search area (the nucleus).", [["nucleus", "ANATOMY", 196, 203], ["nucleus", "CELLULAR_COMPONENT", 196, 203], ["increasing radii", "PROBLEM", 52, 68], ["increasing", "OBSERVATION_MODIFIER", 52, 62], ["radii", "OBSERVATION_MODIFIER", 63, 68], ["spots", "OBSERVATION_MODIFIER", 116, 121], ["circles", "OBSERVATION_MODIFIER", 141, 148], ["overall", "OBSERVATION_MODIFIER", 171, 178], ["nucleus", "ANATOMY_MODIFIER", 196, 203]]], ["The K function is then based on the number of spots that are closer than the radius, calculated for each increasing radius.", [["The K function", "TEST", 0, 14], ["each increasing radius", "PROBLEM", 100, 122], ["spots", "OBSERVATION", 46, 51], ["radius", "ANATOMY", 77, 83], ["increasing", "OBSERVATION_MODIFIER", 105, 115], ["radius", "OBSERVATION", 116, 122]]], ["The amplitude of the K-function can then be compared to corresponding low and high quantiles (0.01 and 0.99 here).", [["amplitude", "OBSERVATION_MODIFIER", 4, 13], ["low", "OBSERVATION_MODIFIER", 70, 73]]], ["When K is higher than the high quantile for a certain radius, the foci are significantly organised in clusters.", [["foci", "ANATOMY", 66, 70], ["K", "CHEMICAL", 5, 6], ["K", "TEST", 5, 6], ["a certain radius", "PROBLEM", 44, 60], ["the foci", "PROBLEM", 62, 70], ["foci", "OBSERVATION", 66, 70], ["significantly", "OBSERVATION_MODIFIER", 75, 88]]], ["Conversely, when K is lower than the low quantile, the foci are dispersed.", [["foci", "ANATOMY", 55, 59], ["K", "CHEMICAL", 17, 18], ["K", "TEST", 17, 18], ["foci", "OBSERVATION", 55, 59]]], ["Quantitative analysis of individual particles was performed as described for Fig 4 and in materials and methods.", [["Quantitative analysis", "TEST", 0, 21], ["individual particles", "PROBLEM", 25, 45], ["Fig", "TEST", 77, 80]]], ["We used a customised Image J plugin based on the find maxima protocol accompanied by pixel quantification in defined ROIs for each channel (top panel VP5, red; bottom panel EdC, green).", [["VP5", "PROTEIN", 150, 153], ["red", "PROTEIN", 155, 158], ["EdC", "PROTEIN", 173, 176], ["a customised Image J plugin", "TREATMENT", 8, 35], ["maxima protocol", "TREATMENT", 54, 69], ["pixel quantification", "TEST", 85, 105], ["each channel (top panel VP5", "TREATMENT", 126, 153]]], ["Frequency distributions of signal intensities for each channel of individual VP5 positive particles were quantitated with bin width automatically selected using the Friedman-Diaconis criteria for interquartile-ranges [74, 75] .", [["VP5", "GENE_OR_GENE_PRODUCT", 77, 80], ["VP5", "PROTEIN", 77, 80], ["signal intensities", "PROBLEM", 27, 45], ["individual VP5 positive particles", "PROBLEM", 66, 99], ["signal intensities", "OBSERVATION", 27, 45]]], ["The raw mean and SD together with the coefficient of variance are reported on the right-hand side, with fitted means and SDs reported on the left hand side after Gaussian distributions were fitted to each channel frequency data using Image J curve fitter.", [["right-hand", "ANATOMY", 82, 92], ["left hand", "ANATOMY", 141, 150], ["SDs", "PROBLEM", 121, 124], ["Gaussian distributions", "PROBLEM", 162, 184], ["Image J curve fitter", "TREATMENT", 234, 254], ["right", "ANATOMY_MODIFIER", 82, 87], ["left", "ANATOMY_MODIFIER", 141, 145]]], ["HSV-1 EdC virus particles were adsorbed onto borosilicate coverslips, detected by cycloaddition and immunofluorescence and analysed as described for Fig 4. (b) HSV-1 EdC was examined by cycloaddition in solution prior to adsorption on coverslips.", [["borosilicate", "CHEMICAL", 45, 57], ["HSV-1", "ORGANISM", 0, 5], ["EdC virus", "ORGANISM", 6, 15], ["HSV-1", "ORGANISM", 160, 165], ["EdC", "ORGANISM", 166, 169], ["HSV-1 EdC virus", "SPECIES", 0, 15], ["HSV-1 EdC virus", "SPECIES", 0, 15], ["HSV-1", "SPECIES", 160, 165], ["HSV", "TEST", 0, 3], ["EdC virus particles", "PROBLEM", 6, 25], ["borosilicate coverslips", "TREATMENT", 45, 68], ["immunofluorescence", "TEST", 100, 118], ["HSV", "TEST", 160, 163], ["adsorption on coverslips", "TREATMENT", 221, 245]]], ["The reaction was then blocked by addition of 1 mM EDTA to chelate the copper catalyst and the sample then adsorbed to borosilicate coverslips, stained for VP5 and analysed by ImageJ.", [["sample", "ANATOMY", 94, 100], ["copper", "CHEMICAL", 70, 76], ["EDTA", "CHEMICAL", 50, 54], ["copper", "CHEMICAL", 70, 76], ["borosilicate", "CHEMICAL", 118, 130], ["EDTA", "SIMPLE_CHEMICAL", 50, 54], ["copper catalyst", "SIMPLE_CHEMICAL", 70, 85], ["VP5", "GENE_OR_GENE_PRODUCT", 155, 158], ["VP5", "PROTEIN", 155, 158], ["The reaction", "PROBLEM", 0, 12], ["1 mM EDTA", "TREATMENT", 45, 54], ["chelate the copper catalyst", "TREATMENT", 58, 85], ["borosilicate coverslips", "TREATMENT", 118, 141], ["VP5", "TEST", 155, 158], ["ImageJ", "TEST", 175, 181], ["borosilicate coverslips", "OBSERVATION", 118, 141]]], ["Graphs show quantified data of particles under each condition for VP5 and EdC. (c) HSV-1 EdC was adsorbed to borosilicate coverslips as above and then heated to 70\u02daC for 2 min before fixation and detection by cycloaddition and immunofluorescence for VP5.", [["borosilicate", "CHEMICAL", 109, 121], ["VP5", "GENE_OR_GENE_PRODUCT", 66, 69], ["EdC", "GENE_OR_GENE_PRODUCT", 89, 92], ["VP5", "GENE_OR_GENE_PRODUCT", 250, 253], ["VP5", "PROTEIN", 66, 69], ["EdC", "PROTEIN", 89, 92], ["VP5", "PROTEIN", 250, 253], ["HSV-1", "SPECIES", 83, 88], ["VP5", "TEST", 66, 69], ["HSV", "TEST", 83, 86], ["fixation", "TREATMENT", 183, 191], ["cycloaddition", "TREATMENT", 209, 222], ["immunofluorescence", "TEST", 227, 245], ["VP5", "PROBLEM", 250, 253]]], ["VP5, red; EdC, green (scale bar 10 \u03bcm).", [["VP5", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP5", "PROTEIN", 0, 3], ["EdC", "PROTEIN", 10, 13], ["VP5", "PROBLEM", 0, 3], ["red", "OBSERVATION", 5, 8], ["green", "OBSERVATION_MODIFIER", 15, 20]]], ["(TIF) S6 Fig. Control experiments on entry and uncoating of HSV-1 EdC genomes.", [["HSV-1 EdC", "ORGANISM", 60, 69], ["HSV-1 EdC genomes", "DNA", 60, 77], ["HSV-1", "SPECIES", 60, 65], ["HSV-1", "SPECIES", 60, 65], ["HSV", "PROBLEM", 60, 63]]], ["RPE-1 cells were infected with HSV-1 EdC and fixed at 2 hpi for detection by cycloaddition and immunofluorescence for VP5 (scale bar 10 \u03bcm).", [["RPE-1 cells", "ANATOMY", 0, 11], ["RPE-1 cells", "CELL", 0, 11], ["HSV-1 EdC", "ORGANISM", 31, 40], ["VP5", "GENE_OR_GENE_PRODUCT", 118, 121], ["RPE-1 cells", "CELL_LINE", 0, 11], ["VP5", "PROTEIN", 118, 121], ["HSV-1", "SPECIES", 31, 36], ["HSV-1", "SPECIES", 31, 36], ["RPE", "TEST", 0, 3], ["HSV", "TEST", 31, 34], ["cycloaddition", "TREATMENT", 77, 90], ["immunofluorescence", "TEST", 95, 113], ["VP5 (scale bar", "TREATMENT", 118, 132]]], ["Experimental variations from the normal process were as follows: (i) During the cycloaddition, Cu(I) was omitted from the reaction mixture; (ii) the virus inoculum was treated with clinical grade neutralizing antibody IVIg (100 mg/ml) for 0.5 hr at room temperature prior to infection; (iii) the inoculum was treated with DNase I (500 U/ ml) for 0.5 h at 10\u02daC prior to infection; (iv) cells were infected with a 'mock' inoculum which consisted of concentrated supernatant from uninfected RPE-1 cells pulsed and prepared as for an infected HSV-1 EdC stock.", [["cells", "ANATOMY", 385, 390], ["supernatant", "ANATOMY", 460, 471], ["RPE-1 cells", "ANATOMY", 488, 499], ["Cu", "CHEMICAL", 95, 97], ["IVIg", "CHEMICAL", 218, 222], ["infection", "DISEASE", 275, 284], ["infection", "DISEASE", 369, 378], ["Cu(I)", "CHEMICAL", 95, 100], ["Cu(I)", "SIMPLE_CHEMICAL", 95, 100], ["IVIg", "SIMPLE_CHEMICAL", 218, 222], ["DNase I", "GENE_OR_GENE_PRODUCT", 322, 329], ["cells", "CELL", 385, 390], ["RPE-1 cells", "CELL", 488, 499], ["HSV-1 EdC", "ORGANISM", 539, 548], ["DNase I", "PROTEIN", 322, 329], ["uninfected RPE-1 cells", "CELL_LINE", 477, 499], ["HSV-1", "SPECIES", 539, 544], ["HSV-1", "SPECIES", 539, 544], ["Experimental variations", "PROBLEM", 0, 23], ["the reaction mixture", "PROBLEM", 118, 138], ["the virus inoculum", "PROBLEM", 145, 163], ["clinical grade neutralizing antibody IVIg", "TREATMENT", 181, 222], ["infection", "PROBLEM", 275, 284], ["the inoculum", "TREATMENT", 292, 304], ["DNase I", "TREATMENT", 322, 329], ["infection", "PROBLEM", 369, 378], ["(iv) cells", "TREATMENT", 380, 390], ["a 'mock' inoculum", "TREATMENT", 410, 427], ["an infected HSV", "PROBLEM", 527, 542], ["normal", "OBSERVATION", 33, 39], ["infection", "OBSERVATION", 275, 284], ["infection", "OBSERVATION", 369, 378], ["infected", "OBSERVATION", 530, 538]]], ["(TIF)S7 Fig. Video of iso-rendered 3D-SIM data of HSV EdC infected cell.3D-SIM data of a representative RPE-1 cell infected with HSV-1 EdC (moi 20) at 0.5 hpi, iso-rendered in Huygens analysis software as described in materials and methods.", [["cell", "ANATOMY", 67, 71], ["RPE-1 cell", "ANATOMY", 104, 114], ["HSV", "ORGANISM", 50, 53], ["cell", "CELL", 67, 71], ["RPE-1 cell", "CELL", 104, 114], ["HSV-1 EdC", "ORGANISM", 129, 138], ["HSV EdC infected cell", "CELL_LINE", 50, 71], ["RPE-1 cell", "CELL_LINE", 104, 114], ["HSV-1", "SPECIES", 129, 134], ["HSV", "SPECIES", 50, 53], ["HSV-1", "SPECIES", 129, 134], ["HSV EdC infected cell", "PROBLEM", 50, 71], ["a representative RPE", "TEST", 87, 107], ["HSV", "TEST", 129, 132], ["infected cell", "OBSERVATION", 58, 71], ["infected", "OBSERVATION_MODIFIER", 115, 123]]], ["Channels have been rendered partially transparent for ease of inspection of features as discussed in the text Red channel, VP5; Green channel, EdC; blue channel, DAPI.", [["DAPI", "CHEMICAL", 162, 166], ["VP5", "GENE_OR_GENE_PRODUCT", 123, 126], ["Green", "GENE_OR_GENE_PRODUCT", 128, 133], ["DAPI", "SIMPLE_CHEMICAL", 162, 166], ["text Red channel", "PROTEIN", 105, 121], ["VP5", "PROTEIN", 123, 126], ["Green channel", "PROTEIN", 128, 141], ["EdC", "PROTEIN", 143, 146], ["blue channel", "PROTEIN", 148, 160], ["Green channel", "ANATOMY", 128, 141]]], ["(AVI) S8 Fig. Control experiments on effects of drug treatments. (a) Representative images of the localisation of ICP4 in cells infected with HSV-1 EdC (moi 10) and either untreated or incubated in the presence of ActD (5 \u03bcg/ml), CHX (100 \u03bcg/ml), or ACV (500 \u03bcM), PAA (400 \u03bcg/ml), as indicated.", [["cells", "ANATOMY", 122, 127], ["ActD", "CHEMICAL", 214, 218], ["CHX", "CHEMICAL", 230, 233], ["ACV", "CHEMICAL", 250, 253], ["PAA", "CHEMICAL", 264, 267], ["ActD", "CHEMICAL", 214, 218], ["CHX", "CHEMICAL", 230, 233], ["ACV", "CHEMICAL", 250, 253], ["PAA", "CHEMICAL", 264, 267], ["ICP4", "GENE_OR_GENE_PRODUCT", 114, 118], ["cells", "CELL", 122, 127], ["HSV-1 EdC", "ORGANISM", 142, 151], ["moi 10", "ORGANISM", 153, 159], ["ActD", "SIMPLE_CHEMICAL", 214, 218], ["CHX", "SIMPLE_CHEMICAL", 230, 233], ["ACV", "SIMPLE_CHEMICAL", 250, 253], ["PAA", "SIMPLE_CHEMICAL", 264, 267], ["ICP4", "PROTEIN", 114, 118], ["HSV-1", "SPECIES", 142, 147], ["HSV-1", "SPECIES", 142, 147], ["drug treatments", "TREATMENT", 48, 63], ["Representative images", "TEST", 69, 90], ["HSV", "TEST", 142, 145], ["ActD", "TREATMENT", 214, 218], ["CHX", "TREATMENT", 230, 233], ["ACV", "TREATMENT", 250, 253], ["PAA", "TREATMENT", 264, 267], ["Fig", "OBSERVATION_MODIFIER", 9, 12]]], ["Cells were fixed (3 hr post infection) and processed for immunofluorescence of ICP4.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ICP4", "GENE_OR_GENE_PRODUCT", 79, 83], ["ICP4", "PROTEIN", 79, 83], ["Cells", "TEST", 0, 5], ["infection", "PROBLEM", 28, 37], ["immunofluorescence of ICP4", "PROBLEM", 57, 83]]], ["Scale bar 10 \u03bcm. (b) Uninfected cells were treated with MG132 (10 \u03bcM), nocodazole (2 \u03bcM), or Leptomycin B (20 nM) for 1.5 hr, as during analysis of infection, then fixed and processed for immunofluorescence for PML, \u03b1-tubulin, or cyclin B1 respectively (red channel).", [["cells", "ANATOMY", 32, 37], ["MG132", "CHEMICAL", 56, 61], ["nocodazole", "CHEMICAL", 71, 81], ["Leptomycin B", "CHEMICAL", 93, 105], ["infection", "DISEASE", 148, 157], ["MG132", "CHEMICAL", 56, 61], ["nocodazole", "CHEMICAL", 71, 81], ["Leptomycin B", "CHEMICAL", 93, 105], ["cells", "CELL", 32, 37], ["MG132", "SIMPLE_CHEMICAL", 56, 61], ["nocodazole", "SIMPLE_CHEMICAL", 71, 81], ["Leptomycin B", "SIMPLE_CHEMICAL", 93, 105], ["PML", "GENE_OR_GENE_PRODUCT", 211, 214], ["\u03b1-tubulin", "GENE_OR_GENE_PRODUCT", 216, 225], ["cyclin B1", "GENE_OR_GENE_PRODUCT", 230, 239], ["Uninfected cells", "CELL_TYPE", 21, 37], ["PML", "PROTEIN", 211, 214], ["\u03b1-tubulin", "PROTEIN", 216, 225], ["cyclin B1", "PROTEIN", 230, 239], ["red channel", "PROTEIN", 254, 265], ["Uninfected cells", "PROBLEM", 21, 37], ["MG132", "TREATMENT", 56, 61], ["nocodazole", "TREATMENT", 71, 81], ["Leptomycin B", "TREATMENT", 93, 105], ["infection", "PROBLEM", 148, 157], ["immunofluorescence", "TEST", 188, 206], ["PML", "PROBLEM", 211, 214], ["\u03b1-tubulin", "TREATMENT", 216, 225], ["cyclin B1", "TREATMENT", 230, 239], ["infection", "OBSERVATION", 148, 157]]], ["Cells were counterstained with DAPI.", [["Cells", "ANATOMY", 0, 5], ["DAPI", "CHEMICAL", 31, 35], ["Cells", "CELL", 0, 5], ["DAPI", "SIMPLE_CHEMICAL", 31, 35], ["DAPI", "TEST", 31, 35]]], ["Panels I and IV show MG132 treatment increases PML number and size per nuclei; panels II and V demonstrate microtubule depolymerisation upon nocodazole treatment; panels III and VI show inhibition of nuclear export and nuclear accumulation of cyclin B1.", [["PML", "ANATOMY", 47, 50], ["nuclei", "ANATOMY", 71, 77], ["microtubule", "ANATOMY", 107, 118], ["nuclear", "ANATOMY", 200, 207], ["nuclear", "ANATOMY", 219, 226], ["MG132", "CHEMICAL", 21, 26], ["nocodazole", "CHEMICAL", 141, 151], ["MG132", "CHEMICAL", 21, 26], ["nocodazole", "CHEMICAL", 141, 151], ["MG132", "SIMPLE_CHEMICAL", 21, 26], ["PML", "GENE_OR_GENE_PRODUCT", 47, 50], ["nuclei", "CELLULAR_COMPONENT", 71, 77], ["microtubule", "CELLULAR_COMPONENT", 107, 118], ["nocodazole", "SIMPLE_CHEMICAL", 141, 151], ["nuclear", "CELLULAR_COMPONENT", 200, 207], ["nuclear", "CELLULAR_COMPONENT", 219, 226], ["cyclin B1", "GENE_OR_GENE_PRODUCT", 243, 252], ["PML", "PROTEIN", 47, 50], ["microtubule", "PROTEIN", 107, 118], ["cyclin B1", "PROTEIN", 243, 252], ["Panels I", "TEST", 0, 8], ["IV", "TREATMENT", 13, 15], ["MG132 treatment", "TREATMENT", 21, 36], ["microtubule depolymerisation", "PROBLEM", 107, 135], ["nocodazole treatment", "TREATMENT", 141, 161], ["panels III", "TEST", 163, 173], ["nuclear export", "TEST", 200, 214], ["cyclin B1", "PROBLEM", 243, 252], ["size", "OBSERVATION_MODIFIER", 62, 66], ["microtubule depolymerisation", "OBSERVATION", 107, 135], ["nuclear export", "OBSERVATION", 200, 214]]], ["Scale bar for MG132 and nocodazole panels, 10 \u03bcm; scale bar for Leptomycin treatment, 100 \u03bcm (TIF) The spatial distribution analysis examines the overall distribution of inter-point distances, including any local clusters, and calculates whether there is any evidence for a non-random distribution in the population of cells. (b) The distances between every point and its nearest neighbour are generated as a cumulative distribution function (CDF) of those distances (see materials and methods).", [["cells", "ANATOMY", 319, 324], ["MG132", "CHEMICAL", 14, 19], ["nocodazole", "CHEMICAL", 24, 34], ["Leptomycin", "CHEMICAL", 64, 74], ["MG132", "CHEMICAL", 14, 19], ["nocodazole", "CHEMICAL", 24, 34], ["Leptomycin", "CHEMICAL", 64, 74], ["MG132", "SIMPLE_CHEMICAL", 14, 19], ["nocodazole", "SIMPLE_CHEMICAL", 24, 34], ["Leptomycin", "SIMPLE_CHEMICAL", 64, 74], ["cells", "CELL", 319, 324], ["MG132", "TREATMENT", 14, 19], ["nocodazole panels", "TREATMENT", 24, 41], ["Leptomycin treatment", "TREATMENT", 64, 84], ["The spatial distribution analysis", "TEST", 99, 132], ["inter-point distances", "PROBLEM", 170, 191], ["a non-random distribution", "PROBLEM", 272, 297], ["non-random", "OBSERVATION_MODIFIER", 274, 284], ["distribution", "OBSERVATION_MODIFIER", 285, 297]]], ["A theoretical CDF for a truly random distribution (black line; 95% confidence limits, grey lines) is generated (specific for each nucleus and number of foci) and then compared with the actual distribution obtained for the test set (red line).", [["nucleus", "ANATOMY", 130, 137], ["nucleus", "CELLULAR_COMPONENT", 130, 137], ["red line", "CELL_LINE", 232, 240], ["A theoretical CDF", "PROBLEM", 0, 17], ["a truly random distribution (black line", "PROBLEM", 22, 61], ["grey lines", "TEST", 86, 96], ["the test", "TEST", 218, 226], ["CDF", "OBSERVATION", 14, 17], ["foci", "OBSERVATION", 152, 156]]], ["For an actual random pattern the red line will be close to the black, while for clustered and evenly spaced the red line will deviate left or right respectively.", [["red line", "ANATOMY", 33, 41], ["red line", "ANATOMY", 112, 120], ["an actual random pattern", "PROBLEM", 4, 28], ["the red line", "TREATMENT", 29, 41], ["red line", "OBSERVATION", 33, 41], ["red line", "OBSERVATION", 112, 120], ["left", "ANATOMY_MODIFIER", 134, 138], ["right", "ANATOMY_MODIFIER", 142, 147]]], ["This difference is transformed to a spatial distribution index (SDI).", [["spatial", "OBSERVATION_MODIFIER", 36, 43], ["distribution", "OBSERVATION_MODIFIER", 44, 56]]], ["Point patterns that tend to be clustered have a SDI closer to 0 while evenly spaced patterns have a SDI closer to 1. (c) The corresponding SDI frequency distributions between 0 and 1 for populations of cells.", [["cells", "ANATOMY", 202, 207], ["cells", "CELL", 202, 207], ["The corresponding SDI frequency distributions", "PROBLEM", 121, 166], ["populations of cells", "PROBLEM", 187, 207]]], ["The CDFs of SDIs of different populations are compared using the Kolmogorov-Smirnoff (KS) test, which is non-parametric and distribution free.", [["different populations", "PROBLEM", 20, 41], ["the Kolmogorov", "TEST", 61, 75], ["different", "OBSERVATION_MODIFIER", 20, 29], ["populations", "OBSERVATION_MODIFIER", 30, 41], ["distribution", "OBSERVATION_MODIFIER", 124, 136], ["free", "OBSERVATION_MODIFIER", 137, 141]]], ["A p-value for the difference between the two populations is calculated, as well as the D statistic which is the largest deviation between the two CDFs. (e) Capsids applied on coverslips were fixed, stained with anti-VP5 and images processed to calculate the SDI, expected to be random. (f) The results compare the theoretical cumulative inter-point distances for a random distribution (black line; 95% confidence limits, grey lines) with the actual distribution obtained for the capsids (red line).", [["coverslips", "ANATOMY", 175, 185], ["anti-VP5", "SIMPLE_CHEMICAL", 211, 219], ["anti-VP5", "PROTEIN", 211, 219], ["A p-value", "TEST", 0, 9], ["Capsids applied on coverslips", "TREATMENT", 156, 185], ["anti-VP5", "TREATMENT", 211, 219], ["images", "TEST", 224, 230], ["a random distribution (black line", "PROBLEM", 363, 396], ["grey lines", "TEST", 421, 431], ["the capsids (red line", "TREATMENT", 475, 496], ["largest", "OBSERVATION_MODIFIER", 112, 119], ["red line", "OBSERVATION", 488, 496]]], ["The capsid distribution precisely conforms to a random distribution.", [["capsid distribution", "OBSERVATION", 4, 23], ["random distribution", "OBSERVATION", 48, 67]]], ["The algorithm calculates whether there is any evidence overall for a significant non-random distribution.", [["a significant non-random distribution", "PROBLEM", 67, 104], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["non-random distribution", "OBSERVATION", 81, 104]]]], "7b522466daa394bd343a72e46e982cf7ac3e65c4": [["To the Editor-The limited supply of more conventional disposable personal protective equipment (PPE), namely single-use N95 filtering facepiece respirators (FFRs), among hospital systems in the United States during the COVID-19 pandemic has been alleviated with the adoption of extended use and reuse policies by the Centers for Disease Control and Prevention (CDC).", [["Disease Control", "TREATMENT", 329, 344]]], ["1 These measures, along with a variety of implemented decontamination methodologies (eg, ultraviolet germicidal irradiation, vaporized hydrogen peroxide, etc), have prolonged PPE supplies during pressing times.", [["hydrogen peroxide", "CHEMICAL", 135, 152], ["hydrogen peroxide", "CHEMICAL", 135, 152], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 135, 152], ["implemented decontamination methodologies", "TREATMENT", 42, 83], ["ultraviolet germicidal irradiation", "TREATMENT", 89, 123], ["vaporized hydrogen peroxide", "TREATMENT", 125, 152], ["prolonged PPE supplies", "TREATMENT", 165, 187]]], ["Another strategy adopted by the CDC and health systems to protect healthcare providers caring for COVID-19 patients and patients under investigation in limited resource settings includes the use of elastomeric FFRs with reusable cartridges.", [["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 120, 128], ["elastomeric FFRs with reusable cartridges", "TREATMENT", 198, 239]]], ["Although elastomeric respirators have not been approved by the Food and Drug Administration for fluid resistance, they have been endorsed by the CDC as reasonable alternatives for N95 FFRs during the COVID-19 pandemic due to their filtration approval by the National Institutes for Occupational and Safety Health (NIOSH).", [["elastomeric respirators", "TREATMENT", 9, 32], ["Drug Administration", "TREATMENT", 72, 91], ["fluid resistance", "TREATMENT", 96, 112], ["N95 FFRs", "TREATMENT", 180, 188], ["the COVID", "TEST", 196, 205]]], ["2 Subsequently, elastomeric respirators have formed a major arm of the COVID-19 pandemic response strategy in many hospital systems.", [["the COVID", "TEST", 67, 76]]]], "PMC7224141": [["BackgroundNeurally adjusted ventilatory assist (NAVA) uses electromyographic signals from the diaphragm (Edi) detected via a specialized naso-gastric feeding catheter (Getinge, Solna, Sweden), as a measure of neural respiratory drive and as a means of controlling the delivery of inspiratory support by a mechanical ventilator [1].", [["diaphragm", "ANATOMY", 94, 103], ["gastric", "ANATOMY", 142, 149], ["neural", "ANATOMY", 209, 215], ["diaphragm", "ORGAN", 94, 103], ["gastric", "ORGAN", 142, 149], ["BackgroundNeurally adjusted ventilatory assist", "TREATMENT", 0, 46], ["electromyographic signals", "TEST", 59, 84], ["a specialized naso-gastric feeding catheter", "TREATMENT", 123, 166], ["inspiratory support", "TREATMENT", 280, 299], ["a mechanical ventilator", "TREATMENT", 303, 326], ["ventilatory assist", "OBSERVATION", 28, 46], ["diaphragm", "ANATOMY", 94, 103], ["gastric", "ANATOMY", 142, 149], ["feeding catheter", "OBSERVATION", 150, 166], ["respiratory drive", "OBSERVATION", 216, 233]]], ["Over the last 12 years, studies have suggested several important physiological benefits associated with NAVA, including improved breath synchronization and effective assist that is proportional to neural respiratory drive [2, 3].", [["neural", "ANATOMY", 197, 203], ["NAVA", "CHEMICAL", 104, 108], ["NAVA", "TREATMENT", 104, 108], ["improved breath synchronization", "TREATMENT", 120, 151], ["respiratory drive", "OBSERVATION", 204, 221]]], ["Studies have not yet, however, demonstrated improved patient outcomes as was originally suggested [1], with only two, relatively small trials finding non-statistically significant effects on secondary outcomes [3, 4].BackgroundAlthough there is a demand for adequately powered trials of NAVA [5], uncertainties remain in relation to its use over prolonged durations.", [["NAVA", "CHEMICAL", 287, 291], ["NAVA", "CHEMICAL", 287, 291], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["Studies", "TEST", 0, 7], ["NAVA", "TREATMENT", 287, 291], ["small", "OBSERVATION_MODIFIER", 129, 134], ["significant", "OBSERVATION_MODIFIER", 168, 179]]], ["Estimates of intervention adherence and protocol compliance provide critical information for the calculation of statistical power [6].", [["intervention adherence", "TREATMENT", 13, 35], ["protocol compliance", "TREATMENT", 40, 59]]], ["Randomized controlled clinical trials are expensive [7], and poor adherence risks a type II error, with an intervention deemed ineffective when it was actually not delivered with sufficient fidelity [8, 9].", [["a type II error", "PROBLEM", 82, 97], ["an intervention", "TREATMENT", 104, 119]]], ["Although good NAVA mode adherence was observed up to 48 h from randomization in a recent efficacy RCT [3], conflicting results were reported in a subsequent physiological RCT where NAVA failed in 7/20 (35%) participants across the same time period.", [["NAVA", "CHEMICAL", 181, 185], ["NAVA", "CHEMICAL", 181, 185], ["participants", "SPECIES", 207, 219], ["NAVA", "TEST", 181, 185], ["good", "OBSERVATION_MODIFIER", 9, 13], ["NAVA", "OBSERVATION", 14, 18]]], ["To date, no trial has investigated adherence to a NAVA trial protocol beyond 48 h or determined the reasons for adherence or lack thereof.BackgroundThe primary aim of this study was, therefore, to assess the feasibility of a trial protocol comparing NAVA to PSV, via an assessment of mode adherence.", [["a NAVA trial protocol", "TREATMENT", 48, 69], ["lack thereof", "PROBLEM", 125, 137], ["this study", "TEST", 167, 177], ["a trial protocol", "TREATMENT", 223, 239], ["NAVA", "TREATMENT", 250, 254], ["PSV", "TREATMENT", 258, 261], ["an assessment", "TEST", 267, 280]]], ["Our primary feasibility objectives were to assess mode adherence (proportion of time adherent to assigned mode) and protocol compliance (binary\u2014\u2265 65% mode adherence) during the entire study period.", [["protocol compliance (binary\u2014\u2265 65% mode adherence", "TREATMENT", 116, 164]]], ["In contrast to previous trials, recruitment was commenced soon after intubation (ability to trigger the ventilator was not a requirement for inclusion), and the intervention was continued to the end of MV support or D28.", [["MV", "SPECIES", 202, 204], ["recruitment", "TREATMENT", 32, 43], ["intubation", "TREATMENT", 69, 79], ["the ventilator", "TREATMENT", 100, 114], ["the intervention", "TREATMENT", 157, 173], ["MV support", "TREATMENT", 202, 212], ["D28", "TREATMENT", 216, 219]]], ["In addition, reasons for mode cross-over and poor adherence were recorded.", [["mode cross-over", "PROBLEM", 25, 40], ["poor adherence", "PROBLEM", 45, 59]]], ["Some study results have been previously reported in the form of abstracts [10, 11].Participants ::: MethodsThe inclusion criteria were as follows: adults receiving invasive MV with at least one of the following risk factors for prolonged MV [12]: (1) COPD, (2) heart failure (HF), or (3) acute respiratory distress syndrome (ARDS).", [["heart", "ANATOMY", 261, 266], ["respiratory", "ANATOMY", 294, 305], ["COPD", "DISEASE", 251, 255], ["heart failure", "DISEASE", 261, 274], ["HF", "DISEASE", 276, 278], ["acute respiratory distress syndrome", "DISEASE", 288, 323], ["ARDS", "DISEASE", 325, 329], ["adults", "ORGANISM", 147, 153], ["heart", "ORGAN", 261, 266], ["Participants", "SPECIES", 83, 95], ["MV", "SPECIES", 173, 175], ["MV", "SPECIES", 238, 240], ["Some study", "TEST", 0, 10], ["invasive MV", "TREATMENT", 164, 175], ["prolonged MV", "PROBLEM", 228, 240], ["COPD", "PROBLEM", 251, 255], ["heart failure (HF)", "PROBLEM", 261, 279], ["acute respiratory distress syndrome", "PROBLEM", 288, 323], ["ARDS", "PROBLEM", 325, 329], ["COPD", "OBSERVATION", 251, 255], ["heart", "ANATOMY", 261, 266], ["failure", "OBSERVATION", 267, 274], ["acute", "OBSERVATION_MODIFIER", 288, 293], ["respiratory", "ANATOMY", 294, 305], ["distress", "OBSERVATION", 306, 314]]], ["Diagnoses by senior grade specialist physicians (respiratory, cardiac, intensivist) or by a non-specialist physician combined with either objective test results (spirometry, a CT scan, lung biopsy, cardiac echocardiogram) and/or prescribed treatment were required prior to enrolment (Additional file 1).", [["respiratory", "ANATOMY", 49, 60], ["cardiac", "ANATOMY", 62, 69], ["lung", "ANATOMY", 185, 189], ["cardiac", "ANATOMY", 198, 205], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 185, 196], ["objective test", "TEST", 138, 152], ["spirometry", "TEST", 162, 172], ["a CT scan", "TEST", 174, 183], ["lung biopsy", "TEST", 185, 196], ["cardiac echocardiogram", "TEST", 198, 220], ["treatment", "TREATMENT", 240, 249], ["cardiac", "ANATOMY", 62, 69], ["lung", "ANATOMY", 185, 189]]], ["The exclusion criteria were as follows: expected extubation, death, or treatment withdrawal within 48 h; > 96 h from intubation; > 24 h of spontaneously triggered ventilation mode support; suspected or proven hypoxic brain injury; high spinal injury; severe traumatic brain injury; neurological cause of ventilator dependency such as Guillain-Barr\u00e9 syndrome or Myasthenia Gravis; contraindication to nasogastric tube insertion; requirement for domiciliary ventilation; enrolment in any other interventional clinical trial; non-English speakers with inadequate translation available to allow informed consent; and pregnancy.Participants ::: MethodsResearch staff obtained informed consent from the participant\u2019s legally authorized representative or proxy, and participant consent was sought once capacity was regained as required by the UK law [13].Randomization ::: MethodsUsing a 1:1 allocation ratio, treatment order was randomized with permuted blocks of random sizes using online randomization software, managed by an independent clinical trial unit [14].", [["brain", "ANATOMY", 217, 222], ["spinal", "ANATOMY", 236, 242], ["brain", "ANATOMY", 268, 273], ["neurological", "ANATOMY", 282, 294], ["death", "DISEASE", 61, 66], ["brain injury", "DISEASE", 217, 229], ["spinal injury", "DISEASE", 236, 249], ["traumatic brain injury", "DISEASE", 258, 280], ["ventilator dependency", "DISEASE", 304, 325], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 334, 357], ["Myasthenia Gravis", "DISEASE", 361, 378], ["brain", "ORGAN", 217, 222], ["spinal", "ORGANISM_SUBDIVISION", 236, 242], ["brain", "ORGAN", 268, 273], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 400, 416], ["Participants", "SPECIES", 623, 635], ["participant", "SPECIES", 697, 708], ["death", "PROBLEM", 61, 66], ["treatment withdrawal", "PROBLEM", 71, 91], ["intubation", "TREATMENT", 117, 127], ["spontaneously triggered ventilation mode support", "TREATMENT", 139, 187], ["hypoxic brain injury", "PROBLEM", 209, 229], ["high spinal injury", "PROBLEM", 231, 249], ["severe traumatic brain injury", "PROBLEM", 251, 280], ["ventilator dependency", "PROBLEM", 304, 325], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 334, 357], ["Myasthenia Gravis", "PROBLEM", 361, 378], ["nasogastric tube insertion", "TREATMENT", 400, 426], ["domiciliary ventilation", "TREATMENT", 444, 467], ["enrolment", "TREATMENT", 469, 478], ["a 1:1 allocation ratio", "TREATMENT", 879, 901], ["online randomization software", "TREATMENT", 977, 1006], ["hypoxic brain injury", "OBSERVATION", 209, 229], ["spinal", "ANATOMY", 236, 242], ["injury", "OBSERVATION", 243, 249], ["severe", "OBSERVATION_MODIFIER", 251, 257], ["traumatic", "OBSERVATION_MODIFIER", 258, 267], ["brain", "ANATOMY", 268, 273], ["injury", "OBSERVATION", 274, 280], ["ventilator dependency", "OBSERVATION", 304, 325], ["Myasthenia", "OBSERVATION", 361, 371], ["nasogastric tube", "OBSERVATION", 400, 416]]], ["The study intervention could not be blinded; treating clinicians, researchers, participants, families, and outcome assessors were aware of study group allocations.Procedures ::: MethodsIn the NAVA group, NAVA catheters were inserted within 4 h of randomization.", [["NAVA", "CANCER", 192, 196], ["participants", "SPECIES", 79, 91], ["The study intervention", "TEST", 0, 22], ["MethodsIn the NAVA group", "TREATMENT", 178, 202], ["NAVA catheters", "TREATMENT", 204, 218], ["randomization", "TREATMENT", 247, 260], ["NAVA catheters", "OBSERVATION", 204, 218]]], ["Clinicians were instructed to record the maximum Edi hourly, to use the NAVA mode in place of PSV, and to target an Edi of \u2265 8 \u03bcV by adjustment of sedation dose and/or adjustment of MV settings where appropriate.", [["MV", "SPECIES", 182, 184], ["the NAVA mode", "TREATMENT", 68, 81], ["PSV", "TREATMENT", 94, 97], ["sedation dose", "TREATMENT", 147, 160], ["MV settings", "TREATMENT", 182, 193]]], ["A lower target level of 8 \u03bcV was set following basic analysis of existing literature and local audit data to avoid over-ventilation and over-sedation.", [["basic analysis", "TEST", 47, 61], ["local audit data", "TEST", 89, 105], ["ventilation", "TREATMENT", 120, 131], ["sedation", "TREATMENT", 141, 149]]], ["NAVA parameters were set by clinicians according to a pragmatic protocol (Additional file 1), which involved matching hypothetical to actual pressure delivery (NAVA preview mode) and a brief period of observation to ensure stability.", [["NAVA parameters", "TEST", 0, 15], ["actual pressure delivery", "TREATMENT", 134, 158], ["stability", "OBSERVATION", 223, 232]]], ["In the PSV group, ventilation settings were adjusted according to tidal volumes, clinicians were advised to review cycling criteria to optimize synchrony, and participants were otherwise ventilated according to local practice.Procedures ::: MethodsIn both groups, protective tidal volumes of between 6 and 8 ml/kg of predicted body weight were recommended (Additional file 2, Table 4).", [["body", "ANATOMY", 327, 331], ["body", "ORGANISM_SUBDIVISION", 327, 331], ["participants", "SPECIES", 159, 171], ["the PSV group", "TREATMENT", 3, 16], ["ventilation settings", "TREATMENT", 18, 38], ["MethodsIn both groups", "TREATMENT", 241, 262], ["protective tidal volumes", "TREATMENT", 264, 288], ["predicted body weight", "TEST", 317, 338]]], ["Weaning guidelines included performing an assessment of readiness for a spontaneous mode, gradual stepwise reduction in ventilation support, sedation limitation according to Richmond Agitation and Sedation Scale (RASS) targets [16], and daily consideration of sedation holds and spontaneous breathing trials determined by the clinical team.", [["Weaning guidelines", "TREATMENT", 0, 18], ["an assessment", "TEST", 39, 52], ["a spontaneous mode", "TREATMENT", 70, 88], ["gradual stepwise reduction", "TREATMENT", 90, 116], ["ventilation support", "TREATMENT", 120, 139], ["sedation limitation", "TREATMENT", 141, 160], ["Richmond Agitation", "TREATMENT", 174, 192], ["Sedation Scale (RASS) targets", "TREATMENT", 197, 226], ["sedation", "TREATMENT", 260, 268], ["spontaneous breathing trials", "TREATMENT", 279, 307]]], ["A full description of the weaning process is provided in Additional file 1.", [["the weaning process", "TREATMENT", 22, 41]]], ["Study documents also guided troubleshooting of NAVA technical difficulties.", [["NAVA technical difficulties", "PROBLEM", 47, 74]]], ["The protocol was continued for up to 28 days from randomization.Outcomes ::: MethodsThe primary feasibility outcome was the proportion of MV time spent in assigned mode from randomization to extubation, death, or D28.", [["death", "DISEASE", 203, 208], ["MV", "SPECIES", 138, 140], ["The protocol", "TREATMENT", 0, 12], ["randomization", "TREATMENT", 50, 63], ["Methods", "TREATMENT", 77, 84], ["extubation", "TREATMENT", 191, 201]]], ["Continuous MV (CMV) modes and CPAP were permitted in both groups, but no other exclusively spontaneously triggered modes were allowed.", [["CMV", "ORGANISM", 15, 18], ["MV", "SPECIES", 11, 13], ["Continuous MV (CMV) modes", "TREATMENT", 0, 25], ["CPAP", "TREATMENT", 30, 34]]], ["A priori, we considered a participant to be protocol compliant if mode adherence was \u2265 65% (binary) and the trial to be feasible if \u2265 65% of participants were compliant.", [["participants", "ORGANISM", 141, 153], ["participants", "SPECIES", 141, 153]]], ["Secondary feasibility outcomes were the proportion of participants with mode cross-over, duration of cross-over, reasons for cross-over, protocol acceptability (participant consent/physician refusal rates), and recruitment rates.", [["participants", "SPECIES", 54, 66], ["recruitment rates", "TEST", 211, 228]]], ["Secondary exploratory outcomes included ventilator-free days (VFDs) to D28 and D90 and duration of MV from randomization; ICU, hospital, D28, and D90 mortality; ICU and hospital length-of-stay from randomization; mean RASS; and sedation dose and bolus dose frequency per infusion day.", [["MV", "SPECIES", 99, 101], ["ventilator-free days (VFDs)", "TREATMENT", 40, 67], ["D28", "TREATMENT", 71, 74], ["D90", "TREATMENT", 79, 82], ["MV", "TREATMENT", 99, 101], ["D28", "TREATMENT", 137, 140], ["randomization", "TREATMENT", 198, 211], ["mean RASS", "TEST", 213, 222], ["sedation dose", "TREATMENT", 228, 241], ["bolus dose frequency", "TREATMENT", 246, 266]]], ["Safety outcomes included ventilator-associated pneumonia (VAP), pneumothoraxes, and incidence of unplanned extubation (Additional file 1).Sample size and statistical analyses ::: MethodsUsing 65% as the lower bound of the confidence interval (CI) (the minimum acceptable proportion to indicate trial feasibility) and an expected attrition of 5% (i.e. no NAVA or PSV weaning), a sample size of 76 patients (38 in each arm) would estimate a protocol compliance of 75% to within a 95% CI of \u00b1 10% [17].", [["pneumonia", "DISEASE", 47, 56], ["VAP", "DISEASE", 58, 61], ["pneumothoraxes", "DISEASE", 64, 78], ["patients", "ORGANISM", 396, 404], ["patients", "SPECIES", 396, 404], ["pneumonia", "PROBLEM", 47, 56], ["VAP", "PROBLEM", 58, 61], ["pneumothoraxes", "PROBLEM", 64, 78], ["unplanned extubation", "TREATMENT", 97, 117], ["Sample size", "TEST", 138, 149], ["MethodsUsing", "TREATMENT", 179, 191], ["NAVA", "TREATMENT", 354, 358], ["PSV weaning", "TREATMENT", 362, 373], ["a sample size", "TEST", 376, 389], ["a protocol compliance", "TEST", 437, 458], ["pneumonia", "OBSERVATION", 47, 56], ["size", "OBSERVATION_MODIFIER", 145, 149]]], ["Categorical data were compared using chi-square or Fisher exact tests and continuous variables using Mann-Whitney or independent samples t tests as appropriate.", [["Categorical data", "TEST", 0, 16], ["Fisher exact tests", "TEST", 51, 69], ["independent samples t tests", "TEST", 117, 144]]], ["Effect sizes are reported as median difference (MD) using the Hodges-Lehmann estimating method [15] for continuous variables, and as relative risk (RR) for binary data [18].", [["the Hodges-Lehmann estimating method", "TREATMENT", 58, 94], ["RR", "TEST", 148, 150], ["binary data", "TEST", 156, 167], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["Effect estimates are reported with 95% CIs [18, 19].", [["Effect estimates", "TEST", 0, 16]]], ["Time to breathing without assistance and live ICU discharge are displayed using Kaplan-Meier curves with log-rank tests.", [["log-rank tests", "TEST", 105, 119]]], ["A two-sided P value of < 0.05 was considered statistically significant.", [["A two-sided P value", "TEST", 0, 19], ["sided", "ANATOMY_MODIFIER", 6, 11]]], ["Analysis of clinical outcomes was exploratory and uncorrected for multiple comparisons; therefore, the statistically significant results could be due to chance.", [["multiple comparisons", "TEST", 66, 86]]], ["Qualitative descriptions of cross-over were categorized using content analysis [20].", [["content analysis", "TEST", 62, 78]]], ["Statistical analyses were performed using GraphPad Prism version 7.04 (GraphPad Software, La Jolla, CA, USA).Feasibility outcomes ::: ResultsThe average recruitment rate was 1.7 patients per month.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["Statistical analyses", "TEST", 0, 20], ["GraphPad Prism version", "TEST", 42, 64], ["GraphPad", "TEST", 71, 79], ["Software", "TEST", 80, 88], ["The average recruitment rate", "TEST", 141, 169]]], ["Low rates of physician enrolment refusal (15 patients, 11.8%) (Fig. 1) suggests the trial was acceptable to clinical staff.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Of the 78 randomized participants, one withdrew consent and five (three NAVA, two PSV) did not commence weaning and were excluded from the adherence analysis.", [["participants", "SPECIES", 21, 33], ["NAVA", "TREATMENT", 72, 76], ["the adherence analysis", "TEST", 135, 157]]], ["In the 72 participants in whom weaning was attempted, median (95% CI) proportion of time in assigned ventilator mode from randomization to extubation, death, or D28 was 83.1% (64.0 to 97.1%) (NAVA) and 100% (100 to 100%) (PSV).", [["death", "DISEASE", 151, 156], ["participants", "SPECIES", 10, 22], ["extubation", "TREATMENT", 139, 149], ["death", "PROBLEM", 151, 156], ["D28", "TEST", 161, 164], ["NAVA", "TEST", 192, 196], ["PSV", "TEST", 222, 225]]], ["Compliance, i.e. \u2265 65% adherence to assigned mode, was met in 82.2% (95% CI 71.7 to 89.4%) of all participants, 66.7% of NAVA participants (95% CI 50.3 to 80.0%), and 100% of PSV participants (95% CI 89.0 to 100.0%).", [["participants", "SPECIES", 98, 110], ["participants", "SPECIES", 126, 138], ["participants", "SPECIES", 179, 191], ["CI", "TEST", 73, 75], ["NAVA", "TEST", 121, 125], ["CI", "TEST", 144, 146], ["PSV", "TEST", 175, 178], ["CI", "TEST", 197, 199]]], ["Mode cross-over occurred in 28 (71.8%) NAVA and 3 (8.3%) PSV participants; the proportion of time cross-over from randomization to extubation, death, or D28 was 17.7% (95% CI 3.2 to 51.4%) and 0% (95% CI 0 to 0%) respectively (Table 2).", [["death", "DISEASE", 143, 148], ["NAVA", "CANCER", 39, 43], ["participants", "SPECIES", 61, 73], ["Mode cross-over", "TEST", 0, 15], ["NAVA", "TEST", 39, 43], ["PSV", "TREATMENT", 57, 60], ["death", "PROBLEM", 143, 148], ["D28", "TEST", 153, 156], ["CI", "TEST", 172, 174], ["CI", "TEST", 201, 203]]]], "bab261d7f938e60476fd3bfa614a36be5c933ff3": [["INTRODUCTIONOn 11 March 2020, the WHO declared COVID-19, the disease caused by SARS-CoV-2 a global pandemic.", [["SARS", "DISEASE", 79, 83], ["SARS-CoV-2", "ORGANISM", 79, 89], ["SARS-CoV", "SPECIES", 79, 87], ["the disease", "PROBLEM", 57, 68], ["SARS", "PROBLEM", 79, 83], ["a global pandemic", "PROBLEM", 90, 107], ["disease", "OBSERVATION", 61, 68], ["pandemic", "OBSERVATION", 99, 107]]], ["COVID-19 has placed an immense burden on healthcare systems and has had a great impact on society.", [["COVID-19", "CHEMICAL", 0, 8], ["immense", "OBSERVATION_MODIFIER", 23, 30], ["burden", "OBSERVATION", 31, 37], ["great", "OBSERVATION_MODIFIER", 74, 79], ["impact", "OBSERVATION", 80, 86]]], ["1 COVID-19 has largely been described as a respiratory illness, with the most common symptoms reported as cough, shortness of breath and fever.", [["respiratory", "ANATOMY", 43, 54], ["COVID-19", "CHEMICAL", 2, 10], ["respiratory illness", "DISEASE", 43, 62], ["cough", "DISEASE", 106, 111], ["shortness of breath", "DISEASE", 113, 132], ["fever", "DISEASE", 137, 142], ["a respiratory illness", "PROBLEM", 41, 62], ["the most common symptoms", "PROBLEM", 69, 93], ["cough", "PROBLEM", 106, 111], ["shortness of breath", "PROBLEM", 113, 132], ["fever", "PROBLEM", 137, 142], ["respiratory illness", "OBSERVATION", 43, 62], ["cough", "OBSERVATION", 106, 111]]], ["2 3 Recent literature has suggested that COVID-19 is not solely a respiratory disease but has the potential to affect multiple organs.", [["respiratory", "ANATOMY", 66, 77], ["organs", "ANATOMY", 127, 133], ["respiratory disease", "DISEASE", 66, 85], ["COVID-19", "GENE_OR_GENE_PRODUCT", 41, 49], ["organs", "ORGAN", 127, 133], ["COVID", "TEST", 41, 46], ["a respiratory disease", "PROBLEM", 64, 85], ["respiratory disease", "OBSERVATION", 66, 85]]], ["4 5 There is emerging evidence supporting the development of severe coagulopathies among patients with COVID-19, as demonstrated in a Dutch study by Klok et al, which showed that 31% of patients in the intensive care unit had thrombotic complications.", [["coagulopathies", "DISEASE", 68, 82], ["thrombotic complications", "DISEASE", 226, 250], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 186, 194], ["severe coagulopathies", "PROBLEM", 61, 82], ["COVID", "TEST", 103, 108], ["a Dutch study", "TEST", 132, 145], ["thrombotic complications", "PROBLEM", 226, 250], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["coagulopathies", "OBSERVATION", 68, 82], ["thrombotic", "OBSERVATION_MODIFIER", 226, 236], ["complications", "OBSERVATION", 237, 250]]], ["[6] [7] [8] There are also increasing reports of acute ischaemic stroke (AIS), with a reported incidence between 2.5% and 5.6% of patients with COVID-19.", [["acute ischaemic stroke", "DISEASE", 49, 71], ["AIS", "DISEASE", 73, 76], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["acute ischaemic stroke", "PROBLEM", 49, 71], ["COVID", "TEST", 144, 149], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["ischaemic", "OBSERVATION_MODIFIER", 55, 64], ["stroke", "OBSERVATION", 65, 71]]], ["4 9 A recently published mini case series by Oxley et al 10 found an increase in AIS due to large-vessel occlusion (LVO) among patients aged 50 years and younger with COVID-19.", [["vessel", "ANATOMY", 98, 104], ["AIS", "DISEASE", 81, 84], ["large-vessel occlusion", "DISEASE", 92, 114], ["LVO", "DISEASE", 116, 119], ["vessel", "MULTI-TISSUE_STRUCTURE", 98, 104], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["an increase in AIS", "PROBLEM", 66, 84], ["large-vessel occlusion", "PROBLEM", 92, 114], ["COVID", "TEST", 167, 172], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["large", "OBSERVATION_MODIFIER", 92, 97], ["vessel", "ANATOMY", 98, 104], ["occlusion", "OBSERVATION", 105, 114]]], ["Emerging theories suggest that patients may be at risk for stroke due to multiple factors, including an excessive inflammatory response, hypercytokinaemia, prothrombotic state and endothelial dysfunction secondary to depletion of angiotensinconverting enzyme 2 (ACE2).", [["endothelial", "ANATOMY", 180, 191], ["stroke", "DISEASE", 59, 65], ["hypercytokinaemia", "DISEASE", 137, 154], ["endothelial dysfunction", "DISEASE", 180, 203], ["patients", "ORGANISM", 31, 39], ["endothelial", "TISSUE", 180, 191], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 230, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 262, 266], ["angiotensinconverting enzyme 2", "PROTEIN", 230, 260], ["ACE2", "PROTEIN", 262, 266], ["patients", "SPECIES", 31, 39], ["stroke", "PROBLEM", 59, 65], ["multiple factors", "PROBLEM", 73, 89], ["an excessive inflammatory response", "PROBLEM", 101, 135], ["hypercytokinaemia", "PROBLEM", 137, 154], ["prothrombotic state", "PROBLEM", 156, 175], ["endothelial dysfunction", "PROBLEM", 180, 203], ["depletion of angiotensinconverting enzyme", "PROBLEM", 217, 258], ["stroke", "OBSERVATION", 59, 65], ["excessive", "OBSERVATION_MODIFIER", 104, 113], ["inflammatory", "OBSERVATION", 114, 126], ["prothrombotic state", "OBSERVATION", 156, 175], ["endothelial dysfunction", "OBSERVATION", 180, 203]]], ["8 11 We present our initial experience of AIS in patients with COVID-19 in a tertiary comprehensive stroke centre located in one of the COVID-19 hotspots in the USA.METHODSThis is a retrospective, observational study, which was conducted at University Hospital in Newark, New Jersey, a designated comprehensive stroke centre.", [["AIS", "DISEASE", 42, 45], ["stroke", "DISEASE", 100, 106], ["stroke", "DISEASE", 311, 317], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["AIS", "PROBLEM", 42, 45], ["COVID", "TEST", 63, 68], ["the COVID", "TEST", 132, 141], ["observational study", "TEST", 197, 216]]], ["The first patient with confirmed COVID-19 was admitted to our hospital on 15 March 2020.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17]]], ["We reviewed all patients admitted to our hospital from 15 March 2020 through 30 April 2020.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["All patients with positive results for SARS-CoV-2 reverse transcriptase PCR (RT-PCR) assay of nasopharyngeal swab were included for analysis.", [["nasopharyngeal swab", "ANATOMY", 94, 113], ["patients", "ORGANISM", 4, 12], ["nasopharyngeal swab", "CANCER", 94, 113], ["patients", "SPECIES", 4, 12], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["transcriptase PCR", "TEST", 58, 75], ["RT-PCR", "TEST", 77, 83], ["nasopharyngeal swab", "TEST", 94, 113], ["analysis", "TEST", 132, 140], ["nasopharyngeal", "ANATOMY", 94, 108]]], ["We further identified all patients with SARS-CoV-2 who had AIS by chart review and reviewed all stroke team consults during this period.METHODSWe investigated the electronic medical records, laboratory data and imaging studies for all patients with AIS and Open access laboratory-confirmed SARS-CoV-2 infection.", [["AIS", "DISEASE", 59, 62], ["stroke", "DISEASE", 96, 102], ["AIS", "DISEASE", 249, 252], ["SARS-CoV-2 infection", "DISEASE", 290, 310], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 235, 243], ["SARS-CoV-2", "SPECIES", 290, 300], ["AIS", "PROBLEM", 59, 62], ["laboratory data", "TEST", 191, 206], ["imaging studies", "TEST", 211, 226], ["AIS", "PROBLEM", 249, 252], ["Open access laboratory", "TEST", 257, 279], ["SARS", "PROBLEM", 290, 294], ["CoV", "PROBLEM", 295, 298], ["2 infection", "PROBLEM", 299, 310], ["infection", "OBSERVATION", 301, 310]]], ["We collected data on age, sex and risk factors for stroke, including a documented history of, or treatments for, hypertension, atrial fibrillation, diabetes mellitus, smoking, obesity, hyperlipidaemia and prior ischaemic stroke.", [["atrial", "ANATOMY", 127, 133], ["stroke", "DISEASE", 51, 57], ["hypertension", "DISEASE", 113, 125], ["atrial fibrillation", "DISEASE", 127, 146], ["diabetes mellitus", "DISEASE", 148, 165], ["obesity", "DISEASE", 176, 183], ["hyperlipidaemia", "DISEASE", 185, 200], ["ischaemic stroke", "DISEASE", 211, 227], ["stroke", "PROBLEM", 51, 57], ["treatments", "TREATMENT", 97, 107], ["hypertension", "PROBLEM", 113, 125], ["atrial fibrillation", "PROBLEM", 127, 146], ["diabetes mellitus", "PROBLEM", 148, 165], ["obesity", "PROBLEM", 176, 183], ["hyperlipidaemia", "PROBLEM", 185, 200], ["prior ischaemic stroke", "PROBLEM", 205, 227], ["hypertension", "OBSERVATION", 113, 125], ["atrial", "ANATOMY", 127, 133], ["fibrillation", "OBSERVATION", 134, 146], ["diabetes mellitus", "OBSERVATION", 148, 165], ["obesity", "OBSERVATION", 176, 183], ["hyperlipidaemia", "OBSERVATION", 185, 200], ["ischaemic", "OBSERVATION_MODIFIER", 211, 220], ["stroke", "OBSERVATION", 221, 227]]], ["We included chronic kidney disease, heart failure and systemic atherosclerosis in our data collection.", [["kidney", "ANATOMY", 20, 26], ["heart", "ANATOMY", 36, 41], ["chronic kidney disease", "DISEASE", 12, 34], ["heart failure", "DISEASE", 36, 49], ["atherosclerosis", "DISEASE", 63, 78], ["kidney", "ORGAN", 20, 26], ["heart", "ORGAN", 36, 41], ["chronic kidney disease", "PROBLEM", 12, 34], ["heart failure", "PROBLEM", 36, 49], ["systemic atherosclerosis", "PROBLEM", 54, 78], ["our data collection", "TEST", 82, 101], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["kidney", "ANATOMY", 20, 26], ["disease", "OBSERVATION", 27, 34], ["heart", "ANATOMY", 36, 41], ["failure", "OBSERVATION", 42, 49], ["systemic", "OBSERVATION_MODIFIER", 54, 62], ["atherosclerosis", "OBSERVATION", 63, 78]]], ["We documented the prior use of antiplatelet agents and anticoagulants.", [["antiplatelet agents", "SIMPLE_CHEMICAL", 31, 50], ["antiplatelet agents", "TREATMENT", 31, 50], ["anticoagulants", "TREATMENT", 55, 69]]], ["For each patient, we recorded presenting symptoms, including respiratory, systemic and neurological symptoms.", [["respiratory", "ANATOMY", 61, 72], ["neurological", "ANATOMY", 87, 99], ["respiratory, systemic and neurological symptoms", "DISEASE", 61, 108], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["presenting symptoms", "PROBLEM", 30, 49], ["respiratory, systemic and neurological symptoms", "PROBLEM", 61, 108], ["respiratory", "ANATOMY", 61, 72]]], ["We documented the initial National Institute of Health Stroke Scale (NIHSS).", [["Stroke", "DISEASE", 55, 61]]], ["We recorded the date of onset of respiratory symptoms (if present), in relation to the date of onset of AIS.", [["respiratory", "ANATOMY", 33, 44], ["respiratory symptoms", "DISEASE", 33, 53], ["AIS", "DISEASE", 104, 107], ["respiratory symptoms", "PROBLEM", 33, 53], ["AIS", "PROBLEM", 104, 107], ["respiratory", "ANATOMY", 33, 44], ["symptoms", "OBSERVATION", 45, 53]]], ["Interventions, including administration of tissue plasminogen activator (tPA) and mechanical thrombectomy (MT), were reviewed for each patient.", [["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 43, 71], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["Interventions", "TREATMENT", 0, 13], ["tissue plasminogen activator", "TREATMENT", 43, 71], ["tPA)", "TREATMENT", 73, 77], ["mechanical thrombectomy (MT)", "TREATMENT", 82, 110], ["thrombectomy", "OBSERVATION", 93, 105]]], ["Inflammatory and coagulation markers, including platelets, international normalised ratio, D-dimer, ferritin, fibrinogen and C reactive protein (CRP) were collected for each patient.", [["platelets", "ANATOMY", 48, 57], ["platelets", "CELL", 48, 57], ["D-dimer", "GENE_OR_GENE_PRODUCT", 91, 98], ["ferritin", "GENE_OR_GENE_PRODUCT", 100, 108], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 110, 120], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 125, 143], ["CRP", "GENE_OR_GENE_PRODUCT", 145, 148], ["patient", "ORGANISM", 174, 181], ["coagulation markers", "PROTEIN", 17, 36], ["platelets", "CELL_TYPE", 48, 57], ["D-dimer", "PROTEIN", 91, 98], ["ferritin", "PROTEIN", 100, 108], ["fibrinogen", "PROTEIN", 110, 120], ["C reactive protein", "PROTEIN", 125, 143], ["CRP", "PROTEIN", 145, 148], ["patient", "SPECIES", 174, 181], ["coagulation markers", "TEST", 17, 36], ["platelets", "TEST", 48, 57], ["international normalised ratio", "TEST", 59, 89], ["D-dimer", "TEST", 91, 98], ["ferritin", "TEST", 100, 108], ["fibrinogen", "TEST", 110, 120], ["C reactive protein", "PROBLEM", 125, 143], ["CRP", "TEST", 145, 148], ["coagulation markers", "OBSERVATION", 17, 36]]], ["Laboratory values collected closest to the time of stroke onset were used in our analysis.", [["stroke", "DISEASE", 51, 57], ["Laboratory values", "TEST", 0, 17], ["stroke onset", "PROBLEM", 51, 63], ["our analysis", "TEST", 77, 89]]], ["We reviewed all neuroimaging, as well as echocardiogram reports for each patient, if available.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["all neuroimaging", "TEST", 12, 28], ["echocardiogram", "TEST", 41, 55]]], ["Severity of COVID-19 infection was evaluated based on evidence of multiorgan dysfunction syndrome (MODS) and respiratory support required during hospital admission.", [["multiorgan", "ANATOMY", 66, 76], ["respiratory", "ANATOMY", 109, 120], ["infection", "DISEASE", 21, 30], ["multiorgan dysfunction syndrome", "DISEASE", 66, 97], ["MODS", "DISEASE", 99, 103], ["multiorgan", "ORGAN", 66, 76], ["COVID", "TEST", 12, 17], ["19 infection", "PROBLEM", 18, 30], ["multiorgan dysfunction syndrome", "PROBLEM", 66, 97], ["MODS", "PROBLEM", 99, 103], ["respiratory support", "TREATMENT", 109, 128], ["infection", "OBSERVATION", 21, 30], ["evidence of", "UNCERTAINTY", 54, 65], ["multiorgan dysfunction", "OBSERVATION", 66, 88], ["respiratory support", "OBSERVATION", 109, 128]]], ["We documented the outcomes for all patients, which included discharge to home, discharge to acute rehabilitation centre, discharge to skilled nursing facility or death.METHODSContinuous variables, including laboratory values, are presented as means and SD for normally distributed data.", [["death", "DISEASE", 162, 167], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["death", "PROBLEM", 162, 167], ["laboratory values", "TEST", 207, 224]]], ["Categorical variables are presented as counts and percentages.", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 50, 61]]], ["For factors determining outcomes, we calculated the p value using Z score and \u03c7 2 test.RESULTSWe analysed a total of 683 patients admitted to the hospital with laboratory-confirmed COVID-19 between 15 March 2020 to 30 April 2020.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["the p value", "TEST", 48, 59], ["Z score", "TEST", 66, 73], ["COVID", "TEST", 181, 186]]], ["Twenty patients (2\u00b79%) had documented AIS.", [["AIS", "DISEASE", 38, 41], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["documented AIS", "PROBLEM", 27, 41], ["AIS", "OBSERVATION", 38, 41]]], ["We found three additional patients with large-vessel AIS, who had known exposure to COVID-19, elevated inflammatory markers and bilateral chest infiltrates suggestive of viral pneumonia.", [["chest infiltrates", "ANATOMY", 138, 155], ["AIS", "DISEASE", 53, 56], ["viral pneumonia", "DISEASE", 170, 185], ["patients", "ORGANISM", 26, 34], ["vessel", "MULTI-TISSUE_STRUCTURE", 46, 52], ["chest infiltrates", "PATHOLOGICAL_FORMATION", 138, 155], ["inflammatory markers", "PROTEIN", 103, 123], ["patients", "SPECIES", 26, 34], ["large-vessel AIS", "PROBLEM", 40, 56], ["COVID", "TEST", 84, 89], ["elevated inflammatory markers", "PROBLEM", 94, 123], ["bilateral chest infiltrates", "PROBLEM", 128, 155], ["viral pneumonia", "PROBLEM", 170, 185], ["large", "OBSERVATION_MODIFIER", 40, 45], ["vessel", "ANATOMY", 46, 52], ["AIS", "OBSERVATION", 53, 56], ["elevated", "OBSERVATION_MODIFIER", 94, 102], ["inflammatory markers", "OBSERVATION", 103, 123], ["bilateral", "ANATOMY_MODIFIER", 128, 137], ["chest", "ANATOMY", 138, 143], ["infiltrates", "OBSERVATION", 144, 155], ["suggestive of", "UNCERTAINTY", 156, 169], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["pneumonia", "OBSERVATION", 176, 185]]], ["Multiple nasopharyngeal swab tests were negative for SARS-CoV-2 in these patients; therefore, they were not included in our analysis.Demographics and risk factors for patients with AISThe mean age of the 20 patients included in our analysis was 63\u00b110\u00b77 (range: 37-78), and 14 (63%) were men.", [["nasopharyngeal swab", "ANATOMY", 9, 28], ["nasopharyngeal swab", "CANCER", 9, 28], ["CoV-2", "ORGANISM", 58, 63], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 207, 215], ["men", "ORGANISM", 287, 290], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 207, 215], ["men", "SPECIES", 287, 290], ["SARS-CoV", "SPECIES", 53, 61], ["Multiple nasopharyngeal swab tests", "TEST", 0, 34], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["our analysis", "TEST", 120, 132], ["our analysis", "TEST", 228, 240], ["nasopharyngeal", "ANATOMY", 9, 23]]], ["The most common risk factors identified were hypertension in 18 patients (90%), diabetes mellitus in 13 (65%) and obesity in 10 patients (50%).", [["hypertension", "DISEASE", 45, 57], ["diabetes mellitus", "DISEASE", 80, 97], ["obesity", "DISEASE", 114, 121], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 128, 136], ["hypertension", "PROBLEM", 45, 57], ["diabetes mellitus", "PROBLEM", 80, 97], ["obesity", "PROBLEM", 114, 121], ["hypertension", "OBSERVATION", 45, 57], ["obesity", "OBSERVATION", 114, 121]]], ["Other risk factors are summarised in table 1.", [["Other risk factors", "PROBLEM", 0, 18]]], ["All patients had at least one stroke risk factor, and nine patients (45%) had three or more risk factors.Stroke characteristicsThirteen patients were diagnosed with AIS on presentation to the emergency room, four patients were diagnosed during their hospitalisation and three patients presented to outside hospitals with AIS and were transferred for endovascular intervention.", [["stroke", "DISEASE", 30, 36], ["Stroke", "DISEASE", 105, 111], ["AIS", "DISEASE", 165, 168], ["AIS", "DISEASE", 321, 324], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 276, 284], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 350, 362], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 276, 284], ["Stroke characteristics", "PROBLEM", 105, 127], ["AIS", "PROBLEM", 165, 168], ["AIS", "PROBLEM", 321, 324], ["endovascular intervention", "TREATMENT", 350, 375]]], ["The mean NIHSS on presentation was 11.9\u00b17.5 (range: 2-26).", [["The mean NIHSS", "TEST", 0, 14]]], ["LVO was seen in 11 patients (55%), and high-grade large-vessel stenosis was seen in 5 patients (20%), which includes one patient who had both and was therefore included in both categories.", [["high-grade large-vessel", "ANATOMY", 39, 62], ["LVO", "DISEASE", 0, 3], ["vessel stenosis", "DISEASE", 56, 71], ["LVO", "CANCER", 0, 3], ["patients", "ORGANISM", 19, 27], ["vessel", "MULTI-TISSUE_STRUCTURE", 56, 62], ["patients", "ORGANISM", 86, 94], ["patient", "ORGANISM", 121, 128], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 86, 94], ["patient", "SPECIES", 121, 128], ["LVO", "TEST", 0, 3], ["high-grade large-vessel stenosis", "PROBLEM", 39, 71], ["high", "OBSERVATION_MODIFIER", 39, 43], ["grade", "OBSERVATION_MODIFIER", 44, 49], ["large", "OBSERVATION_MODIFIER", 50, 55], ["-vessel", "ANATOMY", 55, 62], ["stenosis", "OBSERVATION", 63, 71]]], ["Four patients had a normal CT angiogram (CTA) and one patient did not complete a CTA before discharge (table 1) .", [["patients", "ORGANISM", 5, 13], ["patient", "ORGANISM", 54, 61], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 54, 61], ["a normal CT angiogram", "TEST", 18, 39], ["CTA", "TEST", 41, 44], ["a CTA", "TEST", 79, 84]]], ["Fifty-five per cent of patients arrived outside the therapeutic window for intravenous (IV) tPA, while four patients (20%) received IV tPA.", [["intravenous", "ANATOMY", 75, 86], ["patients", "ORGANISM", 23, 31], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["tPA", "GENE_OR_GENE_PRODUCT", 92, 95], ["patients", "ORGANISM", 108, 116], ["tPA", "GENE_OR_GENE_PRODUCT", 135, 138], ["tPA", "PROTEIN", 135, 138], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 108, 116], ["intravenous (IV) tPA", "TREATMENT", 75, 95], ["IV tPA", "TREATMENT", 132, 138]]], ["Endovascular procedures were performed in five patients (table 1) , while six LVO patients were not candidates for MT (table 1) .", [["LVO", "DISEASE", 78, 81], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 82, 90], ["Endovascular procedures", "TREATMENT", 0, 23]]], ["Two patients (10%) had recurrent strokes within 2 days of initial stroke (table 1) .", [["strokes", "DISEASE", 33, 40], ["stroke", "DISEASE", 66, 72], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["recurrent strokes", "PROBLEM", 23, 40], ["initial stroke", "PROBLEM", 58, 72], ["recurrent", "OBSERVATION_MODIFIER", 23, 32], ["strokes", "OBSERVATION", 33, 40], ["stroke", "OBSERVATION", 66, 72]]], ["Five patients developed asymptomatic haemorrhagic conversion while on a single antiplatelet agent.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["asymptomatic haemorrhagic conversion", "PROBLEM", 24, 60], ["a single antiplatelet agent", "TREATMENT", 70, 97], ["asymptomatic", "OBSERVATION_MODIFIER", 24, 36], ["haemorrhagic", "OBSERVATION", 37, 49]]], ["One patient developed subarachnoid haemorrhage after internal carotid artery aneurysm rupture.", [["subarachnoid", "ANATOMY", 22, 34], ["internal carotid artery aneurysm", "ANATOMY", 53, 85], ["subarachnoid haemorrhage", "DISEASE", 22, 46], ["carotid artery aneurysm rupture", "DISEASE", 62, 93], ["patient", "ORGANISM", 4, 11], ["subarachnoid haemorrhage", "PATHOLOGICAL_FORMATION", 22, 46], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 62, 76], ["patient", "SPECIES", 4, 11], ["subarachnoid haemorrhage", "PROBLEM", 22, 46], ["internal carotid artery aneurysm rupture", "PROBLEM", 53, 93], ["subarachnoid", "ANATOMY_MODIFIER", 22, 34], ["haemorrhage", "OBSERVATION", 35, 46], ["internal carotid artery", "ANATOMY", 53, 76], ["aneurysm", "OBSERVATION", 77, 85], ["rupture", "OBSERVATION", 86, 93]]], ["This patient had not received IV tPA nor endovascular treatment but was treated with IV heparin for pulmonary embolism.Stroke characteristicsOne patient received IV heparin as part of a critical care protocol for elevated D-dimer.", [["pulmonary", "ANATOMY", 100, 109], ["heparin", "CHEMICAL", 88, 95], ["pulmonary embolism", "DISEASE", 100, 118], ["Stroke", "DISEASE", 119, 125], ["heparin", "CHEMICAL", 165, 172], ["patient", "ORGANISM", 5, 12], ["tPA", "GENE_OR_GENE_PRODUCT", 33, 36], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 53], ["IV heparin", "SIMPLE_CHEMICAL", 85, 95], ["pulmonary", "ORGAN", 100, 109], ["patient", "ORGANISM", 145, 152], ["IV heparin", "SIMPLE_CHEMICAL", 162, 172], ["D-dimer", "SIMPLE_CHEMICAL", 222, 229], ["D-dimer", "PROTEIN", 222, 229], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 145, 152], ["IV tPA", "TREATMENT", 30, 36], ["endovascular treatment", "TREATMENT", 41, 63], ["IV heparin", "TREATMENT", 85, 95], ["pulmonary embolism", "PROBLEM", 100, 118], ["Stroke characteristics", "PROBLEM", 119, 141], ["IV heparin", "TREATMENT", 162, 172], ["a critical care protocol", "TREATMENT", 184, 208], ["elevated D-dimer", "PROBLEM", 213, 229], ["endovascular", "OBSERVATION", 41, 53], ["pulmonary", "ANATOMY", 100, 109], ["embolism", "OBSERVATION", 110, 118]]], ["This patient did not have recurrent stroke or haemorrhage.", [["stroke", "DISEASE", 36, 42], ["haemorrhage", "DISEASE", 46, 57], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["recurrent stroke", "PROBLEM", 26, 42], ["haemorrhage", "PROBLEM", 46, 57], ["recurrent", "OBSERVATION_MODIFIER", 26, 35], ["stroke", "OBSERVATION", 36, 42], ["haemorrhage", "OBSERVATION", 46, 57]]], ["AIS mechanism was identified in nine patients.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["AIS mechanism", "PROBLEM", 0, 13]]], ["Large artery atherosclerosis was deemed to be responsible in five (25%) cases, atrial fibrillation in two (10%), small vessel in one and arterial dissection in one.", [["artery", "ANATOMY", 6, 12], ["atrial", "ANATOMY", 79, 85], ["vessel", "ANATOMY", 119, 125], ["arterial", "ANATOMY", 137, 145], ["artery atherosclerosis", "DISEASE", 6, 28], ["atrial fibrillation", "DISEASE", 79, 98], ["artery", "MULTI-TISSUE_STRUCTURE", 6, 12], ["vessel", "MULTI-TISSUE_STRUCTURE", 119, 125], ["arterial", "MULTI-TISSUE_STRUCTURE", 137, 145], ["Large artery atherosclerosis", "PROBLEM", 0, 28], ["atrial fibrillation", "PROBLEM", 79, 98], ["small vessel in one and arterial dissection", "PROBLEM", 113, 156], ["artery", "ANATOMY", 6, 12], ["atherosclerosis", "OBSERVATION", 13, 28], ["atrial", "ANATOMY", 79, 85], ["fibrillation", "OBSERVATION", 86, 98], ["small", "OBSERVATION_MODIFIER", 113, 118], ["vessel", "ANATOMY", 119, 125], ["arterial", "ANATOMY", 137, 145], ["dissection", "OBSERVATION", 146, 156]]], ["One patient had known atrial fibrillation and one was newly diagnosed following AIS.", [["atrial", "ANATOMY", 22, 28], ["atrial fibrillation", "DISEASE", 22, 41], ["AIS", "DISEASE", 80, 83], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["known atrial fibrillation", "PROBLEM", 16, 41], ["AIS", "PROBLEM", 80, 83], ["atrial", "ANATOMY", 22, 28], ["fibrillation", "OBSERVATION", 29, 41]]], ["Heart failure was seen in four patients, two of which were new in onset and two were acute exacerbations of chronic illness.", [["Heart", "ANATOMY", 0, 5], ["Heart failure", "DISEASE", 0, 13], ["chronic illness", "DISEASE", 108, 123], ["Heart", "ORGAN", 0, 5], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Heart failure", "PROBLEM", 0, 13], ["acute exacerbations of chronic illness", "PROBLEM", 85, 123], ["failure", "OBSERVATION", 6, 13], ["new", "OBSERVATION_MODIFIER", 59, 62], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["exacerbations", "OBSERVATION", 91, 104], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["illness", "OBSERVATION", 116, 123]]], ["Atrial enlargement was present in three patients, one of which was identified on echocardiogram, and two were noted on ECG.", [["Atrial", "ANATOMY", 0, 6], ["Atrial enlargement", "DISEASE", 0, 18], ["Atrial", "MULTI-TISSUE_STRUCTURE", 0, 6], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Atrial enlargement", "PROBLEM", 0, 18], ["echocardiogram", "TEST", 81, 95], ["ECG", "TEST", 119, 122], ["enlargement", "OBSERVATION", 7, 18]]], ["The aetiology of AIS could not be determined in 11 patients by the time of discharge.COVID-19 characteristicsThe first patient with AIS with COVID-19 was admitted on 27 March 2020, 12 days after the first admission to our hospital for SARS-CoV-2 infection.", [["AIS", "DISEASE", 17, 20], ["AIS", "DISEASE", 132, 135], ["SARS-CoV-2 infection", "DISEASE", 235, 255], ["patients", "ORGANISM", 51, 59], ["patient", "ORGANISM", 119, 126], ["COVID", "PROTEIN", 85, 90], ["patients", "SPECIES", 51, 59], ["patient", "SPECIES", 119, 126], ["AIS", "PROBLEM", 17, 20], ["COVID", "TEST", 85, 90], ["AIS", "PROBLEM", 132, 135], ["COVID", "TEST", 141, 146], ["SARS", "PROBLEM", 235, 239], ["CoV-2 infection", "PROBLEM", 240, 255], ["19 characteristics", "OBSERVATION_MODIFIER", 91, 109], ["infection", "OBSERVATION", 246, 255]]], ["We compared the demographics and outcomes of all COVID-19 admissions and COVID-19 admissions with stroke (table 2) .COVID-19 characteristicsFourteen patients (70%) had documented history of respiratory symptoms prior to AIS onset.", [["respiratory", "ANATOMY", 190, 201], ["stroke", "DISEASE", 98, 104], ["respiratory symptoms", "DISEASE", 190, 210], ["AIS", "DISEASE", 220, 223], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["stroke", "PROBLEM", 98, 104], ["COVID", "TEST", 116, 121], ["respiratory symptoms", "PROBLEM", 190, 210], ["AIS onset", "PROBLEM", 220, 229], ["respiratory", "ANATOMY", 190, 201], ["symptoms", "OBSERVATION", 202, 210]]], ["Two patients (10%) who initially presented with AIS developed respiratory symptoms during hospitalisation.", [["respiratory", "ANATOMY", 62, 73], ["AIS", "DISEASE", 48, 51], ["respiratory symptoms", "DISEASE", 62, 82], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["AIS", "PROBLEM", 48, 51], ["respiratory symptoms", "PROBLEM", 62, 82], ["respiratory", "ANATOMY", 62, 73], ["symptoms", "OBSERVATION", 74, 82]]], ["Four patients (20%) did not have respiratory symptoms, though one of them had bilateral lung infiltrates consistent with viral pneumonia.", [["respiratory", "ANATOMY", 33, 44], ["lung", "ANATOMY", 88, 92], ["respiratory symptoms", "DISEASE", 33, 53], ["viral pneumonia", "DISEASE", 121, 136], ["patients", "ORGANISM", 5, 13], ["lung", "ORGAN", 88, 92], ["patients", "SPECIES", 5, 13], ["respiratory symptoms", "PROBLEM", 33, 53], ["bilateral lung infiltrates", "PROBLEM", 78, 104], ["viral pneumonia", "PROBLEM", 121, 136], ["bilateral", "ANATOMY_MODIFIER", 78, 87], ["lung", "ANATOMY", 88, 92], ["infiltrates", "OBSERVATION", 93, 104], ["consistent with", "UNCERTAINTY", 105, 120], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["pneumonia", "OBSERVATION", 127, 136]]], ["The onset of respiratory symptoms in patients that were symptomatic on arrival ranged from 1 (table 1) .", [["respiratory", "ANATOMY", 13, 24], ["respiratory symptoms", "DISEASE", 13, 33], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["respiratory symptoms", "PROBLEM", 13, 33], ["symptomatic", "PROBLEM", 56, 67], ["respiratory", "ANATOMY", 13, 24], ["symptoms", "OBSERVATION", 25, 33], ["symptomatic", "OBSERVATION_MODIFIER", 56, 67]]], ["Acquired respiratory distress syndrome (ARDS) was seen in 10 patients (50%), and MODS in 10 patients (50%), and 9 (45%) patients had both.Laboratory findingsThe coagulation and inflammatory markers at the time of AIS presentation are summarised in table 3.", [["respiratory", "ANATOMY", 9, 20], ["Acquired respiratory distress syndrome", "DISEASE", 0, 38], ["ARDS", "DISEASE", 40, 44], ["MODS", "DISEASE", 81, 85], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 120, 128], ["coagulation and inflammatory markers", "PROTEIN", 161, 197], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 120, 128], ["Acquired respiratory distress syndrome", "PROBLEM", 0, 38], ["ARDS", "PROBLEM", 40, 44], ["MODS", "PROBLEM", 81, 85], ["Laboratory findings", "TEST", 138, 157], ["The coagulation", "TEST", 157, 172], ["inflammatory markers", "PROBLEM", 177, 197], ["AIS presentation", "PROBLEM", 213, 229], ["respiratory distress", "OBSERVATION", 9, 29], ["ARDS", "OBSERVATION", 40, 44], ["MODS", "OBSERVATION", 81, 85], ["coagulation", "OBSERVATION", 161, 172], ["inflammatory", "OBSERVATION_MODIFIER", 177, 189]]], ["The mean values of all inflammatory markers, including D-dimer, ferritin and CRP, were elevated (online supplementary table 1).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 55, 62], ["ferritin", "GENE_OR_GENE_PRODUCT", 64, 72], ["CRP", "GENE_OR_GENE_PRODUCT", 77, 80], ["inflammatory markers", "PROTEIN", 23, 43], ["D-dimer", "PROTEIN", 55, 62], ["ferritin", "PROTEIN", 64, 72], ["CRP", "PROTEIN", 77, 80], ["The mean values", "TEST", 0, 15], ["all inflammatory markers", "TEST", 19, 43], ["D-dimer", "TEST", 55, 62], ["ferritin", "TEST", 64, 72], ["CRP", "TEST", 77, 80], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["inflammatory markers", "OBSERVATION", 23, 43]]], ["The coagulation markers were normal in all patients at the time of AIS, except for one with prolonged activated partial thromboplastin time (aPTT) in the absence of therapeutic anticoagulation.", [["AIS", "DISEASE", 67, 70], ["patients", "ORGANISM", 43, 51], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 120, 134], ["coagulation markers", "PROTEIN", 4, 23], ["patients", "SPECIES", 43, 51], ["The coagulation markers", "TEST", 0, 23], ["AIS", "TEST", 67, 70], ["prolonged activated partial thromboplastin time", "TREATMENT", 92, 139], ["aPTT", "TEST", 141, 145], ["therapeutic anticoagulation", "TREATMENT", 165, 192], ["normal", "OBSERVATION", 29, 35], ["partial thromboplastin", "OBSERVATION", 112, 134], ["therapeutic", "OBSERVATION_MODIFIER", 165, 176], ["anticoagulation", "OBSERVATION", 177, 192]]], ["The mean D-dimer could not be accurately calculated due to capping of the laboratory value at 7955 in our hospital, although 30% of our patients showed values of '>7955'.OutcomesTen patients (50%) died during hospitalisation and one was discharged to hospice.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 9, 16], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 182, 190], ["D-dimer", "PROTEIN", 9, 16], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 182, 190], ["The mean D-dimer", "TEST", 0, 16]]], ["The mortality in patients with AIS and COVID-19 was significantly higher than mortality in patients with COVID-19 without stroke (p value 0.01).", [["AIS", "DISEASE", 31, 34], ["stroke", "DISEASE", 122, 128], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 91, 99], ["AIS", "TEST", 31, 34], ["COVID", "TEST", 39, 44], ["COVID", "TEST", 105, 110], ["stroke", "PROBLEM", 122, 128]]], ["The immediate cause of death was neurological in three patients, secondary to herniation.", [["neurological", "ANATOMY", 33, 45], ["death", "DISEASE", 23, 28], ["herniation", "DISEASE", 78, 88], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["death", "PROBLEM", 23, 28], ["herniation", "PROBLEM", 78, 88], ["herniation", "OBSERVATION", 78, 88]]], ["Patients who had ARDS or MODS had poor outcomes.", [["ARDS", "DISEASE", 17, 21], ["MODS", "DISEASE", 25, 29], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ARDS", "PROBLEM", 17, 21], ["MODS", "PROBLEM", 25, 29], ["poor outcomes", "PROBLEM", 34, 47], ["ARDS", "OBSERVATION", 17, 21]]], ["We also noted that patients with very elevated D-dimer had higher mortality.DISCUSSIONTo the best of our knowledge, we present the largest case series of AIS in patients with COVID-19 from a single centre in the USA.", [["AIS", "DISEASE", 154, 157], ["patients", "ORGANISM", 19, 27], ["D-dimer", "GENE_OR_GENE_PRODUCT", 47, 54], ["patients", "ORGANISM", 161, 169], ["D-dimer", "PROTEIN", 47, 54], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 161, 169], ["very elevated D-dimer", "PROBLEM", 33, 54], ["AIS", "PROBLEM", 154, 157], ["COVID", "TEST", 175, 180]]], ["Initial data presented in Mao et al, 4 Almost all patients had multiple risk factors for stroke including old age, obesity, hypertension, diabetes, atrial fibrillation, hyperlipidaemia, cancer or prior strokes.", [["atrial", "ANATOMY", 148, 154], ["cancer", "ANATOMY", 186, 192], ["stroke", "DISEASE", 89, 95], ["obesity", "DISEASE", 115, 122], ["hypertension", "DISEASE", 124, 136], ["diabetes", "DISEASE", 138, 146], ["atrial fibrillation", "DISEASE", 148, 167], ["hyperlipidaemia", "DISEASE", 169, 184], ["cancer", "DISEASE", 186, 192], ["strokes", "DISEASE", 202, 209], ["patients", "ORGANISM", 50, 58], ["atrial", "MULTI-TISSUE_STRUCTURE", 148, 154], ["cancer", "CANCER", 186, 192], ["patients", "SPECIES", 50, 58], ["Initial data", "TEST", 0, 12], ["stroke", "PROBLEM", 89, 95], ["obesity", "PROBLEM", 115, 122], ["hypertension", "PROBLEM", 124, 136], ["diabetes", "PROBLEM", 138, 146], ["atrial fibrillation", "PROBLEM", 148, 167], ["hyperlipidaemia", "PROBLEM", 169, 184], ["cancer", "PROBLEM", 186, 192], ["prior strokes", "PROBLEM", 196, 209], ["obesity", "OBSERVATION", 115, 122], ["hypertension", "OBSERVATION", 124, 136], ["diabetes", "OBSERVATION", 138, 146], ["atrial", "ANATOMY", 148, 154], ["fibrillation", "OBSERVATION", 155, 167], ["hyperlipidaemia", "OBSERVATION", 169, 184], ["cancer", "OBSERVATION", 186, 192], ["strokes", "OBSERVATION", 202, 209]]], ["It has been proposed that many of these conditions are associated with increased severity and mortality in COVID-19.", [["increased severity", "PROBLEM", 71, 89], ["COVID", "TEST", 107, 112], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["severity", "OBSERVATION_MODIFIER", 81, 89]]], ["12 13 Fifty-five per cent of our patients had LVO compared with the 27%-37% previously reported.", [["LVO", "DISEASE", 46, 49], ["patients", "ORGANISM", 33, 41], ["LVO", "CANCER", 46, 49], ["patients", "SPECIES", 33, 41], ["LVO", "TEST", 46, 49]]], ["14 15 Multiple mechanisms regarding SARS-CoV-2 as a trigger for stroke have been proposed.", [["stroke", "DISEASE", 64, 70], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["stroke", "PROBLEM", 64, 70]]], ["Such mechanisms include an imbalance between angiotensin II and angiotensin 1-7 via ACE2 sequestration producing a hypercoagulable state, cytokine release syndrome inducing plaque rupture, as well as direct and indirect cardiac effects.", [["plaque", "ANATOMY", 173, 179], ["cardiac", "ANATOMY", 220, 227], ["angiotensin II", "CHEMICAL", 45, 59], ["angiotensin 1-7", "CHEMICAL", 64, 79], ["plaque rupture", "DISEASE", 173, 187], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 45, 59], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 64, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["plaque", "PATHOLOGICAL_FORMATION", 173, 179], ["cardiac", "ORGAN", 220, 227], ["angiotensin II", "PROTEIN", 45, 59], ["ACE2", "PROTEIN", 84, 88], ["cytokine", "PROTEIN", 138, 146], ["an imbalance", "PROBLEM", 24, 36], ["angiotensin II and angiotensin", "TREATMENT", 45, 75], ["a hypercoagulable state", "PROBLEM", 113, 136], ["cytokine release syndrome", "PROBLEM", 138, 163], ["plaque rupture", "PROBLEM", 173, 187], ["imbalance", "OBSERVATION", 27, 36], ["hypercoagulable state", "OBSERVATION", 115, 136], ["plaque", "OBSERVATION_MODIFIER", 173, 179], ["rupture", "OBSERVATION", 180, 187]]], ["[16] [17] [18] [19] [20] [21] [22] [23] [24] Given the increased incidence of LVO without intracranial atherosclerosis, we entertain the theory of cardioembolic causes including paroxysmal atrial fibrillation triggered by the infection.", [["LVO", "ANATOMY", 78, 81], ["intracranial", "ANATOMY", 90, 102], ["atrial", "ANATOMY", 189, 195], ["LVO", "DISEASE", 78, 81], ["intracranial atherosclerosis", "DISEASE", 90, 118], ["cardioembolic", "DISEASE", 147, 160], ["paroxysmal atrial fibrillation", "DISEASE", 178, 208], ["infection", "DISEASE", 226, 235], ["[16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 44], ["LVO", "CANCER", 78, 81], ["atrial", "MULTI-TISSUE_STRUCTURE", 189, 195], ["intracranial atherosclerosis", "PROBLEM", 90, 118], ["cardioembolic causes", "PROBLEM", 147, 167], ["paroxysmal atrial fibrillation", "PROBLEM", 178, 208], ["the infection", "PROBLEM", 222, 235], ["without", "UNCERTAINTY", 82, 89], ["intracranial", "ANATOMY", 90, 102], ["atherosclerosis", "OBSERVATION", 103, 118], ["cardioembolic", "OBSERVATION", 147, 160], ["atrial", "ANATOMY", 189, 195], ["fibrillation", "OBSERVATION", 196, 208], ["infection", "OBSERVATION", 226, 235]]], ["Ten per cent of our patients had recurrent strokes during the same hospitalisation compared with the 0.8% previously reported.", [["strokes", "DISEASE", 43, 50], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["recurrent strokes", "PROBLEM", 33, 50], ["recurrent", "OBSERVATION_MODIFIER", 33, 42], ["strokes", "OBSERVATION", 43, 50]]], ["25 An opinion by Elkind 26 describes the need to differentiate between stroke risk factors and stroke triggers.", [["stroke", "DISEASE", 71, 77], ["stroke", "DISEASE", 95, 101], ["stroke risk factors", "PROBLEM", 71, 90], ["stroke triggers", "PROBLEM", 95, 110]]], ["Based on our preliminary findings, we hypothesise that infection with SARS-CoV-2 can potentially trigger hypercoagulable state, which can lead to AIS in a person with stroke risk factors.DISCUSSIONIn our analysis, 85% of patients had either respiratory symptoms or imaging findings consistent with viral pneumonia.", [["respiratory", "ANATOMY", 241, 252], ["infection", "DISEASE", 55, 64], ["SARS", "DISEASE", 70, 74], ["AIS", "DISEASE", 146, 149], ["stroke", "DISEASE", 167, 173], ["viral pneumonia", "DISEASE", 298, 313], ["SARS-CoV-2", "ORGANISM", 70, 80], ["patients", "ORGANISM", 221, 229], ["person", "SPECIES", 155, 161], ["patients", "SPECIES", 221, 229], ["SARS-CoV", "SPECIES", 70, 78], ["infection", "PROBLEM", 55, 64], ["SARS", "PROBLEM", 70, 74], ["hypercoagulable state", "PROBLEM", 105, 126], ["AIS", "PROBLEM", 146, 149], ["stroke risk factors", "PROBLEM", 167, 186], ["our analysis", "TEST", 200, 212], ["either respiratory symptoms", "PROBLEM", 234, 261], ["imaging findings", "TEST", 265, 281], ["viral pneumonia", "PROBLEM", 298, 313], ["infection", "OBSERVATION", 55, 64], ["consistent with", "UNCERTAINTY", 282, 297], ["viral", "OBSERVATION_MODIFIER", 298, 303], ["pneumonia", "OBSERVATION", 304, 313]]], ["While symptomatology varied, 70% demonstrated respiratory symptoms at the time of AIS.", [["respiratory", "ANATOMY", 46, 57], ["respiratory symptoms", "DISEASE", 46, 66], ["AIS", "DISEASE", 82, 85], ["symptomatology", "TEST", 6, 20], ["respiratory symptoms", "PROBLEM", 46, 66], ["AIS", "PROBLEM", 82, 85], ["respiratory symptoms", "OBSERVATION", 46, 66]]], ["We postulate that AIS may be a late complication of COVID-19, lagging behind respiratory symptoms by days to weeks.", [["respiratory", "ANATOMY", 77, 88], ["AIS", "DISEASE", 18, 21], ["respiratory symptoms", "DISEASE", 77, 97], ["COVID-19", "CHEMICAL", 52, 60], ["a late complication", "PROBLEM", 29, 48], ["COVID", "TEST", 52, 57], ["respiratory symptoms", "PROBLEM", 77, 97]]], ["Mao et al 4 suggested that most neurological symptoms in patients with COVID-19 present early except AIS and altered mental status, which are late presentations.", [["neurological", "ANATOMY", 32, 44], ["neurological symptoms", "DISEASE", 32, 53], ["AIS", "DISEASE", 101, 104], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Mao et al 4", "TEST", 0, 11], ["most neurological symptoms", "PROBLEM", 27, 53], ["COVID", "TEST", 71, 76], ["AIS", "PROBLEM", 101, 104], ["altered mental status", "PROBLEM", 109, 130], ["altered", "OBSERVATION_MODIFIER", 109, 116], ["mental status", "OBSERVATION", 117, 130]]], ["As far as we know, this is the first study elucidating the timeline of respiratory symptoms in relation to AIS onset.", [["respiratory", "ANATOMY", 71, 82], ["respiratory symptoms", "DISEASE", 71, 91], ["AIS", "DISEASE", 107, 110], ["the first study", "TEST", 27, 42], ["respiratory symptoms", "PROBLEM", 71, 91], ["AIS onset", "PROBLEM", 107, 116]]], ["It can be inferred that the timeline for AIS in COVID-19 may depend on stroke mechanism.DISCUSSIONWe would like to bring attention to patients with typical clinical characteristics of COVID-19, including findings on lung imaging and inflammatory markers, who presented with AIS with multiple negative nasopharyngeal swab tests for SARS-CoV-2.", [["lung", "ANATOMY", 216, 220], ["nasopharyngeal swab", "ANATOMY", 301, 320], ["AIS", "DISEASE", 41, 44], ["COVID-19", "CHEMICAL", 48, 56], ["stroke", "DISEASE", 71, 77], ["AIS", "DISEASE", 274, 277], ["SARS", "DISEASE", 331, 335], ["COVID-19", "CHEMICAL", 48, 56], ["patients", "ORGANISM", 134, 142], ["lung", "ORGAN", 216, 220], ["inflammatory markers", "PROTEIN", 233, 253], ["patients", "SPECIES", 134, 142], ["SARS-CoV", "SPECIES", 331, 339], ["AIS", "TEST", 41, 44], ["COVID", "TEST", 48, 53], ["stroke mechanism", "PROBLEM", 71, 87], ["COVID", "TEST", 184, 189], ["lung imaging", "TEST", 216, 228], ["inflammatory markers", "PROBLEM", 233, 253], ["AIS", "PROBLEM", 274, 277], ["nasopharyngeal swab tests", "TEST", 301, 326], ["SARS", "PROBLEM", 331, 335], ["CoV", "TEST", 336, 339], ["lung", "ANATOMY", 216, 220], ["inflammatory", "OBSERVATION_MODIFIER", 233, 245], ["nasopharyngeal", "ANATOMY", 301, 315]]], ["In these patients, the onset of respiratory symptoms preceded stroke symptoms by as many as 3 weeks, while the peak positivity for nasopharyngeal swab test is thought to be 1 to 2 weeks after symptom onset.", [["respiratory", "ANATOMY", 32, 43], ["nasopharyngeal swab", "ANATOMY", 131, 150], ["respiratory symptoms", "DISEASE", 32, 52], ["stroke", "DISEASE", 62, 68], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["respiratory symptoms", "PROBLEM", 32, 52], ["stroke symptoms", "PROBLEM", 62, 77], ["the peak positivity", "TEST", 107, 126], ["nasopharyngeal swab test", "TEST", 131, 155], ["symptom onset", "PROBLEM", 192, 205], ["respiratory", "ANATOMY", 32, 43]]], ["As this pandemic continues to progress, we should consider using additional confirmatory testing, such as RT-PCR testing from other sources or antibody testing to extend the window of confirmatory testing.", [["additional confirmatory testing", "TEST", 65, 96], ["RT-PCR testing", "TEST", 106, 120], ["antibody testing", "TEST", 143, 159], ["confirmatory testing", "TEST", 184, 204]]], ["27 The mortality in all patients with COVID-19 admitted during the study time period in our hospital was 26%, which is similar to 24.5% mortality reported among 5700 patients with COVID-19 hospitalised in New York City.", [["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 166, 174], ["COVID", "TEST", 38, 43], ["COVID", "TEST", 180, 185]]], ["28 A study from Wuhan reported 38% mortality among patients with COVID-19 who developed stroke.", [["stroke", "DISEASE", 88, 94], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["A study", "TEST", 3, 10], ["COVID", "TEST", 65, 70], ["stroke", "PROBLEM", 88, 94], ["stroke", "OBSERVATION", 88, 94]]], ["4 The mortality among our patients with AIS was 50%.", [["AIS", "DISEASE", 40, 43], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["AIS", "TEST", 40, 43]]], ["In our hospital, ARDS, MODS and elevated D-dimer were independently associated with higher mortality in patients with AIS.", [["ARDS", "DISEASE", 17, 21], ["MODS", "DISEASE", 23, 27], ["AIS", "DISEASE", 118, 121], ["D-dimer", "GENE_OR_GENE_PRODUCT", 41, 48], ["patients", "ORGANISM", 104, 112], ["D-dimer", "PROTEIN", 41, 48], ["patients", "SPECIES", 104, 112], ["ARDS", "PROBLEM", 17, 21], ["MODS", "PROBLEM", 23, 27], ["elevated D-dimer", "PROBLEM", 32, 48], ["AIS", "PROBLEM", 118, 121], ["ARDS", "OBSERVATION", 17, 21], ["MODS", "OBSERVATION", 23, 27]]], ["The poor Open access outcome of patients with AIS may be caused by the presence of underlying risk factors such as diabetes, hypertension, cardiovascular disease and male sex, which are independently known to be associated with increased risk of death from COVID-19 infection.", [["cardiovascular", "ANATOMY", 139, 153], ["AIS", "DISEASE", 46, 49], ["diabetes", "DISEASE", 115, 123], ["hypertension", "DISEASE", 125, 137], ["cardiovascular disease", "DISEASE", 139, 161], ["death", "DISEASE", 246, 251], ["COVID-19", "CHEMICAL", 257, 265], ["infection", "DISEASE", 266, 275], ["patients", "ORGANISM", 32, 40], ["COVID-19", "GENE_OR_GENE_PRODUCT", 257, 265], ["patients", "SPECIES", 32, 40], ["AIS", "PROBLEM", 46, 49], ["underlying risk factors", "PROBLEM", 83, 106], ["diabetes", "PROBLEM", 115, 123], ["hypertension", "PROBLEM", 125, 137], ["cardiovascular disease", "PROBLEM", 139, 161], ["death", "PROBLEM", 246, 251], ["COVID-19 infection", "PROBLEM", 257, 275], ["poor", "OBSERVATION_MODIFIER", 4, 8], ["diabetes", "OBSERVATION", 115, 123], ["hypertension", "OBSERVATION", 125, 137], ["cardiovascular disease", "OBSERVATION", 139, 161], ["infection", "OBSERVATION", 266, 275]]], ["13 29 A 39% decrease in stroke imaging was noted after the announcement of the first COVID-19-related death in the USA.", [["stroke", "DISEASE", 24, 30], ["COVID-19", "CHEMICAL", 85, 93], ["death", "DISEASE", 102, 107], ["stroke imaging", "TEST", 24, 38], ["the first COVID", "TEST", 75, 90], ["decrease", "OBSERVATION_MODIFIER", 12, 20]]], ["30 Approximately half of our patients were out of the window for therapeutic intervention, which may have contributed to a poorer outcome.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["therapeutic intervention", "TREATMENT", 65, 89]]], ["Fear of contracting COVID-19 may have prevented them from seeking care in a timely manner.", [["COVID-19", "CHEMICAL", 20, 28], ["COVID-19", "CHEMICAL", 20, 28], ["contracting COVID", "PROBLEM", 8, 25]]], ["10 Limitations Limitations of our study are small sample size and incomplete stroke workup in some patients.", [["stroke", "DISEASE", 77, 83], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["our study", "TEST", 30, 39], ["small sample size", "PROBLEM", 44, 61], ["incomplete stroke workup", "TEST", 66, 90], ["small", "OBSERVATION_MODIFIER", 44, 49], ["size", "OBSERVATION_MODIFIER", 57, 61]]], ["Due to the pandemic, there was decreased availability of diagnostic testing, such as echocardiogram and lower extremity Doppler.", [["diagnostic testing", "TEST", 57, 75], ["echocardiogram", "TEST", 85, 99], ["lower extremity Doppler", "TEST", 104, 127], ["lower extremity", "ANATOMY", 104, 119]]], ["In addition, we recognise that prevalence of stroke may be underestimated in patients receiving critical care due to limited histories and bedside examinations, haemodynamic instability preventing neuroimaging and paralytic use.", [["stroke", "DISEASE", 45, 51], ["haemodynamic instability", "DISEASE", 161, 185], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["stroke", "PROBLEM", 45, 51], ["bedside examinations", "TEST", 139, 159], ["haemodynamic instability", "PROBLEM", 161, 185], ["neuroimaging", "TEST", 197, 209], ["paralytic use", "TREATMENT", 214, 227], ["stroke", "OBSERVATION", 45, 51]]], ["Possibly inaccuracies of the information extracted from medical records may have been an additional limitation, which is inherent in retrospective studies.CONCLUSIONHigher mortality and severe disease were noted in our patients with AIS and COVID-19 compared with patients with COVID-19 without AIS.", [["AIS", "DISEASE", 233, 236], ["AIS", "DISEASE", 295, 298], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 264, 272], ["retrospective studies", "TEST", 133, 154], ["severe disease", "PROBLEM", 186, 200], ["AIS", "TEST", 233, 236], ["COVID", "TEST", 241, 246], ["COVID", "TEST", 278, 283], ["AIS", "PROBLEM", 295, 298], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["disease", "OBSERVATION", 193, 200]]], ["Factors contributing to mortality include severe ARDS and possibly an excessive inflammatory response.", [["ARDS", "DISEASE", 49, 53], ["severe ARDS", "PROBLEM", 42, 53], ["an excessive inflammatory response", "PROBLEM", 67, 101], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["ARDS", "OBSERVATION", 49, 53], ["possibly", "UNCERTAINTY", 58, 66], ["excessive", "OBSERVATION_MODIFIER", 70, 79], ["inflammatory response", "OBSERVATION", 80, 101]]], ["Although stroke seems to occur in almost all stages of the disease, it is most often seen after the first week of illness or later.", [["stroke", "DISEASE", 9, 15], ["stroke", "PROBLEM", 9, 15], ["the disease", "PROBLEM", 55, 66], ["illness", "PROBLEM", 114, 121], ["stroke", "OBSERVATION", 9, 15], ["disease", "OBSERVATION", 59, 66]]], ["This could explain why some patients who presented with stroke and were highly suspected to have a COVID-19 infection tested negative after multiple nasopharyngeal swabs.", [["nasopharyngeal swabs", "ANATOMY", 149, 169], ["stroke", "DISEASE", 56, 62], ["infection", "DISEASE", 108, 117], ["patients", "ORGANISM", 28, 36], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 149, 169], ["patients", "SPECIES", 28, 36], ["stroke", "PROBLEM", 56, 62], ["a COVID-19 infection", "PROBLEM", 97, 117], ["multiple nasopharyngeal swabs", "PROBLEM", 140, 169], ["infection", "OBSERVATION", 108, 117], ["nasopharyngeal", "ANATOMY", 149, 163], ["swabs", "OBSERVATION", 164, 169]]], ["Larger studies are needed to prove the association of COVID-19 and AIS and to identify the mechanisms causing thromboembolic phenomenon in these patients.Twitter Ivo Bach Contributors IB and NM contributed to study concept and design, data collection, interpretation of data, literature search, drafting of manuscript, critical revision and final approval.", [["AIS", "DISEASE", 67, 70], ["thromboembolic phenomenon", "DISEASE", 110, 135], ["COVID-19", "GENE_OR_GENE_PRODUCT", 54, 62], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["Larger studies", "TEST", 0, 14], ["COVID", "TEST", 54, 59], ["AIS", "PROBLEM", 67, 70], ["thromboembolic phenomenon", "PROBLEM", 110, 135], ["study concept", "TEST", 209, 222], ["design, data collection", "TEST", 227, 250], ["critical revision", "TREATMENT", 319, 336], ["thromboembolic", "OBSERVATION", 110, 124], ["revision", "OBSERVATION", 328, 336]]], ["PS contributed to study concept and design, data collection, literature search, drafting of manuscript, analysis and interpretation of data, critical revision and final approval.", [["PS", "TREATMENT", 0, 2], ["study concept", "TEST", 18, 31], ["data collection", "TEST", 44, 59], ["literature search", "TEST", 61, 78], ["critical revision", "TREATMENT", 141, 158], ["revision", "OBSERVATION", 150, 158]]], ["OA-H contributed to study design, literature search, drafting of manuscript, analysis and interpretation of data and final approval.SRubenstein contributed to data collection, literature search, interpretation of data, drafting of manuscript, critical revision and final approval.", [["OA-H", "CHEMICAL", 0, 4], ["SRubenstein", "CHEMICAL", 132, 143], ["SRubenstein", "TREATMENT", 132, 143], ["data collection", "TEST", 159, 174], ["critical revision", "TREATMENT", 243, 260], ["revision", "OBSERVATION", 252, 260]]], ["SRedko contributed to study design, data collection, interpretation of data and final approval.", [["data collection", "TEST", 36, 51]]], ["SG contributed to data collection and critical revision.", [["data collection", "TEST", 18, 33], ["critical revision", "TREATMENT", 38, 55], ["critical", "OBSERVATION_MODIFIER", 38, 46], ["revision", "OBSERVATION", 47, 55]]], ["MH contributed to critical revision, interpretation of data and final approval.", [["MH", "DISEASE", 0, 2], ["critical revision", "TREATMENT", 18, 35], ["revision", "OBSERVATION", 27, 35]]], ["PP contributed to critical revision, literature search, interpretation of data and final approval.", [["PP", "PROBLEM", 0, 2], ["critical revision", "TREATMENT", 18, 35], ["revision", "OBSERVATION", 27, 35]]], ["PK (Co-Guarantor) contributed to study concept, critical revision, interpretation of data and final approval.", [["PK", "GENE_OR_GENE_PRODUCT", 0, 2], ["critical revision", "TREATMENT", 48, 65], ["revision", "OBSERVATION", 57, 65]]], ["AK (Co-Guarantor/PI) contributed to study concept, critical revision, interpretation of data and final approval.Twitter Ivo Bach Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Twitter Ivo Bach Competing interests None declared.", [["AK (Co-Guarantor/PI", "PROBLEM", 0, 19], ["critical revision", "TREATMENT", 51, 68], ["revision", "OBSERVATION", 60, 68]]], ["Patient consent for publication Not required.Twitter Ivo Bach Ethics approval This study was approved by the institutional review board of Rutgers University.", [["Patient", "SPECIES", 0, 7], ["This study", "TEST", 78, 88]]], ["Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.", [["the study", "TEST", 49, 58]]], ["See: http:// creativecommons. org/ licenses/ by-nc/ 4.", [["http", "GENE_OR_GENE_PRODUCT", 5, 9], ["org", "GENE_OR_GENE_PRODUCT", 30, 33]]], ["0/.ORCID iDIvo Bach http:// orcid. org/ 0000-0003-2215-1240", [["org/ 0000-0003-2215-1240", "CHEMICAL", 35, 59], ["org/ 0000-0003-2215-1240", "SPECIES", 35, 59]]]], "2468815380ef0da6656eafec81936b459b5b210e": [["In the primary care setting, infectious diseases pose a particular challenge.IntroductionSpecifically, patients with emerging, re-emerging, or highly infectious diseases may develop nonspecific symptoms (e.g., fever, cough, rash) subacutely.", [["infectious diseases", "DISEASE", 29, 48], ["infectious diseases", "DISEASE", 150, 169], ["fever", "DISEASE", 210, 215], ["cough", "DISEASE", 217, 222], ["rash", "DISEASE", 224, 228], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["a particular challenge", "TREATMENT", 54, 76], ["highly infectious diseases", "PROBLEM", 143, 169], ["nonspecific symptoms", "PROBLEM", 182, 202], ["fever", "PROBLEM", 210, 215], ["cough", "PROBLEM", 217, 222], ["rash", "PROBLEM", 224, 228], ["infectious", "OBSERVATION", 29, 39]]], ["Thus, these patients may be more likely to present to a primary care clinic compared with patients affected by a relatively acute emergency (e.g., natural disasters, fires, radiation, or chemical attacks), who are more likely to present to a hospital emergency room [1, 2] .", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 90, 98], ["radiation", "TREATMENT", 173, 182], ["acute", "OBSERVATION_MODIFIER", 124, 129]]], ["Hence, primary care clinics are especially important for screening and isolating patients with potentially infectious disease in order to prevent transmission to other patients, health care workers, and the community.IntroductionResearch on emergency preparedness for infectious diseases has hitherto focused on hospital emergency rooms.", [["infectious disease", "DISEASE", 107, 125], ["infectious diseases", "DISEASE", 268, 287], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 168, 176], ["screening", "TEST", 57, 66], ["infectious diseases", "PROBLEM", 268, 287]]], ["Several studies have used \"mystery patient drills\"-nonotice drills with patient-actors simulating diseases-for avian influenza [3] [4] [5] , smallpox [6] , inhalational anthrax [7] , Ebola virus disease [8, 9] , Middle East respiratory syndrome coronavirus [10] , and measles [10] .", [["influenza", "DISEASE", 117, 126], ["smallpox", "DISEASE", 141, 149], ["inhalational anthrax", "DISEASE", 156, 176], ["Ebola virus disease", "DISEASE", 183, 202], ["Middle East respiratory syndrome coronavirus", "DISEASE", 212, 256], ["measles", "DISEASE", 268, 275], ["patient", "ORGANISM", 35, 42], ["patient", "ORGANISM", 72, 79], ["avian", "ORGANISM", 111, 116], ["influenza", "ORGANISM", 117, 126], ["Ebola virus", "ORGANISM", 183, 194], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 212, 256], ["patient", "SPECIES", 35, 42], ["patient", "SPECIES", 72, 79], ["avian influenza", "SPECIES", 111, 126], ["Ebola virus disease", "SPECIES", 183, 202], ["coronavirus", "SPECIES", 245, 256], ["Ebola virus", "SPECIES", 183, 194], ["Middle East respiratory syndrome coronavirus", "SPECIES", 212, 256], ["Several studies", "TEST", 0, 15], ["simulating diseases", "PROBLEM", 87, 106], ["avian influenza", "PROBLEM", 111, 126], ["smallpox", "PROBLEM", 141, 149], ["inhalational anthrax", "PROBLEM", 156, 176], ["Ebola virus disease", "PROBLEM", 183, 202], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 212, 256], ["Middle", "ANATOMY_MODIFIER", 212, 218], ["respiratory syndrome", "ANATOMY", 224, 244]]], ["These studies enabled assessment of current emergency preparedness 1 3 protocols, evaluation of the effectiveness of specific procedures within protocols (e.g., use of electronic health record workflows to guide screening), and identification of strengths and areas for improvement.", [["These studies", "TEST", 0, 13], ["assessment", "TEST", 22, 32], ["current emergency preparedness", "TREATMENT", 36, 66], ["evaluation", "TEST", 82, 92], ["specific procedures", "TREATMENT", 117, 136], ["guide screening", "TEST", 206, 221]]], ["Activities that assess and improve emergency preparedness for infectious diseases in the primary care setting have been relatively underreported, with most published studies either highlighting this as an area of need [11] [12] [13] [14] or showing the willingness of primary care practitioners to help in emergency preparedness and response [11, 15] .IntroductionIn order to assess and improve emergency preparedness for infectious disease among primary care clinics, the New York City Department of Health and Mental Hygiene (NYC DOHMH) coordinated a series of no-notice mystery patient drills at community health centers across the city from April 2015 through December 2016.", [["infectious diseases", "DISEASE", 62, 81], ["infectious disease", "DISEASE", 422, 440], ["patient", "ORGANISM", 581, 588], ["patient", "SPECIES", 581, 588], ["infectious diseases", "PROBLEM", 62, 81], ["primary care practitioners", "TREATMENT", 268, 294]]], ["Here we describe both quantitative and qualitative findings of the project and discuss the value of conducting such drills for emergency preparedness for infectious diseases in the primary care setting.Drill Design and Clinic SelectionThe mystery patient drill scenarios were designed by PCEPN with input from their advisory group, which has representation from all five NYC boroughs (Bronx, Brooklyn, Queens, Manhattan, and Staten Island).", [["infectious diseases", "DISEASE", 154, 173], ["patient", "ORGANISM", 247, 254], ["patient", "SPECIES", 247, 254], ["conducting such drills", "TREATMENT", 100, 122], ["emergency preparedness", "TREATMENT", 127, 149], ["infectious diseases", "PROBLEM", 154, 173]]], ["Scenarios were designed describing a patient walking into a community health center and reporting either (1) fever, generalized body aches, and respiratory symptoms (e.g., cough, shortness of breath) or (2) fever and rash on the trunk and back in the context of attending a children's birthday party 1-2 weeks prior during which a child may have been sick.", [["body", "ANATOMY", 128, 132], ["respiratory", "ANATOMY", 144, 155], ["trunk", "ANATOMY", 229, 234], ["fever", "DISEASE", 109, 114], ["body aches", "DISEASE", 128, 138], ["respiratory symptoms", "DISEASE", 144, 164], ["cough", "DISEASE", 172, 177], ["shortness of breath", "DISEASE", 179, 198], ["fever", "DISEASE", 207, 212], ["rash", "DISEASE", 217, 221], ["patient", "ORGANISM", 37, 44], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["aches", "ORGANISM_SUBDIVISION", 133, 138], ["trunk", "ORGANISM_SUBDIVISION", 229, 234], ["children", "ORGANISM", 274, 282], ["child", "ORGANISM", 331, 336], ["patient", "SPECIES", 37, 44], ["children", "SPECIES", 274, 282], ["fever", "PROBLEM", 109, 114], ["generalized body aches", "PROBLEM", 116, 138], ["respiratory symptoms", "PROBLEM", 144, 164], ["cough", "PROBLEM", 172, 177], ["shortness of breath", "PROBLEM", 179, 198], ["fever", "PROBLEM", 207, 212], ["rash on the trunk and back", "PROBLEM", 217, 243], ["respiratory", "ANATOMY", 144, 155], ["rash", "OBSERVATION", 217, 221], ["trunk", "ANATOMY", 229, 234], ["back", "ANATOMY", 239, 243]]], ["These scenarios corresponded to influenza-like illness (ILI) and measles, respectively.", [["influenza-like illness", "DISEASE", 32, 54], ["ILI", "DISEASE", 56, 59], ["measles", "DISEASE", 65, 72], ["These scenarios", "PROBLEM", 0, 15], ["influenza", "PROBLEM", 32, 41], ["influenza", "OBSERVATION", 32, 41]]], ["Clinics chose their preferred patient scenario in advance of their own drill.Drill Design and Clinic SelectionAll PCEPN-affiliated community health centers were invited by e-mail to participate; an announcement was also included in PCEPN's quarterly newsletter.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37]]], ["The project was exempted by the NYC DOHMH institutional review board.Drill Conduct and EvaluationThe drills were completed from April 2015 through December 2016.", [["Drill Conduct", "TEST", 69, 82], ["Evaluation", "TEST", 87, 97]]], ["Drill team staff consisted of an actor, two controllers (one from PCEPN and one from the clinic) who coordinated all drill setup and operations, and one or two trusted agents who acted as planning partners to assist with implementation and execution of the drill at the clinic site.", [["operations", "TREATMENT", 133, 143]]], ["The actor simulating the patient was recruited from the NYC Medical Reserve Corps, a group of volunteer health care professionals trained to respond to public health emergencies.", [["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32]]], ["Patient-actors were trained with a 30-min webinar and provided scripts detailing the history of present illness and other relevant components of the medical history.", [["illness", "DISEASE", 104, 111], ["Patient", "SPECIES", 0, 7]]], ["The PCEPN controller directed the drill and accompanied the \"patient\" as a friend or relative.Drill Conduct and EvaluationTo prepare for the drill, all drill team staff completed 3-hour-long webinars (available at https ://www.pcepn .org/mpd).", [["patient", "ORGANISM", 61, 68], ["https", "DNA", 214, 219], ["patient", "SPECIES", 61, 68], ["The PCEPN controller", "TREATMENT", 0, 20], ["Drill Conduct", "TEST", 94, 107], ["Evaluation", "TEST", 112, 122]]], ["In sequence, the webinars (1) introduced the drill and its components; (2) described standard infection control protocols, including considerations for enhancing screening and isolation capabilities; and (3) reviewed the drill plan and logistics.", [["infection", "DISEASE", 94, 103], ["standard infection control protocols", "TREATMENT", 85, 121], ["enhancing screening", "TEST", 152, 171], ["isolation capabilities", "TEST", 176, 198], ["infection", "OBSERVATION", 94, 103]]], ["Clinic staff were instructed prior to the exercise to follow their site-specific infection control protocols.", [["infection", "DISEASE", 81, 90], ["specific infection control protocols", "TREATMENT", 72, 108], ["infection", "OBSERVATION", 81, 90]]], ["Participating clinics that were designated Federally Qualified Health Centers (FQHCs)-organizations receiving grants under United States' Health Center Program statutes (Section 330 of the Public Health Service Act) [17] -were also provided $1000 USD to purchase supplies or equipment related to emergency management, as an incentive to increase participation.", [["emergency management", "TREATMENT", 296, 316]]], ["This funding came from NYC DOHMH, supported by Grant 1U90TP000546 from the United States' Department of Health and Human Services.Drill Conduct and EvaluationEvaluators used a standardized exercise evaluation guide adapted from the Homeland Security Exercise Evaluation Program (HSEEP); the guide included time-based measures for screening and isolation [18] .", [["Human", "ORGANISM", 115, 120], ["Human", "SPECIES", 115, 120], ["Drill Conduct", "TEST", 130, 143], ["Evaluation", "TEST", 148, 158], ["a standardized exercise evaluation", "TEST", 174, 208], ["screening", "TEST", 330, 339]]], ["Time to screening was measured from the moment the patient-actor entered the clinic to the time she or he was given a mask or referred by clinic staff to the medical team because of concern of infection.", [["infection", "DISEASE", 193, 202], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["a mask", "TREATMENT", 116, 122], ["infection", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 193, 202]]], ["Time to isolation was measured from when patient was screened to when she or he was placed in a separate and closed room.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["The processes of screening and isolation were also graded qualitatively using adapted HSEEP criteria: performed without challenges (P), performed with some challenges (S), performed with major challenges (M), and unable to perform (U).", [["screening", "TEST", 17, 26]]], ["The PCEPN controller concluded the drill when the health care provider began his or her medical evaluation (e.g., taking vital signs, asking the patient's permission to examine the reported rash).", [["rash", "DISEASE", 190, 194], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["The PCEPN controller", "TREATMENT", 0, 20], ["her medical evaluation", "TEST", 84, 106], ["vital signs", "TEST", 121, 132], ["the reported rash", "PROBLEM", 177, 194]]], ["If the patient waited for 15 min without being seen, a trusted agent would inform triage staff to call the \"patient,\" without disclosing the drill, and proceed with screening to determine if isolation was needed, and, if needed, offer the patient a surgical mask and call a clinical staff member to receive the patient and place him or her in a designated isolation room or space for medical evaluation.Drill Conduct and EvaluationAfter the drill, the controller and trusted agents debriefed for 30 min with all drill participants (both drill team staff and clinic staff) using the exercise evaluation guide to provide feedback and document strengths and areas of improvement for screening and isolation separately.", [["patient", "ORGANISM", 7, 14], ["patient", "ORGANISM", 108, 115], ["patient", "ORGANISM", 239, 246], ["patient", "ORGANISM", 311, 318], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 108, 115], ["patient", "SPECIES", 239, 246], ["patient", "SPECIES", 311, 318], ["participants", "SPECIES", 518, 530], ["screening", "TEST", 165, 174], ["a surgical mask", "TREATMENT", 247, 262], ["medical evaluation", "TEST", 384, 402], ["the drill", "TREATMENT", 437, 446], ["the exercise evaluation", "TEST", 578, 601], ["screening", "TEST", 680, 689], ["isolation", "TREATMENT", 694, 703]]], ["All drill participants also rated the usefulness of the drill using a 5-point Likert scale.Data AnalysisCategorical variables were reported as frequencies and proportions, and continuous variables were reported using median and interquartile range (IQR).", [["participants", "SPECIES", 10, 22], ["Data AnalysisCategorical variables", "TEST", 91, 125]]], ["Nonparametric methods were used for inferential analyses.", [["Nonparametric methods", "TEST", 0, 21], ["inferential analyses", "TEST", 36, 56]]], ["In terms of sample size, to detect a change in time to screening or isolation of at least 5 min per round (e.g., 11 min in round 1, 6 min in round 2, and 1 min in round 3), we required 10 clinic networks to participate in multiple rounds of the drill, assuming a two-sided test, alpha of .05, and power of 84% (adjusted from 80% due to 95.5% efficiency of nonparametric tests compared to parametric equivalent) [19] .", [["screening", "TEST", 55, 64], ["isolation", "TREATMENT", 68, 77], ["a two-sided test", "TEST", 261, 277], ["alpha", "TEST", 279, 284], ["nonparametric tests", "TEST", 356, 375], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["A p value of < .05 was considered statistically significant, and Stata MP version 14.1 (College Station, TX) was used for data analysis.Data AnalysisFor qualitative analysis, after-action reports were reviewed to identify recurring themes (i.e., noted in at least three drills) in strengths and areas for improvement pertaining to screening and isolation.ResultsFifty drills at 41 clinics were conducted.", [["A p value", "TEST", 0, 9], ["Stata MP version", "TEST", 65, 81], ["TX)", "TREATMENT", 105, 108], ["data analysis", "TEST", 122, 135], ["Data Analysis", "TEST", 136, 149], ["qualitative analysis", "TEST", 153, 173], ["screening", "TEST", 331, 340], ["isolation", "TREATMENT", 345, 354]]], ["In terms of clinic type, 45 (90%) of the clinics were FQHCs, 4 (8%) were primary care clinics, and 1 (2%) was a FQHC look-alike (a center that fulfills requirements to be a FQHC but is not yet formally certified).", [["FQHCs", "DISEASE", 54, 59], ["FQHCs", "TEST", 54, 59]]], ["In terms of drill scenario, 32 were for ILI and 17 were for measles; the scenario for one drill is unknown due to missing data.ResultsAll but one drill screened the patient within the specified time; in that drill, 18 min elapsed without the patient being called.", [["ILI", "DISEASE", 40, 43], ["measles", "DISEASE", 60, 67], ["patient", "ORGANISM", 165, 172], ["patient", "ORGANISM", 242, 249], ["patient", "SPECIES", 165, 172], ["patient", "SPECIES", 242, 249], ["drill scenario", "TEST", 12, 26], ["ILI", "PROBLEM", 40, 43], ["measles", "PROBLEM", 60, 67], ["drill scenario", "OBSERVATION", 12, 26]]], ["HSEEP grading for screening was known for all 50 drills; 35 (70%) of the drills performed the screening without any challenges, 8 (16%) with some challenges, 6 (12%) with major challenges, and 1 (2%) was unable to perform screening.ResultsMasking status was known for 47 drills, of which the patient was masked in 38 (81%) drills.", [["patient", "ORGANISM", 292, 299], ["patient", "SPECIES", 292, 299], ["screening", "TEST", 18, 27], ["the drills", "TEST", 69, 79], ["the screening", "TEST", 90, 103], ["screening", "TEST", 222, 231]]], ["Among the 38 drills in which the patient was masked, 30 (79%) completed this step at the first point of contact in the clinic.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["38 drills", "OBSERVATION_MODIFIER", 10, 19]]], ["Patients presenting with ILI were more likely to be masked compared with patients presenting as measles cases; 28 (93%) of 30 ILI patients were masked compared to 10 (59%) of 17 measles patients (p = 0.007), and 23 (77%) of 30 ILI patients were masked at the first point of contact compared to 7 (41%) of 17 measles patients (p = 0.026).", [["ILI", "DISEASE", 25, 28], ["ILI", "DISEASE", 126, 129], ["measles", "DISEASE", 178, 185], ["ILI", "DISEASE", 227, 230], ["measles", "DISEASE", 308, 315], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 231, 239], ["patients", "ORGANISM", 316, 324], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 316, 324], ["ILI", "PROBLEM", 25, 28], ["measles cases", "TEST", 96, 109]]], ["Masking status data were missing from 3 drills.ResultsAmong the 49 drills in which the patient was screened, 47 isolated the patient.", [["patient", "ORGANISM", 87, 94], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 87, 94], ["patient", "SPECIES", 125, 132], ["Masking status data", "PROBLEM", 0, 19]]], ["In the remaining 2 drills, the patient was referred out either to an urgent care clinic or to an emergency room.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38]]], ["Time to isolation from screening was known for 41 drills; median time was 1 min (IQR 0-2 min), with no drill taking more than 5 min to isolate.", [["screening", "TEST", 23, 32]]], ["HSEEP grading for isolation was known for all 50 drills; 29 (58%) of the drills performed isolation without any challenges, 17 (34%) with some challenges, 2 (4%) with major challenges, and 2 (4%) were unable to perform isolation.ResultsAnalyses for trends across rounds of the drill are shown in Table 2 .", [["isolation", "TREATMENT", 18, 27], ["the drills", "TREATMENT", 69, 79], ["ResultsAnalyses", "TEST", 229, 244]]], ["There were statistically significant trends in the number of patients masked at the first point of contact (47% in round 1 to 75% in round 3; p trend = 0.048) and median time to isolation (0-2 min; p trend = 0.022).", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["statistically", "OBSERVATION_MODIFIER", 11, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["trends", "OBSERVATION_MODIFIER", 37, 43]]], ["There were no statistically significant trends by round in terms of drill scenario (ILI vs. measles), percentage of patients masked, median time to screening, percentage of drills that performed screening without any challenges, or percentage of drills that performed isolation without any challenges.", [["measles", "DISEASE", 92, 99], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["screening", "TEST", 195, 204], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39]]], ["Table 3 shows the median change in duration and quality of screening and isolation per round among 13 clinic networks that participated in multiple rounds of the drill.", [["the median change in duration", "PROBLEM", 14, 43], ["screening", "TEST", 59, 68], ["isolation", "TREATMENT", 73, 82], ["the drill", "TREATMENT", 158, 167]]], ["There were no significant differences in either duration or quality for either screening or isolation in later rounds.ResultsIn terms of perceived usefulness, among 132 drill participants from 42 drills representing 22 clinic networks, approximately 95% agreed or strongly agreed to each of Time to isolate 2 (0-2) min 0 (-0.5, 0.5) min .97 HSEEP grade S (S, P) 0 (0, + 0.5) categories .10 the following statements: the drill (1) was plausible and realistic, (2) included participants from appropriate disciplines, (3) engaged participants actively, (4) was appropriate for their level of training and experience, and (5) made them better prepared to deal with the hazards addressed.", [["participants", "SPECIES", 175, 187], ["participants", "SPECIES", 472, 484], ["participants", "SPECIES", 527, 539], ["screening", "TEST", 79, 88], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Qualitative analysis of after-action reports revealed recurring themes across drills for strengths of both screening and isolation (Table 4 ); these included presence of established protocols, trained staff, effective communication during the drill, and availability of relevant personal protective equipment and other technical requirements (e.g., masks, alcohol-based hand sanitizer, designated room for isolation).ResultsIn terms of areas for improvement, recurring themes for screening were masking at the first point of contact (e.g., clarifying indications to include a measles-like case of fever and rash without respiratory symptoms), improving visibility of signage instructing patients with pre-specified symptoms and travel history to wear a mask, and optimizing registration procedures on paper-based or electronic medical records such that they do not hinder screening.", [["hand", "ANATOMY", 370, 374], ["respiratory", "ANATOMY", 620, 631], ["alcohol", "CHEMICAL", 356, 363], ["fever", "DISEASE", 597, 602], ["rash", "DISEASE", 607, 611], ["respiratory symptoms", "DISEASE", 620, 640], ["alcohol", "CHEMICAL", 356, 363], ["alcohol", "SIMPLE_CHEMICAL", 356, 363], ["hand", "ORGANISM_SUBDIVISION", 370, 374], ["patients", "ORGANISM", 687, 695], ["patients", "SPECIES", 687, 695], ["Qualitative analysis", "TEST", 0, 20], ["both screening", "TEST", 102, 116], ["established protocols", "TREATMENT", 170, 191], ["personal protective equipment", "TREATMENT", 279, 308], ["screening", "TEST", 480, 489], ["a measles", "PROBLEM", 574, 583], ["fever", "PROBLEM", 597, 602], ["rash", "PROBLEM", 607, 611], ["respiratory symptoms", "PROBLEM", 620, 640], ["pre-specified symptoms", "PROBLEM", 701, 723], ["a mask", "TREATMENT", 751, 757], ["optimizing registration procedures", "TREATMENT", 763, 797]]], ["For isolation, recurring themes for improvement were hand hygiene compliance, awareness and adherence to requirements (e.g., use of masks), explaining isolation protocol to patients to reduce psychological impact of sudden isolation, and using signage to indicate an occupied isolation room.DiscussionWe conducted 50 mystery patient drills at 41 community health centers across NYC.", [["hand", "ANATOMY", 53, 57], ["patients", "ORGANISM", 173, 181], ["patient", "ORGANISM", 325, 332], ["patients", "SPECIES", 173, 181], ["patient", "SPECIES", 325, 332], ["isolation", "TREATMENT", 4, 13], ["hand hygiene compliance", "TREATMENT", 53, 76], ["masks", "TREATMENT", 132, 137], ["isolation protocol", "TREATMENT", 151, 169], ["sudden isolation", "TREATMENT", 216, 232]]], ["To our knowledge, this is the largest study of such drills to assess emergency preparedness for infectious diseases in the primary care setting.", [["infectious diseases", "DISEASE", 96, 115], ["such drills", "TREATMENT", 47, 58], ["infectious diseases", "PROBLEM", 96, 115]]], ["Only one previous study has reported the use of mystery patient drills for this purpose, with eight drills held in Catalonia, Spain, in 2007, to assess preparedness against avian influenza [5] .", [["avian influenza", "DISEASE", 173, 188], ["patient", "ORGANISM", 56, 63], ["avian", "ORGANISM", 173, 178], ["patient", "SPECIES", 56, 63], ["avian influenza", "SPECIES", 173, 188], ["one previous study", "TEST", 5, 23], ["mystery patient drills", "TREATMENT", 48, 70], ["influenza", "PROBLEM", 179, 188]]], ["In that study, no clinic gave the patient-actor a surgical mask before or after triage, only 2 (25%) performed chest X-rays, and none reported the suspected case to the local public health department.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41], ["a surgical mask", "TREATMENT", 48, 63], ["triage", "TEST", 80, 86], ["chest X-rays", "TEST", 111, 123], ["chest", "ANATOMY", 111, 116]]], ["These concerning findings highlight the importance of conducting such drills to assess the emergency preparedness of primary care clinics and identify areas of improvement.DiscussionWe evaluated preparedness in terms of duration and quality of both screening and isolation.", [["conducting such drills", "TREATMENT", 54, 76], ["both screening", "TEST", 244, 258], ["isolation", "TREATMENT", 263, 272]]], ["While the median time to screening from entry was 2 min, about one in six drills took more than 10 min to screen the patient.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124]]], ["Furthermore, 30% of drills had at least some challenges with screening.", [["drills", "TREATMENT", 20, 26], ["screening", "TEST", 61, 70]]], ["After the patient-actor was screened, median time to isolation was only 1 min, with no drill taking longer than 5 min to isolate the patient-actor.", [["patient", "ORGANISM", 10, 17], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 10, 17], ["patient", "SPECIES", 133, 140]]], ["However, in terms of quality, 42% of drills had at least some challenges with isolation.", [["drills", "TREATMENT", 37, 43], ["isolation", "TREATMENT", 78, 87]]], ["Similarly, there was no statistically significant difference in terms of quality of screening; 65% of drills screened the patient-actor without any challenges in round 1, compared with 75% in round 3.", [["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["screening", "TEST", 84, 93], ["drills", "TEST", 102, 108], ["no", "UNCERTAINTY", 21, 23], ["statistically", "OBSERVATION_MODIFIER", 24, 37], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["difference", "OBSERVATION", 50, 60]]], ["Interestingly, median time to isolation increased in later rounds of the drill, from under 1 min in round 1 to 2 min in round 3 (p trend = 0.022).", [["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["However, there was no statistically significant trend in terms of quality of isolation; 50% of drills isolated the patient-actor without any challenges in round 1, compared to 69% in round 3.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["drills", "TEST", 95, 101], ["no", "UNCERTAINTY", 19, 21], ["statistically", "OBSERVATION_MODIFIER", 22, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["trend", "OBSERVATION_MODIFIER", 48, 53]]], ["There are multiple explanations for these findings.", [["multiple", "OBSERVATION_MODIFIER", 10, 18]]], ["This study was likely underpowered to detect smaller but still clinically significant differences.", [["This study", "TEST", 0, 10], ["smaller", "OBSERVATION_MODIFIER", 45, 52]]], ["While the increase in time to isolation may be due to random error, it may also be due to a clinically significant (but statistically nonsignificant) improvement in quality of isolation.", [["random error", "PROBLEM", 54, 66], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["may also be due to", "UNCERTAINTY", 71, 89]]], ["Supporting evidence for the latter explanation is that clinics identified several areas for improvement regarding isolation (e.g., explaining to the patient the rationale for isolation, performing hand hygiene, using signage to indicate occupied rooms), which clinics may have incorporated in later rounds, thereby lengthening the time to isolation.DiscussionThe patient-actor was appropriately masked in 81% of drills, though this indicates that one in five patient-actors were never masked.", [["hand", "ANATOMY", 197, 201], ["patient", "ORGANISM", 149, 156], ["hand", "ORGANISM_SUBDIVISION", 197, 201], ["patient", "ORGANISM", 363, 370], ["patient", "ORGANISM", 459, 466], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 363, 370], ["patient", "SPECIES", 459, 466], ["isolation", "TREATMENT", 175, 184]]], ["We also found that actors simulating ILI were much more likely to be masked than those simulating measles (93% vs. 59%, p = 0.007), a finding that persisted when restricting the analysis to only patients who were masked at the first point of contact (77% vs. 41%, p = 0.026).", [["ILI", "DISEASE", 37, 40], ["measles", "DISEASE", 98, 105], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["p", "TEST", 120, 121]]], ["This association may reflect causation since clarifying indications for masking to include a measleslike case of fever and rash without respiratory symptoms was consistently identified as an area for improvement among drill participants.", [["respiratory", "ANATOMY", 136, 147], ["fever", "DISEASE", 113, 118], ["rash", "DISEASE", 123, 127], ["respiratory symptoms", "DISEASE", 136, 156], ["participants", "SPECIES", 224, 236], ["fever", "PROBLEM", 113, 118], ["rash", "PROBLEM", 123, 127], ["respiratory symptoms", "PROBLEM", 136, 156], ["may reflect", "UNCERTAINTY", 17, 28], ["fever", "OBSERVATION", 113, 118]]], ["Furthermore, a greater proportion of cases were masked at the first point of contact in later rounds of the drill (47% in round 1 vs. 75% in round 3, p trend = 0.048), which may reflect improvement by round.", [["the drill", "TEST", 104, 113], ["greater", "OBSERVATION_MODIFIER", 15, 22], ["may reflect", "UNCERTAINTY", 174, 185], ["improvement", "OBSERVATION_MODIFIER", 186, 197], ["round", "OBSERVATION_MODIFIER", 201, 206]]], ["However, it may also be due to confounding, as there was a marginally nonsignificant trend for drill scenario by round, with a greater proportion of drills being ILI in later rounds (58% in round 1 to 81% in round 3; p trend = 0.08).", [["ILI", "DISEASE", 162, 165], ["may also be due to", "UNCERTAINTY", 12, 30], ["confounding", "OBSERVATION", 31, 42]]], ["Nevertheless, these findings highlight the importance of ensuring masking indications also include potentially infectious patients without respiratory symptoms.", [["respiratory", "ANATOMY", 139, 150], ["respiratory symptoms", "DISEASE", 139, 159], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["respiratory symptoms", "PROBLEM", 139, 159], ["infectious", "OBSERVATION_MODIFIER", 111, 121]]], ["For measles, this is especially important since it is highly contagious and has recently re-emerged in the face of declining immunization coverage [20] .", [["measles", "DISEASE", 4, 11], ["measles", "PROBLEM", 4, 11], ["declining immunization coverage", "TREATMENT", 115, 146]]], ["Newly emerging and re-emerging infectious diseases (a recent notable example includes Ebola virus disease [21] ) may also present without respiratory symptoms.DiscussionMystery patient drills for infectious disease of public health concern can serve multiple functions.", [["respiratory", "ANATOMY", 138, 149], ["infectious diseases", "DISEASE", 31, 50], ["Ebola virus disease", "DISEASE", 86, 105], ["respiratory symptoms", "DISEASE", 138, 158], ["infectious disease", "DISEASE", 196, 214], ["Ebola virus", "ORGANISM", 86, 97], ["patient", "ORGANISM", 177, 184], ["Ebola virus", "SPECIES", 86, 97], ["patient", "SPECIES", 177, 184], ["Ebola virus", "SPECIES", 86, 97], ["re-emerging infectious diseases", "PROBLEM", 19, 50], ["Ebola virus disease", "PROBLEM", 86, 105], ["respiratory symptoms", "PROBLEM", 138, 158], ["infectious", "OBSERVATION", 31, 41]]], ["First, they can provide a practical assessment of emergency preparedness using both quantitative and qualitative methods.", [["a practical assessment", "TEST", 24, 46], ["emergency preparedness", "TREATMENT", 50, 72]]], ["Qualitative data are valuable because they can enable triangulation when evaluating quantitative associations, as we show by analyzing participant feedback regarding the exercise that suggests a causal factor to our finding that measles patients were less likely to be masked.DiscussionSecond, these drills can be used to understand and improve the process of screening and isolation, in part by analyzing components of each process that predict \"good performance.\"", [["measles", "DISEASE", 229, 236], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["Qualitative data", "TEST", 0, 16], ["screening", "TEST", 360, 369], ["isolation", "TREATMENT", 374, 383]]], ["Given the pilot nature of this project, we did not collect quantitative data to analyze components of screening and isolation that were predictive of good performance.", [["quantitative data", "TEST", 59, 76], ["screening", "TEST", 102, 111], ["isolation", "TREATMENT", 116, 125]]], ["However, in our qualitative analysis, drill participants consistently identified use of protocols, appropriate training of staff, effective communication, and availability of required equipment (e.g., personal protective equipment) as strengths in their screening and isolation procedures.", [["participants", "SPECIES", 44, 56], ["our qualitative analysis", "TEST", 12, 36], ["protocols", "TREATMENT", 88, 97], ["personal protective equipment", "TREATMENT", 201, 230], ["their screening", "TEST", 248, 263], ["isolation procedures", "TREATMENT", 268, 288]]], ["Areas for improvement pertained to improving the quality of standard operating procedures, including clarifying indications for masking and isolation, optimizing the registration process to avoid delays in screening, promoting hand hygiene compliance, and explaining to patients the rationale for isolation.", [["hand", "ANATOMY", 227, 231], ["hand", "ORGANISM_SUBDIVISION", 227, 231], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["standard operating procedures", "TREATMENT", 60, 89], ["masking and isolation", "TREATMENT", 128, 149], ["the registration process", "TREATMENT", 162, 186], ["screening", "TEST", 206, 215], ["isolation", "TREATMENT", 297, 306], ["improvement", "OBSERVATION_MODIFIER", 10, 21]]], ["This is consistent with a previous study of mystery patient drills for pandemic influenza in the emergency room setting that found that comprehensive standard operating procedures were an important predictor of drill performance [3] .DiscussionThird, from a public health perspective, mystery patient drills can facilitate an important partnership between community health centers and the local health department for emergency preparedness.", [["influenza", "DISEASE", 80, 89], ["patient", "ORGANISM", 52, 59], ["patient", "ORGANISM", 293, 300], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 293, 300], ["a previous study", "TEST", 24, 40], ["pandemic influenza", "PROBLEM", 71, 89], ["comprehensive standard operating procedures", "TREATMENT", 136, 179], ["consistent with", "UNCERTAINTY", 8, 23]]], ["In our study, the drills were well received by participants, approximately 95% of whom reported they were plausible, realistic, feasible, engaging, and helped them prepare for the hazards addressed.", [["participants", "SPECIES", 47, 59], ["our study", "TEST", 3, 12]]], ["Furthermore, previous research suggests that disaster preparedness drills conducted in community clinics are an effective means to develop and improve clinic emergency plans, specifically regarding when and how to activate such plans, the individual roles of staff, and how to participate in a coordinated response [22] .DiscussionThis study has several limitations.", [["disaster preparedness drills", "TREATMENT", 45, 73], ["This study", "TEST", 331, 341]]], ["Although it is the largest study to date using mystery patient drills in the primary care setting, the study was likely underpowered to detect smaller but clinically significant differences.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["the study", "TEST", 99, 108], ["smaller", "OBSERVATION_MODIFIER", 143, 150]]], ["This may explain why we found no other statistically significant trends for duration or quality of screening and isolation.", [["screening", "TEST", 99, 108], ["isolation", "TREATMENT", 113, 122]]], ["Furthermore, as mentioned above, we did not collect quantitative data on components of screening and isolation given the pilot nature of this project.", [["screening", "TEST", 87, 96], ["isolation", "TREATMENT", 101, 110]]], ["Thus, we could not analyze such factors as predictors of good performance, although we were able to examine factors that were identified in the qualitative portion of our study.", [["our study", "TEST", 167, 176]]], ["Finally, we cannot assess the degree to which desirability bias affected participants' feedback regarding the usefulness of the drill.", [["participants", "SPECIES", 73, 85]]], ["However, we encouraged participants to reflect on both strengths and weaknesses of the drill before providing feedback.DiscussionFuture research using mystery patient drills should aim to further describe and characterize the screening and isolation processes, including analysis of predictors of performance.", [["patient", "ORGANISM", 159, 166], ["participants", "SPECIES", 23, 35], ["patient", "SPECIES", 159, 166], ["mystery patient drills", "TREATMENT", 151, 173], ["the screening", "TEST", 222, 235], ["isolation processes", "TREATMENT", 240, 259]]], ["These drills can also be expanded to evaluate other important outcomes (e.g., decontamination, contacting patient contacts, reporting to the health department).", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113]]], ["Future studies can also focus on cost considerations and other diseases.", [["Future studies", "TEST", 0, 14], ["other diseases", "PROBLEM", 57, 71]]], ["Such research will provide insight into the role of mystery patient drills for evaluating emergency preparedness of community health centers and whether these drills can serve as a component of federal certification for these clinics.DiscussionIn summary, to our knowledge, this is the first study to conduct multiple rounds of drills (three rounds between April 2005 through December 2016) and assess time-based performance metrics (time to screening and time to isolation) in order to investigate the value of these drills in assessing, iteratively informing, and improving the emergency preparedness plans of community health centers.DiscussionWe evaluated screening and isolation of actors simulating patients with ILI or measles in 50 drills at 41 clinics in New York City.", [["ILI", "DISEASE", 719, 722], ["measles", "DISEASE", 726, 733], ["patient", "ORGANISM", 60, 67], ["patients", "ORGANISM", 705, 713], ["patient", "SPECIES", 60, 67], ["patients", "SPECIES", 705, 713], ["these drills", "TREATMENT", 153, 165], ["screening", "TEST", 660, 669], ["ILI", "PROBLEM", 719, 722]]], ["In almost every drill, the patient was screened and isolated, although 1 of 3 drills had at least some challenges with either process.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["Patients simulating ILI were more likely to be masked than those simulating measles, which may reflect a causal association.", [["ILI", "DISEASE", 20, 23], ["measles", "DISEASE", 76, 83], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Patients simulating ILI", "PROBLEM", 0, 23], ["may reflect", "UNCERTAINTY", 91, 102]]], ["Approximately 95% of participants reported the drill was realistic and prepared them to deal with the hazards addressed.", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33]]], ["Qualitative analysis revealed several recurring themes for strengths and areas for improvement.", [["Qualitative analysis", "TEST", 0, 20], ["several", "OBSERVATION_MODIFIER", 30, 37]]], ["We conclude that mystery patient drills are an effective and feasible longitudinal collaboration between health departments and primary care clinics to assess and inform emergency preparedness for infectious diseases.", [["infectious diseases", "DISEASE", 197, 216], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["infectious diseases", "PROBLEM", 197, 216]]]]}